

PR detecting cpds. which inhibit the ability of HBV pX protein to
 PR promote DNA binding to bZIP-contg. transcription factors.

XX Example 1; Page 14; 47pp; English.

CC The invention relates to novel methods of screening for inhibitors of
 CC hepatitis B virus (HBV) replication by identifying inhibitors of the HBV
 CC protein pX, which activates viral transcription by binding multiple
 CC transcription factors such as proteins contg. a bZIP domain, from binding
 CC to the transcription factors. This sequence was used to investigate the
 CC effect of pX on the binding of the bZIP-contg. transcription factors
 CC of the AP-1 family such as C/EBP, to its cognate binding site, in a gel
 CC shift assay. The inhibitory cpds. may be antibodies, small organic mols.
 CC or peptides.

XX Sequence 20 BP; 5 A; 5 C; 5 G; 5 T; 0 other;

Query Match 100.0%; Score 20; DB 17; Length 20;

Best Local Similarity 100.0%; Pred. No. 0.53; Mismatches 0; Indels 0; Gaps 0;

0Y 1 TGCAGATTGCCAATCTGCA 20
 DB 1 TGCAGATTGCCAATCTGCA 20

RESULT 2

AAT32689/c AAT32689 standard; DNA; 20 BP.

AC AAT32689;

XX 24-FEB-1997 (first entry)

XX C/EBP binding site sequence.

XX Inhibitor: hepatitis B virus; replication; protein pX; activation;
 KW transcription factor; bZIP domain; AP-1; collagenase TRE binding site;
 KW c-Jun; gel shift assay; ss.

XX Synthetic.

XX MO9617960-A2.

XX 13-JUN-1996.

XX 06-DEC-1995; 95WO-US16821.

XX 07-DEC-1994; 94US-0351659.

PA (SCRT-) SCRIPTEGEN PHARM INC.
 PA (OTMA-) UNITV MASSACHUSETTS MEDICAL CENT.

PI Green MD, Lillie J, Perini G;

XX WPI; 1996-287203/29.

PR Identifying inhibitors of hepatitis B virus replication - by
 PR detecting cpds. which inhibit the ability of HBV pX protein to
 PR promote DNA binding to bZIP-contg. transcription factors.

PS Example 1; Page 14; 47pp; English.

CC The invention relates to novel methods of screening for inhibitors of
 CC hepatitis B virus (HBV) replication by identifying inhibitors of the HBV
 CC protein pX, which activates viral transcription by binding multiple
 CC transcription factors such as proteins contg. a bZIP domain, from binding
 CC to the transcription factors. This sequence was used to investigate the
 CC effect of pX on the binding of the bZIP-contg. transcription factors
 CC of the AP-1 family such as C/EBP, to its cognate binding site, in a gel
 CC shift assay. The inhibitory cpds. may be antibodies, small organic mols.
 CC or peptides.

SQ Sequence 20 BP; 5 A; 5 C; 5 G; 5 T; 0 other;

Query Match 100.0%; Score 20; DB 17; Length 20;

Best Local Similarity 100.0%; Pred. No. 0.53; Mismatches 0; Indels 0; Gaps 0;

0Y 1 TGCAGATTGCCAATCTGCA 20
 DB 20 TGCAGATTGCCAATCTGCA 1

RESULT 3

AAV46005 AAV46005 standard; DNA; 20 BP.

XX AAV46005;

XX 16-OCT-1998 (first entry)

XX Immune adjuvant C/EBP.

XX Immune system; adjuvant; vaccine; cancer; prophylactic; pathogenicity;
 KW modulator; tolerance; regulator; helper cell; antigen; immunoglobulin;
 KW Ig class; autoimmune response; T-cell; B-cell; tumour; ss.

XX Class Bacteria.

XX EP855184-A1.

XX 29-JUL-1998.

XX 23-JAN-1997; 97EP-0101019.

XX 23-JAN-1997; 97EP-0101019.

PA (HEEG/) HEEG K.
 PA (LIPF/) LIPFORD G B.
 PA (WAGN/) WAGNER H.

PI Heeg K, Lipford GB, Wagner H;

XX WPI; 1998-389630/34.

PR Antigenic composition comprises polynucleotide fragment and antigen
 PR - used as vaccine to treat or prevent e.g. cancer or pathogen
 PR infections and to modulate immune response e.g. tolerance break and
 PR regulation of TH1/TH2 cells

PS Example 5; Page 9; 28pp; English.

CC AAV45993-V46019 are fragments of bacterial polynucleotides which are
 CC used as immune adjuvants for inclusion into vaccines to treat cancer and
 CC for prophylaxis and/or treatment of conditions caused by pathogenic
 CC micro-organisms. The polynucleotide is used for modulation of an immune
 CC response and the modulation is selected from the group break of
 CC tolerance, regulation of TH1/TH2 helper cell responses, switch of Ig
 CC classes, treatment of autoimmune responses and induction of tolerances.
 CC DNA oligomers are used to enhance the reactivity of immune cells to
 CC viral, bacterial and parasitic antigens, as adjuvants in vaccination
 CC and B cells e.g. against tumour antigens, as adjuvants in vaccination
 CC against tumour-defined antigens and immunostimulatory substances in an
 CC immune response against tumours and to suppress immune reactions of the
 CC innate and acquired immune system. The composition is inexpensive and
 CC stable and does not cause lethal shock, which happens with prior art
 CC bacterial sequences.

XX Sequence 20 BP; 5 A; 5 C; 5 G; 5 T; 0 other;

Query Match 100.0%; Score 20; DB 19; Length 20;

Best Local Similarity 100.0%; Pred. No. 0.53; Mismatches 0; Indels 0; Gaps 0;

0Y 1 TGCAGATTGCCAATCTGCA 20

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 26, 2003, 09:43:36 ; Search time 226.087 Seconds
(without alignments)
199.215 Million cell updates/sec

Title: US-09-355-254f-13

Perfect score: 20

Sequence: 1 tgcagattgcgcacatcgca 20

Scoring table: IDENTITY_NUC
Gapop 10.0, Gapext 1.0

Searched: 2185239 seqs, 112599159 residues 4370478

Total number of hits satisfying chosen parameters:

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :
1: /SID52/gcgdata/geneseq/geneseq-emb1/NA1980.DAT:*
2: /SID52/gcgdata/geneseq/geneseq-emb1/NA1981.DAT:*
3: /SID52/gcgdata/geneseq/geneseq-emb1/NA1982.DAT:*
4: /SID52/gcgdata/geneseq/geneseq-emb1/NA1983.DAT:*
5: /SID52/gcgdata/geneseq/geneseq-emb1/NA1984.DAT:*
6: /SID52/gcgdata/geneseq/geneseq-emb1/NA1985.DAT:*
7: /SID52/gcgdata/geneseq/geneseq-emb1/NA1986.DAT:*
8: /SID52/gcgdata/geneseq/geneseq-emb1/NA1987.DAT:*
9: /SID52/gcgdata/geneseq/geneseq-emb1/NA1988.DAT:*
10: /SID52/gcgdata/geneseq/geneseq-emb1/NA1989.DAT:*
11: /SID52/gcgdata/geneseq/geneseq-emb1/NA1990.DAT:*
12: /SID52/gcgdata/geneseq/geneseq-emb1/NA1991.DAT:*
13: /SID52/gcgdata/geneseq/geneseq-emb1/NA1992.DAT:*
14: /SID52/gcgdata/geneseq/geneseq-emb1/NA1993.DAT:*
15: /SID52/gcgdata/geneseq/geneseq-emb1/NA1994.DAT:*
16: /SID52/gcgdata/geneseq/geneseq-emb1/NA1995.DAT:*
17: /SID52/gcgdata/geneseq/geneseq-emb1/NA1996.DAT:*
18: /SID52/gcgdata/geneseq/geneseq-emb1/NA1997.DAT:*
19: /SID52/gcgdata/geneseq/geneseq-emb1/NA1998.DAT:*
20: /SID52/gcgdata/geneseq/geneseq-emb1/NA1999.DAT:*
21: /SID52/gcgdata/geneseq/geneseq-emb1/NA2000.DAT:*
22: /SID52/gcgdata/geneseq/geneseq-emb1/NA2001.DAT:*
23: /SID52/gcgdata/geneseq/geneseq-emb1/NA2001B.DAT:*
24: /SID52/gcgdata/geneseq/geneseq-emb1/NA2002.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match Length	ID	Description
1	20	17	AAT32689	C/EBP binding site
2	20	17	AAT32689	C/EBP binding site
3	20	19	AAV46005	Immune adjuvant C/
4	20	19	AAV46005	Immune adjuvant C/
5	20	20	AAZ25682	Transcription fact
6	20	20	AAZ25682	Transcription fact
7	20	20	AAZ25682	Transcription fact
8	20	20	AAZ25682	Transcription fact
9	20	20	AAZ25682	Transcription fact
10	20	20	AAZ25682	Transcription fact
11	20	20	AAZ25682	Transcription fact
12	20	20	AAZ25682	Transcription fact
13	20	20	AAZ25682	Transcription fact
14	20	20	AAZ25682	Transcription fact
15	20	20	AAZ25682	Transcription fact
16	20	20	AAZ25682	Transcription fact
17	20	20	AAZ25682	Transcription fact
18	20	20	AAZ25682	Transcription fact
19	20	20	AAZ25682	Transcription fact
20	20	20	AAZ25682	Transcription fact
21	20	20	AAZ25682	Transcription fact
22	20	20	AAZ25682	Transcription fact
23	20	20	AAZ25682	Transcription fact
24	20	20	AAZ25682	Transcription fact
25	20	20	AAZ25682	Transcription fact
26	20	20	AAZ25682	Transcription fact
27	20	20	AAZ25682	Transcription fact
28	20	20	AAZ25682	Transcription fact
29	20	20	AAZ25682	Transcription fact
30	20	20	AAZ25682	Transcription fact
31	20	20	AAZ25682	Transcription fact
32	20	20	AAZ25682	Transcription fact
33	20	20	AAZ25682	Transcription fact
34	20	20	AAZ25682	Transcription fact
35	20	20	AAZ25682	Transcription fact
36	20	20	AAZ25682	Transcription fact
37	20	20	AAZ25682	Transcription fact
38	20	20	AAZ25682	Transcription fact
39	20	20	AAZ25682	Transcription fact
40	20	20	AAZ25682	Transcription fact
41	20	20	AAZ25682	Transcription fact
42	20	20	AAZ25682	Transcription fact
43	20	20	AAZ25682	Transcription fact
44	20	20	AAZ25682	Transcription fact
45	20	20	AAZ25682	Transcription fact

C	10	20	100.0	20	21	AAZ53297	Fluorescein C/EBP
C	11	20	100.0	20	21	AAZ75522	Electrophoretic mo
C	12	20	100.0	20	21	AAZ75522	Electrophoretic mo
C	13	20	100.0	20	21	AAZ27523	Electrophoretic mo
C	14	20	100.0	20	21	AAZ27523	Electrophoretic mo
C	15	20	100.0	20	21	AAZ89652	Electrophoretic mo
C	16	20	100.0	20	21	AAZ89652	Electrophoretic mo
C	17	20	100.0	20	21	AAZ89652	Electrophoretic mo
C	18	20	100.0	20	21	AAZ89652	Electrophoretic mo
C	19	20	100.0	20	21	AAZ89652	Electrophoretic mo
C	20	20	100.0	20	22	AAZ89652	Electrophoretic mo
C	21	20	100.0	20	22	AAZ89652	Electrophoretic mo
C	22	20	100.0	20	22	AAZ89652	Electrophoretic mo
C	23	20	100.0	20	22	AAZ89652	Electrophoretic mo
C	24	20	100.0	20	22	AAZ89652	Electrophoretic mo
C	25	20	100.0	20	22	AAZ89652	Electrophoretic mo
C	26	20	100.0	20	22	AAZ89652	Electrophoretic mo
C	27	20	100.0	20	22	AAZ89652	Electrophoretic mo
C	28	20	100.0	20	22	AAZ89652	Electrophoretic mo
C	29	20	100.0	20	22	AAZ89652	Electrophoretic mo
C	30	20	100.0	20	22	AAZ89652	Electrophoretic mo
C	31	20	100.0	20	22	AAZ89652	Electrophoretic mo
C	32	20	100.0	20	22	AAZ89652	Electrophoretic mo
C	33	20	100.0	20	22	AAZ89652	Electrophoretic mo
C	34	20	100.0	20	22	AAZ89652	Electrophoretic mo
C	35	20	100.0	20	22	AAZ89652	Electrophoretic mo
C	36	20	100.0	20	22	AAZ89652	Electrophoretic mo
C	37	20	100.0	20	22	AAZ89652	Electrophoretic mo
C	38	20	100.0	20	22	AAZ89652	Electrophoretic mo
C	39	20	100.0	20	22	AAZ89652	Electrophoretic mo
C	40	20	100.0	20	22	AAZ89652	Electrophoretic mo
C	41	20	100.0	20	22	AAZ89652	Electrophoretic mo
C	42	20	100.0	20	22	AAZ89652	Electrophoretic mo
C	43	20	100.0	20	22	AAZ89652	Electrophoretic mo
C	44	20	100.0	20	22	AAZ89652	Electrophoretic mo
C	45	20	100.0	20	22	AAZ89652	Electrophoretic mo

ALIGNMENTS

RESULT 1
AAT32689 standard; DNA; 20 BP.
AAT32689:
24-FEB-1997 (first entry)
C/EBP binding site sequence.
Inhibitor: hepatitis B virus; replication; protein pX; activation;
transcription factor; BZIP domain; AP-1; collagenase TRE binding site;
c-Jun; gel shift assay; ss.
OS Synthetic.
PN WO9617960-A2
PD 13-JUN-1996.
PF 06-DEC-1995; 95WO-US16821.
PR 07-DEC-1994; 94US-0351659.
PA (SCRI-) SCRIPGEN PHARM INC.
PA (UTMA-) UNIV MASSACHUSETTS MEDICAL CENT.
PI Green MD, Lillie J, Perini G;
DR WPI; 1996-287203/29.
PT Identifying inhibitors of hepatitis B virus replication - by

THIS PAGE BLANK (USE)

sequences of 1032, 1050 or 1032 amino acids as given in specification, or their fragments, where TLR9, TLR7 and TLR8 polypeptides or their fragments have an amino acid sequence which is identical to human TLR9, TLR7 or TLR8 polypeptides or their fragment except for at least one amino acid of a murine TLR polypeptide. The isolated nucleic acids of the invention are useful for inhibiting TLR9 signalling activity in a cell. TLR7, TLR8 and TLR9 polypeptides are useful for identifying nucleic acid molecules which interact with a TLR polypeptide or its fragment. The TLR7, TLR8 or TLR9 polypeptides are also useful for identifying TLR9, TLR7, TLR8 and TLR9 polypeptides that is not a nucleic acid, and signalling activity of a test compound (that is not a nucleic acid) with is a polypeptide or a part of a combinatorial library of compounds) with an ISNA. The TLR7, TLR8 and TLR9 polypeptides are also useful for identifying species specificity of an ISNA. The isolated nucleic acids of the invention are useful as probes or primers. This polynucleotide sequence represents DNA relating to the isolated Toll-like receptors of the invention.

Sequence 20 BP; 2 A; 5 C; 11 G; 2 T; 0 other:

Query Match 100.0%; Score 20; DB 24; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TCGATCGGGCGGGCGAGC 20
|||||
DB 1 TCGATCGGGCGGGCGAGC 20

RESULT 4
AA18820
AA18820 standard; DNA; 22 BP.

AC AA18820:
DT 17-AUG-1996 (first entry)
XX
DE SPl motif.

XX NF- κ I; transcription factor; major histocompatibility complex; MHC;
KW allergy; HLA-DRA; ds.

OS Homo sapiens.
XX
PN W09612823-A1
XX
PD 02-MAY-1996.

XX 20-OCT-1995; 95WO-US12749.
XX
PR 21-OCT-1994; 94US-0327832.

XX (HARD) HARVARD COLLEGE.
PA (UYJO) UNIV JOHNS HOPKINS.
XX

PI Ono SJ, Strominger JL;
XX
DR WPI; 1996-230621/23.

XX Transcription factor, NF- κ I and DNA encoding it - used in regulation
PT of MHC class II expression and in treatment of allergic disease

XX Example 4; Page 42; 93pp; English.

XX Recombinant transcription factor NF- κ I (see AAR94957) forms a
CC specific complex with the HLA-DRA XI box oligonucleotide (AA18817)
CC which is competed for by 100-fold excess cold, double-stranded
CC oligonucleotides containing the analogous regions from the HLA-DRB,
CC -DRA, -DPB, -DQA and -DOB promoters, but not by HLA-DRA Y-box
CC (AA18818), S-box (AA18819), SPl (AA18820) or the interferon-beta gene
CC positive-regulatory domain II element (AA18821). It is concluded
CC that NF- κ I binds sequence-specifically with all human class II
CC major histocompatibility XI boxes (see also AA18812).

XX Sequence 22 BP; 3 A; 5 C; 11 G; 3 T; 0 other;

Query Match 100.0%; Score 20; DB 17; Length 22;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TCGATCGGGCGGGCGAGC 20
|||||
DB 3 TCGATCGGGCGGGCGAGC 22

RESULT 5
AA177128
AA177128 standard; DNA; 22 BP.

AC AA177128:
DT 07-DEC-1997 (first entry)
XX

DE SPl consensus.
XX

XX 17-Beta-hydroxysteroid dehydrogenase type I; HSD17B1; human;
KW promoter; ds.

XX Synthetic.
XX
PN W09720942-A1.

PD 12-JUN-1997.
XX
PP 04-DEC-1996; 96WO-F100647.

PR 05-DEC-1995; 95US-0007976.
XX
XX (OIKK) OIKARINEN J A.
PA (PELT) PELTOKETO E H.
PA (PIAO) PIAO Y.
PA (VIHK) VIHKO R K.

XX Oikarinen JA, Peltoketo EH, Piao Y, Viikko RK;
FI
DR WPI; 1997-319788/29.

XX Human 17-beta-hydroxysteroid dehydrogenase type I (HSD17B1)
PT transcription regulatory elements - used for identifying agents
PT which can up- or down-regulate HSD17B1 expression to increase or
PT decrease oestrogen production
XX
PS Example 6; Page 38; 69pp; English.

XX This oligonucleotide comprises a consensus sequence for SPl
CC binding sites. It was used with oligonucleotides (see
CC AA177122-24 and AA177126-27) based on the promoter region of the human
CC 17-beta-hydroxysteroid dehydrogenase type I (HSD17B1) gene (see
CC AA177112), and with an Ap-2 consensus oligonucleotide (see AA177125),
CC in the detailed characterisation of the HSD17B1 promoter, and to
CC examine the role of SPl and Ap-2 binding sites in promoter
CC function.
XX

XX Sequence 22 BP; 3 A; 5 C; 11 G; 3 T; 0 other;

Query Match 100.0%; Score 20; DB 18; Length 22;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TCGATCGGGCGGGCGAGC 20
|||||
DB 3 TCGATCGGGCGGGCGAGC 22

RESULT 6
AA176050

THIS PAGE BLANK (USE)

Jun 27 14:14:49 2003

us-09-355-254f-17.rge

exon /number=3
4032.4524
/partial
/gene="Ly-6A"

BASE COUNT 1103 a 1031 c 1149 g 1241 t
ORIGIN Chromosome XV.

Query Match 100.0%; Score 20; DB 10; Length 4524;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TATGATATTCCTGTAAGT 20
|||||
Db 375 TATGATATTCCTGTAAGT 394

RESULT 5
MUSLY6A 4524 bp DNA linear ROD 28-JUL-1999
LOCUS Mus musculus Ly-6A.2 (Ly-6A) gene, complete cds.
ACCESSION M74013
VERSION M74013.1 GI:198923
KEYWORDS
SOURCE Mus musculus.
ORGANISM Mus musculus.
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus. 1 (bases 1 to 4524)
AUTHORS Stanford, W.L., Brynys, E. and Snodgrass, H.R.
JOURNAL Unpublished
FEATURES
Location/Qualifiers
1..4524
/organism="Mus musculus"
/db_xref="taxon:10090"
/chromosome="15"
1611..4524
/gene="Ly-6A"
join(1611..1649,1895..1976,2943..3059,4032..4249)
/gene="Ly-6A"
join(1907..1976,2943..3059,4032..4249)
/gene="Ly-6A"
/codon_start=1
/product="Ly-6A.2"
/protein_id="AA039464.1"
/db_xref="GI:198924"
/translation="MDTSHTKSCILITLVALCAERAGIECYGVFPESCPSI
TCYPDGCYTOEAAVYDSOTRKNKLCIPCPPIESMEIIGTKVNVKTSQCD
LCNVAAPNGSGSTFMAGVILFSLSSVLTQTL"

BASE COUNT 1103 a 1031 c 1149 g 1241 t
ORIGIN

Query Match 100.0%; Score 20; DB 10; Length 4524;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TATGATATTCCTGTAAGT 20
|||||
Db 375 TATGATATTCCTGTAAGT 394

RESULT 6
MUSLY6A 6249 bp DNA linear ROD 27-APR-1993
LOCUS Mouse Ly-6E/A gene, complete cds.
ACCESSION M37707
VERSION M37707.1 GI:198929
KEYWORDS differentiation antigen; interferon inducible antigen.
SOURCE Mouse (strain BALB/c) DNA.
ORGANISM Mus musculus
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus. 1 (bases 1 to 6249)

AUTHORS Khan, K.D., Lindvall, G., Maher, S.E. and Bothwell, A.L.
TITLE Characterization of promoter elements of an interferon-inducible Ly-6E/A differentiation antigen, which is expressed on activated T cells and hematopoietic stem cells (1990)
JOURNAL Mol. Cell. Biol. 10 (10), 5150-5159 (1990)
MEDLINE 90377204
PubMed 1697928

COMMENT Draft entry and computer-readable sequence for [Mol. Cell. Biol. (1990) in press] kindly submitted by A.L.M. Bothwell, 13-AUG-1990.

FEATURES
Location/Qualifiers
1..6249
/organism="Mus musculus"
/strain="BALB/c"
/sub_species="domesticus"
/db_xref="taxon:10090"
join(3206..3258,3474..3571,4533..4649,5649..56249)
/gene="Ly-6E/A"
join(3206..3258,3474..3571,4533..4649,5649..56249)
/gene="Ly-6E/A"
/product="differentiation antigen Ly-6E/A"
3206..3258
/gene="Ly-6E/A"
/number=1
3259..3473
/gene="Ly-6E/A"
/number=1
3474..3571
/gene="Ly-6E/A"
/number=2
join(3502..3571,4533..4649,5649..5866)
/gene="Ly-6E/A"
/codon_start=1
/product="differentiation antigen Ly-6E/A"
/protein_id="AA039467.1"
/db_xref="GI:198930"
/translation="MDTSHTKSCILITLVALCAERAGIECYGVFPESCPSI
TCYPDGCYTOEAAVYDSOTRKNKLCIPCPPIESMEIIGTKVNVKTSQCD
LCNVAAPNGSGSTFMAGVILFSLSSVLTQTL"

exon
intron
CDS
mat_peptide
intron
exon
intron
exon

BASE COUNT 1592 a 1419 c 1572 g 1666 t
ORIGIN

Query Match 100.0%; Score 20; DB 10; Length 6249;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TATGATATTCCTGTAAGT 20
|||||
Db 1973 TATGATATTCCTGTAAGT 1992

RESULT 7
AC117802 161084 bp DNA linear HTG 09-AUG-2002
LOCUS Mus musculus clone RP24-56018, WORKING DRAFT SEQUENCE, 6 unordered pieces.
DEFINITION
ACCESSION AC117802
VERSION AC117802.2 GI:22165187

THIS PAGE BLANK (USE)

LOCUS HUMIRF2 585 bp DNA linear PRI 29-MAY-2002
 DEFINITION Human gene for Interferon regulatory factor-2 (IRF-2), exon 1.
 ACCESSION D14082
 VERSION D14082.1 GI:468933
 KEYWORDS IRF-2; Interferon regulatory factor-2; transcription factor.
 SOURCE Homo sapiens DNA, clone lib: Dr. Tom Maniatis's library.
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
 1 Itoh, S., Harada, H., Fujita, T., Mamura, T. and Taniguchi, T.
 Sequence of a cDNA coding for human IRF-2
 Nucleic Acids Res. 17 (20), 8372 (1989)
 JOURNAL 90045964
 MEDLINE
 REFERENCE
 2 (bases 1 to 585)
 Harada, H., Takahashi, E., Itoh, S., Harada, K., Horii, T. A. and
 Taniguchi, T.
 Structure and regulation of the human Interferon regulatory factor
 1 (IRF-1) and IRF-2 genes: implications for a gene network in the
 interferon system
 JOURNAL Mol. Cell. Biol. 14 (2), 1500-1509 (1994)
 MEDLINE 94119101
 REFERENCE
 3 (bases 1 to 585)
 Harada, H.
 Direct Submission
 Submitted (20-JAN-1993) Hisashi Harada, Osaka University, Institute
 for Molecular and Cellular Bio: 1-3, Yamada-oka, Suita, Osaka Pref.
 565, Japan (tel:06-877-5289, Fax:06-878-9846)
 Submitted (20-JAN-1993) to DDBJ by:
 Hisashi Harada
 Institute for Molecular and
 Cellular Biology, Osaka University
 1-3 Yamadaoka
 Suita-shi, Osaka 565
 Japan
 Phone: 06-877-5289
 Fax: 06-878-9846.
 Location/Qualifiers
 1..585
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /map="4q35.1"
 /chromosome="4"
 /clone_lib="Dr. Tom Maniatis's library"
 415..585
 /product="IRF-2"
 /number=1
 415
 /note="major cap site"
 /evidence="experimental"
 BASE COUNT 102 a 184 c 185 g 114 t
 ORIGIN

Query Match 100.0%; Score 20; DB 9; Length 585;
 Best Local Similarity 100.0%; Pred. No. 1e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AACCGAAATGAATGACT 20
 ||||||||||||||||
 DB 153 AACCGAAATGAATGACT 172

RESULT 7
 LOCUS HUMIRF2A 1565 bp DNA linear PRI 06-JAN-1995
 DEFINITION Homo sapiens Interferon regulatory factor 2 (IRF2) gene, 5' flank.
 ACCESSION L24442
 VERSION L24442.1 GI:438637
 KEYWORDS Interferon regulatory factor 2.
 SOURCE Homo sapiens
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1 (bases 1 to 1565)
 AUTHORS Cha, Y. and Deisseroth, A.B.
 TITLE Human Interferon regulatory factor 2 gene. Intron-exon organization
 and functional analysis of 5'-flanking region
 JOURNAL J. Biol. Chem. 269 (7), 5279-5287 (1994)
 MEDLINE 94148994
 PUBMED 8106512

FEATURES
 source Location/Qualifiers
 1..1565
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /map="unassigned"
 /cell_type="leukocyte"
 /tissue_type="placenta"
 complement(1119..1124)
 /note="putative"
 /bound_moiety="Sp1"
 1278..1565
 /gene="IRF2"
 1278..1282
 /note="G00-127-270; putative"
 1386..1391
 /gene="IRF2"
 /note="putative"
 1400..1405
 /bound_moiety="Sp1"
 /gene="IRF2"
 /note="putative"
 1441..1446
 /bound_moiety="Sp1"
 /gene="IRF2"
 /note="putative"
 1455..1464
 /bound_moiety="Sp1"
 /gene="IRF2"
 /note="putative"
 /bound_moiety="NF kappa B"
 1555..1565
 /gene="IRF2"
 /note="5' untranslated region; G00-127-270"
 /evidence="experimental"
 BASE COUNT 340 a 429 c 424 g 372 t
 ORIGIN

Query Match 100.0%; Score 20; DB 9; Length 1565;
 Best Local Similarity 100.0%; Pred. No. 98;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AACCGAAATGAATGACT 20
 ||||||||||||||||
 DB 1226 AACCGAAATGAATGACT 1245

RESULT 8
 LOCUS AC099343/c 196216 bp DNA linear PRI 22-FEB-2002
 DEFINITION Homo sapiens BAC clone RP11-326111 from 4, complete sequence.
 ACCESSION AC099343
 VERSION AC099343.3 GI:18543145
 KEYWORDS HTG.
 SOURCE Homo sapiens
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1 (bases 1 to 196216)
 AUTHORS Sulston, J.E. and Waterston, R.
 TITLE Toward a complete human genome sequence
 JOURNAL Genome Res. 8 (11), 1097-1108 (1998)
 MEDLINE 99063792
 PUBMED 9847074
 REFERENCE 2 (bases 1 to 196216)
 AUTHORS Levy, A., Haakenson, W. and Spalding, L.

THIS PAGE BLANK (US)

FEATURES
SOURCE
16/10, Moscow V-437, 117871 GSP7, Russia
location/Qualifiers
1. 4740
/organism="Homo sapiens"
/db_xref="taxon:9606"
/cell_type="leukocyte"
/tissue_type="blood"
/clone_id="human genome library"
2124. 4176
/gene="IL13"
join(2124. 2255,3312. 3365,3618. 3722,4072. 4176)
CDS
gene
2124. 4176
/gene="IL13"
/product="Interleukin 13"
/protein_id="AA83738.1"
/db_xref="GI:1127548"
/translation="MALLTFTVIALTCGAFSPGPPSTALRELTIELVNTONOK
RPLNGSNVMSINLTAGMTCALLESILNVSGLAIKRTORMLSGCPHVSAGFSSL
VADTKIEVAVQFVDLHLKTLREGREN"
BASE COUNT
1023 a 1444 c 1305 g 968 t
ORIGIN
Query Match
Best Local Similarity 100.0%; Score 18; DB 9; Length 4740;
Pred. No. 16;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY
1 GGATGACGTCCTCGTG 18
|||||
Db 824 GGATGACGTCCTCGTG 841
RESULT 9
HSU31120 5670 bp DNA linear PRI 05-JUN-1996
LOCUS
DEFINITION
Human Interleukin-13 (IL-13) precursor gene, complete cds.
U31120
U31120.1 GI:1045451
KEYWORDS
SOURCE
Homo sapiens.
ORGANISM
Homo sapiens.
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
AUTHORS
1 (bases 1 to 5670)
Dolganov, G., Bort, S., Lovett, M., Burr, J., Schubert, L., Short, D.,
McGunn, M., Gibson, C. and Lewis, D.B.
Coexpression of the interleukin-13 and interleukin-4 genes
correlates with their physical linkage in the cytokine gene cluster
on human chromosome 5q23-31
on human chromosome 5q23-31
R1002 87 (8), 3316-3326 (1996)
66184791
8605348
2 (bases 1 to 5670)
Dolganov, G.M.
REFERENCE
AUTHORS
Direct Submission
Submitted (06-JUL-1995) Gregory M. Dolganov, Human Genetics,
Genelabs, Inc., 505 Penobscot, Redwood City, CA 94063, USA
JOURNAL
Genelabs, Inc., 505 Penobscot, Redwood City, CA 94063, USA
FEATURES
SOURCE
1. 5670
/organism="Homo sapiens"
/db_xref="taxon:9606"
/chromosome="5"
/map="5q23-31"
/clone="58D9"
1360. 1490
/rpt_family="Alu-repeat, left monomer"
/rpt_type="other"
2158. 5095
/gene="IL-13"
join(2158. 2345,3403. 3456,3709. 3813,4160. 5095)
/gene="IL-13"
/product="Interleukin-13 precursor"
2158. 2345
/gene="IL-13"
/gene="IL-13"

CDS
sig_peptide
mat_peptide
2214. 2273
/gene="IL-13"
join(2274. 2345,3403. 3456,3709. 3813,4160. 4264)
/gene="IL-13"
/product="Interleukin-13 precursor"
/protein_id="AA801681.1"
/db_xref="GI:1045452"
/translation="MALLTFTVIALTCGAFSPGPPSTALRELTIELVNTONOK
RPLNGSNVMSINLTAGMTCALLESILNVSGLAIKRTORMLSGCPHVSAGFSSL
VADTKIEVAVQFVDLHLKTLREGREN"
HVDTKIEVAVQFVDLHLKTLREGREN"
2214. 2273
/gene="IL-13"
/product="Interleukin-13"
/function="cytokine"
/evidence="experimental"
2346. 3402
/gene="IL-13"
3403. 3456
/gene="IL-13"
3457. 3708
/gene="IL-13"
3709. 3813
/gene="IL-13"
3814. 4159
/gene="IL-13"
4160. 5095
/gene="IL-13"
4831. 4878
/rpt_type="direct"
5076. 5081
/gene="IL-13"
polya_site
repeat_region
5522. 5567
BASE COUNT
1243 a 1676 c 1582 g 1169 t
ORIGIN
Query Match
Best Local Similarity 100.0%; Score 18; DB 9; Length 5670;
Pred. No. 16;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY
1 GGATGACGTCCTCGTG 18
|||||
Db 826 GGATGACGTCCTCGTG 843
RESULT 10
AF377331 6919 bp DNA linear PRI 01-JUN-2001
LOCUS
DEFINITION
Homo sapiens Interleukin 13 (IL13) gene, complete cds.
AF377331
AF377331.2 GI:14278714
KEYWORDS
SOURCE
Homo sapiens.
ORGANISM
Homo sapiens.
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
AUTHORS
1 (bases 1 to 6919)
Rieder, M.J., Carrington, D.P., Chung, M.-W., Lee, K.L., Poel, C.L.,
Yi, Q. and Nickerson, D.A.
Direct Submission
Submitted (04-MAY-2001) Molecular Biotechnology, University of
Washington, 1705 NE Pacific, Seattle, WA 98195, USA
2 (bases 1 to 6919)
Washington, 1705 NE Pacific, Seattle, WA 98195, USA
Yi, Q. and Nickerson, D.A.
Direct Submission
Submitted (01-JUN-2001) Molecular Biotechnology, University of
Washington, 1705 NE Pacific, Seattle, WA 98195, USA
JOURNAL
Sequence update by submitter
To cite this work please use: SeattleSNPs, NHI Program for
Genomic Applications, UW-FRCRC, Seattle, WA (URL:
http://pga.mbt.washington.edu).

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 26, 2003, 10:58:25 ; Search time 30.2174 Seconds
(without alignments)
202,980 Million cell updates/sec

Title: US-09-355-254F-12

Perfect score: 20

Sequence: 1 tcgacgcggcgagcgagc 20

Scoring table: IDENTITY_NUC
Gapop 10.0, Gapext 1.0

Searched: 441362 seqs, 15338381 residues

Total number of hits satisfying chosen parameters: 882724

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 08
Maximum Match 1008
Listing first 45 summaries

Database :

1: /cgn2_6/prodata/1/lna/5A_COMB.seq:*
2: /cgn2_6/prodata/1/lna/5B_COMB.seq:*
3: /cgn2_6/prodata/1/lna/6A_COMB.seq:*
4: /cgn2_6/prodata/1/lna/6B_COMB.seq:*
5: /cgn2_6/prodata/1/lna/PCITUS_COMB.seq:*
6: /cgn2_6/prodata/1/lna/backfileseq1.seq:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	20	100.0	22	2	US-08-327-832-12
2	20	100.0	22	2	US-08-828-584-12
3	20	100.0	22	5	PCT-US94-05659-16
4	19	95.0	46	1	US-08-122-433-12
5	19	95.0	46	1	US-08-122-433-12
6	18	90.0	46	1	US-08-122-433-12
7	18	90.0	46	1	US-08-122-433-12
8	16.8	84.0	2875	3	US-08-458-434A-4
9	16.8	84.0	15144	3	US-08-458-434A-6
10	16.4	82.0	379	1	US-08-145-617-5
11	15.8	79.0	31	1	US-08-153-563-4
12	15.8	79.0	31	2	US-09-038-227-9
13	15.8	79.0	31	2	US-08-460-507-4
14	15.8	79.0	944	2	US-08-786-606-4
15	15.8	79.0	1112	2	US-08-933-750C-97
16	15.8	79.0	1112	3	US-09-234-613-97
17	15.8	79.0	1919	1	US-07-991-587A-1
18	15.8	79.0	1919	1	US-08-309-985-1
19	15.8	79.0	3314	1	US-07-973-324A-5
20	15.8	79.0	3314	1	US-08-343-380-5
21	15.8	79.0	3314	4	US-09-072-435-5
22	15.8	79.0	3314	4	US-09-072-917A-5
23	15.2	76.0	80	3	US-09-039-555B-4
24	15.2	76.0	730	3	US-08-743-637B-11
25	15.2	76.0	730	3	US-08-526-840B-11
26	15.2	76.0	1007	4	US-08-836-500A-13
27	15.2	76.0	1008	3	US-08-721-979A-13

C	28	15.2	76.0	1008	4	US-09-654-289-13	Sequence 13, Appl
	29	15.2	76.0	9704	4	US-09-814-951A-3	Sequence 3, Appl
	30	15.2	76.0	44377	2	US-08-804-227C-7	Sequence 7, Appl
	31	15.2	76.0	44377	2	US-08-804-198-1	Sequence 1, Appl
C	32	15.2	76.0	4403765	4	US-09-103-840A-2	Sequence 2, Appl
	33	15.2	76.0	4411529	4	US-09-103-840A-1	Sequence 1, Appl
	34	14.8	74.0	645	4	US-08-998-616-114	Sequence 114, App
	35	14.8	74.0	4060	1	US-08-164-292B-1	Sequence 1, Appl
	36	14.8	74.0	4060	1	US-08-164-292B-3	Sequence 3, Appl
	37	14.8	74.0	4060	1	US-08-164-292B-5	Sequence 5, Appl
	38	14.8	74.0	4060	1	US-08-164-292B-7	Sequence 7, Appl
	39	14.8	74.0	4060	3	US-08-845-623-1	Sequence 1, Appl
	40	14.8	74.0	4060	3	US-08-845-623-3	Sequence 3, Appl
	41	14.8	74.0	4060	3	US-08-845-623-5	Sequence 5, Appl
	42	14.8	74.0	4060	3	US-08-845-623-7	Sequence 7, Appl
	43	14.8	74.0	4060	3	US-08-815-927-1	Sequence 1, Appl
	44	14.8	74.0	4060	3	US-08-815-927-3	Sequence 3, Appl
	45	14.8	74.0	4060	3	US-08-815-927-5	Sequence 5, Appl

ALIGNMENTS

RESULT 1
US-08-327-832-12
Sequence 12, Application US/08327832
Patent No. 5840832
GENERAL INFORMATION:
APPLICANT: Onco, Santa J.
APPLICANT: Strominger, Jack L.
TITLE OF INVENTION: Transcription Factor Regulating MHC
TITLE OF INVENTION: Expression, cDNA and Genomic Clones Encoding Same and
TITLE OF INVENTION: Retroviral Expression Constructs Thereof
NUMBER OF SEQUENCES: 16
CORRESPONDENCE ADDRESS:
ADDRESSEE: Banner, Birch, McKie & Beckett
STREET: 1001 G Street, N.W.
CITY: Washington, D.C.
STATE: District of Columbia
COUNTRY: U.S.A.
ZIP: 20001
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/327,832
FILING DATE:
CLASSIFICATION: 530
ATTORNEY/AGENT INFORMATION:
NAME: Posorske, Laurence H.
REGISTRATION NUMBER: 34,698
TELEPHONE: 20-2 508-9153
TELECOMMUNICATION INFORMATION:
TELEPHONE: 20-2 508-9299
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 22 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: cDNA
ORGANISM: homo sapiens
US-08-327-832-12
Query Match 100.0%; Score 20; DB 2; Length 22;
Best Local Similarity 100.0%; Pred. No. 3.3;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 TCGATCGGGCGGCGAGC 20

Db 3 TCGATCGGGGGCGGCGAGC 22
|||||
RESULT 2
US-08-828-584-12
Sequence 12, Application US/08828584
Patent No. 5908762
GENERAL INFORMATION:
APPLICANT: Ono, Santa J.
TITLE OF INVENTION: Transcription Factor Regulating MHC
TITLE OF INVENTION: Expression, cDNA and Genomic Clones Encoding Same and
NUMBER OF INVENTION: Retroviral Expression Constructs Thereof
NUMBER OF SEQUENCES: 16
CORRESPONDENCE ADDRESS:
ADDRESSEE: Banner, Birch, McKie & Beckett
STREET: 1001 G Street, N.W.
CITY: Washington, D.C.
STATE: District of Columbia
COUNTRY: U.S.A.
ZIP: 20001
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/828,584
FILING DATE:
CLASSIFICATION: A35
ATTORNEY/AGENT INFORMATION:
NAME: Posorske, Laurence H.
REGISTRATION NUMBER: 34,698
REFERENCE/DOCKET NUMBER: 1107.46362
TELECOMMUNICATION INFORMATION:
TELEPHONE: 202-508-9153
TELEFAX: 202-508-9299
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 22 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: cDNA
ORIGINAL SOURCE:
ORGANISM: homo sapiens
US-08-828-584-12
Query Match 100.0%; Score 20; DB 2; Length 22;
Best Local Similarity 100.0%; Pred. No. 3.3;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Oy 1 TCGATCGGGGGCGGCGAGC 20
|||||
Db 3 TCGATCGGGGGCGGCGAGC 22
RESULT 3
PCT-US94-05659-16
Sequence 16, Application PC/TUS9405659
GENERAL INFORMATION:
APPLICANT:
TITLE OF INVENTION: TNF-RESPONSIVE ELEMENT, TNF-INDUCED DNA-BINDING
NUMBER OF SEQUENCES: 24
CORRESPONDENCE ADDRESS:
ADDRESSEE: Hamilton, Brook, Smith & Reynolds, P.C.
STREET: Two Millita Drive
CITY: Lexington
STATE: Massachusetts
COUNTRY: U.S.A.
ZIP: 02173
COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US94/05659
FILING DATE:
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Granahan, Patricia
REGISTRATION NUMBER: 32,227
REFERENCE/DOCKET NUMBER: FDC93-01 FF
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617-861-6240
TELEFAX: 617-861-9540
INFORMATION FOR SEQ ID NO: 16:
SEQUENCE CHARACTERISTICS:
LENGTH: 22 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
PCT-US94-05659-16
Query Match 100.0%; Score 20; DB 5; Length 22;
Best Local Similarity 100.0%; Pred. No. 3.3;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Oy 1 TCGATCGGGGGCGGCGAGC 20
|||||
Db 3 TCGATCGGGGGCGGCGAGC 22
RESULT 4
US-08-122-433-12
Sequence 12, Application US/08122433
Patent No. 5683965
GENERAL INFORMATION:
APPLICANT: Chu, Barbara C.F.
TITLE OF INVENTION: OLIGOPEPTIDES AND
TITLE OF INVENTION: OLIGOPEPTIDES USEFUL AS DECOYS FOR PROTEINS WHICH
TITLE OF INVENTION: SELECTIVELY BIND TO DEFINED DNA SEQUENCES
NUMBER OF SEQUENCES: 47
CORRESPONDENCE ADDRESS:
ADDRESSEE: PRETTY, SCHROEDER, BRUEGGEMANN & CLARK
STREET: 444 South Flower Street, Suite 2000
CITY: Los Angeles
STATE: California
COUNTRY: USA
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/122,433
FILING DATE: 22-SEP-1993
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/687,337
FILING DATE: 18-APR-1991
ATTORNEY/AGENT INFORMATION:
NAME: Reiter, Stephen E.
REGISTRATION NUMBER: 31,192
REFERENCE/DOCKET NUMBER: P31 9308
TELECOMMUNICATION INFORMATION:
TELEPHONE: 619-546-1995
TELEFAX: 619-546-9392
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 46 base pairs

TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
US-08-122-433-12

Query Match 95.0%; Score 19; DB 1; Length 46;
Best Local Similarity 100.0%; Pred. No. 7.8;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TCGATCGGGCGGGCGAG 19
DB 28 TCGATCGGGCGGGCGAG 46

RESULT 5
US-08-122-433-13

Sequence 13, Application US/08122433
Patent No. 5683985

GENERAL INFORMATION:

APPLICANT: Chu, Barbara C.F.

TITLE OF INVENTION: OLIGODEOXYNUCLEOTIDES AND

TITLE OF INVENTION: OLIGONUCLEOTIDES USEFUL AS DECOYS FOR PROTEINS WHICH

NUMBER OF SEQUENCES: 47

CORRESPONDENCE ADDRESS:

ADDRESSEE: PRETTY, SCHROEDER, BRUEGGEMANN & CLARK

STREET: 444 South Flower Street, Suite 2000

CITY: Los Angeles

STATE: California

COUNTRY: USA

ZIP: 90071

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patentin Release #1.0, Version #1.30

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/122,433

FILING DATE: 22-SEP-1993

CLASSIFICATION: 514

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/687,337

FILING DATE: 18-APR-1991

ATTORNEY/AGENT INFORMATION:

NAME: Reiter, Stephen E.

REGISTRATION NUMBER: 31,192

REFERENCE/DOCKET NUMBER: P31 9308

TELECOMMUNICATION INFORMATION:

TELEPHONE: 619-546-1995

TELEFAX: 619-546-9392

INFORMATION FOR SEQ ID NO: 13:

SEQUENCE CHARACTERISTICS:

LENGTH: 46 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: circular

MOLECULE TYPE: other nucleic acid

US-08-122-433-13

Query Match 95.0%; Score 19; DB 1; Length 46;
Best Local Similarity 100.0%; Pred. No. 7.8;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TCGATCGGGCGGGCGAG 19
DB 28 TCGATCGGGCGGGCGAG 46

RESULT 6

US-08-122-433-12/c
Sequence 12, Application US/08122433

Patent No. 5683985

GENERAL INFORMATION:

APPLICANT: Chu, Barbara C.F.

APPLICANT: Orgel, Leslie

TITLE OF INVENTION: OLIGODEOXYNUCLEOTIDES AND

TITLE OF INVENTION: OLIGONUCLEOTIDES USEFUL AS DECOYS FOR PROTEINS WHICH

NUMBER OF SEQUENCES: 47

CORRESPONDENCE ADDRESS:

ADDRESSEE: PRETTY, SCHROEDER, BRUEGGEMANN & CLARK

STREET: 444 South Flower Street, Suite 2000

CITY: Los Angeles

STATE: California

COUNTRY: USA

ZIP: 90071

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patentin Release #1.0, Version #1.30

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/122,433

FILING DATE: 22-SEP-1993

CLASSIFICATION: 514

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/687,337

FILING DATE: 18-APR-1991

ATTORNEY/AGENT INFORMATION:

NAME: Reiter, Stephen E.

REGISTRATION NUMBER: 31,192

REFERENCE/DOCKET NUMBER: P31 9308

TELECOMMUNICATION INFORMATION:

TELEPHONE: 619-546-1995

TELEFAX: 619-546-9392

INFORMATION FOR SEQ ID NO: 12:

SEQUENCE CHARACTERISTICS:

LENGTH: 46 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: other nucleic acid

US-08-122-433-12

Query Match 90.0%; Score 18; DB 1; Length 46;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 GATCGGGCGGGCGAGC 20
DB 24 GATCGGGCGGGCGAGC 7

RESULT 7

US-08-122-433-13/c
Sequence 13, Application US/08122433

Patent No. 5683985

GENERAL INFORMATION:

APPLICANT: Chu, Barbara C.F.

TITLE OF INVENTION: OLIGODEOXYNUCLEOTIDES AND

TITLE OF INVENTION: OLIGONUCLEOTIDES USEFUL AS DECOYS FOR PROTEINS WHICH

NUMBER OF SEQUENCES: 47

CORRESPONDENCE ADDRESS:

ADDRESSEE: PRETTY, SCHROEDER, BRUEGGEMANN & CLARK

STREET: 444 South Flower Street, Suite 2000

CITY: Los Angeles

STATE: California

COUNTRY: USA

ZIP: 90071

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/122.433
FILING DATE: 22-SEP-1993
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/687,337
FILING DATE: 18-APR-1991
ATTORNEY/AGENT INFORMATION:
NAME: Reiter, Stephen E.
REGISTRATION NUMBER: 31,192
REFERENCE/DOCKET NUMBER: P31 9308
TELEPHONE: 619-546-1995
TELEFAX: 619-546-9392
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 46 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: circular
MOLECULE TYPE: other nucleic acid
US-08-122-433-13

Query Match 90.0%; Score 18; DB 1; Length 46;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 GATCGGGGGGGCGAGC 20
DB 24 GATCGGGGGGGCGAGC 7

RESULT 8
US-08-458-434A-4/c
Sequence 4, Application US/08458434A
Patent No. 6083690
GENERAL INFORMATION:
APPLICANT: Harris Ph.D., Stephen E.
APPLICANT: Mundy M.D., Gregory R.
APPLICANT: Gosh-Choudhury Ph.D., Nandini
APPLICANT: Feng Ph.D., Jian Q.
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR IDENTIFYING
NUMBER OF SEQUENCES: 13
CORRESPONDENCE ADDRESS:
ADDRESSEE: James C. Weseman, Esq.
STREET: 401 B. Street, Suite 1700
CITY: San Diego
STATE: CA
COUNTRY: USA
ZIP: 92101
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/458.434A
FILING DATE:
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Weseman, James C.
REGISTRATION NUMBER: 30,507
REFERENCE/DOCKET NUMBER: P00060US0
TELEPHONE: (619) 699-3604
TELEFAX: 619-236-1048
INFORMATION FOR SEQ ID NO: 4:
SEQUENCE CHARACTERISTICS:
LENGTH: 2875 base pairs
TYPE: nucleic acid

STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-458-434A-4

Query Match 84.0%; Score 16.8; DB 3; Length 2875;
Best Local Similarity 90.0%; Pred. No. 41;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 TCGATCGGGGGCGGCGAGC 20
DB 1805 TCGAGCGGGGGCGGCGAGC 1786

RESULT 9
US-08-458-434A-6/c
Sequence 6, Application US/08458434A
Patent No. 6083690
GENERAL INFORMATION:
APPLICANT: Harris Ph.D., Stephen E.
APPLICANT: Mundy M.D., Gregory R.
APPLICANT: Gosh-Choudhury Ph.D., Nandini
APPLICANT: Feng Ph.D., Jian Q.
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR IDENTIFYING
NUMBER OF SEQUENCES: 13
CORRESPONDENCE ADDRESS:
ADDRESSEE: James C. Weseman, Esq.
STREET: 401 B. Street, Suite 1700
CITY: San Diego
STATE: CA
COUNTRY: USA
ZIP: 92101
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/458.434A
FILING DATE:
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Weseman, James C.
REGISTRATION NUMBER: 30,507
REFERENCE/DOCKET NUMBER: P00060US0
TELEPHONE: (619) 699-3604
TELEFAX: 619-236-1048
INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:
LENGTH: 15144 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-458-434A-6

Query Match 84.0%; Score 16.8; DB 3; Length 15144;
Best Local Similarity 90.0%; Pred. No. 35;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 TCGATCGGGGGCGGCGAGC 20
DB 1805 TCGAGCGGGGGCGGCGAGC 1786

RESULT 10
US-08-145-617-5/c
Sequence 5, Application US/08145617
Patent No. 5766847
GENERAL INFORMATION:
APPLICANT: Jackie, Herbert

APPLICANT: Tautz, Diethard
TITLE OF INVENTION: PROCESS FOR ANALYZING LENGTH
POLYMORPHISMS IN DNA REGIONS
NUMBER OF SEQUENCES: 6
CORRESPONDENCE ADDRESS:
ADDRESSER: BIRCH, STEWART, KOLASCH & BIRCH
STREET: 301 N. Washington Street, P.O. Box 747
CITY: Falls Church
STATE: Virginia
COUNTRY: United States of America
ZIP: 22046
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/145,617
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/681,494
FILING DATE: 10-JUN-1991
APPLICATION NUMBER: DE P3834636.2
FILING DATE: 11-OCT-1988
ATTORNEY/AGENT INFORMATION:
NAME: Svensson, Leonard R.
REGISTRATION NUMBER: 30,330
REFERENCE/DOCKET NUMBER: 147-122PCT
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-241-1300
TELEFAX: 703-241-2848
TELEX: 248345
INFORMATION FOR SEQ ID NO: 5:
SEQUENCE CHARACTERISTICS:
LENGTH: 379 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-145-617-5

Query Match 82.0%; Score 16.4; DB 1; Length 379;
Best Local Similarity 94.4%; Pred. No. 73;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 3 GATGGGGGGGGGAGC 20
DB 64 GATTGGGGGGGGGAGC 47

RESULT 11
US-08-153-563-4/c
Sequence 4, Application US/08153563
Patent No. 5693506
GENERAL INFORMATION:
APPLICANT: Rodriguez, Raymond L.
TITLE OF INVENTION: PROCESS FOR PROTEIN PRODUCTION
NUMBER OF SEQUENCES: 7
CORRESPONDENCE ADDRESS:
ADDRESSER: Townsend and Townsend Kourie and Crew
STREET: Stewart Street Tower, One Market Plaza
CITY: San Francisco
STATE: California
COUNTRY: US
ZIP: 94105-1493
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/153,563
FILING DATE: 16-NOV-1993
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Weber, Kenneth A.
REGISTRATION NUMBER: 31,677
REFERENCE/DOCKET NUMBER: 2307E-515
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 543-9600
TELEFAX: (415) 543-5043
INFORMATION FOR SEQ ID NO: 4:
SEQUENCE CHARACTERISTICS:
LENGTH: 31 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
FEATURE:
NAME/KEY: misc_feature
LOCATION: 1..31
OTHER INFORMATION: /standard_name="31 bp Ramy3E"

US-08-153-563-4

Query Match 79.0%; Score 15.8; DB 1; Length 31;
Best Local Similarity 89.5%; Pred. No. 1.6e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2 CGATCGGGGGGGGAGC 20
DB 23 CGATCGAGCGCGCGAGC 5

RESULT 12
US-09-038-227-9/c
Sequence 9, Application US/09038227
Patent No. 5917029
GENERAL INFORMATION:
APPLICANT: Yu, Su-May
TITLE OF INVENTION: SUGAR-RESPONSIVE ENHANCERS
NUMBER OF SEQUENCES: 53
CORRESPONDENCE ADDRESS:
ADDRESSER: Fish & Richardson P.C.
STREET: 225 Franklin Street
CITY: Boston
STATE: MA
COUNTRY: US
ZIP: 02110-2804
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: Windows95
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/038,227
FILING DATE: 11-MAR-1998
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Tsao, Y. Rocky
REGISTRATION NUMBER: 34,053
REFERENCE/DOCKET NUMBER: 05228/031001
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617/542-5070
TELEFAX: 617/542-8906
TELEX: 200154
INFORMATION FOR SEQ ID NO: 9:
SEQUENCE CHARACTERISTICS:
LENGTH: 31 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear

MOLECULE TYPE: Genomic DNA
US-09-038-227-9
Query Match 79.0%; Score 15.8; DB 2; Length 31;
Best Local Similarity 89.5%; Pred. No. 1.6e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2 CGATCGGGCGGGCGGAGC 20
DB 23 CGATCGAGCGCGCGGAGC 5
RESULT 13
US-08-460-507-4/c
Sequence 4, Application US/08460507
Patent No. 5994628
GENERAL INFORMATION:
APPLICANT:
TITLE OF INVENTION: PROCESS FOR PROTEIN PRODUCTION
TITLE OF INVENTION: IN PLANTS
NUMBER OF SEQUENCES: 7
CORRESPONDENCE ADDRESS:
ADDRESSEE: Denlinger & Associates
STREET: 350 Cambridge Avenue, Suite 250
CITY: Palo Alto
STATE: CA
COUNTRY: USA
ZIP: 94306
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/460,507
FILING DATE:
CLASSIFICATION: 800
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/153,563
FILING DATE: 16-NOV-1993
ATTORNEY/AGENT INFORMATION:
NAME: Fabian, Gary R.
REGISTRATION NUMBER: 33,875
REFERENCE/DOCKET NUMBER: 2000-0452.41
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 324-0880
TELEFAX: (415) 324-0960
INFORMATION FOR SEQ ID NO: 4:
SEQUENCE CHARACTERISTICS:
LENGTH: 31 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
FEATURE:
NAME/KEY: misc_feature
LOCATION: 1..31
OTHER INFORMATION: /standard_name="31 bp Ramy3E"
US-08-460-507-4
Query Match 79.0%; Score 15.8; DB 2; Length 31;
Best Local Similarity 89.5%; Pred. No. 1.6e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2 CGATCGGGCGGGCGGAGC 20
DB 23 CGATCGAGCGCGCGGAGC 5
RESULT 14
US-08-786-606-4
Sequence 4, Application US/08786606
Patent No. 5861495

GENERAL INFORMATION:
APPLICANT: Hallman, Jennifer L.
APPLICANT: Au-Yang, Janice
APPLICANT: Coleman, Roger
APPLICANT: Golt, Surya K.
TITLE OF INVENTION: NOVEL HUMAN ZINC-BINDING
TITLE OF INVENTION: PROTEINS
NUMBER OF SEQUENCES: 9
CORRESPONDENCE ADDRESS:
ADDRESSEE: Incyte Pharmaceuticals, Inc.
STREET: 3174 Porter Drive
CITY: Palo Alto
STATE: CA
COUNTRY: USA
ZIP: 94304
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FASTSEQ for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/786,606
FILING DATE:
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Billings, Lucy RJ
REGISTRATION NUMBER: 36,749
REFERENCE/DOCKET NUMBER: PF-0173 US
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415-855-0555
TELEFAX: 415-845-4166
TELEX:
INFORMATION FOR SEQ ID NO: 4:
SEQUENCE CHARACTERISTICS:
LENGTH: 944 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-786-606-4
Query Match 79.0%; Score 15.8; DB 2; Length 944;
Best Local Similarity 89.5%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2 CGATCGGGCGGGCGGAGC 20
DB 145 CGAGCGGGCGGGCGGAGC 163
RESULT 15
US-08-933-750C-97
Sequence 97, Application US/08933750C
Patent No. 5932442
GENERAL INFORMATION:
APPLICANT: Lal, Preeti
APPLICANT: Hillman, Jennifer L.
APPLICANT: Bandman, Olga
APPLICANT: Shah, Purni
APPLICANT: Au-Young, Janice
APPLICANT: Yue, Henry
APPLICANT: Guegler, Karl J.
APPLICANT: Corley, Neil C.
TITLE OF INVENTION: HUMAN REGULATORY MOLECULES
NUMBER OF SEQUENCES: 98
CORRESPONDENCE ADDRESS:
ADDRESSEE: Incyte Pharmaceuticals, Inc.
STREET: 3174 Porter Drive
CITY: Palo Alto
STATE: CA
COUNTRY: USA

```

: ZIP: 94304
:
: COMPUTER READABLE FORM:
: MEDIUM TYPE: Diskette
: COMPUTER: IBM Compatible
: OPERATING SYSTEM: DOS
: SOFTWARE: FASTSEQ for Windows Version 2.0
:
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/08/933,750C
: FILING DATE: September 23, 1997
: CLASSIFICATION: 536
: PRIOR APPLICATION DATA:
: APPLICATION NUMBER:
: FILING DATE:
: ATTORNEY/AGENT INFORMATION:
: NAME: Billings, Lucy J.
: REGISTRATION NUMBER: 36,749
: REFERENCE/DOCKET NUMBER: PF-0356 US
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: 415-855-0555
: TELEFAX: 415-845-4166
:
: TELEX:
: INFORMATION FOR SEQ ID NO: 97:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 1112 base pairs
: TYPE: nucleic acid
: STRANDEDNESS: single
: TOPOLOGY: linear
: IMMEDIATE SOURCE:
: LIBRARY: TESTNOT07
: CLONE: 3217567
:
: US-08-933-750C-97

```

```

Query Match          79.0%; Score 15.8; DB 2; Length 1112;
Best Local Similarity 89.5%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY      2 CGATCGGGCGGGCGGCGAGC 20
       11111111111111111111
Db      147 CGAGCGGGCGGGCGGCGGCG 165

```

Search completed: June 26, 2003, 16:20:51
 Job time : 35.2868 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Comugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 26, 2003, 10:58:25 ; Search time 30.2174 Seconds
(without alignments)
202.980 Million cell updates/sec

Title: US-09-355-254F-11

Perfect score: 20

Sequence: 1 gcttgatgactcagccgaa 20

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 441362 seqs, 15338381 residues

Total number of hits satisfying chosen parameters: 882724

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Issued_Patents_MN:*

1: /cgn2_6/ptodata/1/1na/5A_COMB.seq:*

2: /cgn2_6/ptodata/1/1na/5B_COMB.seq:*

3: /cgn2_6/ptodata/1/1na/6A_COMB.seq:*

4: /cgn2_6/ptodata/1/1na/6B_COMB.seq:*

5: /cgn2_6/ptodata/1/1na/PCTUS_COMB.seq:*

6: /cgn2_6/ptodata/1/1na/backfiles1.seq:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	20	100.0	21	2	US-08-507-598-2
2	20	100.0	21	2	US-08-507-750-2
3	20	100.0	21	3	US-08-764-522A-2
4	20	100.0	21	3	US-08-764-528-2
5	20	100.0	21	3	US-08-872-859-2
6	18.4	92.0	21	1	US-08-283-591-15
7	18.4	92.0	21	1	US-08-210-8808-3
8	18.4	92.0	21	2	US-08-632-275-1
9	18.4	92.0	21	2	US-08-771-411-3
10	18.4	92.0	21	3	US-09-097-929-1
11	18.4	92.0	21	4	US-09-021-247-8
12	18.4	92.0	21	4	US-08-088-661F-8
13	18.4	92.0	21	4	US-08-088-661F-42
14	15.2	76.0	14	3	US-09-191-099-7
15	15.2	76.0	14	3	US-09-191-099-8
16	15.2	76.0	14	3	US-08-665-259-24
17	15.2	76.0	14	3	US-08-762-500-24
18	15.2	76.0	14	3	US-08-762-500-74
19	14.8	74.0	80161	4	US-09-036-987A-1
20	14.8	74.0	80161	4	US-09-370-700-1
21	14.4	72.0	903	4	US-09-457-046B-5
22	14.4	72.0	1338	4	US-08-800-682-1
23	14.4	72.0	22306	4	US-09-457-046B-51
24	14.4	72.0	46819	4	US-09-453-702B-251
25	14.2	71.0	400	4	US-09-453-702B-72
26	14.2	71.0	534	2	US-08-301-718-1
27	14.2	71.0	534	2	US-08-770-544-19

28	14.2	71.0	590	2	US-08-600-999-1	Sequence 1, Appl1
29	14.2	71.0	1251	4	US-09-355-115-1	Sequence 1, Appl1
30	14.2	71.0	1462	3	US-08-961-083-41	Sequence 41, Appl1
31	14.2	71.0	2384	1	US-07-688-352C-27	Sequence 27, Appl1
32	14.2	71.0	2384	2	US-08-474-379C-27	Sequence 27, Appl1
33	14.2	71.0	2384	3	US-09-146-249A-27	Sequence 27, Appl1
34	14.2	71.0	2384	3	US-08-206-188B-27	Sequence 27, Appl1
35	14.2	71.0	2384	5	PCT-US91-02714-25	Sequence 25, Appl1
36	14.2	71.0	15239	1	US-08-390-878-17	Sequence 17, Appl1
37	14.2	71.0	19702	4	US-08-961-527-7	Sequence 7, Appl1
38	14.2	71.0	4403765	4	US-09-103-840A-2	Sequence 2, Appl1
39	14.2	71.0	4403765	4	US-09-103-840A-2	Sequence 2, Appl1
40	14.2	71.0	4411529	4	US-09-103-840A-1	Sequence 1, Appl1
41	14.2	71.0	4411529	4	US-09-103-840A-1	Sequence 1, Appl1
42	13.8	69.0	21	1	US-08-203-198-1	Sequence 1, Appl1
43	13.8	69.0	945	4	US-09-149-476-168	Sequence 168, App
44	13.8	69.0	12720	1	US-08-403-866-11	Sequence 11, Appl1
45	13.6	68.0	26	1	US-07-791-213D-68	Sequence 68, Appl1

ALIGNMENTS

RESULT 1
US-08-507-598-2
Sequence 2, Application US/08507598
Patent No. 5834188
GENERAL INFORMATION:
APPLICANT: HARADA, SHUN-ICHI
APPLICANT: SAMPATH, T. K.
APPLICANT: RODAN, GIDEON A.
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR IDENTIFYING
NUMBER OF SEQUENCES: 4
CORRESPONDENCE ADDRESS:
ADDRESSEE: PATENT ADMINISTRATOR, TESTA, HURWITZ &
ADDRESS: TRIBAULT
STREET: 53 STATE STREET
CITY: BOSTON
STATE: MA
COUNTRY: USA
ZIP: 02109
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/507,598
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: PITCHER, EDMOND R.
REGISTRATION NUMBER: 27,829
REFERENCE/DOCKET NUMBER: CRP-107
TELECOMMUNICATION INFORMATION:
TELEPHONE: (617)-248-7000
TELEFAX: (617)-248-7100
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
FEATURE:
NAME/KEY: misc.feature
LOCATION: 1..21
OTHER INFORMATION: /product= "API SEQUENCE"
US-08-507-598-2
Query Match 100.0%; Score 20; DB 2; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.058;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCTGATGACTAGCCGGAA 20
|||||
DB 2 GCTGATGACTAGCCGGAA 21

RESULT 2

US-08-507-750-2
; Sequence 2, Application US/08507750
; Patent No. 5932716
; GENERAL INFORMATION:
; APPLICANT: SAMPATH, T. K.
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR IDENTIFYING
; TITLE OF INVENTION: MORPHOGEN ANALOGS
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: PATENT ADMINISTRATOR, TESTA, HURWITZ &
; ADDRESS: TRIBEAULT
; STREET: 53 STATE STREET
; CITY: BOSTON
; STATE: MA
; COUNTRY: USA
; ZIP: 02109

COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/507,750
; FILING DATE:
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: PITCHER, EDMUND R.
; REGISTRATION NUMBER: 27,829
; REFERENCE/DOCKET NUMBER: CRP-116
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617)-248-7000
; TELEFAX: (617)-248-7100
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: misc.feature
; LOCATION: 1..21
; OTHER INFORMATION: /product="API SEQUENCE"

US-08-507-750-2

Query Match 100.0%; Score 20; DB 2; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.058;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCTGATGACTAGCCGGAA 20
|||||
DB 2 GCTGATGACTAGCCGGAA 21

RESULT 3

US-08-764-522A-2
; Sequence 2, Application US/08764522A
; Patent No. 6090544
; GENERAL INFORMATION:
; APPLICANT: HARADA, SHUN-ICHI
; APPLICANT: SAMPATH, T. K.
; APPLICANT: RODAN, GIDEON A.
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR IDENTIFYING
; TITLE OF INVENTION: MORPHOGEN ANALOGS
; NUMBER OF SEQUENCES: 10

; CORRESPONDENCE ADDRESS:
; ADDRESSEE: PATENT ADMINISTRATOR, CREATIVE BIOMOLECULES
; STREET: 45 SOUTH STREET
; CITY: HOPKINTON
; STATE: MA
; COUNTRY: USA
; ZIP: 01748

COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/764,522A
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: VITO, CHRISTINE C.
; REGISTRATION NUMBER: 39,061
; REFERENCE/DOCKET NUMBER: CRP-126
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617)-248-7000
; TELEFAX: (617)-248-7100
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: misc.feature
; LOCATION: 1..21
; OTHER INFORMATION: /product="API SEQUENCE A"

US-08-764-522A-2

Query Match 100.0%; Score 20; DB 3; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.058;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCTGATGACTAGCCGGAA 20
|||||
DB 2 GCTGATGACTAGCCGGAA 21

RESULT 4

US-08-764-528-2
; Sequence 2, Application US/08764528
; Patent No. 6103451
; GENERAL INFORMATION:
; APPLICANT: SAMPATH, K. T.
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR IDENTIFYING
; TITLE OF INVENTION: MORPHOGEN ANALOGS
; NUMBER OF SEQUENCES: 8
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: PATENT ADMINISTRATOR, CREATIVE BIOMOLECULES
; STREET: 45 SOUTH STREET
; CITY: HOPKINTON
; STATE: MA
; COUNTRY: USA
; ZIP: 01748
COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/764,528
; FILING DATE:
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: VITO, CHRISTINE C.
; REGISTRATION NUMBER: 39,061

REFERENCE/DOCKET NUMBER: CRP-127
TELECOMMUNICATION INFORMATION:
TELEPHONE: (617)-248-7000
TELEFAX: (617)-248-7100
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
FEATURE:
NAME/KEY: misc_feature
LOCATION: 1..21
OTHER INFORMATION: /product= "API SEQUENCE A"
US-08-764-528-2

Query Match 100.0%; Score 20; DB 3; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.058;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GCTTGATGACTCAGCCGGAA 20
Db 2 GCTTGATGACTCAGCCGGAA 21

RESULT 5
US-08-872-859-2
Sequence 2, Application US/08872859
Patent No. 6110460
GENERAL INFORMATION:
APPLICANT: SAMPATH, T. K.
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR IDENTIFYING
TITLE OF INVENTION: MORPHOGEN ANALOGS
NUMBER OF SEQUENCES: 4
CORRESPONDENCE ADDRESS:
ADDRESSEE: PATENT ADMINISTRATOR, TESTA, HOFMUTZ &
ADDRESSEE: THIBEAULT
STREET: 53 STATE STREET
CITY: BOSTON
STATE: MA
COUNTRY: USA
ZIP: 02109
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/872,859
FILING DATE: 11-JUN-1997
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/507,750
FILING DATE: 26-JUL-1995
ATTORNEY/AGENT INFORMATION:
NAME: PITCHER, EDMUND R.
REGISTRATION NUMBER: 27,829
REFERENCE/DOCKET NUMBER: CRP-116
TELECOMMUNICATION INFORMATION:
TELEPHONE: (617)-248-7000
TELEFAX: (617)-248-7100
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
FEATURE:
NAME/KEY: misc_feature
LOCATION: 1..21
OTHER INFORMATION: /product= "API SEQUENCE"

US-08-872-859-2

Query Match 100.0%; Score 20; DB 3; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.058;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GCTTGATGACTCAGCCGGAA 20
Db 2 GCTTGATGACTCAGCCGGAA 21

RESULT 6
US-08-283-591-15
Sequence 15, Application US/08283591
Patent No. 5629152
GENERAL INFORMATION:
APPLICANT: Ravikumar, Vasullaga
TITLE OF INVENTION: NOVEL TRISUBSTITUTED -LACTAMS AND
TITLE OF INVENTION: OLIGO -LACTAMAMIDES
NUMBER OF SEQUENCES: 28
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz and
ADDRESSEE: No. 5629152r1s
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: U.S.A.
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/283,591
FILING DATE: N/A
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME:
REGISTRATION NUMBER:
REFERENCE/DOCKET NUMBER:
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3439
INFORMATION FOR SEQ ID NO: 15:
SEQUENCE CHARACTERISTICS:
LENGTH: 21
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: unknown
US-08-283-591-15

Query Match 92.0%; Score 18.4; DB 1; Length 21;
Best Local Similarity 95.0%; Pred. No. 0.42;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1 GCTTGATGACTCAGCCGGAA 20
Db 2 GCTTGATGACTCAGCCGGAA 21

RESULT 7
US-08-210-880B-3
Sequence 3, Application US/08210880B
Patent No. 5641486
GENERAL INFORMATION:
APPLICANT: HINRICHS, STEVEN H.
APPLICANT: ORTEN, DANA J.
TITLE OF INVENTION: METHOD AND COMPOSITION FOR INHIBITING
TITLE OF INVENTION: CREB/ATF1 FAMILY DETERMINED TRANSCRIPTION

NUMBER OF SEQUENCES: 11
CORRESPONDENCE ADDRESS:
ADDRESSEE: HENDERSON & STURM
STREET: 1125 S. 103RD ST., #330
CITY: OMAHA
STATE: NE
COUNTRY: US
ZIP: 68124
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/210,880B
FILING DATE: 18-MAR-1994
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: JONDL, ROBERT J.
REGISTRATION NUMBER: 33,915
REFERENCE/DOCKET NUMBER: 63066
TELECOMMUNICATION INFORMATION:
TELEPHONE: 402-398-9000
TELEFAX: 402-398-9005
INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: unknown
MOLECULE TYPE: DNA (genomic)
US-08-210-880B-3

Query Match
Best Local Similarity 92.0%; Score 18.4; DB 1; Length 21;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 GCTTGATGACTGACCGGAA 20
DB 2 GCTTGATGACTGACCGGAA 21

RESULT 8
US-08-632-275-1/c
Sequence 1, Application US/08632275
Patent No. 5840277
GENERAL INFORMATION:
APPLICANT: GILLO, Andrew J.
TITLE OF INVENTION: Treatment of Chronic Pulmonary
NUMBER OF SEQUENCES: 4
CORRESPONDENCE ADDRESS:
ADDRESSEE: Bell, Seltzer, Park & Gibson
STREET: 1211 East Morehead Street
CITY: Charlotte
STATE: No. 5840277th Carolina
COUNTRY: USA
ZIP: 28234
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/632,275
FILING DATE: 15-APR-1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/413,699
FILING DATE: 30-MAR-1995
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:

NAME: Lipscomb, Ernest B.
REGISTRATION NUMBER: 24,733
REFERENCE/DOCKET NUMBER: 8751-5-1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 704-334-6000
TELEFAX: 704-334-2014
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
FRAGMENT TYPE: linear
US-08-632-275-1

Query Match
Best Local Similarity 92.0%; Score 18.4; DB 2; Length 21;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 GCTTGATGACTGACCGGAA 20
DB 2 GCTTGATGACTGACCGGAA 1

RESULT 9
US-08-771-411-3
Sequence 3, Application US/08771411
Patent No. 5844096
GENERAL INFORMATION:
APPLICANT: HIRNICH, STEVEN H.
TITLE OF INVENTION: METHOD AND COMPOSITION FOR INHIBITING
NUMBER OF SEQUENCES: 11
CORRESPONDENCE ADDRESS:
ADDRESSEE: HENDERSON & STURM
STREET: 1125 S. 103RD ST., #330
CITY: OMAHA
STATE: NE
COUNTRY: US
ZIP: 68124
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/771,411
FILING DATE: 20-DEC-1996
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/210,880
FILING DATE: 18-MAR-1994
ATTORNEY/AGENT INFORMATION:
NAME: JONDL, ROBERT J.
REGISTRATION NUMBER: 33,915
REFERENCE/DOCKET NUMBER: 63066
TELECOMMUNICATION INFORMATION:
TELEPHONE: 402-398-9000
TELEFAX: 402-398-9005
INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: unknown
MOLECULE TYPE: DNA (genomic)
US-08-771-411-3

Query Match
Best Local Similarity 92.0%; Score 18.4; DB 2; Length 21;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1 GCTTGATGACTCAGCCGGAA 20
|||||
Db 2 GCTTGATGACTCAGCCGGAA 21

RESULT 10
US-09-097-929-1/c
Sequence 1, Application US/09097929
Patent No. 6024940
GENERAL INFORMATION:
APPLICANT: Ghio, Andrew J.
TITLE OF INVENTION: Treatment of Chronic Pulmonary
TITLE OF INVENTION: Inflammation
NUMBER OF SEQUENCES: 4
CORRESPONDENCE ADDRESS:
ADDRESSEE: Bell, Seltzer, Park & Gibson
STREET: 1211 East Morehead Street
CITY: Charlotte
STATE: No. 6024940th Carolina
COUNTRY: USA
ZIP: 28234
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/097,929
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/632,275
FILING DATE:
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Lipscomb, Ernest B.
REGISTRATION NUMBER: 24,733
REFERENCE/DOCKET NUMBER: 8751-5-1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 704-331-6000
TELEFAX: 704-334-2014
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
FRAGMENT TYPE: linear
US-09-097-929-1

Query Match 92.0%; Score 18.4; DB 3; Length 21;
Best Local Similarity 95.0%; Pred. No. 0.42;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1 GCTTGATGACTCAGCCGGAA 20
|||||
Db 20 GCTTGATGACTCAGCCGGAA 1

RESULT 11
US-09-021-247-8
Sequence 8, Application US/09021247
Patent No. 6225444
GENERAL INFORMATION:
APPLICANT: Shashoua, Victor E.
TITLE OF INVENTION: NEUROPROTECTIVE PEPTIDES AND USES THEREOF
NUMBER OF SEQUENCES: 19
CORRESPONDENCE ADDRESS:
ADDRESSEE: Wolf, Greenfield & Sacks, P.C.
STREET: 600 Atlantic Avenue
CITY: Boston
STATE: MA

COUNTRY: USA
ZIP: 02210
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/021,247
FILING DATE:
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Van Amsterdam, John R.
REGISTRATION NUMBER: 40,212
REFERENCE/DOCKET NUMBER: N0260/7023
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617-720-3500
TELEFAX: 617-720-2441
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 nucleotides
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: oligonucleotide
HYPOTHETICAL: NO
US-09-021-247-8

Query Match 92.0%; Score 18.4; DB 4; Length 21;
Best Local Similarity 95.0%; Pred. No. 0.42;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1 GCTTGATGACTCAGCCGGAA 20
|||||
Db 2 GCTTGATGACTCAGCCGGAA 21

RESULT 12
US-08-088-661F-8
Sequence 8, Application US/08088661F
Patent No. 6228982
GENERAL INFORMATION:
APPLICANT: No. 6228982den, Bengel
APPLICANT: Wiltung, Pernilla
APPLICANT: Buchardt, Ole
APPLICANT: Egholm, Michael
APPLICANT: Nielsen, Peter E.
APPLICANT: Berg, Rolf
TITLE OF INVENTION: Double-Stranded Peptide Nucleic Acids
FILE REFERENCE: ISIS1108
CURRENT APPLICATION NUMBER: US/08/088,661F
CURRENT FILING DATE: 1993-07-02
PRIOR APPLICATION NUMBER: 08/054,363
PRIOR FILING DATE: 1993-04-26
PRIOR APPLICATION NUMBER: PCT/EP92/01219
PRIOR FILING DATE: 1992-05-19
NUMBER OF SEQ ID NOS: 42
SOFTWARE: Patentin Ver. 2.1
SEQ ID NO 8
LENGTH: 21
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: No. 6228982zel Sequence
US-08-088-661F-8

Query Match 92.0%; Score 18.4; DB 4; Length 21;
Best Local Similarity 95.0%; Pred. No. 0.42;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1 GCTTGATGACTCAGCCGGAA 20
|||||
Db 2 GCTTGATGACTCAGCCGGAA 21

```

LOCATION: (24)
OTHER INFORMATION: n = unknown
FEATURE:
NAME/KEY: modified_base
LOCATION: (26)
OTHER INFORMATION: n = unknown
FEATURE:
NAME/KEY: modified_base
LOCATION: (122)
OTHER INFORMATION: n = unknown
FEATURE:
NAME/KEY: modified_base
LOCATION: (173)..(174)
OTHER INFORMATION: n = unknown
FEATURE:
NAME/KEY: modified_base
LOCATION: (182)
OTHER INFORMATION: n = unknown
FEATURE:
NAME/KEY: modified_base
LOCATION: (606)
OTHER INFORMATION: n = unknown
FEATURE:
NAME/KEY: modified_base
LOCATION: (980)
OTHER INFORMATION: n = unknown
FEATURE:
NAME/KEY: modified_base
LOCATION: (1293)
OTHER INFORMATION: n = unknown
US-09-191-099-7

Query Match 76.0%: Score 15.2; DB 3; Length 1400;
Best Local Similarity 85.0%: Pred. No. 40;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0
QY 1 GCTTGATGACTCAGCCGGA 20
||||| ||||| |||||
DB 1097 GCTTGAGACTCTGCGGA 1116

RESULT 15
US-09-191-099-8
Sequence 8, Application US/09191099
Patent No. 6096323
GENERAL INFORMATION:
APPLICANT: Walker, Richard L.
APPLICANT: Read, Deryck H.
APPLICANT: Hird, David W.
APPLICANT: Lefebvre, Rance B.
APPLICANT: Berry, Steven L.
APPLICANT: Cullor, James S.
APPLICANT: Letlier, Hank M.
TITLE OF INVENTION: Vaccine Against Papillomatous Digital Dermatitis (PDD)
FILE REFERENCE: 023070-081110US
CURRENT FILING DATE: US/09/191,099
EARLIER APPLICATION NUMBER: US 08/943,571
EARLIER FILING DATE: 1997-10-03
NUMBER OF SEQ ID NOS: 20
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 8
LENGTH: 1446
TYPE: DNA
ORGANISM: Treponema sp.
US-09-191-099-8

Query Match 76.0%: Score 15.2; DB 3; Length 1446;
Best Local Similarity 85.0%: Pred. No. 41;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0
Y 1 GCTTGATGACTCAGCCGGA 20

```

Fri Jun 27 14:14:39 2003

us-09-355-254f-11.rni

Page 7

||||| ||||| |||||
Db 1112 GCTTGAGGACTCTGCGGAA 1131

Search completed: June 26, 2003, 16:20:46
Job time : 40.2888 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 26, 2003, 11:19:15 ; Search time 1529.13 seconds
(without alignments)
211.826 Million cell updates/sec

Title: US-09-355-254f-12

Perfect score: 20

Sequence: 1 tcgacggggcgggcgagc 20

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 1.0

Searched: 16154066 seqs, 8097743376 residues

Total number of hits satisfying chosen parameters: 32308132

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-Processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :

EST:*
1: em_estba:*
2: em_esthum:*
3: em_estin:*
4: em_estmu:*
5: em_estov:*
6: em_estpl:*
7: em_estro:*
8: em_hic:*
9: gb_est1:*
10: gb_est2:*
11: gb_hic:*
12: gb_est3:*
13: gb_est4:*
14: gb_est5:*
15: em_estfun:*
16: em_estom:*
17: gb_ggs:*
18: em_ggs_hum:*
19: em_ggs_inv:*
20: em_ggs_pin:*
21: em_ggs_vrt:*
22: em_ggs_fun:*
23: em_ggs_mam:*
24: em_ggs_mus:*
25: em_ggs_other:*
26: em_ggs_pro:*
27: em_ggs_rod:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	19	95.0	311	10	BE654158 UI-M-ANI-
2	19	95.0	429	9	AT005447 AT005447
3	17.4	87.0	375	10	AM122220 UI-M-BH2.
4	17.4	87.0	379	9	AI846527 UI-M-ANI-
5	17.4	87.0	406	9	AA615769 VO72608.F
6	17.4	87.0	423	13	BI220387 602935686

7	17.4	87.0	437	10	BB859799
8	17.4	87.0	448	9	AI194235
9	17.4	87.0	493	10	BE650594
10	17.4	87.0	530	12	BF015640
11	17.4	87.0	679	13	BI111370
12	17.4	87.0	709	14	BQ445767
13	17.4	87.0	735	14	BQ444735
14	17.4	87.0	741	14	BQ445216
15	17.4	87.0	764	14	BI146925
16	17.4	87.0	774	12	BI172820
17	17.4	87.0	776	14	BQ746273
18	17.4	87.0	791	13	BI100531
19	17.4	87.0	795	13	BG288481
20	17.4	87.0	795	13	BI332398
21	17.4	87.0	807	13	BG966084
22	17.4	87.0	827	13	BI648699
23	17.4	87.0	832	13	BI1444709
24	17.4	87.0	843	13	BI110250
25	17.4	87.0	864	12	BF134731
26	17.4	87.0	865	13	BI949499
27	17.4	87.0	883	13	BI328998
28	17.4	87.0	907	14	BO930419
29	17.4	87.0	918	12	BF134993
30	17.4	87.0	919	12	BG244020
31	17.4	87.0	919	12	BF383950
32	17.4	87.0	934	12	BI412920
33	17.4	87.0	938	13	BF384726
34	17.4	87.0	976	11	AK012729
35	17.4	87.0	994	12	BE540625
36	17.4	87.0	997	12	BE580130
37	17.4	87.0	1073	11	AK020514
38	17.4	87.0	1081	13	BI852239
39	17.4	87.0	1083	11	BC012031
40	17.4	87.0	1101	11	AK010792
41	17.4	87.0	1114	11	AK020515
42	17.4	87.0	1115	11	AK019289
43	17.4	87.0	1254	13	BI554612
44	17.4	85.0	508	10	BE232703
45	17.4	85.0	525	13	BI360501

ALIGNMENTS

RESULT 1
BE654158
LOCUS
DEFINITION
UI-M-ANI-aff-f-04-0-0-UI-r2 NIH-BMAP_MBG_N Mus musculus CDNA clone
ACCESSION
BE654158
VERSION
BE654158.1 GI:9980071
KEYWORDS
EST.
SOURCE
house mouse.
ORGANISM
Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE
1 (bases 1 to 311)
AUTHORS
Bonaldo, M.F., Lennon, G. and Soares, M.B.
TITLE
Normalization and subtraction: two approaches to facilitate gene
discovery
JOURNAL
genome Res. 6 (9), 791-806 (1996)
MEDLINE
97044477
COMMENT
Contact: Chn, H
National Institute of Mental Health
6001 Executive Blvd. Room 7N-7190, MSC 9643, Bethesda, MD
20892-9643, USA
Tel: 301 443 1706
Fax: 301 443 9890
Email: MEST@mail.nih.gov
CDNA Library Preparation: M.B. Soares lab Clone distribution:
Researchers may obtain BMAP CDNA clones from RESEARCH GENETICS. It
should be noted that Bento Soares is generating a small number of
additional specialized non-redundant arrays of BMAP cDNAs whose

availability will be considered under appropriate and limited collaborative arrangements. The following repetitive elements were found in this cDNA sequence: 119-174, >(CA)n#Simple_repeat
Seq primer: M13 Reverse.

FEATURES

SOURCE

Location/Qualifiers

1..311

/organism="Mus musculus"

/strain="C57BL/6J"

/db_xref="taxon:10090"

/clone="UI-M-AN1-af-f-04-0-UI"

/clone_1lb="NIH_BMAP_MBG_N"

/dev_stage="27-32 days"

/lab_host="DH10B (Life Technologies)"

/note="Vector: pRT3D-Pac (Pharmacia) with a modified

polylinker; Site_1: Not I; Site_2: Eco RI; The

NIH_BMAP_MBG_N library is a normalized library constructed

from mouse basal ganglia. The tag is a string of 5

nucleotides present between the Not I site and the

oligo-dT track. The library was constructed as described

by Bonaldo, Lennon and Soares, Genome Research 6: 791-806

, 1996. Tissue provided by Ms. Annie Novakovich,

Zivic-Miller Laboratories."

BASE COUNT

62 a 62 c 116 g 71 t

ORIGIN

Query Match 95.0%; Score 19; DB 10; Length 311;
Best Local Similarity 100.0%; Pred. No. 1e+03;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 2 CGATCGGGGGGGCGAGC 20

Db 217 CGATCGGGGGGGCGAGC 235

RESULT 2

AT005447/c

LOCUS AT005447 429 bp mRNA linear EST 25-MAR-2002

DEFINITION AT005447 POMBO1 Pleurotus ostreatus cDNA clone MFB34-F01, mRNA

sequence.

ACCESSION AT005447

VERSION AT005447.1 GI:13420306

KEYWORDS EST.

SOURCE oyster mushroom.

ORGANISM

Pleurotus ostreatus

Eukaryota; Fungi; Basidiomycota; Hymenomycetes; Homobasidiomycetes;

Agaricales; Pleurotaceae; Pleurotus.

1 (bases 1 to 429)

Lee, S.H., Kim, B.G., Kim, K.J., Lee, J.S., Yun, D.W., Hahn, J.H., Kim

, G.H., Lee, K.H., Suh, D.S., Kwon, S.T., Lee, C.S. and Yoo, Y.B.

Comparative Analysis of Sequences Expressed during the

Liquid-Cultured Mycelia and Fruit Body Stages of Pleurotus

ostreatus

Fungal Genet. Biol. 35 (2), 115-134 (2002)

CONTACT: Beom-Gi Kim

21838665

Division of Applied Microbiology

Institute of Agricultural Science and Technology (NIAST)

249 Seodundong Kweonseonku, Suwon 441707, Korea

Tel: 82-331-290-0347

Fax: 82-331-290-0399

Email: bkimyes@da.go.kr

Submitted through BRIC(Biological Research Information Center) of

Korea

URL: http://bric.postech.ac.kr/

GeneBank No. KS105130.

Location/Qualifiers

1..429

/organism="Pleurotus ostreatus"

/cultivar="ASI 2029"

/db_xref="taxon:5322"

/clone="MFB34-F01"

/clone_1lb="POMBO1"

/dev_stage="mature fruiting body"

/lab_host="E.coli"

/note="Vector: lambda Triplex2; Site_1: SfiI; Site_2:

SfiBI; average insert size:1500 bp; initial pfu:5 * 10⁷;

Isolation of total RNA from the mature fruiting body

cultivated in poplar tree sawdust bottle.

BASE COUNT 101 a 135 c 92 g 101 t

ORIGIN

Query Match 95.0%; Score 19; DB 9; Length 429;
Best Local Similarity 100.0%; Pred. No. 9.9e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 TCGATCGGGGGGGCGAG 19

Db 119 TCGATCGGGGGGGCGAG 101

RESULT 3

AM122220/c

LOCUS AM122220 375 bp mRNA linear EST 22-OCT-1999

DEFINITION UI-M-BH2.2-aeov-d-07-0-UI.51 NIH_BMAP_M.S3.2 Mus musculus cDNA clone

UI-M-BH2.2-aeov-d-07-0-UI 3', mRNA sequence.

ACCESSION AM122220.1 GI:6097683

VERSION EST.

KEYWORDS house mouse.

SOURCE Mus musculus

ORGANISM

REFERENCE

AUTHORS

TITLE

JOURNAL

MEDLINE

COMMENT

97044477

Contact: Chin, H

National Institute of Mental Health

6001 Executive Blvd. Room 7N-7190, MSC 9643, Bethesda, MD

20892-9643, USA

Tel: 301 443 1706

Fax: 301 443 9890

Email: mestr@mail.nih.gov

Oligo-dT track not found, Not I site shown in beginning of sequence

is likely internal to the message. cDNA library preparation: M.B.

Soares lab clone distribution: NIH BMAP cDNA clones will be made

available by the means that is soon to be determined. When NIH

determines the means for distribution of the BMAP cDNA clones, this

record will be updated accordingly when that means is determined.

The following repetitive elements were found in this cDNA sequence:

192-247, >(CA)n#Simple_repeat

Seq primer: M13 Forward

POLYA-No.

Location/Qualifiers

1..375

/organism="Mus musculus"

/strain="C57BL/6J"

/db_xref="taxon:10090"

/clone="UI-M-BH2.2-aeov-d-07-0-UI"

/clone_1lb="NIH_BMAP_M.S3.2"

/dev_stage="27-32 days"

/lab_host="DH10B (Life Technologies)"

/note="Vector: pRT3D-Pac (Pharmacia) with a modified

polylinker; Site_1: Not I; Site_2: Eco RI; The

NIH_BMAP_M.S3.2 library is a subcloned library of a

series, ultimately derived from a mixture of individually

tagged normalized libraries from ten regions of the mouse

brain (cerebellum, brain stems, olfactory bulbs,

hypothalamus, cortex, amygdala, basal ganglia, pineal

gland, striatum, hippocampus) after a series of

subtractions to reduce the representation of cDNAs from

which ESTs had already been generated. The following

serially subtracted libraries were generated in this

process: NIH_BMAP_M.S3.2, NIH_BMAP_M.S2, NIH_BMAP_M.S1.


```

BASE COUNT      81 a      99 c      142 g      83 t      1 others
ORIGIN

Query Match      87.0%  Score 17.4;  DB 9;  Length 406;
Best Local Similarity 94.7%  Pred. No. 3.9e+03;
Matches 18;  Conservative 0;  Mismatches 1;  Indels 0;  Gaps 0;

OY      2  CGATCGGGGGGGGGCGAC 20
      ||| |||||||
Db      158  CGACGGGGGGGGCGGCGAC 176

RESULT 6
LOCUS      B1220387
DEFINITION 602935686.1 NCI_CGAP_L19 Mus musculus cDNA clone IMAGE:5098916 5',
ACCESSION  B1220387
VERSION     B1220387.1 GI:14673831
KEYWORDS    EST.
SOURCE      house mouse.
ORGANISM    Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1 (bases 1 to 423)
AUTHORS     NIH-MGC http://mgc.nci.nih.gov/.
TITLE       National Institutes of Health, Mammalian Gene Collection (MGC)
JOURNAL     Unpublished (1999)
COMMENT     Contact: Robert Stransberg, Ph.D.
            Email: gga@b-remail.nih.gov
            Tissue Procurement: Jeffrey E. Green, M.D.
            cDNA Library Preparation: Life Technologies, Inc.
            cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
            DNA sequencing by: Incyte Genomics, Inc.
            Clone distribution: MGC clone distribution information can be
            found through the I.M.A.G.E. Consortium/LLNL at:
            http://image.lln.gov
            Plate: L16M11237 row: 1 column: 21
            High quality sequence stop: 419.
FEATURES
  source
    1..423
      /organism="Mus musculus"
      /strain="FVB/N"
      /db_xref="taxon:10090"
      /clone_image="5098916"
      /clone_id="NCI_CGAP_L19"
      /lab_host="DH10B (TI phage-resistant)"
      /note="Organ: liver; Vector: PCMV-Sport6; Site.1: NotI;
            Site.2: SalI; Cloned unidirectionally. Primer: Oligo dT.
            Average insert size 1.9 kb. Constructed by Life
            Technologies. Note: this is a NCI_CGAP library."
BASE COUNT      88 a      104 c      155 g      76 t
ORIGIN

Query Match      87.0%  Score 17.4;  DB 13;  Length 423;
Best Local Similarity 94.7%  Pred. No. 3.9e+03;
Matches 18;  Conservative 0;  Mismatches 1;  Indels 0;  Gaps 0;

OY      2  CGATCGGGGGGGGGCGAC 20
      ||| |||||||
Db      138  CGACGGGGGGGGGGCGAC 156

RESULT 7
LOCUS      BB859799
DEFINITION BB859799 RIKEN full-length enriched, kidney CCL-142 RAG cDNA Mus
ACCESSION  BB859799
VERSION     BB859799.1 GI:17101253
KEYWORDS    EST.

```

SOURCE mouse mouse.
ORGANISM Mus musculus.
REFERENCE Euzatyola, Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus. 1 (bases 1 to 437)
AUTHORS Akimura,T., Arakawa,T., Carninci,P., Furuno,M., Hanagaki,T., Hayatsu,N., Hiromoto,K., Hirooka,T., Hirozane,T., Imotani,K., Ishii,Y., Ito,M., Kawai,J., Kojima,Y., Konno,H., Koude,M., Matsuyama,T., Mekawa,M., Nishi,K., Nomura,K., Numasaki,R., Okazaki,T., Okido,T., Saito,R., Sakai,C., Sakai,K., Sakazume,N., Sasaki,D., Sato,K., Shibata,K., Shimagawa,A., Shiraki,T., Sogabe,Y., Suzuki,H., Tagawa,A., Takahashi,F., Takaku-Akahira,S., Tanaka,T., Tomaru,A., Toya,T., Watanishi,A., Yasunishi,A., Muramatsu,M. and Hayashizaki,Y.
TITLE RIKEN Encyclopedia of Mouse Full-length cDNAs (Akimura,T., et al. 2001)
JOURNAL Unpublished (2001)
COMMENT Contact: Yoshihide Hayashizaki
Laboratory for Genome Exploration Research Group, RIKEN Genomic Sciences Center (GSC), Yokohama Institute
The Institute of Physical and Chemical Research (RIKEN)
1-7-22 Saitama-cho, Tsukuba-Ku, Yokohama, Kanagawa 230-0045, Japan
Tel: 81-45-503-8222
Fax: 81-45-503-9216
Email: genome-res@gsc.riken.go.jp,
URL: http://genome.gsc.riken.go.jp/
Carninci,P., Shibata,Y., Hayatsu,N., Sugahara,Y., Shibata,K., Itoh,M., Konno,H., Okazaki,Y., Muramatsu,M. and Hayashizaki,Y.
Normalization and subtraction of cap-trapped selected cDNAs to prepare full-length cDNA libraries for rapid discovery of new genes. Genome Res. 10 (10), 1617-1630 (2000)
Wegli,K., Fujiwara,S., Inoue,K., Togawa,Y., Iawa,M., Ohara,E., Watanishi,A., Yoneda,Y., Ishikawa,T., Ozawa,K., Tanaka,T., Matsuzura,S., Kawai,J., Okazaki,Y., Muramatsu,M., Inoue,Y., Kira,A. and Hayashizaki,Y.
RIKEN integrated sequence analysis (RISA) system-384-format sequencing pipeline with 384 multichipillary sequencer. Genome Res. 10 (11), 1757-1771 (2000)
Konno,H., Fukunishi,Y., Shibata,K., Itoh,M., Carninci,P., Sugahara,Y. and Hayashizaki,Y.
Computer-based methods for the mouse full-length cDNA encyclopedia: real-time sequence clustering for construction of a nonredundant cDNA library. Genome Res. 11 (2), 281-289 (2001)
Please visit our web site (<http://genome.gsc.riken.go.jp>) for further details.
e mouse tissues.
FEATURES
SOURCE Location/Qualifiers
1..437
/organism="Mus musculus"
/db_xref="taxon:10090"
/clone="G430010A01"
/clone_id="RIKEN full-length enriched, kidney CCL-142 RAG cDNA"
/tissue-type="kidney"
/cell_line="CCL-142 RAG"
/note="pooled cell lines : (cell_line=CRL-1751 WEHI 164), (cell_line=CRL-2116 JC), (cell_line=RCB-0033 WEHI-3), (cell_line=RCB-0464 Meth-A), (cell_line=RCB-0545 OHTA), (cell_line=RCB-0559 K-1, F1), (cell_line=RCB-1283 B16 melanoma), (cell_type=B cells, (cell_line=CRL-1702 WEHI 231), (cell_type=IgdG cells, (cell_line=CRL-2065 M12C-1), (cell_type=Nullipotent stem cell, (cell_line=CRL-2070 NE), (tissue_type=bladder, cell_line=RCB-0544 M12-2), (tissue_type=bone marrow, cell_type=stoma cell, cell_line=CRL-2028 SR-4987), (tissue_type=colon, cell_line=RCB-0549 C1e-H3), (tissue_type=kidney, cell_line=CCL-142 RAG) (tissue_type=suprarenal gland, cell_line=CRL-1754 SCA-9 clone 15), (strain=BA16/C, cell_type=B cells, cell_line=CRL-1669 BCL1 clone 13, 20-3B3), (strain=C3H, tissue_type=brain, cell_line=CRL-1443 BC3H1)"
BASE COUNT 89 a 103 c 160 g 85 t
ORIGIN

Query Match 87.0%; Score 17.4; DB 10; Length 437;
 Best Local Similarity 94.7%; Pred. No. 3.9e+03;
 Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 2 CGATCGGGGGCGGCGAGC 20
 DB 168 CGAGCGGGGGCGGCGAGC 186

RESULT 8
 AII194235 448 bp mRNA linear EST 13-OCT-1998
 LOCUS ues2ell.r1 Soares.mammary_gland_NMLMG Mus musculus cDNA clone
 DEFINITION IMAGE:1494764 5' similar to TR:035445 035445 HYPOTHETICAL 19.8 KD
 ACCESSION AII194235
 VERSION AII194235.1 GI:3745442
 KEYWORDS EST.
 SOURCE house mouse.
 ORGANISM Mus musculus
 Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 1 (bases 1 to 448)
 AUTHORS Mair, M., Hillier, L., Allen, M., Bowles, M., Dietrich, N., Dubuque, T.,
 Geisel, S., Kucaba, T., Lacy, M., Le, M., Martin, J., Morris, M.,
 Schellenberg, K., Steptoe, M., Tan, F., Underwood, K., Moore, B.,
 Theising, B., Wylie, T., Lennon, G., Soares, B., Wilson, R. and
 Waterston, R.
 TITLE The WashU-HMI Mouse EST Project
 JOURNAL Unpublished (1996)
 COMMENT Contact: Maria M/Mouse EST Project
 WashU-HMI Mouse EST Project
 Washington University School of Medicine
 4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
 Tel: 314 286 1800
 Fax: 314 286 1810
 Email: mouseest@wustl.edu
 This clone is available royalty-free through LML; contact the
 IMAGE Consortium (info@image.llnl.gov) for further information.
 MGI:932368
 Seq primer: -28ml3 rev2 ET from Amersham.
 Location/Qualifiers
 1..448
 /organism="Mus musculus"
 /db_xref="taxon:10090"
 /clone_image="1494764"
 /clone_1bp="Soares.mammary_gland_NMLMG"
 /sex="female (lactating)"
 /tissue_type="mammary gland"
 /lab_host="DH10B"
 /note="Vector: p773D-Pac (Pharmacia) with a modified
 polylinker; 1st strand cDNA was prepared from mammary
 gland tissue from a lactating female, and was then primed
 with a Not I - oligo(dT) primer. Double-stranded cDNA was
 ligated to Eco RI adaptors (Pharmacia), digested with Not
 I and cloned into the Not I and Eco RI sites of the
 modified p773 vector. Library is normalized. Library
 was constructed by Bento Soares and M. Fatima Bonaldo."

BASE COUNT 90 a 110 c 161 g 87 t

ORIGIN
 Query Match 87.0%; Score 17.4; DB 9; Length 448;
 Best Local Similarity 94.7%; Pred. No. 3.9e+03;
 Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 2 CGATCGGGGGCGGCGAGC 20
 DB 143 CGAGCGGGGGCGGCGAGC 161

RESULT 9
 BE650594 493 bp mRNA linear EST 06-SEP-2000
 LOCUS BE650594

DEFINITION UI-M-BH2.2-rov-d-01-01-UI.r1 NIH_BMAP_M.S3.2 Mus musculus cDNA clone
 UI-M-BH2.2-rov-d-01-01-UI 5', mRNA sequence.
 ACCESSION BE650594
 VERSION BE650594.1 GI:9976418
 KEYWORDS EST.
 SOURCE house mouse.
 ORGANISM Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 1 (bases 1 to 493)
 AUTHORS Bonaldo, M.F., Lennon, G. and Soares, M.B.
 TITLE Normalization and subtraction: two approaches to facilitate gene
 discovery
 JOURNAL Genome Res. 6 (9), 791-806 (1996)
 MEDLINE 97044477
 COMMENT Contact: Chih, H
 National Institute of Mental Health
 6001 Executive Blvd. Room 7N-7190, MSC 9643, Bethesda, MD
 20892-9643, USA
 Tel: 301 443 1706
 Fax: 301 443 9890
 Email: mestr@mail.nih.gov
 CDNA library preparation: M.B. Soares Lab Clone distribution:
 Researchers may obtain BMAP cDNA clones from RESEARCH GENETICS. It
 should be noted that Bento Soares is generating a small number of
 additional specialized non-redundant arrays of BMAP cDNAs whose
 availability will be considered under appropriate and limited
 collaborative arrangements. The following repetitive elements were
 found in this cDNA sequence: 118-173, >(CA)n/simple_repeat
 Seq primer: M13 Reverse.
 Location/Qualifiers
 1..493
 /organism="Mus musculus"
 /strain="C57BL/6J"
 /db_xref="taxon:10090"
 /clone_image="UI-M-BH2.2-rov-d-01-01-UI"
 /clone_1bp="NIH_BMAP_M.S3.2"
 /dev_stage="27-32 days"
 /lab_host="DH10B (Life Technologies)"
 /note="Vector: p773D-Pac (Pharmacia) with a modified
 polylinker; Site 1: Not I; Site 2: Eco RI; The
 NIH_BMAP_M.S3.2 library is a subtracted library of a
 series, ultimately derived from a mixture of individually
 tagged normalized libraries from ten regions of the mouse
 brain (cerebellum, brain stems, olfactory bulbs,
 hypothalamus, cortex, amygdala, basal ganglia, pineal
 gland, striatum, hippocampus) after a series of
 subtractions to reduce the representation of cDNAs from
 which ESTs had already been generated. The following
 serially subtracted libraries were generated in this
 process: NIH_BMAP_M.S3.2, NIH_BMAP_M.S2, NIH_BMAP_M.S1.
 The subtracted library (NIH_BMAP_M.S3.2) was constructed
 as follows: PCR amplified cDNA inserts from NIH_BMAP_M.S2
 clones from which 3' ESTs had been derived was used as a
 driver in a hybridization with the NIH_BMAP_M.S2 library
 in the form of single-stranded circles. The remaining
 single-stranded circles (subtracted library) was purified
 by hydroxyapatite column chromatography, converted to
 double-stranded circles and electroporated into DH10B
 bacteria (Life Technologies) to generate the
 NIH_BMAP_M.S3.2 library. This procedure has been
 previously described (Bonaldo, Lennon and Soares, Genome
 Research 6:791-806, 1996).
 Research 6:791-806, 1996"

BASE COUNT 99 a 112 c 158 g 124 t

ORIGIN
 Query Match 87.0%; Score 17.4; DB 10; Length 493;
 Best Local Similarity 94.7%; Pred. No. 3.8e+03;
 Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 2 CGATCGGGGGCGGCGAGC 20
 DB 265 CGAGCGGGGGCGGCGAGC 283

RESULT 10
LOCUS BF015640
DEFINITION uyt2b02.y1 NCI-CGAP Lu30 Mus musculus cDNA clone IMAGE:3660747 5' similar to TR:035445 035445 HYPOTHETICAL 19.8 KD PROTEIN.; mRNA sequence.
ACCESSION BF015640
VERSION BF015640.1 GI:10746972
KEYWORDS EST.
SOURCE house mouse.
ORGANISM Mus musculus
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
AUTHORS 1 (bases 1 to 530)
TITLE NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
COMMENT National Cancer Institute, Cancer Genome Anatomy Project (CGAP).
JOURNAL Tumor Gene Index
UNPUBLISHED (1997)
CONTACT Robert Strausberg, Ph.D.
EMAIL cgapbs-remail.nih.gov
TISSUE Procurement: Gilbert Smith, Ph.D.
CDNA Library Preparation: Life Technologies, Inc.
CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
DNA Sequencing by: Washington University Genome Sequencing Center
Clone Distribution: NCI-CGAP clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at: imgc.llnl.gov/image/html/resources.shtml
MG1:1421515
Seq primer: -40RP from Glbco
High quality sequence stop: 457.
FEATURES
source
1. 530
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone_image="3660747"
/clone_lib="NCI-CGAP_Lu30"
/tissue_type="tumor, metastatic to mammary"
/lab_host="DH10B"
/note="Organ: Lung; Vector: pCMV-SPORT6; Site_1: NotI; Site_2: SalI; transgenic model MMT-1, expression driven by MMTV-LTR enhancer; Cloned unidirectionally. Primer: Oligo dt. Library constructed by Life Technologies.
Investigator providing samples: Gilbert Smith, NIH"
BASE COUNT 101 a 135 c 179 g 115 t
ORIGIN
Query Match 87.0%; Score 17.4; DB 12; Length 530;
Best Local Similarity 94.7%; Pred. No. 3.8e+03;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

RESULT 11
LOCUS B1111370
DEFINITION B1111370 . 679 bp mRNA linear EST 26-JUN-2001
602899252P1 NCI-CGAP Mam5 Mus musculus cDNA clone IMAGE:5028924 5', mRNA sequence.
ACCESSION B1111370
VERSION B1111370.1 GI:14562271
KEYWORDS EST.
SOURCE house mouse.
ORGANISM Mus musculus
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
AUTHORS 1 (bases 1 to 679)
TITLE NIH-MGC http://imgc.ncbi.nlm.nih.gov/.

TITLE National Institutes of Health, Mammalian Gene Collection (MGC)
JOURNAL Unpublished (1999)
COMMENT Contact: Robert Strausberg, Ph.D.
EMAIL cgapbs-remail.nih.gov
TISSUE Procurement: Lothar Hennighausen Ph.D., Robin Humphreys
CDNA Library Preparation: Life Technologies, Inc.
CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
DNA Sequencing by: Incyte Genomics, Inc.
Clone Distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at: <http://imgc.llnl.gov>
Plate: LLM11081 row: h column: 13
High quality sequence stop: 666.
FEATURES
source
1. 679
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone_image="5028924"
/clone_lib="NCI-CGAP_Mam5"
/tissue_type="tumor, gross tissue"
/dev_stage="7 months"
/lab_host="DH10B"
/note="Organ: mammary; Vector: pCMV-SPORT6; Site_1: SalI; Site_2: NotI; Cloned unidirectionally. Primer: Oligo dt. Library constructed by Life Technologies. Investigators providing samples: Lothar Hennighausen/Robin Humphreys, NIH"
BASE COUNT 126 a 190 c 216 g 146 t 1 others
ORIGIN
Query Match 87.0%; Score 17.4; DB 13; Length 679;
Best Local Similarity 94.7%; Pred. No. 3.8e+03;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

RESULT 12
LOCUS B0445767
DEFINITION B0445767 709 bp mRNA linear EST 29-MAY-2002
UT-M-ERO-bxm-g-18-0-UI-r2 NIH-BMAP-ERO Mus musculus cDNA clone IMAGE:5710121 5', mRNA sequence.
ACCESSION B0445767
VERSION B0445767.1 GI:21248879
KEYWORDS EST.
SOURCE house mouse.
ORGANISM Mus musculus
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
AUTHORS 1 (bases 1 to 709)
TITLE NIH-MGC http://imgc.ncbi.nlm.nih.gov/.
JOURNAL National Institutes of Health, Mammalian Gene Collection (MGC)
COMMENT Contact: Robert Strausberg, Ph.D.
EMAIL cgapbs-remail.nih.gov
TISSUE Procurement: Dr. James Lin, University of Iowa
CDNA Library Preparation: Dr. M. Bento Soares, University of Iowa
CDNA Library Arrayed by: Dr. M. Bento Soares, University of Iowa
DNA Sequencing by: Dr. M. Bento Soares, University of Iowa
Clone Distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at: <http://imgc.llnl.gov>
Plate: LLM11081 row: h column: 13
High quality sequence stop: 666.
FEATURES
source
1. 709
/organism="Mus musculus"
/strain="C57BL/6"
/db_xref="taxon:10090"

Seq primer: PYX-5.
Location: Brain Molecular Anatomy Project (BMAP)
Location: Qualifiers
1. 709
/organism="Mus musculus"
/strain="C57BL/6"
/db_xref="taxon:10090"

/clone="IMAGE:5710121"
/clone_1lb="NIH_BMAP_ER0"
/tissue_type="whole brain"
/dev_stage="embryo 15.5 dpc"
/lab_host="DH10B (T1 phage resistant)."
/note="Organ: Brain; Vector: pYX-Asc; Site: 1; EcoR I;
Site: 2; Not I; The library was constructed according to
Bonaldo, Lennon and Soares, Genome Research, 6:791-806,
1996. Denatured mRNA was size fractionated on a 1% agarose
gel. First strand cDNA synthesis was primed with an
oligo-dT primer containing a Not I site. Double stranded
cDNA was size selected according to mRNA size fraction,
ligated with EcoR I adaptor, digested with Not I, and then
sequence located between the Not I site and the polyA tail
, is GTCCGTGGA. This library was created for the
University of Iowa Mouse Brain Molecular Anatomy Project
(BMAP). 'Gene discovery in the Developing Mouse Nervous
System', supported by National Institutes of Mental Health
(NIMH), Hemm Chin, Ph.D., program coordinator."

BASE COUNT 131 a 201 c 211 g 164 t 2 others

ORIGIN

Query Match 87.0%; Score 17.4; DB 14; Length 709;
Best Local Similarity 94.7%; Pred. No. 3.8e+03;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 2 CGATCGGGCGGGCGGCGAGC 20
||| ||||| ||||| |||||
90 CGAGCGGGCGGGCGGCGAGC 108

RESULT 13
LOCUS B0444735 735 bp mRNA linear EST 29-MAY-2002
DEFINITION UI-M-ERO-bm-h-21-0-UI.r1 NIH_BMAP_ER0 Mus musculus cDNA clone
IMAGE:5710148 5', mRNA sequence.
ACCESSION B0444735
VERSION B0444735.1 GI:21247847
KEYWORDS EST.
SOURCE house mouse.
ORGANISM Mus musculus.
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 735)
NIH-MGC http://mgc.nci.nih.gov/.
National Institutes of Health, Mammalian Gene Collection (MGC)
Unpublished (1999)
Contact: Robert Strausberg, Ph.D.
Email: cgabs-remail.nih.gov
Tissue Procurement: Dr. James Lin, University of Iowa
CDNA Library Preparation: Dr. M. Bento Soares, University of Iowa
CDNA Library Arrayed by: Dr. M. Bento Soares, University of Iowa
DNA Sequencing by: Dr. M. Bento Soares, University of Iowa
Clone Distribution: MGC clone distribution information can be
found through the I.M.A.G.E. Consortium/LINL at:
http://image.llnl.gov
This clone was contributed by the Brain Molecular Anatomy Project
(BMAP)

REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT

FEATURES
source

Seq primer: pYX-5
Location/Qualifiers
1. 735
/organism="Mus musculus"
/strain="C57BL/6"
/db_xref="taxon:10090"
/clone="IMAGE:5710148"
/clone_1lb="NIH_BMAP_ER0"
/tissue_type="whole brain"
/dev_stage="embryo 15.5 dpc"
/lab_host="DH10B (T1 phage resistant)."
/note="Organ: Brain; Vector: pYX-Asc; Site: 1; EcoR I;
Site: 2; Not I; The library was constructed according to
Bonaldo, Lennon and Soares, Genome Research, 6:791-806,

1996. Denatured mRNA was size fractionated on a 1% agarose
gel. First strand cDNA synthesis was primed with an
oligo-dT primer containing a Not I site. Double stranded
cDNA was size selected according to mRNA size fraction,
ligated with EcoR I adaptor, digested with Not I, and then
sequence located between the Not I site and the polyA tail
, is GTCCGTGGA. This library was created for the
University of Iowa Mouse Brain Molecular Anatomy Project
(BMAP). 'Gene discovery in the Developing Mouse Nervous
System', supported by National Institutes of Mental Health
(NIMH), Hemm Chin, Ph.D., program coordinator."

BASE COUNT 135 a 205 c 225 g 168 t 2 others

ORIGIN

Query Match 87.0%; Score 17.4; DB 14; Length 735;
Best Local Similarity 94.7%; Pred. No. 3.8e+03;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 2 CGATCGGGCGGGCGGCGAGC 20
||| ||||| ||||| |||||
90 CGAGCGGGCGGGCGGCGAGC 108

RESULT 14
LOCUS B0445216 741 bp mRNA linear EST 29-MAY-2002
DEFINITION UI-M-ERO-bxp-d-17-0-UI.r1 NIH_BMAP_ER0 Mus musculus cDNA clone
IMAGE:5711200 5', mRNA sequence.
ACCESSION B0445216
VERSION B0445216.1 GI:21248328
KEYWORDS EST.
SOURCE house mouse.
ORGANISM Mus musculus.
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 741)
NIH-MGC http://mgc.nci.nih.gov/.
National Institutes of Health, Mammalian Gene Collection (MGC)
Unpublished (1999)
Contact: Robert Strausberg, Ph.D.
Email: cgabs-remail.nih.gov
Tissue Procurement: Dr. James Lin, University of Iowa
CDNA Library Preparation: Dr. M. Bento Soares, University of Iowa
CDNA Library Arrayed by: Dr. M. Bento Soares, University of Iowa
DNA Sequencing by: Dr. M. Bento Soares, University of Iowa
Clone Distribution: MGC clone distribution information can be
found through the I.M.A.G.E. Consortium/LINL at:
http://image.llnl.gov
This clone was contributed by the Brain Molecular Anatomy Project
(BMAP)

REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT

FEATURES
source

Seq primer: pYX-5.
Location/Qualifiers
1. 741
/organism="Mus musculus"
/strain="C57BL/6"
/db_xref="taxon:10090"
/clone="IMAGE:5711200"
/clone_1lb="NIH_BMAP_ER0"
/tissue_type="whole brain"
/dev_stage="embryo 15.5 dpc"
/lab_host="DH10B (T1 phage resistant)."
/note="Organ: Brain; Vector: pYX-Asc; Site: 1; EcoR I;
Site: 2; Not I; The library was constructed according to
Bonaldo, Lennon and Soares, Genome Research, 6:791-806,
1996. Denatured mRNA was size fractionated on a 1% agarose
gel. First strand cDNA synthesis was primed with an
oligo-dT primer containing a Not I site. Double stranded
cDNA was size selected according to mRNA size fraction,
ligated with EcoR I adaptor, digested with Not I, and then
sequence located between the Not I site and the polyA tail
, is GTCCGTGGA. This library was created for the

University of Iowa Mouse Brain Molecular Anatomy Project
 (BMAP): 'Gene Discovery in the Developing Mouse Nervous
 System', supported by National Institutes of Mental Health
 (NIMH), Hemlin Chiu, Ph.D., program coordinator."

BASE COUNT 133 a 202 c 224 g 179 t 3 others

ORIGIN

Query Match 87.0%; Score 17.4; DB 14; Length 741;
 Best Local Similarity 94.7%; Pred. No. 3.8e+03;
 Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 CGATCGGGCGGGCGGAGC 20
 DB 129 CGAGCGGGCGGGCGGAGC 147

RESULT 15

LOCUS B1146925 764 bp mRNA linear EST 05-JUL-2001
 DEFINITION 602911551F1 NCI_CGAP_L19 Mus musculus cDNA clone IMAGE:5052660 5',
 mRNA sequence.

ACCESSION B1146925
 VERSION B1146925
 KEYWORDS EST. GI:14606926

SOURCE house mouse.
 ORGANISM Mus musculus

REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 1 (bases 1 to 764)
 NIH-MGC http://mgs.nci.nih.gov/.
 National Institutes of Health, Mammalian Gene Collection (MGC)
 Unpublished (1999)
 COMMENT Contact: Robert Strausberg, Ph.D.
 Email: c9apbs-remail.nih.gov
 Tissue Procurement: Jeffrey E. Green, M.D.
 cDNA Library Preparation: Life Technologies, Inc.
 cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
 DNA Sequencing by: Incyte Genomics, Inc.
 Clone distribution: MGC clone distribution information can be
 found through the I.M.A.G.E. Consortium/LLNL at:
 http://image.llnl.gov
 Plate: LLAM1143 row: e column: 13
 High quality sequence stop: 741.
 Location/Qualifiers

FEATURES
 Source 1..764
 /organism="Mus musculus"
 /strain="FVB/N"
 /db_xref="taxon:10090"
 /clone="IMAGE:5052660"
 /clone_lib="NCI_CGAP_L19"
 /lab_host="DH10B (TI phage-resistant)"
 /note="Organ: liver; Vector: pCMV-SPORT6; Site_1: NotI;
 Site_2: SalI; Cloned unidirectionally. Primer: Oligo dt.
 Average insert size 1.9 kb. Constructed by Life
 Technologies. Note: this is a NCI_CGAP library."

BASE COUNT 138 a 211 c 235 g 180 t
 ORIGIN

Query Match 87.0%; Score 17.4; DB 13; Length 764;
 Best Local Similarity 94.7%; Pred. No. 3.8e+03;
 Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2 CGATCGGGCGGGCGGAGC 20
 DB 115 CGAGCGGGCGGGCGGAGC 133

Search completed: June 26, 2003, 22:12:31
 Job time : 1533.13 secs

GenCore version 5.1.6.
Copyright (c) 1993 - 2003 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 26, 2003, 10:58:25 ; Search time 30.2174 Seconds
(without alignments)
202,980 Million cell updates/sec

Title: US-09-355-254f-13

Perfect score: 1 tgcagattgcgaattgca 20

Scoring table: IDENTITY_NDC

Gapop 10.0 , Gapext 1.0

Searched: 441362 seqs, 153338381 residues

Total number of hits satisfying chosen parameters: 882724

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Issued_Patents.NA.*
1: /cgn2_6/ptodata/1/ina/5A.COMB.seq.*
2: /cgn2_6/ptodata/1/ina/5B.COMB.seq.*
3: /cgn2_6/ptodata/1/ina/6A.COMB.seq.*
4: /cgn2_6/ptodata/1/ina/6B.COMB.seq.*
5: /cgn2_6/ptodata/1/ina/PCrus.COMB.seq.*
6: /cgn2_6/ptodata/1/ina/Backfile1.seq.*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	20	100.0	20	4	US-09-021-247-7
2	20	100.0	20	4	US-09-021-247-7
3	20	100.0	20	4	US-09-425-798-15
4	20	100.0	20	4	US-09-425-798-15
5	14.8	74.0	653	4	US-08-998-416-1111
6	14.8	74.0	653	4	US-08-998-416-1111
7	14.4	72.0	49	1	US-07-601-094-5
8	14.4	72.0	49	1	US-07-601-094-5
9	14.4	72.0	49	1	US-08-012-735-5
10	14.4	72.0	49	1	US-08-012-735-5
11	14.2	71.0	522	2	US-08-767-026-1
12	14.2	71.0	522	2	US-08-767-026-1
13	14.2	71.0	857	4	US-08-998-416-558
14	14.2	71.0	857	4	US-08-998-416-558
15	14.2	71.0	1101	4	US-09-210-843-1
16	14.2	71.0	1101	4	US-09-210-843-1
17	14.2	71.0	1800	1	US-08-366-783-1
18	14.2	71.0	1800	1	US-08-366-783-1
19	14.2	71.0	1800	1	US-08-313-098A-1
20	14.2	71.0	1800	1	US-08-313-098A-1
21	14.2	71.0	1800	2	US-08-846-021A-1
22	14.2	71.0	1800	2	US-08-846-021A-1
23	14.2	71.0	1897	6	RE34606-5
24	14.2	71.0	1897	6	RE34606-5
25	14.2	71.0	2115	2	US-08-767-026-3
26	14.2	71.0	2115	2	US-08-767-026-3
27	14.2	71.0	2133	4	US-09-488-744A-3

C	28	14.2	71.0	2133	4	US-09-488-744A-3	Sequence 3, Appl1
C	29	14.2	71.0	2733	2	US-08-846-021A-6	Sequence 6, Appl1
C	30	14.2	71.0	2733	2	US-08-846-021A-6	Sequence 6, Appl1
C	31	14.2	71.0	3183	1	US-08-849-212-3	Sequence 3, Appl1
C	32	14.2	71.0	3183	1	US-08-849-212-3	Sequence 3, Appl1
C	33	14.2	71.0	3546	4	US-09-118-442-14	Sequence 14, Appl1
C	34	14.2	71.0	3546	4	US-09-118-442-14	Sequence 14, Appl1
C	35	14.2	71.0	3546	4	US-09-118-442-15	Sequence 15, Appl1
C	36	14.2	71.0	3546	4	US-09-118-442-15	Sequence 15, Appl1
C	37	14.2	71.0	3546	4	US-09-677-064-14	Sequence 14, Appl1
C	38	14.2	71.0	3546	4	US-09-677-064-14	Sequence 14, Appl1
C	39	14.2	71.0	3546	4	US-09-677-064-15	Sequence 15, Appl1
C	40	14.2	71.0	3546	4	US-09-677-064-15	Sequence 15, Appl1
C	41	14.2	71.0	9578	4	US-08-961-527-127	Sequence 127, App
C	42	14.2	71.0	9578	4	US-08-961-527-127	Sequence 127, App
C	43	14.2	70.0	960	2	US-08-245-511-3	Sequence 3, Appl1
C	44	14.2	70.0	960	2	US-08-245-511-3	Sequence 3, Appl1
C	45	14.2	70.0	960	2	US-08-600-993A-3	Sequence 3, Appl1

ALIGNMENTS

RESULT 1
US-09-021-247-7
; Sequence 7, Application US/09021247
; Patent No. 6225444
; GENERAL INFORMATION:
; APPLICANT: Shastrou, Victor E.
; TITLE OF INVENTION: NEUROPROTECTIVE PEPTIDES AND USES THEREOF
; NUMBER OF SEQUENCES: 19
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: Wolf, Greenfield & Sacks, P.C.
; STREET: 600 Atlantic Avenue
; CITY: Boston
; STATE: MA
; COUNTRY: USA
; ZIP: 02210
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/021,247
; FILING DATE:
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Van Amsterdam, John R.
; REGISTRATION NUMBER: 40,212
; REFERENCE/DOCKET NUMBER: N0260/7023
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-720-3500
; TELEFAX: 617-720-2441
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 nucleotides
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: oligonucleotide
; HYPOTHETICAL: NO
; US-09-021-247-7

Query Match 100.0%; Score 20; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.083;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TGCAGATGCGCAATGCA 20
DB 1 TGCAGATGCGCAATGCA 20

RESULT 2
US-09-021-247-7/C
; Sequence 7, Application US/09021247
; Patent No. 6225444
; GENERAL INFORMATION:
; APPLICANT: Shashoua, Victor E.
; TITLE OF INVENTION: NEUROPROTECTIVE PEPTIDES AND USES THEREOF
; NUMBER OF SEQUENCES: 19
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Wolf, Greenfield & Sacks, P.C.
; STREET: 600 Atlantic Avenue
; CITY: Boston
; STATE: MA
; COUNTRY: USA
; ZIP: 02210
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/021,247
; FILING DATE:
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Van Amsterdam, John R.
; REGISTRATION NUMBER: 40,212
; REFERENCE/DOCKET NUMBER: N0260/7023
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-720-3500
; TELEFAX: 617-720-2441
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 nucleotides
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: oligonucleotide
; HYPOTHETICAL: NO
; US-09-021-247-7

Query Match 100.0%; Score 20; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.083;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TGCAGATTGCCGCAATCTGCA 20
DB 20 TGCAGATTGCCGCAATCTGCA 1

RESULT 3
US-09-425-798-15
; Sequence 15, Application US/09425798A
; Patent No. 6423493
; GENERAL INFORMATION:
; APPLICANT: Gorenstein Dr., David G.
; APPLICANT: King Dr., David J.
; APPLICANT: Ventura, Daniel A.
; APPLICANT: Brasler Dr., Allan R.
; TITLE OF INVENTION: Combinatorial Selection of Phosphothionate
; TITLE OF INVENTION: Oligonucleotide Aptamers
; FILE REFERENCE: 122144-1005
; CURRENT APPLICATION NUMBER: US/09/425,798A
; CURRENT FILING DATE: 1999-10-25
; PRIOR APPLICATION NUMBER: 60/105,600
; PRIOR FILING DATE: 1999-10-26
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 15
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:

OTHER INFORMATION: Description of Artificial Sequence: aptamer
US-09-425-798-15

Query Match 100.0%; Score 20; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.083;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TGCAGATTGCCGCAATCTGCA 20
DB 1 TGCAGATTGCCGCAATCTGCA 20

RESULT 4
US-09-425-798-15/C
; Sequence 15, Application US/09425798A
; Patent No. 6423493
; GENERAL INFORMATION:
; APPLICANT: Gorenstein Dr., David G.
; APPLICANT: King Dr., David J.
; APPLICANT: Ventura, Daniel A.
; APPLICANT: Brasler Dr., Allan R.
; TITLE OF INVENTION: Combinatorial Selection of Phosphothionate
; TITLE OF INVENTION: Oligonucleotide Aptamers
; FILE REFERENCE: 122144-1005
; CURRENT APPLICATION NUMBER: US/09/425,798A
; CURRENT FILING DATE: 1999-10-25
; PRIOR APPLICATION NUMBER: 60/105,600
; PRIOR FILING DATE: 1999-10-26
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 15
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: aptamer
US-09-425-798-15

Query Match 100.0%; Score 20; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.083;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TGCAGATTGCCGCAATCTGCA 20
DB 20 TGCAGATTGCCGCAATCTGCA 1

RESULT 5
US-08-998-416-1111
; Sequence 1111, Application US/08998416
; Patent No. 6239264
; GENERAL INFORMATION:
; APPLICANT: Philippaen, Peter
; APPLICANT: Pohlmann, Rainer
; APPLICANT: Steiner, Sabine
; APPLICANT: Mohr, Christine
; APPLICANT: Wendland, Jurgen
; APPLICANT: Knechtle, Philipp
; APPLICANT: Redischung, Corinne
; TITLE OF INVENTION: GENOMIC DNA SEQUENCES OF ASHBYA GOSSEYII
; TITLE OF INVENTION: AND USES THEREOF
; NUMBER OF SEQUENCES: 1152
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: No. 6239264artis Corporation
; STREET: 3054 Cornwallis Road
; CITY: Research Triangle Park
; STATE: No. 6239264th Carolina
; COUNTRY: USA
; ZIP: 27709
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS

Db 18 CAGATTGCAATCTG 33

RESULT 8

US-07-601-094-5/C
Sequence 5, Application US/07601094
Patent No. 5215892
GENERAL INFORMATION:
APPLICANT: Kishimoto, Tadamiatsu
APPLICANT: Hirano, Toshio
APPLICANT: Akira, Shizuo
APPLICANT: Ieshiki, Hiroshi
APPLICANT: Tanabe, Osamu
APPLICANT: Kinoshita, Shigeml
APPLICANT: Shlimamoto, Takuya
TITLE OF INVENTION: C/EBP2 Gene and Recombinant
TITLE OF INVENTION: C/EBP2
NUMBER OF SEQUENCES: 34
CORRESPONDENCE ADDRESS:
ADDRESSEE: Sughrue, Mfon, Zinn, Macpeak &
ADDRESSEE: Seas
STREET: 2100 Pennsylvania Avenue, N.W.
CITY: Washington
STATE: D.C.
COUNTRY: United States
ZIP: 20037-3202
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentln Release #1.24
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/07/601,094
FILING DATE: 19901022
CLASSIFICATION: 435
TELECOMMUNICATION INFORMATION:
TELEPHONE: (202) 293-7060
TELEFAX: (202) 293-7860
TELEX: 6491103
INFORMATION FOR SEQ ID NO: 5:
SEQUENCE CHARACTERISTICS:
LENGTH: 49 base pairs
TYPE: NUCLEIC ACID
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: CDNA
US-07-601-094-5

Query Match 72.0%; Score 14.4; DB 1; Length 49;
Best Local Similarity 93.8%; Pred. No. 80;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3 CAGATTGGCAATCTG 18
Db 33 CAGATTGCAATCTG 18

RESULT 9

US-08-012-735-5
Sequence 5, Application US/08012735
Patent No. 5360894
GENERAL INFORMATION:
APPLICANT: Kishimoto, Tadamiatsu
APPLICANT: Hirano, Toshio
APPLICANT: Akira, Shizuo
APPLICANT: Ieshiki, Hiroshi
APPLICANT: Tanabe, Osamu
APPLICANT: Kinoshita, Shigeml
APPLICANT: Shlimamoto, Takuya
TITLE OF INVENTION: C/EBP2 Gene and Recombinant
TITLE OF INVENTION: C/EBP2
NUMBER OF SEQUENCES: 34

CORRESPONDENCE ADDRESS:
ADDRESSEE: Sughrue, Mfon, Zinn, Macpeak &
ADDRESSEE: Seas
STREET: 2100 Pennsylvania Avenue, N.W.
CITY: Washington
STATE: D.C.
COUNTRY: United States
ZIP: 20037-3202
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentln Release #1.24
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/012,735
FILING DATE: 19930203
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/07/601,094
FILING DATE: 22 OCT 1990
TELECOMMUNICATION INFORMATION:
TELEPHONE: (202) 293-7060
TELEFAX: (202) 293-7860
TELEX: 6491103
INFORMATION FOR SEQ ID NO: 5:
SEQUENCE CHARACTERISTICS:
LENGTH: 49 base pairs
TYPE: NUCLEIC ACID
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: CDNA
US-08-012-735-5

Query Match 72.0%; Score 14.4; DB 1; Length 49;
Best Local Similarity 93.8%; Pred. No. 80;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3 CAGATTGGCAATCTG 18
Db 18 CAGATTGCAATCTG 33

RESULT 10

US-08-012-735-5/C
Sequence 5, Application US/08012735
Patent No. 5360894
GENERAL INFORMATION:
APPLICANT: Kishimoto, Tadamiatsu
APPLICANT: Hirano, Toshio
APPLICANT: Akira, Shizuo
APPLICANT: Ieshiki, Hiroshi
APPLICANT: Tanabe, Osamu
APPLICANT: Kinoshita, Shigeml
APPLICANT: Shlimamoto, Takuya
TITLE OF INVENTION: C/EBP2 Gene and Recombinant
TITLE OF INVENTION: C/EBP2
NUMBER OF SEQUENCES: 34
CORRESPONDENCE ADDRESS:
ADDRESSEE: Sughrue, Mfon, Zinn, Macpeak &
ADDRESSEE: Seas
STREET: 2100 Pennsylvania Avenue, N.W.
CITY: Washington
STATE: D.C.
COUNTRY: United States
ZIP: 20037-3202
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentln Release #1.24
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/012,735
FILING DATE: 19930203

CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/07/601,094
FILING DATE: 22 OCT 1990
TELECOMMUNICATION INFORMATION:
TELEPHONE: (202) 293-7060
TELEFAX: (202) 293-7860
INFORMATION FOR SEQ ID NO: 5:
SEQUENCE CHARACTERISTICS:
LENGTH: 49 base pairs
TYPE: NUCLEIC ACID
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
US-08-012-735-5

Query Match 72.0%; Score 14.4; DB 1; Length 49;
Best Local Similarity 93.8%; Pred. No. 80;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 3 CAGATTGGCAATCTG 18
||||| |||||||
DB 33 CAGATTGTGCAATCTG 18

RESULT 11
US-08-767-026-1
Sequence 1, Application US/08767026
Patent No. 5856452
GENERAL INFORMATION:
APPLICANT: Moloney, Maurice
APPLICANT: Boothe, Joseph
APPLICANT: van Rooijen, GJ's
TITLE OF INVENTION: Oil Bodies and Associated Proteins as
NUMBER OF SEQUENCES: 15
CORRESPONDENCE ADDRESS:
ADDRESSEE: BERESKIN & PARR
STREET: 40 King Street West
CITY: Toronto
STATE: Ontario
COUNTRY: Canada
ZIP: M5H 3Y2
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/767,026
FILING DATE:
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Gravelle, Michelle
REGISTRATION NUMBER: 40,261
REFERENCE/DOCKET NUMBER: 9369-001
TELECOMMUNICATION INFORMATION:
TELEPHONE: (416) 364-7311
TELEFAX: (416) 361-1398
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 522 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
ORIGINAL SOURCE:
ORGANISM: Oleosin From Arabidopsis Thaliana
FEATURE:
NAME/KEY: CDS
LOCATION: 1..522
US-08-767-026-1

Query Match 71.0%; Score 14.2; DB 2; Length 522;
Best Local Similarity 84.2%; Pred. No. 1.5e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 2 GCAGATTGGCAATCTGCA 20
||||| || |||||
DB 123 GCAGATTGTAAAGCTGCA 141

RESULT 12
US-08-767-026-1/c
Sequence 1, Application US/08767026
Patent No. 5856452
GENERAL INFORMATION:
APPLICANT: Moloney, Maurice
APPLICANT: Boothe, Joseph
APPLICANT: van Rooijen, GJ's
TITLE OF INVENTION: Oil Bodies and Associated Proteins as
NUMBER OF SEQUENCES: 15
CORRESPONDENCE ADDRESS:
ADDRESSEE: BERESKIN & PARR
STREET: 40 King Street West
CITY: Toronto
STATE: Ontario
COUNTRY: Canada
ZIP: M5H 3Y2
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/767,026
FILING DATE:
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Gravelle, Michelle
REGISTRATION NUMBER: 40,261
REFERENCE/DOCKET NUMBER: 9369-001
TELECOMMUNICATION INFORMATION:
TELEPHONE: (416) 364-7311
TELEFAX: (416) 361-1398
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 522 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
ORIGINAL SOURCE:
ORGANISM: Oleosin From Arabidopsis Thaliana
FEATURE:
NAME/KEY: CDS
LOCATION: 1..522
US-08-767-026-1

Query Match 71.0%; Score 14.2; DB 2; Length 522;
Best Local Similarity 84.2%; Pred. No. 1.5e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1 TGCAGATTGGCAATCTGC 19
||||| || |||||||
DB 141 TGCAGCTTAGCAATCTGC 123

RESULT 13
US-08-998-416-558
Sequence 558, Application US/08998416
Patent No. 6239264
GENERAL INFORMATION:
APPLICANT: Philippsen, Peter

APPLICANT: Pohlmann, Rainer
APPLICANT: Steiner, Sabine
APPLICANT: Mohr, Christine
APPLICANT: Wendland, Jürgen
APPLICANT: Knechtle, Philipp
APPLICANT: Redischung, Corinne
TITLE OF INVENTION: GENOMIC DNA SEQUENCES OF ASHBYA GOSSTYPII
TITLE OF INVENTION: AND USES THEREOF
NUMBER OF SEQUENCES: 1152
CORRESPONDENCE ADDRESS:
ADDRESSEE: No. 6239264artis Corporation
STREET: 3054 Cornwallis Road
CITY: Research Triangle Park
STATE: No. 6239264th Carolina
COUNTRY: USA
ZIP: 27709
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/998,416
FILING DATE: 24-DEC-1997
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: CH 0016/97
FILING DATE: 31-DEC-1996
ATTORNEY/AGENT INFORMATION:
NAME: Meigs, J. Timothy
REGISTRATION NUMBER: 38,241
REFERENCE/DOCKET NUMBER: PF/5-30306/A/CGC1976
TELECOMMUNICATION INFORMATION:
TELEPHONE: 919-541-8587
TELEFAX: 919-541-8689
INFORMATION FOR SEQ ID NO: 558:
SEQUENCE CHARACTERISTICS:
LENGTH: 857 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
ORIGINAL SOURCE:
ORGANISM: PAG1387UP
US-08-998-416-558

Query Match
Best Local Similarity 71.0%; Score 14.2; DB 4; Length 857;
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

OY 1 TGCAGATTGCCGCAATCTGCA 20
||||| ||||||| ||
DB 699 TGCAGCGCGGCAATCTGCA 718

RESULT 14
US-08-998-416-558/c
; Sequence 558, Application US/08998416
; Patent No. 6239264
; GENERAL INFORMATION:
; APPLICANT: Philippesen, Peter
; APPLICANT: Pohlmann, Rainer
; APPLICANT: Steiner, Sabine
; APPLICANT: Mohr, Christine
; APPLICANT: Wendland, Jürgen
; APPLICANT: Knechtle, Philipp
; APPLICANT: Redischung, Corinne
; TITLE OF INVENTION: GENOMIC DNA SEQUENCES OF ASHBYA GOSSTYPII
; TITLE OF INVENTION: AND USES THEREOF
; NUMBER OF SEQUENCES: 1152
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: No. 6239264artis Corporation
; STREET: 3054 Cornwallis Road

CITY: Research Triangle Park
STATE: No. 6239264th Carolina
COUNTRY: USA
ZIP: 27709
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/998,416
FILING DATE: 24-DEC-1997
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: CH 0016/97
FILING DATE: 31-DEC-1996
ATTORNEY/AGENT INFORMATION:
NAME: Meigs, J. Timothy
REGISTRATION NUMBER: 38,241
REFERENCE/DOCKET NUMBER: PF/5-30306/A/CGC1976
TELECOMMUNICATION INFORMATION:
TELEPHONE: 919-541-8587
TELEFAX: 919-541-8689
INFORMATION FOR SEQ ID NO: 558:
SEQUENCE CHARACTERISTICS:
LENGTH: 857 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
ORIGINAL SOURCE:
ORGANISM: PAG1387UP
US-08-998-416-558

Query Match
Best Local Similarity 71.0%; Score 14.2; DB 4; Length 857;
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

OY 1 TGCAGATTGCCGCAATCTGCA 20
||||| ||||||| ||
DB 718 TGCAGATTGCCGCGGCAATCTGCA 699

RESULT 15
US-09-210-843-1
; Sequence 1, Application US/09210843
; Patent No. 6288304
; GENERAL INFORMATION:
; APPLICANT: Moloney, Maurice M.
; APPLICANT: Habibi, Hamid R.
; TITLE OF INVENTION: Expression of Somatotropin in Plant Seeds
; FILE REFERENCE: 9369-69
; CURRENT APPLICATION NUMBER: US/09/210,843
; CURRENT FILING DATE: 1998-12-15
; NUMBER OF SEQ ID NOS: 2
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 1
; LENGTH: 1101
; TYPE: DNA
; ORGANISM: synthetic construct
US-09-210-843-1

Query Match
Best Local Similarity 71.0%; Score 14.2; DB 4; Length 1101;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 2 GCAGATTGCCGCAATCTGCA 20
||||| ||||||| ||
DB 123 GCAGATTGCTAAAGCTGCA 141

Search completed: June 26, 2003, 16:20:52
Job time : 31.2888 secs

THIS PAGE BLANK (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 26, 2003, 11:19:15 ; Search time 1529.13 Seconds
(without alignments)
211.826 Million cell updates/sec

Title: US-09-355-254f-13

Perfect score: 20

Sequence: 1 tgcagatcgcgcacatcga 20

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 16154066 seqs, 8097743376 residues

Total number of hits satisfying chosen parameters: 32308132

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Maximum Match 100%
Listing first 45 summaries

Database :

EST:*
1: em_estba:*
2: em_esthum:*
3: em_estlin:*
4: em_estnu:*
5: em_estov:*
6: em_estpl:*
7: em_estro:*
8: em_hic:*
9: gb_estl:*
10: gb_est2:*
11: gb_hic:*
12: gb_est3:*
13: gb_est4:*
14: gb_est5:*
15: em_estfun:*
16: em_estlom:*
17: gb_gss:*
18: em_gss_hum:*
19: em_gss_inv:*
20: em_gss_pin:*
21: em_gss_vrt:*
22: em_gss_fun:*
23: em_gss_mam:*
24: em_gss_mus:*
25: em_gss_other:*
26: em_gss_pro:*
27: em_gss_fod:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	16.8	84.0	421	10	AM440244 xu42h12.x
2	16.8	84.0	421	10	AM440244 xu42h12.x
3	16.8	84.0	421	10	AM440244 xu42h12.x
4	16.8	84.0	421	10	AM440244 xu42h12.x
5	16.4	82.0	380	17	BH381085 AG-ND-157
6	16.4	82.0	380	17	BH381085 AG-ND-157

7	16.4	82.0	478	17	BH372378 AG-ND-101
8	16.4	82.0	478	17	BH372378 AG-ND-101
9	15.8	79.0	266	17	BH372378 AG-ND-101
10	15.8	79.0	266	17	BH372378 AG-ND-101
11	15.8	79.0	266	17	BH372378 AG-ND-101
12	15.8	79.0	266	17	BH372378 AG-ND-101
13	15.8	79.0	266	17	BH372378 AG-ND-101
14	15.8	79.0	266	17	BH372378 AG-ND-101
15	15.8	79.0	266	17	BH372378 AG-ND-101
16	15.8	79.0	266	17	BH372378 AG-ND-101
17	15.8	79.0	266	17	BH372378 AG-ND-101
18	15.8	79.0	266	17	BH372378 AG-ND-101
19	15.8	79.0	266	17	BH372378 AG-ND-101
20	15.8	79.0	266	17	BH372378 AG-ND-101
21	15.8	79.0	266	17	BH372378 AG-ND-101
22	15.8	79.0	266	17	BH372378 AG-ND-101
23	15.8	79.0	266	17	BH372378 AG-ND-101
24	15.8	79.0	266	17	BH372378 AG-ND-101
25	15.8	79.0	266	17	BH372378 AG-ND-101
26	15.8	79.0	266	17	BH372378 AG-ND-101
27	15.8	79.0	266	17	BH372378 AG-ND-101
28	15.8	79.0	266	17	BH372378 AG-ND-101
29	15.8	79.0	266	17	BH372378 AG-ND-101
30	15.8	79.0	266	17	BH372378 AG-ND-101
31	15.8	79.0	266	17	BH372378 AG-ND-101
32	15.8	79.0	266	17	BH372378 AG-ND-101
33	15.8	79.0	266	17	BH372378 AG-ND-101
34	15.8	79.0	266	17	BH372378 AG-ND-101
35	15.8	79.0	266	17	BH372378 AG-ND-101
36	15.8	79.0	266	17	BH372378 AG-ND-101
37	15.8	79.0	266	17	BH372378 AG-ND-101
38	15.8	79.0	266	17	BH372378 AG-ND-101
39	15.8	79.0	266	17	BH372378 AG-ND-101
40	15.8	79.0	266	17	BH372378 AG-ND-101
41	15.8	79.0	266	17	BH372378 AG-ND-101
42	15.8	79.0	266	17	BH372378 AG-ND-101
43	15.8	79.0	266	17	BH372378 AG-ND-101
44	15.8	79.0	266	17	BH372378 AG-ND-101
45	15.8	79.0	266	17	BH372378 AG-ND-101

ALIGNMENTS

RESULT 1
AM440244
LOCUS
DEFINITION
x42h12.x1 NCI CGAP_HN9 Homo sapiens CDNA clone IMAGE:2804423 3'
similar to contig11.t2 L1 repetitive element ;, mRNA sequence.

AM440244.1 GI:6975550
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM

human.

REFERENCE

AUTHORS

TITLE

JOURNAL

COMMENT

Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
1 (bases 1 to 421)
NCI-CGAP <http://www.ncbi.nlm.nih.gov/ncicgap>.
National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
Tumor Gene Index
Unpublished (1997)
Contact: Robert Strausberg, Ph.D.
Email: cgaps-remail.nih.gov
Tissue Procurement: Edward Shillitoe Ph.D., Silvio Gutkind Ph.D.,
Chidchanok Leethanakul D.D.S., Michael Emmert-Buck M.D. Ph.D.
CDNA Library Preparation: David B. Krizman, Ph.D.
CDNA Library Arrayed by: Greg Lennon, Ph.D.
DNA Sequencing by: Washington University Genome Sequencing Center
Clone distribution: NCI-CGAP clone distribution information can be
found through the I.M.A.G.E. Consortium/LLNL at:
www.bio.llnl.gov/dbp/image/image.html
Possible reversed clone: polyT not found

RESULT 4
A0696464/c 456 bp DNA linear GSS 06-JUL-1999
LOCUS HS-5518.A2.D04.SP6E RPCI-11 Human Male BAC Library Homo sapiens
DEFINITION A0696464 genomic clone Plate-1094 Col-8 Row-G, DNA sequence.
ACCESSION A0696464.1 GI:5386712
VERSION GSS.
KEYWORDS human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.
REFERENCE 1 (bases 1 to 456)
AUTHORS Mahairas,G.G., Wallace,J.C., Smith,K., Swartzell,S., Holzman,T.,
Keller,A., Shaker,R., Furlong,J., Young,J., Zhao,S., Adams,M.D. and
Hood,L.
TITLE Sequence-tagged connectors: A sequence approach to mapping and
scanning the human genome
JOURNAL Proc. Natl. Acad. Sci. U.S.A. 96 (17), 9739-9744 (1999)
MEDLINE 99380589
COMMENT Contact: Mahairas GG, Wallace JC, Hood L
High Throughput Sequencing Center
University of Washington
401 Queen Anne Avenue North, Seattle, WA 98109, USA
Tel: (206) 616-3618
Fax: (206) 616-3887
Email: jwallace@u.washington.edu
Clones are derived from the human BAC library RPCI-11. For BAC
library availability, please contact Pieter de Jong
(pieter@dejong.med.buffalo.edu). Clones may be purchased from
BACPAC Resources (http://bacpac.med.buffalo.edu/ordering_bac.htm)
or from Research Genetics (info@resgen.com). BAC end Web Server:
http://www.htsc.washington.edu
Plate: 1094 row: G column: 8
Seq primer: SP6
Class: BAC ends
High quality sequence stop: 456.
Location/Qualifiers
1..456
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="Plate-1094 Col-8 Row-G"
/clone_id="RPCI-11 Human Male BAC Library"
/sex="male"
/note="Vector: pBAC3.6; Site_1: EcoRI; Site_2: EcoRI;
Male blood DNA was isolated from one randomly chosen donor
and partially digested with a combination of EcoRI and
EcoRII. Size selected DNA was cloned into the
pBAC3.6 vector at EcoRI sites"
BASE COUNT 142 a 92 c 103 g 118 t 1 others
ORIGIN
Query Match 84.0%; Score 16.8; DB 17; Length 456;
Best Local Similarity 90.0%; Pred. No. 6.1e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 1 TCGAGATTGGCAGATCTGCA 20
||||| | | | | | | | | |
Db 384 TCGAGATTGGCAGATCTGCA 365
RESULT 5
BH381085 380 bp DNA linear GSS 10-DEC-2001
LOCUS AG-ND-157L22.TF ND-TAM Anopheles gambiae genomic clone AG-ND-157L22
DEFINITION BH381085 DNA sequence.
ACCESSION BH381085
VERSION BH381085.1 GI:17327227
KEYWORDS African malaria mosquito.
SOURCE Anopheles gambiae
ORGANISM Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
Neoptera; Endopterygota; Diptera; Nematocera; Culicoidae;

REFERENCE 1 (bases 1 to 380)
AUTHORS Shetty,J., Malek,J., Koo,H., Collins,F., Gardner,M. and Loftus,B.J.
TITLE Direct submission of BAC-end sequences from Anopheles gambiae
JOURNAL Unpublished (2001)
COMMENT Other_GSSs: AG-ND-157L22.TF
Contact: Brendan J Loftus
Department of Eukaryotic Genomics
The Institute for Genomic Research
9712 Medical Center Dr., Rockville, MD 20850, USA
Tel: 301 838 0208
Fax: 301 838 3543
Email: b.loftus@tigr.org
This clone is from an A. gambiae BAC library (ND-TAM) provided by
F.H. Collins and sequenced by The Institute for Genomic Research
(TIGR). The BAC library was generated from A. gambiae PEST strain
DNA. All DNA was extracted from newly hatched first instar larvae
to minimize the inclusion of DNA from microorganisms that inhabit
the gut. The DNA is derived from mixed sexes of larvae. The BAC
library was constructed at Texas A&M University BAC Center
University, College Station, Texas 77843-2123, USA using a HindIII
partial digest.
Seq primer: M13 For
Class: BAC ends.
Location/Qualifiers
1..380
/organism="Anopheles gambiae"
/strain="PEST"
/db_xref="taxon:7165"
/clone="AG-ND-157L22"
/clone_id="ND-TAM"
/note="Vector: pECBAC1; Site_1: HindIII"
BASE COUNT 69 a 111 c 119 g 81 t
ORIGIN
Query Match 82.0%; Score 16.4; DB 17; Length 380;
Best Local Similarity 94.4%; Pred. No. 8.9e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 3 CAGATTCGCGCAATCTGCA 20
||||| | | | | | | | | |
Db 280 CAGATTCGCGCAATCTGCA 297
RESULT 6
BH381085 380 bp DNA linear GSS 10-DEC-2001
LOCUS AG-ND-157L22.TF ND-TAM Anopheles gambiae genomic clone AG-ND-157L22
DEFINITION BH381085 DNA sequence.
ACCESSION BH381085
VERSION BH381085.1 GI:17327227
KEYWORDS African malaria mosquito.
SOURCE Anopheles gambiae
ORGANISM Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
Neoptera; Endopterygota; Diptera; Nematocera; Culicoidae;
Anopheles.
1 (bases 1 to 380)
REFERENCE Shetty,J., Malek,J., Koo,H., Collins,F., Gardner,M. and Loftus,B.J.
AUTHORS Direct submission of BAC-end sequences from Anopheles gambiae
JOURNAL Unpublished (2001)
COMMENT Other_GSSs: AG-ND-157L22.TF
Contact: Brendan J Loftus
Department of Eukaryotic Genomics
The Institute for Genomic Research
9712 Medical Center Dr., Rockville, MD 20850, USA
Tel: 301 838 0208
Fax: 301 838 3543
Email: b.loftus@tigr.org
This clone is from an A. gambiae BAC library (ND-TAM) provided by
F.H. Collins and sequenced by The Institute for Genomic Research
(TIGR). The BAC library was generated from A. gambiae PEST strain
DNA. All DNA was extracted from newly hatched first instar larvae

to minimize the inclusion of DNA from microorganisms that inhabit the gut. The DNA is derived from mixed sexes of larvae. The BAC library was constructed at Texas A&M University BAC Center University, College Station, Texas 77843-2123, USA using a HindIII partial digest.

Seq primer: M13 For
Class: BAC ends.

FEATURES
source
Location/Qualifiers

1..380
/organism="Anopheles gambiae"
/strain="PEST"
/db_xref="taxon:7165"
/clone_1lb="AG-ND-157122"
/clone_1lb="ND-TAM"
/note="Vector: pECBAC1; Site_1: HindIII"

BASE COUNT
ORIGIN
69 a 111 c 119 g 81 t

Query Match
Best Local Similarity 94.4%; Score 16.4; DB 17; Length 380;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY
Db
1 TGCAGATTGCGCAATCTG 18
|||||
297 TGCAGATTGCGCAATCTG 280

RESULT 7
LOCUS
BH372378
DEFINITION
AG-ND-101M20.TF ND-TAM Anopheles gambiae genomic clone AG-ND-101M20
, DNA sequence.
ACCESSION
BH372378
VERSION
BH372378.1 GI:17318503
KEYWORDS
GSS.
SOURCE
ORGANISM
African malaria mosquito.

REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT

1 (bases 1 to 478)
Shetty,J., Malek,J., Koo,H., Collins,F., Gardner,M. and Loftus,B.J.
Direct Submission of BAC-end sequences from Anopheles gambiae
Unpublished (2001)
Other_GSSs: AG-ND-101M20.TF
Contact: Brendan J Loftus
Department of Eukaryotic Genomics
The Institute for Genomic Research
9712 Medical Center Dr., Rockville, MD 20850, USA
Tel: 301 838 0208
Fax: 301 838 3543
Email: b.loftus@tigr.org

This clone is from an A. gambiae BAC library (ND-TAM) provided by F.H. Collins and sequenced by The Institute for Genomic Research (TIGR). The BAC library was generated from A. gambiae PEST strain DNA. All DNA was extracted from newly hatched first instar larvae to minimize the inclusion of DNA from microorganisms that inhabit the gut. The DNA is derived from mixed sexes of larvae. The BAC library was constructed at Texas A&M University BAC Center University, College Station, Texas 77843-2123, USA using a HindIII partial digest.

Seq primer: M13 For
Class: BAC ends.

FEATURES
source
Location/Qualifiers

1..478
/organism="Anopheles gambiae"
/strain="PEST"
/db_xref="taxon:7165"
/clone_1lb="AG-ND-101M20"
/clone_1lb="ND-TAM"
/note="Vector: pECBAC1; Site_1: HindIII"

BASE COUNT
ORIGIN
153 a 109 c 123 g 93 t

Query Match
Best Local Similarity 94.4%; Score 16.4; DB 17; Length 478;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY
Db
3 CAGATTGCGCAATCTGCA 20
|||||
17 CCGATTGCGCAATCTGCA 34

RESULT 8
LOCUS
BH372378/c
DEFINITION
AG-ND-101M20.TF ND-TAM Anopheles gambiae genomic clone AG-ND-101M20
, DNA sequence.
ACCESSION
BH372378
VERSION
BH372378.1 GI:17318503
KEYWORDS
GSS.
SOURCE
ORGANISM
African malaria mosquito.

REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT

1 (bases 1 to 478)
Shetty,J., Malek,J., Koo,H., Collins,F., Gardner,M. and Loftus,B.J.
Direct Submission of BAC-end sequences from Anopheles gambiae
Unpublished (2001)
Other_GSSs: AG-ND-101M20.TF
Contact: Brendan J Loftus
Department of Eukaryotic Genomics
The Institute for Genomic Research
9712 Medical Center Dr., Rockville, MD 20850, USA
Tel: 301 838 0208
Fax: 301 838 3543
Email: b.loftus@tigr.org

This clone is from an A. gambiae BAC library (ND-TAM) provided by F.H. Collins and sequenced by The Institute for Genomic Research (TIGR). The BAC library was generated from A. gambiae PEST strain DNA. All DNA was extracted from newly hatched first instar larvae to minimize the inclusion of DNA from microorganisms that inhabit the gut. The DNA is derived from mixed sexes of larvae. The BAC library was constructed at Texas A&M University BAC Center University, College Station, Texas 77843-2123, USA using a HindIII partial digest.

Seq primer: M13 For
Class: BAC ends.

FEATURES
source
Location/Qualifiers

1..478
/organism="Anopheles gambiae"
/strain="PEST"
/db_xref="taxon:7165"
/clone_1lb="AG-ND-101M20"
/clone_1lb="ND-TAM"
/note="Vector: pECBAC1; Site_1: HindIII"

BASE COUNT
ORIGIN
153 a 109 c 123 g 93 t

Query Match
Best Local Similarity 94.4%; Score 16.4; DB 17; Length 478;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY
Db
1 TGCAGATTGCGCAATCTG 18
|||||
34 TGCAGATTGCGCAATCTG 17

RESULT 9
LOCUS
DEFINITION
ACCESSION
VERSION

AZ553458
RPCI-23-211A16.TV RPCI-23 Mus musculus genomic clone RPCI-23-211A16
, DNA sequence.
AZ553458
A2553458.1 GI:11233049

KEYWORDS
SOURCE house mouse.
ORGANISM Mus musculus

REFERENCE
AUTHORS Zhao, S., Nierman, W., Feldblum, T., Malek, J., Shatsman, S., Akhmet, B., Levins, M., McGann, S., Tsegaye, G., Geer, K., Kroll, M., de Jong, P., and Fraser, C.M.
Mouse BAC End Sequences from Library RPCI-23
Unpublished (1999)

TITLE
JOURNAL Other-GSSs: RPCI-23-211A16.TU
Contact: Shaying Zhao
Department of Eukaryotic Genomics
The Institute for Genomic Research
9712 Medical Center Dr., Rockville, MD 20850, USA
Tel: 301 838 0200
Fax: 301 838 0208
Email: szhao@tigr.org

Clones are derived from the mouse BAC library RPCI-23. For BAC library availability, please contact Pieter de Jong (pieter@dejong.med.buffalo.edu). Clones may be purchased from BACPAC Resources (<http://bacpac.med.buffalo.edu/orderingframe.htm>) or from Resea ch Genetics (info@resgen.com). BAC end page: http://www.tigr.org/tdb/bac-ends/mouse/bac_end_intro.html
Plate: 211 row: A column: 16
Seq primer: T7
Class: BAC ends.

FEATURES
source Location/Qualifiers
1..266
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="RPCI-23-211A16"
/clone_lib="RPCI-23"
/sex="Female"
/lab_host="DH10B"
/note="Organ: Kidney/Brain; Vector: pBACe3.6; Site:1; EcoRI; Site:2; EcoRI; Female C57BL/6J mouse kidney and/or brain genomic DNA was isolated and partially digested with a combination of EcoRI and EcoRI Methylase. Size selected DNA was cloned into the pBACe3.6 vector at the EcoRI sites. The ligation products were transformed into DH10B electrocompetent cells (BRL Life Technologies)."
BASE COUNT 88 a 49 c 40 g 89 t
ORIGIN

Query Match 79.0%; Score 15.8; DB 17; Length 266;
Best Local Similarity 89.5%; Pred. No. 1.5e+03;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY
2 GCAGATTGGCGCATCTGCA 20
||||| 11 |||||||
12 GCAGATGCGCATCTGCA 30

Db
2 GCAGATTGGCGCATCTGCA 30

RESULT 10
A2553458 266 bp DNA linear GSS 20-NOV-2000
LOCUS A2553458
DEFINITION RPCI-23-211A16.TV RPCI-23 Mus musculus genomic clone RPCI-23-211A16
DNA sequence.
ACCESSION A2553458
VERSION A2553458.1 GI:11233049
KEYWORDS GSS.
SOURCE house mouse.
ORGANISM Mus musculus

REFERENCE
AUTHORS Zhao, S., Nierman, W., Feldblum, T., Malek, J., Shatsman, S., Akhmet, B., Levins, M., McGann, S., Tsegaye, G., Geer, K., Kroll, M., de Jong, P., and Fraser, C.M.
Mouse BAC End Sequences from Library RPCI-23

JOURNAL
COMMENT Unpublished (1999)
Other-GSSs: RPCI-23-211A16.TU
Contact: Shaying Zhao
Department of Eukaryotic Genomics
The Institute for Genomic Research
9712 Medical Center Dr., Rockville, MD 20850, USA
Tel: 301 838 0200
Fax: 301 838 0208
Email: szhao@tigr.org

Clones are derived from the mouse BAC library RPCI-23. For BAC library availability, please contact Pieter de Jong (pieter@dejong.med.buffalo.edu). Clones may be purchased from BACPAC Resources (<http://bacpac.med.buffalo.edu/orderingframe.htm>) or from Resea ch Genetics (info@resgen.com). BAC end page: http://www.tigr.org/tdb/bac-ends/mouse/bac_end_intro.html
Plate: 211 row: A column: 16
Seq primer: T7
Class: BAC ends.

FEATURES
source Location/Qualifiers
1..266
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="RPCI-23-211A16"
/clone_lib="RPCI-23"
/sex="Female"
/lab_host="DH10B"
/note="Organ: Kidney/Brain; Vector: pBACe3.6; Site:1; EcoRI; Site:2; EcoRI; Female C57BL/6J mouse kidney and/or brain genomic DNA was isolated and partially digested with a combination of EcoRI and EcoRI Methylase. Size selected DNA was cloned into the pBACe3.6 vector at the EcoRI sites. The ligation products were transformed into DH10B electrocompetent cells (BRL Life Technologies)."
BASE COUNT 88 a 49 c 40 g 89 t
ORIGIN

Query Match 79.0%; Score 15.8; DB 17; Length 266;
Best Local Similarity 89.5%; Pred. No. 1.5e+03;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY
1 TGCAGATTGGCGCATCTGC 19
||||| 11 |||||||
30 TGCAGATTGGCGCATCTGC 12

Db
30 TGCAGATTGGCGCATCTGC 12

RESULT 11
A1913095 269 bp mRNA linear EST 16-DEC-1999
LOCUS A1913095
DEFINITION t288a12.x1 NCI-CGAP_K1d11 Homo sapiens cdna clone IMAGE:2295646 3', mRNA sequence.
ACCESSION A1913095
VERSION A1913095.1 GI:5632950
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens

REFERENCE
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
1 (bases 1 to 269)
NCI-CGAP <http://www.ncbi.nlm.nih.gov/ncicgap>.
National Cancer Institute, Cancer Genome Anatomy Project (CGAP), Tumor Gene Index
Unpublished (1997)
Contact: Robert Strausberg, Ph.D.
Email: cgaaps-remail.nih.gov
Tissue Procurement: Christopher Moskaluk, M.D., Ph.D., Michael R. Emmert-Buck, M.D., Ph.D.
CDNA Library Preparation: M. Bento Soares, Ph.D.
DNA Library Arrayed by: Greg Lennon, Ph.D.
DNA Sequencing by: Washington University Genome Sequencing Center
Clone distribution: NCI-CGAP clone distribution information can be found through the I.M.A.G.E. Consortium/TLNT at: www.bio.lnl.gov/bdrrp/image/image.html

Insert Length: 527 Std Error: 0.00
 Seq primer: -400P from GIBCO
 High quality sequence stop: 246.
 Location/Qualifiers

FEATURES

1..269

/organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone="IMAGE:2295646"
 /clone_1lb="NCI_CGAP_K1d11"
 /lab_host="DH10B"
 /note="Organ: kidney; Vector: pT73D-Pac (Pharmacia) with a modified polylinker. Site_1: Not I; Site_2: Eco RI; Plasmid DNA from the normalized library NCI_CGAP_K1d3 was prepared, and 88 circles were made in vitro. Following HAP purification, this DNA was used as tracer in a subtractive hybridization reaction. The driver was PCR-amplified cDNAs from a pool of 5,000 clones made from the same library (clonoids 1322376-1323911, 1456007-1456775, and 1500552-1502855). Subtraction by Bento Soares and M. Fatima Bonaldo."

BASE COUNT 29 a 104 c 91 g 45 t

ORIGIN

Query Match 79.0%; Score 15.8; DB 9; Length 269;
 Best Local Similarity 89.5%; Pred.No. 1.5e+03;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 TGCAAGATTCGCACATCTGC 19
 ||||| ||||| ||||| |||||
 DB 62 TGCAAGATTCGCACATCTGC 80

RESULT 12
 A1913095/LOCUS 269 bp mRNA linear EST 16-DEC-1999
 DEFINITION t288a12.x1 NCI_CGAP_K1d11 Homo sapiens cDNA clone IMAGE:2295646 3',
 mRNA sequence.
 ACCESSION A1913095
 VERSION A1913095.1 GI:5632950
 KEYWORDS EST.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1 (bases 1 to 269)
 NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
 Tumor Gene Index
 National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
 Unpublished (1997)
 JOURNAL COMMENT
 Contact: Robert Strausberg, Ph.D.
 Email: cgaabs-remail.nih.gov
 Tissue Procurement: Christopher Moskaluk, M.D., Ph.D., Michael R.
 Emmert-Buck, M.D., Ph.D.
 CNA Library Preparation: M. Bento Soares, Ph.D.
 DNA Sequencing by: Washington University Genome Sequencing Center
 Clone distribution: NCI-CGAP clone distribution information can be
 found through the I.M.A.G.E. Consortium/MLM at:
 www-bio.lnll.gov/dbirp/image/image.html
 Insert Length: 527 Std Error: 0.00
 Seq primer: -400P from GIBCO
 High quality sequence stop: 246.
 Location/Qualifiers

FEATURES

1..269

/organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone="IMAGE:2295646"
 /clone_1lb="NCI_CGAP_K1d11"
 /lab_host="DH10B"
 /note="Organ: kidney; Vector: pT73D-Pac (Pharmacia) with a modified polylinker. Site_1: Not I; Site_2: Eco RI; Plasmid DNA from the normalized library NCI_CGAP_K1d3 was prepared, and 88 circles were made in vitro. Following HAP

purification, this DNA was used as tracer in a subtractive hybridization reaction. The driver was PCR-amplified cDNAs from a pool of 5,000 clones made from the same library (clonoids 1322376-1323911, 1456007-1456775, and 1500552-1502855). Subtraction by Bento Soares and M. Fatima Bonaldo."

BASE COUNT 29 a 104 c 91 g 45 t

ORIGIN

Query Match 79.0%; Score 15.8; DB 9; Length 269;
 Best Local Similarity 89.5%; Pred.No. 1.5e+03;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2 GCAGATTCGCACATCTGCA 20
 ||||| ||||| ||||| |||||
 DB 80 GCAGATTCGCACATCTGCA 62

RESULT 13

BB071586 301 bp mRNA linear EST 27-JUN-2000
 LOCUS BB071586
 DEFINITION BB071586 RIKEN full-length enriched, 15 days embryo male testis Mus
 musculus cDNA clone 803049B09 3', mRNA sequence.
 ACCESSION BB071586
 VERSION BB071586.1 GI:8581584
 KEYWORDS EST.
 SOURCE house mouse.
 ORGANISM Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sclerognathii; Muridae; Murinae; Mus.

REFERENCE

1 (bases 1 to 301)

Kono, H., Aizawa, K., Akahira, S., Akiyama, J., Arakawa, T., Carninci, P., Endo, T., Fukuda, S., Fukunishi, Y., Hara, A., Hayatsu, N., Hirozane, T., Horii, F., Ishii, Y., Ishikawa, J., Ishikawa, T., Itoh, M., Izawa, M., Kadota, K., Kagawa, I., Kai, C., Kawai, J., Kikuchi, N., Kiyosawa, H., Kojima, Y., Kondo, S., Koya, S., Kurihara, C., Kusakabe, M., Matsuyama, T., Miki, R., Mizuno, Y., Nakamura, M., Oda, H., Okazaki, Y., Ono, T., Owa, C., Saito, H., Sakai, C., Sato, K., Shibata, K., Shibata, Y., Shigemoto, Y., Shinagawa, A., Shiraki, T., Sogabe, Y., Sugahara, Y., Suzuki, H., Suzuki, H., Tagawa, A., Takahashi, F., Tomioka, N., Toya, T., Tsunoda, Y., Watabiki, A., Watanabe, S., Yamamura, T., Yamamoto, I., Yano, R., Yasunishi, A., Yokota, T., Yoshida, K., Yoshiki, A., Yoshino, M., Yamamoto, M., and Hayashizaki, Y.
 RIKEN Mouse ESTs (Kono, H., et al.)
 Unpublished (2000)
 JOURNAL COMMENT
 Title: Yoshihide Hayashizaki
 Laboratory for Genome Exploration Research Group, RIKEN Genomic
 Sciences Center (GSC), Yokohama Institute
 The Institute of Physical and Chemical Research (RIKEN)
 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan
 Tel: 81-45-503-9222
 Fax: 81-45-503-9216
 Email: genome-res@gscc.riken.go.jp,
 URL: http://genome.gsc.riken.go.jp/
 Carninci, P., Nishiyama, Y., Westover, A., Itoh, M., Nagaoaka, S., Sasaki, N., Okazaki, Y., Muramatsu, M., and Hayashizaki, Y.
 Thermostabilization and thermocycling of thermolabile enzymes by
 ThermoStabilization and its application for the synthesis of full length
 cDNA. Proc. Natl. Acad. Sci. U.S.A. 95 (2), 520-524 (1998)
 Itoh, M., Katsunari, T., Akiyama, J., Shibata, K., Izawa, M., Kawai, J.,
 Tomaru, Y., Carninci, P., Shibata, Y., Ozawa, Y., Muramatsu, M., Okazaki, Y., and Hayashizaki, Y.
 Automated filtration-based high-throughput plasmid preparation
 system. Genome Res. 9 (5), 463-470 (1999)
 Carninci, P. and Hayashizaki, Y.
 High-efficiency full-length cDNA cloning. Methods Enzymol. 303,
 19-44 (1999)
 Please visit our web site (http://genome.ritc.riken.go.jp) for
 further details.
 Location/Qualifiers

FEATURES

1..301

/organism="Mus musculus"
 /strain="C57BL/6J"

TITLE

P., Kolman, J., Slabaugh, M.S., Livingston, K., Zhou, Y., Lai, Z., Church, S., Jackson, L. and Bradford, K.
Lettuce and Sunflower ESTs from the Composite Genome Project
<http://compgenomics.ucdavis.edu/>
Unpublished (2002)

JOURNAL

Contact: Alexander Kozik [R.W.Michelmores]
Department of Vegetable Crops, R.W.Michelmores Lab
University of California at Davis (UCD)

Asmundson Hall, UCD, Davis, CA 95616, USA
Tel: 1-(530)-742-1742
Fax: 1-(530)-752-9659

Email: akozik@ucdavis.edu [michelmore@vegmail.ucdavis.edu]
singleton, see <http://cspdb.ucdavis.edu/> for details.
Plate: OHG17 row: A column: 10.

FEATURES

source

Location/Qualifiers

1..393

/organism="Helianthus annuus"

/cultivar="RHA280"

/db_xref="taxon:4332"

/clone="OHG17A10"

/clone_1lb="OH_EFGHJ sunflower RHA280"

/lab_host="E.coli"

/note="Vector: pBRCDNA5flAB: The library was constructed from 11 different sources of RNA from a single genotype. Separate cDNAs were generated using primers that incorporated unique 5' and 3' tags to distinguish each source of RNA. cDNAs were then pooled, size-fractionated, directionally cloned into a custom medium-copy vector and transformations made with four size classes to minimize size bias. Details of each source of RNA and library construction can be obtained at <http://cspdb.ucdavis.edu/>

TAG_L1b-QH_EFGHJ sunflower RHA280

TAG_TISSUE=hu11s

TAG_SEQ=CTAGTCGGG"

BASE COUNT 101 a 108 c 85 g 99 t

ORIGIN

Query Match 79.0%; Score 15.8; DB 14; Length 393;
Best Local Similarity 89.5%; Pred. No. 1.8e+03;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2 GCAGATTGGCAATCTGCA 20
|||||

DB 107 GCAGATTGGCTATCTCCA 125

Search completed: June 26, 2003, 22:12:33
Job time : 1531.13 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 26, 2003, 09:43:36 ; Search time 226.087 Seconds
(without alignments)
199.215 Million cell updates/sec

Title: US-09-355-254f-19

Perfect score: 20

Sequence: 1 ctagattccccaatgatg 20

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 2185239 seqs, 1125999159 residues

Total number of hits satisfying chosen parameters: 4370478

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Database : Listing first 45 summaries

N_Geneseq_101002:*

1: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1980.DAT.*
2: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1981.DAT.*
3: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1982.DAT.*
4: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1983.DAT.*
5: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1984.DAT.*
6: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1985.DAT.*
7: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1986.DAT.*
8: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1987.DAT.*
9: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1988.DAT.*
10: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1989.DAT.*
11: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1990.DAT.*
12: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1991.DAT.*
13: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1992.DAT.*
14: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1993.DAT.*
15: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1994.DAT.*
16: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1995.DAT.*
17: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1996.DAT.*
18: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1997.DAT.*
19: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1998.DAT.*
20: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1999.DAT.*
21: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA2000.DAT.*
22: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA2001A.DAT.*
23: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA2001B.DAT.*
24: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA2002.DAT.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	20	100.0	20	19 AAV46011	Immune adjuvant SR
2	20	100.0	20	24 AAU39159	Murine Toll-like r
3	20	100.0	524	11 AA003455	Recombinant molecu
4	20	100.0	524	11 AA003709	Murine interferon
5	20	100.0	524	14 AA052649	Promoter and regul
6	18.4	92.0	20	18 AAT88819	Leptin response el
7	18.4	92.0	20	19 AAV38478	IRF-1 gamma interf
8	18.4	92.0	25	21 AA292038	STAT5 binding sequ
9	18.4	92.0	669	22 AAH46291	Human Interferon r

10	18.4	92.0	669	22 AAH46292	Human Interferon r
11	18.4	92.0	669	22 AAH46293	Human Interferon r
12	18.4	92.0	700	22 AAH91999	Human inflammatory
13	18	90.0	86	19 AAV59503	Upstream primer fo
14	18	90.0	86	19 AAV34146	Upstream primer fo
15	18	90.0	86	19 AAV34278	Upstream primer fo
16	18	90.0	86	19 AAV69603	Upstream primer fo
17	18	90.0	86	20 AAZ32073	Gamma activation s
18	18	90.0	86	20 AAZ19852	SV40 early promote
19	18	90.0	86	20 AAZ24803	Upstream primer fo
20	18	90.0	86	20 AAZ09776	Synthetic GAS-cont
21	18	90.0	86	20 AAZ10678	PCR primer used to
22	18	90.0	86	20 AAZ00402	Human GAS promoter
23	18	90.0	86	20 AAZ00794	SV40 early promote
24	18	90.0	86	20 AAZ06211	Upstream primer fo
25	18	90.0	86	20 AAZ97908	Upstream primer fo
26	18	90.0	86	20 AAZ79003	Upstream primer fo
27	18	90.0	86	20 AAZ28659	Nucleotide sequenc
28	18	90.0	86	20 AAZ84925	Upstream primer fo
29	18	90.0	86	20 AAZ35893	PCR primer used to
30	18	90.0	86	20 AAZ37361	Human GAS-contant
31	18	90.0	86	20 AAZ37443	Synthetic GAS-cont
32	18	90.0	86	20 AAZ27303	Upstream primer fo
33	18	90.0	86	20 AAZ51693	5' PCR primer used
34	18	90.0	86	20 AAZ30175	Upstream primer fo
35	18	90.0	86	20 AAZ22203	Upstream primer fo
36	18	90.0	86	20 AAZ22103	Upstream primer fo
37	18	90.0	86	20 AAZ30309	5' PCR primer used
38	18	90.0	86	20 AAZ20404	Upstream primer fo
39	18	90.0	86	20 AAZ16170	SV40 early promote
40	18	90.0	86	20 AAZ04303	Upstream primer fo
41	18	90.0	86	20 AAZ00603	Upstream primer fo
42	18	90.0	86	20 AAZ08847	Primer for DNA enc
43	18	90.0	86	20 AAZ84403	Upstream primer fo
44	18	90.0	86	21 AAZ02079	5' PCR primer to g
45	18	90.0	86	21 AAZ02231	SV40 promoter sequ

ALIGNMENTS

RESULT 1	
ID	AAV46011 standard; DNA: 20 BP.
XX	
AC	AAV46011:
XX	
DT	16-OCT-1998 (first entry)
XX	
DE	Immune adjuvant STAT4.
XX	
KW	Immune system; adjuvant; vaccine; cancer; prophylactic; pathogenicity;
KW	modulator; tolerance; regulator; helper cell; antigen; immunoglobulin;
KW	Ig class; autoimmune response; T-cell; B-cell; tumour; ss.
XX	
OS	Class Bacteria.
XX	
PN	EP855184-A1.
XX	
PD	29-JUL-1998.
XX	
PF	23-JAN-1997; 97EP-0101019.
XX	
PR	23-JAN-1997; 97EP-0101019.
XX	
PA	(HEEG/) HEEG K.
PA	(LIPF/) LIPFORD G B.
PA	(WAGN/) WAGNER H.
XX	
PI	Heeg K, Lipford GB, Wagner H;
XX	
DR	WPI: 1998-389630/34.
XX	

XX PT Antigenic composition comprises polynucleotide fragment and antigen
PT - used as vaccine to treat or prevent e.g. cancer or pathogen
PT infections and to modulate immune response e.g. tolerance break and
PT regulation of TH1/TH2 cells
XX
PS Example 5; Page 9; 28pp; English.
XX
CC AAV4593-V46019 are fragments of bacterial polynucleotides which are
CC used as immune adjuvants for inclusion into vaccines to treat cancer and
CC for prophylaxis and/or treatment of conditions caused by pathogenic
CC micro-organisms. The polynucleotide is used for modulation of an immune
CC response and the modulation is selected from the group break of Ig
CC tolerance, regulation of TH1/TH2 helper cell responses, switch of Ig
CC classes, treatment of autoimmune responses and induction of tolerances.
CC DNA oligomers are used to enhance the reactivity of immune cells to
CC viral, bacterial and parasitic antigens, to break tolerance in allergic
CC and B cells e.g. against tumour antigens, as adjuvants in vaccination
CC against tumour-defined antigens and immunostimulatory substances in an
CC immune response against tumours and to suppress immune reactions of the
CC innate and acquired immune system. The composition is inexpensive and
CC stable and does not cause lethal shock, which happens with prior art.
CC bacterial sequences.
XX
S0 Sequence 20 BP; 5 A; 5 C; 4 G; 6 T; 0 other;

Query Match 100.0%; Score 20; DB 19; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.2;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 CTGATTTCCCGGAATGATG 20
Db 1 CTGATTTCCCGGAATGATG 20
|||||
|||

RESULT 2
AAL39169
ID AAL39169 standard; DNA; 20 BP.
XX
XX AAL39169;
XX
XT 05-SEP-2002 (first entry)
XX
DE Murine Toll-like receptor related CpG DNA SEQ ID NO 44.
XX
KW Murine Toll-like receptor; TLR9; TLR7; TLR8; ISNA; ds.
XX
OS Unidentified.
XX
PN WO200222809-A2.
XX
PD 21-MAR-2002.
XX
PE 17-SEP-2001; 2001WO-US292229.
XX
PA 15-SEP-2000; 2000US-233035P.
PR 23-JAN-2001; 2001US-263657P.
PR 17-MAY-2001; 2001US-291726P.
PR 22-JUN-2001; 2001US-300210P.
XX
PA (COLE-) COLEY PHARM GMBH.
XX
PI Bauer S, Lidford G, Wagner H;
XX WPI; 2002-393964/42.
DR
XX
PT New isolated murine Toll-like receptor (TLR)9, TLR7, TLR8 polypeptides,
PT useful for identifying species specificity of immunostimulatory nucleic
PT acid and identifying immunostimulatory nucleic acids
XX
PS Disclosure; Page 76; 195pp; English.

CC	their fragments of 1032, 1050 or 1032 amino acids as given in specification, or
CC	sequences of 1032, 1050 or 1032 amino acids as given in specification, or
CC	fragments have an amino acid sequence which is identical to human TLR9,
CC	TLR7 or TLR8 polypeptides or their fragment except for at least one amino
CC	acid of a murine TLR polypeptide. The isolated nucleic acids of the
CC	invention are useful for inhibiting TLR9 signalling activity in a cell.
CC	TLR7, TLR8 and TLR9 polypeptides are useful for identifying nucleic acid
CC	molecules which interact with a TLR polypeptide or its fragment. The
CC	TLR7, TLR8 or TLR9 polypeptides are also useful for identifying ISNA. The
CC	TLR7, TLR8 and TLR9 polypeptides are also useful for competing TLR9
CC	signalling activity of a test compound (that is not a nucleic acid, and
CC	is a polypeptide or a part of a combinatorial library of compounds) with
CC	an ISNA. The TLR7, TLR8 and TLR9 polypeptides are also useful for
CC	identifying species specificity of an ISNA. The isolated nucleic acids of
CC	the invention are useful as probes or primers. This polynucleotide
CC	sequence represents DNA relating to the isolated Toll-like receptors of
CC	the invention.
XX	
SQ	Sequence 20 BP; 5 A; 5 C; 4 G; 6 T; 0 other:
Query Match	100.0%; Score 20; DB 24; Length 20;
Best Local Similarity	100.0%; Pred. No. 1,2;
Matches	20; Conservative 0; Mismatches 0; Indels 0; Gaps 0
QY	1 CTGATTTCCTCCGAATGATG 20
Db	1 CTGATTTCCTCCGAATGATG 20
RESULT 3	
AAQ03455	
ID	AAQ03455 standard; DNA: 524 BP.
XX	
AC	AAQ03455;
XX	
DT	23-JUL-1990 (first entry)
XX	
DE	Recombinant molecule encoding protein having INF-1 activity.
XX	
RW	Regulatory factor-1, Interferon-beta gene, cis-elements; ss.
OS	Eukaryotic.
XX	
Key	Location/Qualifiers
FT	GC_signal
FT	70..76
FT	/*tag- a
FT	/label-gC Box 1
FT	92..98
FT	/*tag- b
FT	/label-gC Box 2
FT	201..207
FT	/*tag- c
FT	278..280
FT	/*tag- d
FT	/label-Minor Cap site
FT	299..301
FT	/*tag- e
FT	/label-Major Cap site
FT	330..524
FT	/*tag- f
FT	/label-pIRF-1
XX	
PN	EP355202-A.
XX	
PD	28-FEB-1990.
XX	
PF	24-NOV-1988; 88EP-0119602.
XX	
PR	24-NOV-1988; 88EP-0113793.
XX	
PA	(TAN1/) TANIGUCHI T.
XX	
PI	Taniguchi T;

XX DR WPI; 1990-060144/09.
XX PT Interferon regulatory factor-1 - which is active in virus induced
PT activation of Interferon-beta gene transcription by interacting with
PT cis-elements.
XX PS Claim 13; page 46; 65pp; English.
XX CC Recombinant molecule containing promoter and regulatory sequence; can
CC be used for the production of IRF-1. IRF-1 plays an essential role
CC in virus-induced activation of Interferon-beta gene transcription by
CC interacting with the cis-elements. The recombinant molecule can
CC also be designed for expression of pharmaceutically active proteins
CC such as e.g. cytokine or plasmidogen activator.
CC See also AA03452, -51 and -53; and EP-355190-A.
XX CC
SQ Sequence 524 BP; 90 A; 166 C; 185 G; 83 T; 0 other;
Query Match 100.0%; Score 20; DB 11; Length 524;
Best Local Similarity 100.0%; Pred. No. 1.7;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 CTGATTTCCCGAAATGATG 20
DB 171 CTGATTTCCCGAAATGATG 190
RESULT 4
AA03709
ID AA03709 standard; DNA: 524 BP.
XX AC AA03709;
XX AC
XX 03-AUG-1990 (first entry)
XX DE Murine Interferon regulatory factor-1 promoter and regulatory sequence.
XX DE
XX DE Interferon regulatory factor; IRF-1 beta-gene; Interferon;
XX KM murine; ds.
XX KM
XX OS Homo sapiens.
XX OS
XX FH Key Location/Qualifiers
FT CAAAT_signal 201..207
FT /*tag- a
FT GC_signal 70..76
FT /*tag- b
FT GC_signal 92..98
FT /*tag- c
FT misc_feature 77..79
FT /*tag- d
FT misc_feature 298..300
FT /*tag- e
FT CDS /label-Major cap site.
FT 300..523
FT /*tag- f
XX PN EP359998-A.
XX PD 28-MAR-1990.
XX PD
XX PF 17-AUG-1989; 89EP-0115158.
XX PF
XX PR 24-AUG-1988; 88EP-0113793.
XX PR 24-NOV-1988; 88EP-0119602.
XX PA (TANI/) TANIGUCHI T.
XX PI Taniguchi T, Fuchita T;
XX DR WPI; 1990-092658/13.

XX XX
XX PT Recombinant interferon regulator factor-1 -
PT which plays an essential role in virus-induced activation of
PT Interferon-beta gene transcription.
XX PS Claim 10; Fig 7; 55pp; English.
XX CC Promoter and regulator sequence for IFN regulator factor-1.
XX CC
SQ Sequence 524 BP; 90 A; 166 C; 185 G; 83 T; 0 other;
Query Match 100.0%; Score 20; DB 11; Length 524;
Best Local Similarity 100.0%; Pred. No. 1.7;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 CTGATTTCCCGAAATGATG 20
DB 171 CTGATTTCCCGAAATGATG 190
RESULT 5
AA052649
ID AA052649 standard; DNA: 524 BP.
XX AC AA052649;
XX AC
XX 26-MAY-1994 (first entry)
XX DE Promoter and regulatory sequence used in recombinant construct.
XX DE
XX DE Interferon; Interferon-beta; regulation; gene expression;
XX KM regulatory element; ss.
XX KM
XX OS Mus musculus.
XX OS
XX FH Key Location/Qualifiers
FT GC_signal 70..76
FT /*tag- a
FT /*note- "GC Box 1."
FT GC_signal 92..98
FT /*tag- b
FT /*note- "GC box 2."
FT CAAAT_signal 201..207
FT /*tag- c
FT misc_feature 278..280
FT /*tag- d
FT misc_feature 299..301
FT /*tag- e
FT /*note- "Major cap site."
XX PN EP571743-A.
XX PD 01-DEC-1993.
XX PD
XX PF 17-AUG-1989; 89EP-0115158.
XX PF
XX PR 24-AUG-1988; 88EP-0113793.
XX PR 24-NOV-1988; 88EP-0119602.
XX PA (TANI/) TANIGUCHI T.
XX PI Fujita T, Taniguchi T;
XX DR WPI; 1993-378709/48.
XX DR
XX PT Interferon regulatory factor - useful for controlling expression
PT of interferon genes
XX PS Disclosure; Page 8; 45pp; English.
XX CC A protein which binds to the repeated oligomer sequence AAGTGA
CC and regulatory upstream elements of the human interferon regulatory

CC factor (IRF)-beta gene (See AAR44217) can be used to regulate the
CC expression of interferon-beta. In a recombinant molecule, the
CC sequence encoding this protein can be placed under the control of
CC this promoter and regulatory sequence.

XX Sequence 524 BP; 90 A; 166 C; 185 G; 83 T; 0 other;

Query Match 100.0%; Score 20; DB 14; Length 524;
Best Local Similarity 100.0%; Pred. No. 1.7;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 CTGATTTCCTCCGGAATGATG 20
DB 171 CTGATTTCCTCCGGAATGATG 190

RESULT 6
AA788819
ID AA788819 standard; DNA; 20 BP.

XX AA788819;

DE 12-MAY-1998 (first entry)

XX Leptin response element IRF-1 derived gamma interferon activation seq.

KW Leptin response element; IRF-1; gamma interferon activation sequence;

KW detection; obesity; diabetes; infertility; cachexia; anorexia;

XX human; Ob-r; ss.

OS Synthetic.

XX WO9740380-A1.

XX 30-OCT-1997.

XX 18-APR-1997; 97WO-US06505.

XX 15-NOV-1996; 96US-0031002.

XX 22-APR-1996; 96US-0016051.

XX 06-JUN-1996; 96GB-0011785.

XX (MERI) MERCK & CO INC.

XX Chen F, Cully DF, Hese JW, Qureshi SA, Rosenblum CI;
PI Tota MR, Van Der Ploeg L;

XX WPI, 1997-536003/49.

XX Detecting and quantifying leptin and related compounds - used e.g.
PT to assay recombinant leptin products, to identify agonists, etc

XX Claim 3; Page 12; 28pp; English.

CC The present sequence represents a leptin response element IRF-1 derived
CC gamma-interferon activation sequence. A method has been developed for
CC determining the presence of a leptin-receptor binding component (A) in
CC a sample. The method involves: (i) treating the sample with cells
CC containing: (a) nucleic acid (I) comprising a reporter gene (RG) linked
CC to a promoter that includes at least one leptin response element (LRE);
CC and (b) nucleic acid (II) encoding a leptin receptor (LR); and (ii)
CC determining if transcription of RG occurs. The method is used to assay
CC activity in recombinant leptin preparations and to identify leptin
CC (ant)agonists which are potentially useful for treating obesity,
CC diabetes and infertility (agonists) or cachexia or anorexia
CC (antagonists). Cells transformed with the vector are used to confirm
CC activity of putative LRE and to determine their leptin-binding activity
CC (by their response to added leptin). Also the binding of different LR
CC can be compared. The method is an alternative to current animal tests
CC on ob/ob mice.

XX Sequence 20 BP; 5 A; 6 C; 4 G; 5 T; 0 other;

Query Match 92.0%; Score 18.4; DB 18; Length 20;
Best Local Similarity 95.0%; Pred. No. 7.4;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1 CTGATTTCCTCCGGAATGATG 20
DB 1 CTGATTTCCTCCGGAATGATG 20

RESULT 7
AAV38478
ID AAV38478 standard; DNA; 20 BP.

XX AAV38478;

DE 12-OCT-1998 (first entry)

XX IRF-1 gamma interferon activation sequence.

KW Ob-receptor; hypothalamus; obesity; leptin; diabetes; infertility;

XX anorexia; cachexia; ss.

OS Synthetic.

XX WO9824881-A1.

XX 11-JUN-1998.

XX 26-NOV-1997; 97WO-US22165.

XX 02-DEC-1996; 96US-0032367.

XX (MERI) MERCK & CO INC.

XX Fong TM, Huang RC, Van Der Ploeg L;

XX WPI, 1998-333504/29.

XX New mutant ob receptor(s) - used to develop products for drug
PT screening and for gene therapy for weight control, e.g. obesity or
PT anorexia

XX Disclosure; Page 9; 27pp; English.

CC The IRF-1 derived gamma interferon activation sequence is used in
CC in the construction of a reporter gene for use in determining whether an
CC OB-R ligand is present in a sample. The ob-receptor (OB-R), a member of
CC the cytokine receptor family is transcribed in the hypothalamus and is
CC involved in obesity. Mutants lacking a functional first or second CK-P3
CC module or a functional intracellular domain can be used in assays for the
CC detection of ligands, agonists, antagonists and ligand mimetics. The
CC leptin agonists identified can be used in situations where leptin
CC insufficiency causes obesity, diabetes or infertility. The leptin
CC antagonists identified can be used in the treatment of anorexia and
CC cachexia. The mutant receptor nucleic acids can also be used in gene
CC therapy for weight control, e.g. for treating obesity or anorexia.

XX Sequence 20 BP; 5 A; 6 C; 4 G; 5 T; 0 other;

Query Match 92.0%; Score 18.4; DB 19; Length 20;
Best Local Similarity 95.0%; Pred. No. 7.4;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1 CTGATTTCCTCCGGAATGATG 20
DB 1 CTGATTTCCTCCGGAATGATG 20

RESULT 8
AAZ92038
ID AAZ92038 standard; DNA; 25 BP.

XX AAZ92038;

XX 08-JUN-2000 (first entry)
 DT STAT5 binding sequence oligonucleotide IRF-1 GAS.
 DE
 XX
 XX
 KM STAT5 protein; signal transducer and activator of transcription 5;
 KM protein binding sequence; transcription factor modulator; inhibitor;
 KM malignant cell removal; proliferative malignancy; neoplastic disease;
 KM immunological disorder; inflammatory disorder; therapy; ds.
 XX
 OS Synthetic.
 XX
 PN W0200006696-A2.
 XX
 PD 10-FEB-2000.
 XX
 PF 30-JUL-1999; 99MO-US17366.
 XX
 PR 30-JUL-1998; 98US-0094695.
 XX
 PA (UYSF-) UNIV SOUTH FLORIDA.
 XX
 PI Zuckerman KS, Liu RY;
 XX WPI; 2000-195281/17.
 DR
 XX
 PT Therapeutic agent for treating transcription factor-related illnesses
 PT such as proliferative malignancies, comprises an oligonucleotide for
 PT regulating transcription factor function -
 XX
 PS Claim 15; Page 34; 43pp; English.
 XX
 CC This sequence represents a STAT5 (signal transducer and activator of
 CC transcription 5) protein binding sequence. The invention relates to a
 CC therapeutic agent comprising an effective amount of an oligonucleotide
 CC (1) for modulating the function of transcription factors and a
 CC pharmaceutical acceptable carrier. The oligonucleotides can be used in a
 CC method of removing malignant cells in vitro. The oligonucleotides can be
 CC used in compositions to inhibit transcription factors in illnesses where
 CC transcription factors play a role, especially proliferative malignancies,
 CC neoplastic diseases, and immunological and inflammatory disorders.
 CC
 XX
 SO Sequence 25 BP; 6 A; 8 C; 6 G; 5 T; 0 other;
 Query Match 92.0%; Score 18.4; DB 21; Length 25;
 Best Local Similarity 95.0%; Pred. No. 7.6;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 1 CTGATTTCCCGAATGATG 20
 DB 3 CTGATTTCCCGAATGATG 22
 RESULT 9
 AAH46291
 ID AAH46291 standard; DNA; 669 BP.
 AC
 XX
 XX
 DT 25-SEP-2001 (first entry)
 XX
 DE Human interferon regulatory factor-1 promoter region, wild-type allele.
 XX
 XX Human: interferon regulatory factor-1; IRF-1; promoter;
 KM upstream region; genotyping; polymorphism; hepatitis C virus;
 KM HCV infection; interferon therapy efficacy; IFN; RFLP analysis;
 KM restriction fragment length polymorphism; ds.
 XX
 OS Homo sapiens.
 XX
 FH Key
 FT allele
 FT Location/Qualifiers
 FT replace (108, C)
 FT /*tag- a

FT /note- "This nucleotide substitution is present in
 FT the IRF-1 alleles found in HCC-T/HCC-M (IFN-
 FT sensitive) and PLC/PRF/5 (IFN insensitive) liver
 FT cancer cells"
 FT allele
 FT replace (196, A)
 FT /*tag- b
 FT /note- "This nucleotide substitution is present
 FT only in the IRF-1 allele found in PLC/PRF/5
 FT (IFN insensitive) liver cancer cells"
 XX
 PN JP2001136973-A.
 XX
 PD 22-MAY-2001.
 XX
 PF 16-NOV-1999; 99JP-0324975.
 XX
 PR 16-NOV-1999; 99JP-0324975.
 XX
 PA (SAKA) OTSUKA PHARM CO LTD.
 XX
 DR WPI; 2001-460211/50.
 XX
 XX
 PT Detection of abnormal human interferon regulatory factor-1 (IRF-1) gene
 PT
 PT
 PS Example 2; Fig 1-2; 8pp; Japanese.
 XX
 CC The invention relates to a method for the detection of an abnormal
 CC allele of the human interferon regulatory factor-1 (IRF-1) gene. The
 CC abnormal allele (AAH46293) is present in PLC/PRF/5 liver cancer cells
 CC and contains a G to A substitution at position 196 of the IRF-1 promoter
 CC region (normal alleles given in AAH46293 and AAH46294). The abnormal
 CC allele confers an insensitivity to the effects of interferon (IFN).
 CC In the method of the invention, the presence or absence of adenine
 CC at position 196 of the IRF-1 promoter is detected using procedures such
 CC as restriction fragment length polymorphism (RFLP) analysis. Prior to
 CC analysis, an IRF-1 gene fragment containing the polymorphic site can
 CC optionally be prepared (e.g., by PCR). The invention also discloses the
 CC use of IRF-1 gene fragments as probes to detect the A polymorphism. The
 CC method of the invention is used to genotype a patient with hepatitis C
 CC virus (HCV) infection in order to predict whether interferon therapy
 CC will be effective. The present sequence represents the wild-type
 CC allele of the human IRF-1 promoter region (also given in GenBank
 CC accession number X53095) which was used in RFLP analysis.
 CC
 XX
 SO Sequence 669 BP; 97 A; 234 C; 247 G; 91 T; 0 other;
 Query Match 92.0%; Score 18.4; DB 22; Length 669;
 Best Local Similarity 95.0%; Pred. No. 11;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 1 CTGATTTCCCGAATGATG 20
 DB 367 CTGATTTCCCGAATGATG 386
 RESULT 10
 AAH46292
 ID AAH46292 standard; DNA; 669 BP.
 AC
 XX
 XX
 DT 25-SEP-2001 (first entry)
 XX
 DE Human interferon regulatory factor-1 promoter region, HCC-T/HCC-M allele.
 XX
 XX Human: interferon regulatory factor-1; IRF-1; promoter;
 KM upstream region; genotyping; polymorphism; hepatitis C virus;
 KM HCV infection; interferon therapy efficacy; IFN; RFLP analysis;
 KM restriction fragment length polymorphism; HCC-T allele; HCC-M; ds.
 XX
 OS Homo sapiens.
 XX

PH	Key	Location/Qualifiers
FT	allele	replace (108, T)
FT		/tag= a
FT	allele	replace (196, A)
FT		/tag= b
FT		"this nucleotide substitution is additionally present in the IRF-1 allele found in PLC/PRR/5 (IRN insensitive) liver cancer cells"
PM	JFP201136973-A.	
PD		
XX	22-MAY-2001.	
PF	16-NOV-1999;	99JP-0324975.
XX		
PR	16-NOV-1999;	99JP-0324975.
XX		
PA	(SAKA) OTSUKA PHARM CO LTD.	
XA		
XX	WPI: 2001-460211/50.	
XX		
PT	Detection of abnormal human interferon regulatory factor-1 (IRF-1) gene	
PR	-	
XX		
PS	Example 2; Fig 1-2; 8pp; Japanese.	
XX		
CC	The invention relates to a method for the detection of an abnormal	
CC	allele of the human interferon regulatory factor-1 (IRF-1) gene. The	
CC	abnormal allele (AAH46293) is present in PLC/PRR/5 liver cancer cells	
CC	and contains a G to A substitution at position 196 of the IRF-1 promoter	
CC	region (normal alleles given in AAH46293 and AAH46294). The abnormal	
CC	allele confers an insensitivity to the effects of interferon (IFN).	
CC	In the method of the invention, the presence or absence of adenine	
CC	at position 196 of the IRF-1 promoter is detected using procedures such	
CC	as restriction fragment length polymorphism (RFLP) analysis. Prior to	
CC	analysis, an IRF-1 gene fragment containing the polymorphic site can	
CC	optionally be prepared (e.g., by PCR). The invention also discloses the	
CC	use of IRF-1 gene fragments as probes to detect the A polymorphism. The	
CC	method of the invention is used to genotype a patient with hepatitis C	
CC	virus (HCV) infection in order to predict whether interferon therapy	
CC	will be effective. The present sequence represents the allele of the	
CC	human IRF-1 promoter region found in IFN-sensitive HCC-T and HCC-M	
CC	liver cancer cells which was used in RFLP analysis.	
SQ		
	Sequence 669 BP; 97 A; 235 C; 247 G; 90 T; 0 other:	
	Query Match	92.0%; Score 18.4; DB 22; Length 669;
	Best Local Similarity	95.0%; Pred. NO. 11;
	Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
OY	1 CTGATTTCCCGCAATGATG 20	
DB	367 CTGATTTCCTCCGAATGACG 386	
RESULT 11		
ID	AAH46293	
XX	AAH46293 standard; DNA; 669 BP.	
AC		
AAH46293;		
DT		
XX	25-SEP-2001 (first entry)	
DE		
XX	Human Interferon regulatory factor-1 promoter region, PLC/PRR/5 allele.	
XX		
KM	Human; Interferon regulatory factor-1; IRF-1; promoter;	
KM	upstream region; genotyping; polymorphism; hepatitis C virus;	
KM	HCV infection; interferon therapy efficacy; IFN; RFLP analysis;	
KM	restriction fragment length polymorphism; PLC/PRR/5 allele; ds.	
OS		
XX	Homo sapiens.	
XX		
XX		
XX	key	Location/Qualifiers

```

FT      allele      replace (108, T)
FT      /*tag= a
FT      allele      replace (196, G)
FT      /*tag= b
PN      JP2001136973-A.
XX
XX      22-MAY-2001.
XX
XX      16-NOV-1999; 99JP-0324975.
XX
XX      16-NOV-1999; 99JP-0324975.
XX
XX      (SAKA ) OTSUKA PHARM CO LTD.
XX
XX      WPI: 2001-460211/50.
XX
XX      Detection of abnormal human Interferon regulatory factor-1 (IRF-1) gene
PT      -
PT
PS      Example 1; Fig 1-2; 8pp: Japanese.
PS
XX
XX      The invention relates to a method for the detection of an abnormal
CC      allele of the human Interferon regulatory factor-1 (IRF-1) gene. The
CC      abnormal allele (AAH46293) is present in PLC/PRF/5 liver cancer cells
CC      and contains a G to A substitution at position 196 of the IRF-1 promoter
CC      region (normal alleles given in AAH46293 and AAH46294). The abnormal
CC      allele confers an insensitivity to the effects of Interferon (IFN).
CC      In the method of the invention, the presence or absence of adenine
CC      at position 196 of the IRF-1 promoter is detected using procedures such
CC      as restriction fragment length polymorphism (RFLP) analysis. Prior to
CC      analysis, an IRF-1 gene fragment containing the polymorphic site can
CC      optionally be prepared (e.g., by PCR). The invention also discloses the
CC      use of IRF-1 gene fragments as probes to detect the A polymorphism. The
CC      method of the invention is used to genotype a patient with hepatitis C
CC      virus (HCV) infection in order to predict whether interferon therapy
CC      will be effective. The present sequence represents the allele of the
CC      human IRF-1 promoter region found in IFN-insensitive PLC/PRF/5
CC      liver cancer cells which was used in RFLP analysis.
XX
XX      Sequence 669 BP; 98 A; 235 C; 246 G; 90 T; 0 other;
XX
XX
XX      Query Match      92.0%; Score 18.4; DB 22; Length 669;
XX      Best Local Similarity 95.0%; Pred. No. 11;
XX      Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY      1 CTGATTTCCCGAAATGATG 20
OY      |||||||||
OY      |||||||||
DB      367 CTGATTTCCCGAAATGACG 386

RESULT 12
AAH91999
AAH91999 standard; DNA; 700 BP.
XX
XX      AAH91999;
XX
XX      09-OCT-2001 (first entry)
XX
XX      Human inflammatory bowel disease related gene fragment IGR2011a.
XX
XX      Human; inflammatory bowel disease; Crohn's disease; ulcerative colitis;
XX      single nucleotide polymorphism; SNP; chromosome 19p13; paternity test;
XX      chromosome 5q31-33; forensic test; gene therapy; ds.
XX
XX      Homo sapiens.
XX
XX      WO200142511-A2.
XX
XX      14-JUN-2001.
XX
XX      11-DEC-2000; 2000WO-US33632.
XX

```

PR 10-DEC-1999; 99US-0170257.
PR 10-APR-2000; 2000US-0196046.
XX
PA (WHEED) WHITEHEAD INST BIOMEDICAL RES.
PA (ELLI-) ELLIPSIS BIOTHERAPEUTICS CORP.
XX
PI Daly M, Hudson TJ, Lander ES, Rioux J, Siminovitch K;
XX WPI; 2001-367874/38.
XX
PT Testing for the presence of polymorphisms associated with inflammatory
PT bowel disease, using a hybridization assay -
XX
PS Disclosure; Page 89; 463pp; English.
XX
CC The present invention describes a method for detecting the presence of
CC polymorphisms associated with inflammatory bowel diseases such as
CC ulcerative colitis and Crohn's disease. The methods can be used to detect
CC the presence of genetic polymorphisms associated with inflammatory bowel
CC disease and correlating their occurrence with disease states. They may be
CC used in this way for phenotypic correlations, forensics, paternity
CC testing, medicine and genetic analysis. The present sequence is a gene
CC containing a polymorphic site described in the exemplification of the
CC invention.
XX
SQ Sequence 700 BP; 97 A; 255 C; 254 G; 94 T; 0 other;
XX
Query Match 92.0%; Score 18.4; DB 22; Length 700;
Best Local Similarity 95.0%; Pred. No. 11;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 1 CTGATTTCCCGGAATGATG 20
|||||
Db 331 CTGATTTCCCGGAATGATG 350
RESULT 13
AAV59503
ID AAV59503 standard; DNA: 86 BP.
XX
AC AAV59503;
XX
DT 02-FEB-1999 (first entry)
XX
DE Upstream primer for SV40 promoter sequence.
XX
KW Human; secreted protein; fusion protein; gene therapy; protein therapy;
KW diagnosis; tissue; cancer; tumour; neurodegenerative disorder; leukaemia;
KW developmental abnormality; foetal deficiency; blood; allergy; renal; ds;
KW immune system; asthma; lymphocytic disease; brain; hepatic; lymphoma;
KW inflammation; ischaemic shock; Alzheimer's disease; restenosis; AIDS;
KW cognitive disorder; schizophrenia; prostate; obesity; osteoclast; thymus;
KW osteoporosis; arthritis; testis; lung; thyroiditis; thyroid; digestion;
KW endocrine; metabolism; regulation; malabsorption; gastritis; neoplasm.
XX
XX Synthetic.
OS Simian virus 40.
XX
PN WC9839448-A2.
PD 11-SEP-1998.
XX
PF 06-MAR-1998; 98MO-US04493.
XX
PR 02-OCT-1997; 97US-0061060.
PR 07-MAR-1997; 97US-0038621.
PR 07-MAR-1997; 97US-0040161.
PR 07-MAR-1997; 97US-0040162.
PR 07-MAR-1997; 97US-0040163.
PR 07-MAR-1997; 97US-0040333.
PR 07-MAR-1997; 97US-0040334.
PR 07-MAR-1997; 97US-0040336.
PR 07-MAR-1997; 97US-0040626.

PR 11-APR-1997; 97US-0043311.
PR 11-APR-1997; 97US-0043312.
PR 11-APR-1997; 97US-0043313.
PR 11-APR-1997; 97US-0043314.
PR 11-APR-1997; 97US-0043558.
PR 11-APR-1997; 97US-0043559.
PR 11-APR-1997; 97US-0043576.
PR 11-APR-1997; 97US-0043578.
PR 11-APR-1997; 97US-0043580.
PR 11-APR-1997; 97US-0043659.
PR 11-APR-1997; 97US-0043670.
PR 11-APR-1997; 97US-0043671.
PR 11-APR-1997; 97US-0043672.
PR 11-APR-1997; 97US-0043674.
PR 23-MAY-1997; 97US-0047492.
PR 23-MAY-1997; 97US-0047500.
PR 23-MAY-1997; 97US-0047501.
PR 23-MAY-1997; 97US-0047502.
PR 23-MAY-1997; 97US-0047503.
PR 23-MAY-1997; 97US-0047581.
PR 23-MAY-1997; 97US-0047582.
PR 23-MAY-1997; 97US-0047583.
PR 23-MAY-1997; 97US-0047584.
PR 23-MAY-1997; 97US-0047585.
PR 23-MAY-1997; 97US-0047586.
PR 23-MAY-1997; 97US-0047587.
PR 23-MAY-1997; 97US-0047588.
PR 23-MAY-1997; 97US-0047589.
PR 23-MAY-1997; 97US-0047590.
PR 23-MAY-1997; 97US-0047592.
PR 23-MAY-1997; 97US-0047593.
PR 23-MAY-1997; 97US-0047594.
PR 23-MAY-1997; 97US-0047595.
PR 23-MAY-1997; 97US-0047596.
PR 23-MAY-1997; 97US-0047597.
PR 23-MAY-1997; 97US-0047598.
PR 23-MAY-1997; 97US-0047599.
PR 23-MAY-1997; 97US-0047600.
PR 23-MAY-1997; 97US-0047601.
PR 23-MAY-1997; 97US-0047612.
PR 23-MAY-1997; 97US-0047613.
PR 23-MAY-1997; 97US-0047614.
PR 23-MAY-1997; 97US-0047615.
PR 23-MAY-1997; 97US-0047617.
PR 23-MAY-1997; 97US-0047618.
PR 23-MAY-1997; 97US-0047632.
PR 23-MAY-1997; 97US-0047633.
PR 06-JUN-1997; 97US-0048964.
PR 06-JUN-1997; 97US-0048974.
PR 13-JUN-1997; 97US-0049610.
PR 08-JUL-1997; 97US-0051926.
PR 16-JUL-1997; 97US-0052874.
PR 18-AUG-1997; 97US-0055724.
PR 22-AUG-1997; 97US-0056630.
PR 22-AUG-1997; 97US-0056631.
PR 22-AUG-1997; 97US-0056632.
PR 22-AUG-1997; 97US-0056636.
PR 22-AUG-1997; 97US-0056637.
PR 22-AUG-1997; 97US-0056662.
PR 22-AUG-1997; 97US-0056664.
PR 22-AUG-1997; 97US-0056845.
PR 22-AUG-1997; 97US-0056862.
PR 22-AUG-1997; 97US-0056864.
PR 22-AUG-1997; 97US-0056872.
PR 22-AUG-1997; 97US-0056874.
PR 22-AUG-1997; 97US-0056875.
PR 22-AUG-1997; 97US-0056876.
PR 22-AUG-1997; 97US-0056877.
PR 22-AUG-1997; 97US-0056878.
PR 22-AUG-1997; 97US-0056879.
PR 22-AUG-1997; 97US-0056880.
PR 22-AUG-1997; 97US-0056881.
PR 22-AUG-1997; 97US-0056882.

PR 22-AUG-1997; 97US-0056884.
PR 22-AUG-1997; 97US-0056886.
PR 22-AUG-1997; 97US-0056887.
PR 22-AUG-1997; 97US-0056888.
PR 22-AUG-1997; 97US-0056889.
PR 22-AUG-1997; 97US-0056892.
PR 22-AUG-1997; 97US-0056893.
PR 22-AUG-1997; 97US-0056894.
PR 22-AUG-1997; 97US-0056903.
PR 22-AUG-1997; 97US-0056908.
PR 22-AUG-1997; 97US-0056909.
PR 22-AUG-1997; 97US-0056910.
PR 22-AUG-1997; 97US-0056911.
PR 05-SEP-1997; 97US-0057650.
PR 05-SEP-1997; 97US-0057659.
PR 05-SEP-1997; 97US-0057761.
PR 12-SEP-1997; 97US-0058785.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
XX Bednarik DP, Brewer LA, Carter KC, Duan R, Ebner R, Endress GA,
PI Feng P, Ferrle AM, Fischer CL, Florence KA, Greene JM, Hu JS,
PI Kyaw H, Lafleur DM, Li Y, Moore PA, Ni J, Olsen HS, Rosen CA,
PI Ruben SM, Shi Y, Soppet DR, Young PE, Yu GL, Zeng Z,
XX WPI, 1998-506364/43.
XX
XX New isolated human genes and the secreted polypeptide(s) they encode
PT - useful for diagnosis and treatment of e.g. cancers, neurological
PT disorders, immune diseases, inflammation or blood disorders
XX
XX Example 12, Page 220, 721pp: English.
XX
XX The invention relates to 186 novel genes and their fragments (nucleic
CC acid sequences: AAV59511-V59812; amino acid sequences AAW74731-W75026)
CC which are useful for preventing, treating or ameliorating medical
CC conditions e.g. by protein or gene therapy. Also, pathological
CC conditions can be diagnosed by determining the amount of the new
CC polypeptides in a sample or by determining the presence of mutations in
CC the new polynucleotides. Specific uses are described for each of the 186
CC polynucleotides, based on which tissues they are most highly expressed in
CC (see AAV59511 for described uses). The genes can be used to generate
CC fusion proteins by linking to the gene to a sequence encoding human
CC immunoglobulin Fc portion (AAV59502) for increasing the stability of the
CC fused protein as compared to the secreted protein only. Genes encoding
CC the secreted proteins can be used for high-throughput assays for
CC biological activities. Expression of the genes can be driven by a range
CC of promoter active in eukaryotic cells. Primers AAV59503-V59504 are used
CC to amplify the simian virus 40 (SV40) promoter (AAV59505) to generate a
CC construct for identifying proteins involved in signal transduction which
CC bind the gamma activation site (Gas) in a similar manner to the Jaks-STAT
CC pathways.
XX
SQ Sequence 86 BP; 23 A; 26 C; 13 G; 24 T; 0 other;
Query Match 90.0%; Score 18; DB 19; Length 86;
Best Local Similarity 100.0%; Pred. No. 14;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 2 TGATTTCGCCGAATGAT 19
DB 40 TGAATTCGCCGAATGAT 57
RESULT 14
ID AAV34146
AAV34146 standard; DNA; 86 BP.
XX
XX AAV34146;
AC
XX
DT 02-FEB-1999 (first entry)
XX
DE Upstream primer for SV40 promoter sequence.

XX Human; secreted protein; fusion protein; gene therapy; protein therapy;
KW diagnosis; tissue; cancer; tumor; neurodegenerative disorder; leukemia;
KW developmental abnormality; foetal deficiency; blood; allergy; renal; ds;
KW immune system; asthma; lymphocytic disease; brain; hepatic; lymphoma;
KW inflammation; ischemic shock; Alzheimer's disease; restenosis; AIDS;
KW cognitive disorder; schizophrenia; prostate; obesity; osteoclast; thymus;
KW osteoporosis; arthritis; testis; lung; thyroiditis; thyroid; digestion;
KW endocrine; metabolism; regulation; malabsorption; gastritis; neoplasm.
XX
OS Synthetic.
OS Simian virus 40.
XX
XX WO9839446-A2.
XX
XX 11-SEP-1998.
XX
XX 06-MAR-1998; 98WO-US04492.
XX
XX 07-MAR-1997; 97US-0038621.
XX 07-MAR-1997; 97US-0040161.
XX 07-MAR-1997; 97US-0040162.
XX 07-MAR-1997; 97US-0040163.
XX 07-MAR-1997; 97US-0040333.
XX 07-MAR-1997; 97US-0040334.
XX 07-MAR-1997; 97US-0040336.
XX 07-MAR-1997; 97US-0040626.
XX 11-APR-1997; 97US-0043311.
XX 11-APR-1997; 97US-0043312.
XX 11-APR-1997; 97US-0043313.
XX 11-APR-1997; 97US-0043314.
XX 11-APR-1997; 97US-0043315.
XX 11-APR-1997; 97US-0043568.
XX 11-APR-1997; 97US-0043569.
XX 11-APR-1997; 97US-0043576.
XX 11-APR-1997; 97US-0043578.
XX 11-APR-1997; 97US-0043580.
XX 11-APR-1997; 97US-0043669.
XX 11-APR-1997; 97US-0043670.
XX 11-APR-1997; 97US-0043671.
XX 11-APR-1997; 97US-0043672.
XX 11-APR-1997; 97US-0043674.
XX 23-MAY-1997; 97US-0047492.
XX 23-MAY-1997; 97US-0047500.
XX 23-MAY-1997; 97US-0047501.
XX 23-MAY-1997; 97US-0047502.
XX 23-MAY-1997; 97US-0047503.
XX 23-MAY-1997; 97US-0047504.
XX 23-MAY-1997; 97US-0047581.
XX 23-MAY-1997; 97US-0047582.
XX 23-MAY-1997; 97US-0047583.
XX 23-MAY-1997; 97US-0047584.
XX 23-MAY-1997; 97US-0047585.
XX 23-MAY-1997; 97US-0047586.
XX 23-MAY-1997; 97US-0047587.
XX 23-MAY-1997; 97US-0047588.
XX 23-MAY-1997; 97US-0047589.
XX 23-MAY-1997; 97US-0047590.
XX 23-MAY-1997; 97US-0047592.
XX 23-MAY-1997; 97US-0047593.
XX 23-MAY-1997; 97US-0047594.
XX 23-MAY-1997; 97US-0047595.
XX 23-MAY-1997; 97US-0047596.
XX 23-MAY-1997; 97US-0047597.
XX 23-MAY-1997; 97US-0047598.
XX 23-MAY-1997; 97US-0047599.
XX 23-MAY-1997; 97US-0047600.
XX 23-MAY-1997; 97US-0047601.
XX 23-MAY-1997; 97US-0047612.
XX 23-MAY-1997; 97US-0047613.
XX 23-MAY-1997; 97US-0047614.
XX 23-MAY-1997; 97US-0047615.
XX 23-MAY-1997; 97US-0047617.
XX 23-MAY-1997; 97US-0047618.

23-MAY-1997; 9705-0047632.
 PR 23-MAY-1997; 9705-0047633.
 PR 06-JUN-1997; 9705-0048964.
 PR 06-JUN-1997; 9705-0048974.
 PR 22-AUG-1997; 9705-0056630.
 PR 22-AUG-1997; 9705-0056631.
 PR 22-AUG-1997; 9705-0056632.
 PR 22-AUG-1997; 9705-0056636.
 PR 22-AUG-1997; 9705-0056637.
 PR 22-AUG-1997; 9705-0056652.
 PR 22-AUG-1997; 9705-0056664.
 PR 22-AUG-1997; 9705-0056845.
 PR 22-AUG-1997; 9705-0056862.
 PR 22-AUG-1997; 9705-0056864.
 PR 22-AUG-1997; 9705-0056872.
 PR 22-AUG-1997; 9705-0056874.
 PR 22-AUG-1997; 9705-0056875.
 PR 22-AUG-1997; 9705-0056876.
 PR 22-AUG-1997; 9705-0056877.
 PR 22-AUG-1997; 9705-0056878.
 PR 22-AUG-1997; 9705-0056879.
 PR 22-AUG-1997; 9705-0056880.
 PR 22-AUG-1997; 9705-0056881.
 PR 22-AUG-1997; 9705-0056882.
 PR 22-AUG-1997; 9705-0056884.
 PR 22-AUG-1997; 9705-0056886.
 PR 22-AUG-1997; 9705-0056887.
 PR 22-AUG-1997; 9705-0056888.
 PR 22-AUG-1997; 9705-0056889.
 PR 22-AUG-1997; 9705-0056892.
 PR 22-AUG-1997; 9705-0056893.
 PR 22-AUG-1997; 9705-0056894.
 PR 22-AUG-1997; 9705-0056903.
 PR 22-AUG-1997; 9705-0056908.
 PR 22-AUG-1997; 9705-0056909.
 PR 22-AUG-1997; 9705-0056910.
 PR 22-AUG-1997; 9705-0056911.
 PR 05-SEP-1997; 9705-0057650.
 PR 05-SEP-1997; 9705-0057761.
 XX
 XX (HUMA-) HUMAN GENOME SCI INC.
 PA Bednarik DP, Brewer LA, Carter KC, Duan R, Edner R, Endress GA;
 XX Feng P, Ferrle AM, Fischer CL, Graves KA, Greene JM, Hu JS;
 PI Kyaw H, Latleir DW, Li Y, Moore PA, Ni J, Olsen HS, Rosen CA;
 PI Ruben SM, Shi Y, Soppet DR, Young PE, Yu GL, Zeng Z;
 XX WPI: 1998-609887/51.
 DR
 XX New isolated human genes and the secreted polypeptides they encode
 PT - useful for diagnosis and treatment of e.g. cancers, neurological
 PT disorders, immune diseases, inflammation or blood disorders
 XX
 PS Example 12: Page 139; 447pp: English.
 XX
 XX The invention relates to 70 novel genes and their fragments (nucleic
 CC acid sequences: AAV34154-V34276; amino acid sequences AAW75057-W75179)
 CC which are useful for preventing, treating or ameliorating medical
 CC conditions e.g. by protein or gene therapy. Also, pathological
 CC conditions can be diagnosed by determining the amount of the new
 CC polypeptides in a sample or by determining the presence of mutations in
 CC the new polynucleotides. Specific uses are described for each of the 70
 CC polynucleotides, based on which tissues they are most highly expressed in
 CC (see AAV34154 for described uses). The genes can be used to generate
 CC fusion proteins by linking to the gene to a sequence encoding human
 CC immunoglobulin Fc portion (AAV34145) for increasing the stability of the
 CC used protein as compared to the secreted protein only. Genes encoding
 CC the secreted proteins can be used for high-throughput assays for
 CC biological activities. Expression of the genes can be driven by a range
 CC of promoter active in eukaryotic cells. Primers AAV34146-V34147 are used
 CC to amplify the simian virus 40 (SV40) promoter (AAV34148) to generate a
 CC construct for identifying proteins involved in signal transduction which
 CC bind the gamma activation site (GAS) in a similar manner to the Jaks-STAT

CC pathways.
 XX
 SQ Sequence 86 BP; 23 A; 26 C; 13 G; 24 T; 0 other;
 Query Match 90.0%; Score 18; DB 19; Length 86;
 Best Local Similarity 100.0%; Pred. No. 14;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 2 TGATTCCCGAATGAT 19
 DB 40 TGATTCCCGAATGAT 57
 RESULT 15
 AAV34278
 ID AAV34278 standard; DNA: 86 BP.
 XX
 AC AAV34278;
 XX
 DT 29-JAN-1999 (first entry)
 XX
 DE Upstream primer for SV40 promoter sequence.
 XX
 KW Human: secreted protein; fusion protein; gene therapy; protein therapy;
 KW diagnosis; tissue; cancer; tumour; neurodegenerative disorder; leukaemia;
 KW developmental abnormality; foetal deficiency; blood; allergy; renal; ds;
 KW immune system; asthma; lymphocytic disease; brain; hepatic; lymphoma;
 KW inflammation; ischemic shock; Alzheimer's disease; restenosis; AIDS;
 KW cognitive disorder; schizophrenia; prostate; obesity; osteoclast; thymus;
 KW osteoporosis; arthritis; testis; lung; thyroiditis; thyroid; digestion;
 KW endocrine; metabolism; regulation; malabsorption; gastritis; neoplasm.
 XX
 OS Synthetic.
 OS Simian virus 40.
 XX
 XX W09840483-A2.
 PD 17-SEP-1998.
 XX
 PF 12-MAR-1998; 98WO-US04858.
 XX
 PR 19-DEC-1997; 9705-0068368.
 PR 14-MAR-1997; 9705-0040710.
 PR 14-MAR-1997; 9705-0040762.
 PR 30-MAY-1997; 9705-0048100.
 PR 30-MAY-1997; 9705-0048189.
 PR 30-MAY-1997; 9705-0048357.
 PR 30-MAY-1997; 9705-0050934.
 PR 06-JUN-1997; 9705-0048970.
 PR 05-SEP-1997; 9705-0057765.
 XX
 PA (HUMA-) HUMAN GENOME SCI INC.
 XX
 XX Ferrle AM, Fischer CL, Gentz RL, Greene JM, Kyaw H;
 PI Li H, Li Y, Moore PA, Rosen CA, Ruben SM, Soppet DR;
 PI Wei YF, Young PE, Zeng Z;
 XX WPI: 1998-520811/44.
 DR
 XX Isolated human polynucleotide(s) encoding secretory peptide(s) -
 PT used to develop products for the diagnosis and treatment of e.g.
 PT inflammation, cancers, CNS disorders or immune system disorders
 XX
 PS Example 12: Page 89; 201pp: English.
 XX
 XX The invention relates to 28 novel genes and their fragments (nucleic
 CC acid sequences: AAV34286-V34325; amino acid sequences AAW75196-W75235)
 CC which are useful for preventing, treating or ameliorating medical
 CC conditions e.g. by protein or gene therapy. Also, pathological
 CC conditions can be diagnosed by determining the amount of the new
 CC polypeptides in a sample or by determining the presence of mutations in
 CC the new polynucleotides. Specific uses are described for each of the 28
 CC polynucleotides, based on which tissues they are most highly expressed in

CC (see AAV34286 for described uses). The genes can be used to generate
 CC fusion proteins by linking to the gene to a sequence encoding human
 CC immunoglobulin Fc portion (AAV34277) for increasing the stability of the
 CC fused protein as compared to the secreted protein only. Genes encoding
 CC the secreted proteins can be used for high-throughput assays for
 CC biological activities. Expression of the genes can be driven by a range
 CC of promoter active in eukaryotic cells. Primers AAV34278-V34279 are used
 CC to amplify the simian virus 40 (SV40) promoter (AAV34280) to generate a
 CC construct for identifying proteins involved in signal transduction which
 CC bind the gamma activation site (GAS) in a similar manner to the Jaks-STAT
 CC pathways.

xx
 SQ Sequence 86 BP; 23 A; 26 C; 13 G; 24 T; 0 other;

Query Match 90.0%; Score 18; DB 19; Length 86;
 Best Local Similarity 100.0%; Pred. No. 14;

Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 TGATTTCGCCGAATGAT 19
 ||||||||||||||||
 ||||||||||||||||

DB 40 TGATTTCGCCGAATGAT 57

Search completed: June 26, 2003, 12:16:31
 Job time : 228.158 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Comugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 26, 2003, 10:58:25 ; Search time 30.2174 Seconds
(without alignments)
202.980 Million cell updates/sec

Title: US-09-355-254f-19

Perfect score: 20

Sequence: 1 ctagattccccaatgatg 20

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 441362 seqs, 15338381 residues

Total number of hits satisfying chosen parameters: 882724

Minimum DB seq length: 0
Maximum DB seq length: 200000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :
1: /cgn2_6/ptodata/1/lna/5A.COMB.seq:*
2: /cgn2_6/ptodata/1/lna/5B.COMB.seq:*
3: /cgn2_6/ptodata/1/lna/5A.COMB.seq:*
4: /cgn2_6/ptodata/1/lna/5B.COMB.seq:*
5: /cgn2_6/ptodata/1/lna/PCUS.COMB.seq:*
6: /cgn2_6/ptodata/1/lna/backfile1.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
C 1	20	100.0	21	1 US-08-394-191-12	Sequence 12, Appl
C 2	20	100.0	21	1 US-08-458-364-12	Sequence 12, Appl
C 3	18.4	92.0	20	3 US-08-837-635-1	Sequence 1, Appl
C 4	18	90.0	86	3 US-09-106-182-16	Sequence 16, Appl
C 5	18	90.0	86	4 US-09-227-357-3	Sequence 3, Appl
C 6	18	90.0	86	4 US-09-280-839-6	Sequence 6, Appl
C 7	18	90.0	86	4 US-09-411-977-18	Sequence 18, Appl
C 8	18	90.0	86	4 US-09-479-7298-23	Sequence 23, Appl
C 9	18	90.0	86	4 US-09-257-179-3	Sequence 3, Appl
C 10	18	90.0	86	4 US-09-149-476-3	Sequence 3, Appl
C 11	18	90.0	86	4 US-09-288-143-3	Sequence 3, Appl
C 12	18	90.0	86	4 US-09-487-792-25	Sequence 25, Appl
C 13	18	90.0	86	4 US-09-152-060-3	Sequence 3, Appl
C 14	18	90.0	271	3 US-09-106-182-18	Sequence 18, Appl
C 15	18	90.0	271	4 US-09-227-357-5	Sequence 5, Appl
C 16	18	90.0	271	4 US-09-280-839-8	Sequence 8, Appl
C 17	18	90.0	271	4 US-09-411-977-20	Sequence 20, Appl
C 18	18	90.0	271	4 US-09-479-7298-25	Sequence 25, Appl
C 19	18	90.0	271	4 US-09-257-179-5	Sequence 5, Appl
C 20	18	90.0	271	4 US-09-149-476-5	Sequence 5, Appl
C 21	18	90.0	271	4 US-09-288-143-5	Sequence 5, Appl
C 22	18	90.0	271	4 US-09-487-792-27	Sequence 27, Appl
C 23	18	90.0	271	4 US-09-152-060-5	Sequence 5, Appl
C 24	17.4	87.0	20	3 US-08-837-635-2	Sequence 2, Appl
C 25	16.8	84.0	28473	2 US-08-961-527-83	Sequence 83, Appl
C 26	16.4	82.0	22	2 US-08-683-743-24	Sequence 24, Appl
C 27	15.4	77.0	1410	3 US-08-068-392-1	Sequence 1, Appl

C 28	15.4	77.0	1410	4 US-08-396-988-1	Sequence 1, Appl
C 29	15.4	77.0	2200	1 US-08-272-255-21	Sequence 21, Appl
C 30	15.4	77.0	2200	5 PCT-US95-08565-21	Sequence 21, Appl
C 31	15.2	76.0	24	2 US-08-632-5758-56	Sequence 56, Appl
C 32	15.2	76.0	317	4 US-09-732-199A-10	Sequence 10, Appl
C 33	15.2	76.0	321	3 US-09-080-855-25	Sequence 25, Appl
C 34	15.2	76.0	1599	4 US-09-277-565-16	Sequence 16, Appl
C 35	15.2	76.0	7577	4 US-08-961-527-46	Sequence 46, Appl
C 36	15.2	76.0	8898	4 US-08-961-527-69	Sequence 69, Appl
C 37	15	75.0	19	1 US-08-411-020-38	Sequence 38, Appl
C 38	15	75.0	19	1 US-08-411-020-39	Sequence 39, Appl
C 39	15	75.0	19	1 US-08-410-7798-106	Sequence 106, App
C 40	15	75.0	19	1 US-08-410-7798-107	Sequence 107, App
C 41	15	75.0	19	5 PCT-US95-04477-106	Sequence 106, App
C 42	15	75.0	19	5 PCT-US95-04477-107	Sequence 107, App
C 43	14.8	74.0	648	4 US-09-228-986-26	Sequence 26, Appl
C 44	14.4	72.0	1050	1 US-08-204-196A-2	Sequence 2, Appl
C 45	14.4	72.0	1809	1 US-08-204-196A-3	Sequence 3, Appl

ALIGNMENTS

RESULT 1
US-08-394-191-12/c
Sequence 12, Application US/08394191
Patent No. 5616489
GENERAL INFORMATION:
APPLICANT: LEVY, David E.
TITLE OF INVENTION: DNA SEQUENCE WHICH BINDS
TITLE OF INVENTION: TRANSCRIPTIONAL REGULATORY PROTEINS ACTIVATED IN RESPONSE TO
TITLE OF INVENTION: VARIOUS CYTOKINES AND USES THEREOF
NUMBER OF SEQUENCES: 14
CORRESPONDENCE ADDRESS:
ADDRESSEE: Morrison & Foerster
STREET: 2000 Pennsylvania Avenue
CITY: Washington
STATE: D.C.
COUNTRY: USA
ZIP: 20006-1812
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/394,191
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/121,931
FILING DATE: September 15, 1993
ATTORNEY/AGENT INFORMATION:
NAME: LIVNAT, SHMUEL
REGISTRATION NUMBER: 33,949
REFERENCE/DOCKET NUMBER: 15661-20010.00
TELECOMMUNICATION INFORMATION:
TELEPHONE: (202) 887-1500
TELEFAX: (202) 887-0763
TELEX: 90-4030
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-394-191-12
Query Match 100.0%; Score 20; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.086;
Matches 20; Conservative 0; Mismatches 0; Indels 0;
Gaps 0;
Gy 1 CTAGATTCCCGAATGATG 20

DB 20 CTGATTCCCGCAATGATG 1

RESULT 2

US-08-458-364-12/C
 ; Sequence 12, Application US/08458364
 ; Patent No. 5648217
 ; GENERAL INFORMATION:
 ; APPLICANT: LEVY, David E.
 ; TITLE OF INVENTION: DNA SEQUENCE WHICH BINDS
 ; TITLE OF INVENTION: TRANSCRIPTIONAL REGULATORY PROTEINS ACTIVATED IN RESPONSE TO
 ; TITLE OF INVENTION: VARIOUS CITOKINES AND USES THEREOF
 ; NUMBER OF SEQUENCES: 14
 ; CORRESPONDENCE ADDRESSES:
 ; ADDRESSEE: Morrison & Foerster
 ; STREET: 2000 Pennsylvania Avenue
 ; CITY: Washington
 ; STATE: D.C.
 ; COUNTRY: USA
 ; ZIP: 20006-1812
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: Floppy disk
 ; COMPUTER: IBM PC compatible
 ; OPERATING SYSTEM: PC-DOS/MS-DOS
 ; SOFTWARE: Patentin Release #1.0, Version #1.25
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/458,364
 ; FILING DATE: 02-JUN-1995
 ; CLASSIFICATION: 435
 ; PRIORITY APPLICATION DATA:
 ; APPLICATION NUMBER: US 08/394,191
 ; FILING DATE: 24-FEB-1995
 ; APPLICATION NUMBER: 08/121,931
 ; FILING DATE: September 15, 1993
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: LIVNAT, SHMUEL
 ; REGISTRATION NUMBER: 33,949
 ; REFERENCE/DOCKET NUMBER: 15661-20010.00
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (202) 887-1500
 ; TELEFAX: (202) 887-0763
 ; TELEX: 90-4030
 ; INFORMATION FOR SEQ ID NO: 12:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 21 base pairs
 ; TYPE: nucleic acid
 ; STRANDEDNESS: single
 ; TOPOLOGY: linear
 ; US-08-458-364-12

Query Match 100.0%; Score 20; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 0.086;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CTGATTCCCGCAATGATG 20
 DB 20 CTGATTCCCGCAATGATG 1

RESULT 3
 US-08-837-635-1

; Sequence 1, Application US/08837635
 ; Patent No. 6007998
 ; GENERAL INFORMATION:
 ; APPLICANT: ROSENBLUM, CHARLES, I.
 ; APPLICANT: VAN DER PLOEG, LEONARDOUS, H.T.
 ; APPLICANT: OURESHI, SAJJAD, A.
 ; APPLICANT: CULLY, DORIS, F.
 ; APPLICANT: HESS, JOHN W.
 ; APPLICANT: TOTA, MICHAEL, R.
 ; APPLICANT: CHEN, FANG
 ; TITLE OF INVENTION: LEFTIN ASSAY

; NUMBER OF SEQUENCES: 7
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: JOANNE M. GIESSER - MERCK & CO., INC.
 ; STREET: 126 EAST LINCOLN AVENUE - P.O. BOX 2000
 ; CITY: RAHWAY
 ; STATE: NJ
 ; COUNTRY: USA
 ; ZIP: 07065

; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: Diskette
 ; COMPUTER: IBM Compatible
 ; OPERATING SYSTEM: DOS
 ; SOFTWARE: FASTSEQ for Windows Version 2.0
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/837,635
 ; FILING DATE: 21-APR-1997
 ; CLASSIFICATION: 435
 ; PRIORITY APPLICATION DATA:
 ; APPLICATION NUMBER: 60/016,051
 ; FILING DATE: 22-APR-1996
 ; APPLICATION NUMBER: 60/031,002
 ; FILING DATE: 15-NOV-1996
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: GIESSER, JOANNE M.
 ; REGISTRATION NUMBER: 32,838
 ; REFERENCE/DOCKET NUMBER: 19686Y
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: 732-594-3046
 ; TELEFAX: 732-594-4720
 ; TELEX:

; INFORMATION FOR SEQ ID NO: 1:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 20 base pairs
 ; TYPE: nucleic acid
 ; STRANDEDNESS: single
 ; TOPOLOGY: linear
 ; MOLECULE TYPE: Other
 ; US-08-837-635-1

Query Match 92.0%; Score 18.4; DB 3; Length 20;
 Best Local Similarity 95.0%; Pred. No. 0.58;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 CTGATTCCCGCAATGATG 20
 DB 1 CTGATTCCCGCAATGAGC 20

RESULT 4
 US-09-106-182-16

; Sequence 16, Application US/09106182
 ; Patent No. 6046035
 ; GENERAL INFORMATION:
 ; APPLICANT: Shi, Yanguu
 ; APPLICANT: Ruden, Steve
 ; TITLE OF INVENTION: Cardiotrophin-Like Cytokine
 ; NUMBER OF SEQUENCES: 24
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Human Genome Sciences, Inc
 ; STREET: 9410 Key West Ave
 ; CITY: Rockville
 ; STATE: MD
 ; COUNTRY: US
 ; ZIP: 20850
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: Floppy disk
 ; COMPUTER: IBM PC compatible
 ; OPERATING SYSTEM: PC-DOS/MS-DOS
 ; SOFTWARE: Patentin Release #1.0, Version #1.30
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/09/106,182
 ; FILING DATE: Herewith
 ; CLASSIFICATION:

PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 60/051,053
FILING DATE: 30-JUN-1997
ATTORNEY/AGENT INFORMATION:
NAME: Brookes, A. Anders
REGISTRATION NUMBER: 36,373
REFERENCE/DOCKET NUMBER: PP385
TELECOMMUNICATION INFORMATION:
TELEPHONE: 301-309-8504
TELEFAX: 301-309-8439
INFORMATION FOR SEQ ID NO: 16:
SEQUENCE CHARACTERISTICS:
LENGTH: 86 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-09-106-182-16

Query Match 90.0%; Score 18; DB 3; Length 86;
Best Local Similarity 100.0%; Pred. No. 1.2;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 TGATTCCCGGAATGAT 19
DB 40 TGATTCCCGGAATGAT 57

RESULT 5

US-09-227-357-3
Sequence 3, Application US/09227357
Patent No. 6342581
GENERAL INFORMATION:
APPLICANT: Fischer et al.
TITLE OF INVENTION: 123 Human Secreted Proteins
FILE REFERENCE: P01021
CURRENT APPLICATION NUMBER: US/09/227,357
EARLIER FILING DATE: 1999-01-08
EARLIER APPLICATION NUMBER: PCT/US98/13684
EARLIER FILING DATE: 1998-07-07
EARLIER APPLICATION NUMBER: 60/051,926
EARLIER FILING DATE: 1997-07-08
EARLIER APPLICATION NUMBER: 60/052,793
EARLIER FILING DATE: 1997-07-08
EARLIER APPLICATION NUMBER: 60/051,925
EARLIER FILING DATE: 1997-07-08
EARLIER APPLICATION NUMBER: 60/051,929
EARLIER FILING DATE: 1997-07-08
EARLIER APPLICATION NUMBER: 60/052,803
EARLIER FILING DATE: 1997-07-08
EARLIER APPLICATION NUMBER: 60/052,732
EARLIER FILING DATE: 1997-07-08
EARLIER APPLICATION NUMBER: 60/051,931
EARLIER FILING DATE: 1997-07-08
EARLIER APPLICATION NUMBER: 60/051,932
EARLIER FILING DATE: 1997-07-08
EARLIER APPLICATION NUMBER: 60/051,916
EARLIER FILING DATE: 1997-07-08
EARLIER APPLICATION NUMBER: 60/051,920
EARLIER FILING DATE: 1997-07-08
EARLIER APPLICATION NUMBER: 60/052,733
EARLIER FILING DATE: 1997-07-08
EARLIER APPLICATION NUMBER: 60/052,795
EARLIER FILING DATE: 1997-07-08
EARLIER APPLICATION NUMBER: 60/051,919
EARLIER FILING DATE: 1997-07-08
EARLIER APPLICATION NUMBER: 60/051,928
EARLIER FILING DATE: 1997-07-08
EARLIER APPLICATION NUMBER: 60/055,722

EARLIER FILING DATE: 1997-08-18
EARLIER APPLICATION NUMBER: 60/055,723
EARLIER FILING DATE: 1997-08-18
EARLIER APPLICATION NUMBER: 60/055,948
EARLIER FILING DATE: 1997-08-18
EARLIER APPLICATION NUMBER: 60/055,949
EARLIER FILING DATE: 1997-08-18
EARLIER APPLICATION NUMBER: 60/055,953
EARLIER FILING DATE: 1997-08-18
EARLIER APPLICATION NUMBER: 60/055,950
EARLIER FILING DATE: 1997-08-18
EARLIER APPLICATION NUMBER: 60/055,947
EARLIER FILING DATE: 1997-08-18
EARLIER APPLICATION NUMBER: 60/055,964
EARLIER FILING DATE: 1997-08-18
EARLIER APPLICATION NUMBER: 60/056,360
EARLIER FILING DATE: 1997-08-18
EARLIER APPLICATION NUMBER: 60/055,684
EARLIER FILING DATE: 1997-08-18
EARLIER APPLICATION NUMBER: 60/055,984
EARLIER FILING DATE: 1997-08-18
EARLIER APPLICATION NUMBER: 60/055,954
EARLIER FILING DATE: 1997-08-18
EARLIER APPLICATION NUMBER: 60/058,785
EARLIER FILING DATE: 1997-09-12
EARLIER APPLICATION NUMBER: 60/058,664
EARLIER FILING DATE: 1997-09-12
EARLIER APPLICATION NUMBER: 60/058,660
EARLIER FILING DATE: 1997-09-12
EARLIER APPLICATION NUMBER: 60/058,661
EARLIER FILING DATE: 1997-09-12
NUMBER OF SEQ ID NOS: 672
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 3
LENGTH: 86
TYPE: DNA
ORGANISM: Homo sapiens
US-09-227-357-3

Query Match 90.0%; Score 18; DB 4; Length 86;
Best Local Similarity 100.0%; Pred. No. 1.2;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 TGATTCCCGGAATGAT 19
DB 40 TGATTCCCGGAATGAT 57

RESULT 6
US-09-280-839-6
Sequence 6, Application US/09280839
Patent No. 6365369
GENERAL INFORMATION:
APPLICANT: Endress, Gregory A.
TITLE OF INVENTION: Prostate Specific Secreted Protein
FILE REFERENCE: P4457
CURRENT APPLICATION NUMBER: US/09/280,839
EARLIER FILING DATE: 1999-03-30
EARLIER APPLICATION NUMBER: 60/080,311
EARLIER FILING DATE: 1998-04-01
EARLIER APPLICATION NUMBER: 60/080,898
EARLIER FILING DATE: 1998-04-07
NUMBER OF SEQ ID NOS: 15
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 6
LENGTH: 86
TYPE: DNA
ORGANISM: Homo sapiens
US-09-280-839-6

Query Match 90.0%; Score 18; DB 4; Length 86;
Best Local Similarity 100.0%; Pred. No. 1.2;

Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 2 TGATTCCCGGAATGAT 19
|||||
DB 40 TGATTCCCGGAATGAT 57

RESULT 7

US-09-411-977-18
; Sequence 18, Application US/09411977
; Patent No. 6372473
; GENERAL INFORMATION:
; APPLICANT: Moore, Paul A.
; APPLICANT: Ruben, Steven M.
; APPLICANT: Ebner, Reinhard
; TITLE OF INVENTION: Tissue Plasminogen Activator-Like Protease
; FILE REFERENCE: PF378P1
; CURRENT APPLICATION NUMBER: US/09/411,977
; EARLIER APPLICATION NUMBER: 09/084,491
; EARLIER FILING DATE: 1998-05-27
; EARLIER APPLICATION NUMBER: 60/048,000
; EARLIER FILING DATE: 1997-05-28
; NUMBER OF SEQ ID NOS: 30
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 18
; LENGTH: 86
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-411-977-18

Query Match 90.0%; Score 18; DB 4; Length 86;

Best Local Similarity 100.0%; Pred. No. 1.2;

Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 2 TGATTCCCGGAATGAT 19
|||||
DB 40 TGATTCCCGGAATGAT 57

RESULT 8

US-09-479-729B-23
; Sequence 23, Application US/09479729B
; Patent No. 6391589
; GENERAL INFORMATION:
; APPLICANT: Olsen, et al
; TITLE OF INVENTION: Human Chemokine Beta-10 Mutant Polypeptides
; FILE REFERENCE: PF504
; CURRENT APPLICATION NUMBER: US/09/479,729B
; EARLIER APPLICATION NUMBER: PCT/US94/09484
; PRIOR FILING DATE: 1994-08-23
; PRIOR APPLICATION NUMBER: 08/458,355
; PRIOR FILING DATE: 1995-06-02
; PRIOR APPLICATION NUMBER: 08/462,967
; PRIOR FILING DATE: 1995-06-05
; PRIOR APPLICATION NUMBER: 60/115,439
; PRIOR FILING DATE: 1999-01-08
; NUMBER OF SEQ ID NOS: 30
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 23
; LENGTH: 86
; TYPE: DNA
; ORGANISM: oligonucleotide
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: (1)..(86)
; OTHER INFORMATION: 5' primer to generate GAS-SVA0 construct.
US-09-479-729B-23

Query Match 90.0%; Score 18; DB 4; Length 86;
Best Local Similarity 100.0%; Pred. No. 1.2;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 2 TGATTCCCGGAATGAT 19
|||||
DB 40 TGATTCCCGGAATGAT 57

RESULT 9

US-09-257-179-3
; Sequence 3, Application US/09257179
; Patent No. 6410709
; GENERAL INFORMATION:
; APPLICANT: Ruben et al
; TITLE OF INVENTION: 29 Human Secreted Proteins
; FILE REFERENCE: P2015P1
; CURRENT APPLICATION NUMBER: US/09/257,179
; CURRENT FILING DATE: 1999-02-25
; EARLIER APPLICATION NUMBER: PCT/US98/17709
; EARLIER FILING DATE: 1998-08-27
; EARLIER APPLICATION NUMBER: 60/056,270
; EARLIER FILING DATE: 1997-08-29
; EARLIER APPLICATION NUMBER: 60/056,271
; EARLIER FILING DATE: 1997-08-29
; EARLIER APPLICATION NUMBER: 60/056,247
; EARLIER FILING DATE: 1997-08-29
; EARLIER APPLICATION NUMBER: 60/056,073
; EARLIER FILING DATE: 1997-08-29
; NUMBER OF SEQ ID NOS: 128
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 3
; LENGTH: 86
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-257-179-3

Query Match 90.0%; Score 18; DB 4; Length 86;

Best Local Similarity 100.0%; Pred. No. 1.2;

Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 2 TGATTCCCGGAATGAT 19
|||||
DB 40 TGATTCCCGGAATGAT 57

RESULT 10

US-09-149-476-3
; Sequence 3, Application US/09149476
; Patent No. 6420526
; GENERAL INFORMATION:
; APPLICANT: Rosen et al
; TITLE OF INVENTION: 186 Human Secreted proteins
; FILE REFERENCE: P2002P1
; CURRENT APPLICATION NUMBER: US/09/149,476
; CURRENT FILING DATE: 1998-09-08
; EARLIER APPLICATION NUMBER: PCT/US98/04493
; EARLIER FILING DATE: 1998-03-06
; EARLIER APPLICATION NUMBER: 60/040,162
; EARLIER FILING DATE: 1997-03-07
; EARLIER APPLICATION NUMBER: 60/040,333
; EARLIER FILING DATE: 1997-03-07
; EARLIER APPLICATION NUMBER: 60/038,621
; EARLIER FILING DATE: 1997-03-07
; EARLIER APPLICATION NUMBER: 60/040,626
; EARLIER FILING DATE: 1997-03-07
; EARLIER APPLICATION NUMBER: 60/040,334
; EARLIER FILING DATE: 1997-03-07
; EARLIER APPLICATION NUMBER: 60/040,336
; EARLIER FILING DATE: 1997-03-07
; EARLIER APPLICATION NUMBER: 60/040,163
; EARLIER FILING DATE: 1997-03-07
; EARLIER APPLICATION NUMBER: 60/047,600
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,615
; EARLIER FILING DATE: 1997-05-23


```
;; EARLIER APPLICATION NUMBER: 60/056,876
;; EARLIER FILING DATE: 1997-08-22
;; EARLIER APPLICATION NUMBER: 60/056,881
;; EARLIER FILING DATE: 1997-08-22
;; EARLIER APPLICATION NUMBER: 60/056,909
;; EARLIER FILING DATE: 1997-08-22
;; EARLIER APPLICATION NUMBER: 60/056,875
;; EARLIER FILING DATE: 1997-08-22
;; EARLIER APPLICATION NUMBER: 60/056,862
;; EARLIER FILING DATE: 1997-08-22
;; EARLIER APPLICATION NUMBER: 60/056,887
;; EARLIER FILING DATE: 1997-08-22
;; EARLIER APPLICATION NUMBER: 60/056,908
;; EARLIER FILING DATE: 1997-08-22
;; EARLIER APPLICATION NUMBER: 60/048,964
;; EARLIER FILING DATE: 1997-06-06
;; EARLIER APPLICATION NUMBER: 60/057,650
;; EARLIER FILING DATE: 1997-09-05
;; EARLIER APPLICATION NUMBER: 60/056,884
;; EARLIER FILING DATE: 1997-08-22
;; EARLIER APPLICATION NUMBER: 60/057,669
;; EARLIER FILING DATE: 1997-09-05
;; EARLIER APPLICATION NUMBER: 60/049,610
;; EARLIER FILING DATE: 1997-06-13
;; EARLIER APPLICATION NUMBER: 60/061,060
;; EARLIER FILING DATE: 1997-10-02
```

```
Query Match      90.0%; Score 18; DB 4; Length 86;
Best Local Similarity 100.0%; Pred. No. 1.2;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      2 TGATTTCCCGAATGAT 19
         |||
Db      40 TGATTTCCCGAATGAT 57
```

```
RESULT 11
US-09-288-143-3
; Sequence 3, Application US/09288143
; Patent No. 6433139
; GENERAL INFORMATION:
; APPLICANT: Brewer et al.
; TITLE OF INVENTION: 53 Human Secreted Proteins
; FILE REFERENCE: P2018p1
; CURRENT APPLICATION NUMBER: US/09/288,143
; EARLIER APPLICATION NUMBER: PCT/US98/21142
; EARLIER FILING DATE: 1998-10-08
; EARLIER APPLICATION NUMBER: 60/061,463
; EARLIER FILING DATE: 1997-10-09
; EARLIER APPLICATION NUMBER: 60/061,529
; EARLIER FILING DATE: 1997-10-09
; EARLIER APPLICATION NUMBER: 60/071,498
; EARLIER FILING DATE: 1997-10-09
; EARLIER APPLICATION NUMBER: 60/061,527
; EARLIER FILING DATE: 1997-10-09
; EARLIER APPLICATION NUMBER: 60/061,536
; EARLIER FILING DATE: 1997-10-09
; EARLIER APPLICATION NUMBER: 60/061,532
; EARLIER FILING DATE: 1997-10-09
; NUMBER OF SEQ ID NOS: 219
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 3
; LENGTH: 86
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-288-143-3
```

```
Query Match      90.0%; Score 18; DB 4; Length 86;
Best Local Similarity 100.0%; Pred. No. 1.2;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      2 TGATTTCCCGAATGAT 19
```

```
Db      40 TGATTTCCCGAATGAT 57
         |||
```

```
RESULT 12
US-09-487-792-25
; Sequence 25, Application US/09487792
; Patent No. 6433145
; GENERAL INFORMATION:
; APPLICANT: Human Genome Sciences, Inc.
; TITLE OF INVENTION: Keratinocyte Derived Interferon
; FILE REFERENCE: P482p1
; CURRENT APPLICATION NUMBER: US/09/487,792
; EARLIER FILING DATE: 2000-01-20
; EARLIER APPLICATION NUMBER: 60/093,643
; EARLIER FILING DATE: 1998-07-21
; EARLIER APPLICATION NUMBER: PCT/US99/16424
; EARLIER FILING DATE: 1999-07-21
; NUMBER OF SEQ ID NOS: 54
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 25
; LENGTH: 86
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-487-792-25
```

```
Query Match      90.0%; Score 18; DB 4; Length 86;
Best Local Similarity 100.0%; Pred. No. 1.2;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      2 TGATTTCCCGAATGAT 19
         |||
Db      40 TGATTTCCCGAATGAT 57
```

```
RESULT 13
US-09-152-060-3
; Sequence 3, Application US/09152060
; Patent No. 6448230
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: 28 Human Secreted Proteins
; FILE REFERENCE: P2003p1.US
; CURRENT APPLICATION NUMBER: US/09/152,060
; EARLIER APPLICATION NUMBER: PCT/US98/04858
; EARLIER FILING DATE: 1998-03-12
; EARLIER APPLICATION NUMBER: 60/040,762
; EARLIER FILING DATE: 1997-03-14
; EARLIER APPLICATION NUMBER: 60/040,710
; EARLIER FILING DATE: 1997-03-14
; EARLIER APPLICATION NUMBER: 60/050,934
; EARLIER FILING DATE: 1997-05-30
; EARLIER APPLICATION NUMBER: 60/048,100
; EARLIER FILING DATE: 1997-05-30
; EARLIER APPLICATION NUMBER: 60/048,357
; EARLIER FILING DATE: 1997-05-30
; EARLIER APPLICATION NUMBER: 60/048,189
; EARLIER FILING DATE: 1997-05-30
; EARLIER APPLICATION NUMBER: 60/057,765
; EARLIER FILING DATE: 1997-09-05
; EARLIER APPLICATION NUMBER: 60/048,970
; EARLIER FILING DATE: 1997-06-06
; EARLIER APPLICATION NUMBER: 60/068,368
; EARLIER FILING DATE: 1997-12-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 3
; LENGTH: 86
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-152-060-3
```

```
Query Match          90.0%; Score 18; DB 4; Length 86;
Best Local Similarity 100.0%; Pred. No. 1.2;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY      2 TGATTCCCGGAATGAT 19
DB      40 TGATTCCCGGAATGAT 57

RESULT 14
US-09-106-182-18
; Sequence 18, Application US/09106182
; Patent No. 6046035
; GENERAL INFORMATION:
; APPLICANT: Shi, Yangu
; APPLICANT: Ruben, Steve
; TITLE OF INVENTION: Cardiostrophin-like Cytokine
; NUMBER OF SEQUENCES: 24
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Human Genome Sciences, Inc
; STREET: 9410 Key West Ave
; CITY: Rockville
; STATE: MD
; COUNTRY: US
; ZIP: 20850
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/106,182
; FILING DATE: Herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/051,053
; FILING DATE: 30-JUN-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Brooks, A. Anders
; REGISTRATION NUMBER: 36,373
; REFERENCE/DOCKET NUMBER: PF385
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 301-309-8504
; TELEFAX: 301-309-8439
; INFORMATION FOR SEQ ID NO: 18:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 271 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-09-106-182-18

Query Match          90.0%; Score 18; DB 3; Length 271;
Best Local Similarity 100.0%; Pred. No. 1.4;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY      2 TGATTCCCGGAATGAT 19
DB      36 TGATTCCCGGAATGAT 53

RESULT 15
US-09-227-357-5
; Sequence 5, Application US/09227357
; Patent No. 6342581
; GENERAL INFORMATION:
; APPLICANT: Fischer et al.
; TITLE OF INVENTION: 123 Human Secreted Proteins
; FILE REFERENCE: P2010P1
; CURRENT APPLICATION NUMBER: US/09/227,357
; CURRENT FILING DATE: 1999-01-08
; EARLIER APPLICATION NUMBER: PCT/US98/13664

; EARLIER FILING DATE: 1998-07-07
; EARLIER APPLICATION NUMBER: 60/051,926
; EARLIER FILING DATE: 1997-07-08
; EARLIER APPLICATION NUMBER: 60/052,793
; EARLIER FILING DATE: 1997-07-08
; EARLIER APPLICATION NUMBER: 60/051,925
; EARLIER FILING DATE: 1997-07-08
; EARLIER APPLICATION NUMBER: 60/051,929
; EARLIER FILING DATE: 1997-07-08
; EARLIER APPLICATION NUMBER: 60/052,803
; EARLIER FILING DATE: 1997-07-08
; EARLIER APPLICATION NUMBER: 60/052,732
; EARLIER FILING DATE: 1997-07-08
; EARLIER APPLICATION NUMBER: 60/051,931
; EARLIER FILING DATE: 1997-07-08
; EARLIER APPLICATION NUMBER: 60/051,932
; EARLIER FILING DATE: 1997-07-08
; EARLIER APPLICATION NUMBER: 60/051,916
; EARLIER FILING DATE: 1997-07-08
; EARLIER APPLICATION NUMBER: 60/051,930
; EARLIER FILING DATE: 1997-07-08
; EARLIER APPLICATION NUMBER: 60/051,918
; EARLIER FILING DATE: 1997-07-08
; EARLIER APPLICATION NUMBER: 60/051,920
; EARLIER FILING DATE: 1997-07-08
; EARLIER APPLICATION NUMBER: 60/052,733
; EARLIER FILING DATE: 1997-07-08
; EARLIER APPLICATION NUMBER: 60/052,795
; EARLIER FILING DATE: 1997-07-08
; EARLIER APPLICATION NUMBER: 60/051,919
; EARLIER FILING DATE: 1997-07-08
; EARLIER APPLICATION NUMBER: 60/051,928
; EARLIER FILING DATE: 1997-07-08
; EARLIER APPLICATION NUMBER: 60/055,722
; EARLIER FILING DATE: 1997-08-18
; EARLIER APPLICATION NUMBER: 60/055,723
; EARLIER FILING DATE: 1997-08-18
; EARLIER APPLICATION NUMBER: 60/055,948
; EARLIER FILING DATE: 1997-08-18
; EARLIER APPLICATION NUMBER: 60/055,949
; EARLIER FILING DATE: 1997-08-18
; EARLIER APPLICATION NUMBER: 60/055,953
; EARLIER FILING DATE: 1997-08-18
; EARLIER APPLICATION NUMBER: 60/055,950
; EARLIER FILING DATE: 1997-08-18
; EARLIER APPLICATION NUMBER: 60/055,947
; EARLIER FILING DATE: 1997-08-18
; EARLIER APPLICATION NUMBER: 60/055,964
; EARLIER FILING DATE: 1997-08-18
; EARLIER APPLICATION NUMBER: 60/056,360
; EARLIER FILING DATE: 1997-08-18
; EARLIER APPLICATION NUMBER: 60/055,684
; EARLIER FILING DATE: 1997-08-18
; EARLIER APPLICATION NUMBER: 60/055,984
; EARLIER FILING DATE: 1997-08-18
; EARLIER APPLICATION NUMBER: 60/055,954
; EARLIER FILING DATE: 1997-08-18
; EARLIER APPLICATION NUMBER: 60/058,785
; EARLIER FILING DATE: 1997-09-12
; EARLIER APPLICATION NUMBER: 60/058,664
; EARLIER FILING DATE: 1997-09-12
; EARLIER APPLICATION NUMBER: 60/058,660
; EARLIER FILING DATE: 1997-09-12
; EARLIER APPLICATION NUMBER: 60/058,661
; EARLIER FILING DATE: 1997-09-12
; NUMBER OF SEQ ID NOS: 672
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 5
; LENGTH: 271
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-227-357-5
```

Query Match 90.0%; Score 18; DB 4; Length 271;
 Best Local Similarity 100.0%; Pred. No. 1.4;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2 TGATTTCGCCGAAATGAT 19
 ||||||||||||||||
 Db 36 TGATTTCGCCGAAATGAT 53

Search completed: June 26, 2003, 16:21:12
 Job time : 32.288 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 26, 2003, 10:58:25 ; Search time 30.2174 Seconds
(without alignments)
.202.980 Million cell updates/sec

Title: US-09-355-254f-21

Perfect score: 20

Sequence: 1 gtattccagaaagAAC 20

Scoring table: IDENTITY_NUC
Gapop 10.0, Gapext 1.0

Searched: 441362 seqs, 153338381 residues

882724

Total number of hits satisfying chosen parameters:

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	20	100.0	20	1 US-08-276-099A-3	Sequence 3, Appl1
2	20	100.0	20	1 US-08-393-333-3	Sequence 3, Appl1
3	20	100.0	20	1 US-08-408-318-3	Sequence 3, Appl1
4	20	100.0	20	1 US-08-781-890-3	Sequence 3, Appl1
5	20	100.0	20	1 US-08-839-164-3	Sequence 9, Appl1
6	20	100.0	20	4 US-09-511-625B-9	Sequence 14, Appl1
7	20	100.0	20	4 US-09-511-625B-14	Sequence 25, Appl1
8	20	100.0	30	4 US-08-956-653A-25	Sequence 59, Appl1
9	20	100.0	100	4 US-09-522-217-59	Sequence 60, Appl1
10	20	100.0	100	4 US-09-522-217-59	Sequence 5, Appl1
11	18.4	92.0	62	4 US-09-003-903-5	Sequence 22, Appl1
12	17.4	87.0	26	4 US-08-369-796-32	Sequence 22, Appl1
13	17	85.0	17	1 US-08-852-091-22	Sequence 14, Appl1
14	17	85.0	17	2 US-09-178-973B-14	Sequence 14, Appl1
15	17	85.0	17	4 US-09-419-568F-14	Sequence 14, Appl1
16	17	85.0	17	4 US-09-354-243B-14	Sequence 22, Appl1
17	17	85.0	17	5 PCT-US95-17025-22	Sequence 24, Appl1
18	17	85.0	49	4 US-08-956-653A-22	Sequence 104, App
19	17	85.0	1001	4 US-09-641-638-104	Sequence 17, Appl1
20	16.8	84.0	36531	4 US-08-820-894A-3	Sequence 17, Appl1
21	16.4	82.0	25	2 US-08-956-652-17	Sequence 17, Appl1
22	16	80.0	25	3 US-08-956-652-17	Sequence 17, Appl1
23	16	80.0	25	3 US-08-956-652-17	Sequence 17, Appl1
24	16	80.0	25	3 US-08-956-652-17	Sequence 17, Appl1
25	16	80.0	25	3 US-08-956-652-17	Sequence 17, Appl1
26	16	80.0	25	3 US-08-956-652-17	Sequence 17, Appl1
27	16	80.0	30	1 US-08-386-728-4	Sequence 4, Appl1

28	16	80.0	30	5 PCT-US96-01768-4	Sequence 4, Appl1
c 29	15.8	79.0	1364	2 US-08-872-302-3	Sequence 3, Appl1
30	15.8	79.0	1383	1 US-08-289-709-2	Sequence 2, Appl1
31	15.8	79.0	1383	1 US-08-602-656-2	Sequence 2, Appl1
c 32	15.8	79.0	98844	4 US-09-791-211-10	Sequence 10, Appl1
c 33	15.4	77.0	1600	4 US-07-861-458C-37	Sequence 37, Appl1
c 34	15.4	77.0	1607	6 5196333-3	Sequence 35, Appl1
c 35	15.4	77.0	10614	1 US-08-135-511-35	Sequence 35, Appl1
c 36	15.4	77.0	10614	1 US-08-187-453-35	Sequence 35, Appl1
c 37	15.2	76.0	243	4 US-09-134-001C-1717	Sequence 1717, Ap
38	15.2	76.0	8789	1 US-08-328-254-5	Sequence 5, Appl1
39	15.2	76.0	10136	1 US-08-353-700-2	Sequence 2, Appl1
c 40	15.2	76.0	10136	5 PCT-US95-16216-2	Sequence 13, Appl1
c 41	15	75.0	15	1 US-08-141-499A-13	Sequence 13, Appl1
c 42	15	75.0	15	1 US-08-467-940-13	Sequence 13, Appl1
c 43	15	75.0	15	1 US-08-633-772-13	Sequence 13, Appl1
c 44	15	75.0	1266	1 US-09-134-078-3	Sequence 3, Appl1
45	15	75.0	7577	4 US-08-961-527-46	Sequence 46, Appl1

ALIGNMENTS

RESULT 1
US-08-276-099A-3
Sequence 3, Application US/08276099A
Patent No. 5591825
GENERAL INFORMATION:
APPLICANT: McKnight, Steven L
APPLICANT: Hou, Jinhao
TITLE OF INVENTION: INTERLEUKIN-4 SIGNAL TRANSDUCERS AND
TITLE OF INVENTION: BINDING ASSAYS
NUMBER OF SEQUENCES: 17
CORRESPONDENCE ADDRESS:
ADDRESSER: FLEHR, ROBERT, TEST, ALBERTSON & HERBERT
STREET: 4 Embarcadero Center, Suite 3400
CITY: San Francisco
STATE: California
COUNTRY: USA
ZIP: 94111-4187
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/276,099A
FILING DATE: 15-JUL-1994
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Osman, Richard Aron
REGISTRATION NUMBER: 36,627
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 781-1989
TELEFAX: (415) 398-3249
TELEX: 910 277299
INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: CDNA
US-08-276-099A-3
Query Match 100.0%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.17;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 GTATTTCACAGAAAGAAC 20
DB 1 GTATTTCACAGAAAGAAC 20

RESULT 2
US-08-393-333-3
Sequence 3, Application US/08393333
Patent No. 5618693
GENERAL INFORMATION:
APPLICANT: McKnight, Steven L
APPLICANT: Hou, Jinhao
APPLICANT: Schindler, Dirk
TITLE OF INVENTION: INTERLEUKIN-2 SIGNAL TRANSDUCERS AND
TITLE OF INVENTION: BINDING ASSAYS
NUMBER OF SEQUENCES: 4
CORRESPONDENCE ADDRESS:
ADDRESSEE: FLEHR, HOBBACH, TEST, ALBRITTON & HERBERT
STREET: 4 Embarcadero Center, Suite 3400
CITY: San Francisco
STATE: California
COUNTRY: USA
ZIP: 94111-4187
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/393,333
FILING DATE:
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Osman, Richard A
REGISTRATION NUMBER: 36,627
REFERENCE/DOCKET NUMBER: A-60778/RAO
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 781-1989
TELEFAX: (415) 398-3249
TELEX: 910 277299
INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
US-08-393-333-3
Query Match 100.0%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.17;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTATTCCGAGAAAGAAC 20
DB 1 GTATTCCGAGAAAGAAC 20
RESULT 3
US-08-408-318-3
Sequence 3, Application US/08408318
Patent No. 5639858
GENERAL INFORMATION:
APPLICANT: Hoeg, Timothy
TITLE OF INVENTION: Human Signal Transducers and Binding
TITLE OF INVENTION: Assays
NUMBER OF SEQUENCES: 4
CORRESPONDENCE ADDRESS:
ADDRESSEE: Flehr, Hobbach, Test, Albritton & Herber
STREET: 850 Hansen Way, #200
CITY: Palo Alto
STATE: CA
COUNTRY: USA
ZIP: 94304
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/408,318
FILING DATE:
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: Osman, Richard A
REGISTRATION NUMBER: 36,627
REFERENCE/DOCKET NUMBER: A-60845
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415-494-8770
TELEFAX: 415-494-8771
INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-408-318-3
Query Match 100.0%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.17;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTATTCCGAGAAAGAAC 20
DB 1 GTATTCCGAGAAAGAAC 20
RESULT 4
US-08-781-890-3
Sequence 3, Application US/08781890
Patent No. 5710266
GENERAL INFORMATION:
APPLICANT: McKnight, Steven L
APPLICANT: Hou, Jinhao
TITLE OF INVENTION: INTERLEUKIN-4 SIGNAL TRANSDUCERS AND
TITLE OF INVENTION: BINDING ASSAYS
NUMBER OF SEQUENCES: 17
CORRESPONDENCE ADDRESS:
ADDRESSEE: FLEHR, HOBBACH, TEST, ALBRITTON & HERBERT
STREET: 4 Embarcadero Center, Suite 3400
CITY: San Francisco
STATE: California
COUNTRY: USA
ZIP: 94111-4187
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/781,890
FILING DATE: 05-JAN-1997
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/276,099
FILING DATE: 15-JUL-1994
ATTORNEY/AGENT INFORMATION:
NAME: Osman, Richard A
REGISTRATION NUMBER: 36,627
REFERENCE/DOCKET NUMBER: A-59451-1/RAO
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 781-1989
TELEFAX: (415) 398-3249
TELEX: 910 277299
INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: nucleic acid

```
;; STRANDEDNESS: double
;; TOPOLOGY: linear
;; MOLECULE TYPE: cDNA
US-08-781-890-3

Query Match      100.0%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.17;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTATTCCAGAAAAGAAC 20
   |||
Db 1 GTATTCCAGAAAAGAAC 20

RESULT 5
US-08-839-164-3
; Sequence 3, Application US/08839164
; Patent No. 5756700
; GENERAL INFORMATION:
; APPLICANT: Hoey, Timothy
; TITLE OF INVENTION: Human Signal Transducers and Binding
; TITLE OF INVENTION: Assays
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Flehr, Hohbach, Test, Albritton & Herber
; STREET: 850 Hansen Way, #200
; CITY: Palo Alto
; STATE: CA
; COUNTRY: USA
; ZIP: 94304
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/839,164
; FILING DATE: 23-APR-1997
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/408,318
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Osman, Richard A
; REGISTRATION NUMBER: 36,627
; REFERENCE/DOCKET NUMBER: A-60845
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-494-8700
; TELEFAX: 415-494-8771
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-839-164-3

Query Match      100.0%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.17;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTATTCCAGAAAAGAAC 20
   |||
Db 1 GTATTCCAGAAAAGAAC 20

RESULT 6
US-09-511-625B-9
; Sequence 9, Application US/09511625B
; Patent No. 6368828
; GENERAL INFORMATION:
; APPLICANT: Larocheille, William J.
```

```
;; APPLICANT: Patel, Bhavlin
;; APPLICANT: Pierce, Jacalyn H.
; TITLE OF INVENTION: ATTENUATED AND DOMINANT NEGATIVEVARIANT
; TITLE OF INVENTION: CDNA OF STAT6: STAT6B AND STAT6C
; FILE REFERENCE: 14014.0300u1
; CURRENT APPLICATION NUMBER: US/09/511,625B
; CURRENT FILING DATE: 2000-02-23
; PRIOR APPLICATION NUMBER: PCT/US98/17821
; PRIOR FILING DATE: 1998-08-27
; PRIOR APPLICATION NUMBER: 60/070,397
; PRIOR FILING DATE: 1998-01-05
; PRIOR APPLICATION NUMBER: 60/056,075
; PRIOR FILING DATE: 1997-08-27
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 9
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of artificial Sequence./No. 6368828e -
US-09-511-625B-9

Query Match      100.0%; Score 20; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.17;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTATTCCAGAAAAGAAC 20
   |||
Db 1 GTATTCCAGAAAAGAAC 20

RESULT 7
US-09-511-625B-14
; Sequence 14, Application US/09511625B
; Patent No. 6368828
; GENERAL INFORMATION:
; APPLICANT: Larocheille, William J.
; APPLICANT: Patel, Bhavlin
; APPLICANT: Pierce, Jacalyn H.
; TITLE OF INVENTION: ATTENUATED AND DOMINANT NEGATIVEVARIANT
; TITLE OF INVENTION: CDNA OF STAT6: STAT6B AND STAT6C
; FILE REFERENCE: 14014.0300u1
; CURRENT APPLICATION NUMBER: US/09/511,625B
; CURRENT FILING DATE: 2000-02-23
; PRIOR APPLICATION NUMBER: PCT/US98/17821
; PRIOR FILING DATE: 1998-08-27
; PRIOR APPLICATION NUMBER: 60/070,397
; PRIOR FILING DATE: 1998-01-05
; PRIOR APPLICATION NUMBER: 60/056,075
; PRIOR FILING DATE: 1997-08-27
; NUMBER OF SEQ ID NOS: 70
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 14
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of artificial Sequence./No. 6368828e -
US-09-511-625B-14

Query Match      100.0%; Score 20; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.17;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTATTCCAGAAAAGAAC 20
   |||
Db 1 GTATTCCAGAAAAGAAC 20

RESULT 8
```

US-08-956-653A-25
; Sequence 25, Application US/08956653A
; Patent No. 6338949
; GENERAL INFORMATION:
; APPLICANT: Darnell Jr., James E.
; APPLICANT: Schindler, Christian W.
; APPLICANT: Fu, Xian-Yuan
; APPLICANT: Wen, Zilong
; APPLICANT: Zhong, Zhong
; TITLE OF INVENTION: RECEPTOR RECOGNITION FACTORS, PROTEIN
; NUMBER OF SEQUENCES: 34
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Klauder & Jackson
; STREET: 411 Hackensack Avenue
; CITY: Hackensack
; STATE: New Jersey
; COUNTRY: USA
; ZIP: 07601
; COMPUTER READABLE FORM:
; MEDIUM TYPE: floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/956,653A
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/212,185
; FILING DATE: 11-MAR-1994
; APPLICATION NUMBER: US 07/980,498
; FILING DATE: 23-NOV-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/854,296
; FILING DATE: 19-MAR-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: WO US93/02569
; FILING DATE: 19-MAR-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/126,588
; FILING DATE: 24-SEP-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Jackson Esq., David A.
; REGISTRATION NUMBER: 26,742
; REFERENCE/DOCKET NUMBER: 600-1-195
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 201 487-5800
; TELEFAX: 201 343-1684
; TELEX: 133521
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 30 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; DESCRIPTION: oligonucleotide probe for R1.2
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
US-08-956-653A-25
Query Match 100.0%; Score 20; DB 4; Length 30;
Best Local Similarity 100.0%; Pred. No. 0.18;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTATTCCAGAAAGAAC 20
|||||
DB 6 GTATTCCAGAAAGAAC 25

RESULT 9
US-09-522-217-59

; Sequence 59, Application US/09522217
; Patent No. 6307024
; GENERAL INFORMATION:
; APPLICANT: No. 6307024ak, Julia E.
; APPLICANT: Presnell, Scott R.
; APPLICANT: Sprechet, Cindy A.
; APPLICANT: Foster, Donald C.
; APPLICANT: Holly, Richard D.
; APPLICANT: Gross, Jane A.
; APPLICANT: Johnston, Janet V.
; APPLICANT: Nelson, Andrew J.
; APPLICANT: Dillon, Stacey R.
; APPLICANT: Hammond, Angela K.
; TITLE OF INVENTION: NOVEL CYTOKINE ZALPHA1 LIGAND
; FILE REFERENCE: 99-16
; CURRENT APPLICATION NUMBER: US/09/522,217
; CURRENT FILING DATE: 2000-03-09
; EARLIER APPLICATION NUMBER: US 60/123,547
; EARLIER FILING DATE: 1999-03-09
; EARLIER APPLICATION NUMBER: US 60/123,904
; EARLIER FILING DATE: 1999-03-11
; EARLIER APPLICATION NUMBER: US 60/142,013
; EARLIER FILING DATE: 1999-07-01
; NUMBER OF SEQ ID NOS: 115
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 59
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide ZC12749
US-09-522-217-59
Query Match 100.0%; Score 20; DB 4; Length 100;
Best Local Similarity 100.0%; Pred. No. 0.23;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTATTCCAGAAAGAAC 20
|||||
DB 44 GTATTCCAGAAAGAAC 63

RESULT 10
US-09-522-217-60/C
; Sequence 60, Application US/09522217
; Patent No. 6307024
; GENERAL INFORMATION:
; APPLICANT: No. 6307024ak, Julia E.
; APPLICANT: Presnell, Scott R.
; APPLICANT: Sprechet, Cindy A.
; APPLICANT: Foster, Donald C.
; APPLICANT: Holly, Richard D.
; APPLICANT: Gross, Jane A.
; APPLICANT: Johnston, Janet V.
; APPLICANT: Nelson, Andrew J.
; APPLICANT: Dillon, Stacey R.
; APPLICANT: Hammond, Angela K.
; TITLE OF INVENTION: NOVEL CYTOKINE ZALPHA1 LIGAND
; FILE REFERENCE: 99-16
; CURRENT APPLICATION NUMBER: US/09/522,217
; CURRENT FILING DATE: 2000-03-09
; EARLIER APPLICATION NUMBER: US 60/123,547
; EARLIER FILING DATE: 1999-03-09
; EARLIER APPLICATION NUMBER: US 60/123,904
; EARLIER FILING DATE: 1999-03-11
; EARLIER APPLICATION NUMBER: US 60/142,013
; EARLIER FILING DATE: 1999-07-01
; NUMBER OF SEQ ID NOS: 115
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 60
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Artificial Sequence

```
;; FEATURE:
;; OTHER INFORMATION: Oligonucleotide ZC12748
US-09-522-217-60
Query Match      100.0%; Score 20; DB 4; Length 100;
Best Local Similarity 100.0%; Pred. No. 0.23;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY      1 GTATTCCAGAAAAGGAC 20
      61 GTATTCCAGAAAAGGAC 42
Db

RESULT 11
US-09-003-903-5
; Sequence 5, Application US/09003903
; Patent No. 6265160
; GENERAL INFORMATION:
; APPLICANT: The Government of the United States of America
; APPLICANT: as Represented by the Secretary, Department of
; APPLICANT: Health and Human Services
; APPLICANT: Leonard, Warren J.
; TITLE OF INVENTION: METHOD OF IDENTIFYING INHIBITORS OF THE
; FILE REFERENCE: NIH18.001C1
; CURRENT APPLICATION NUMBER: US/09/003.903
; EARLIER FILING DATE: 1998-01-07
; EARLIER APPLICATION NUMBER: PCT/US96/11206
; EARLIER FILING DATE: 1996-07-02
; EARLIER APPLICATION NUMBER: 60/000.971
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 5
; LENGTH: 62
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-09-003-903-5
Query Match      92.0%; Score 18.4; DB 4; Length 62;
Best Local Similarity 95.0%; Pred. No. 1.3;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY      1 GTATTCCAGAAAAGGAC 20
      5 GTATTCCAGAAAAGGATC 24
Db

RESULT 12
US-09-003-903-1
; Sequence 1, Application US/09003903
; Patent No. 6265160
; GENERAL INFORMATION:
; APPLICANT: The Government of the United States of America
; APPLICANT: as Represented by the Secretary, Department of
; APPLICANT: Health and Human Services
; APPLICANT: Leonard, Warren J.
; TITLE OF INVENTION: METHOD OF IDENTIFYING INHIBITORS OF THE
; FILE REFERENCE: NIH18.001C1
; CURRENT APPLICATION NUMBER: US/09/003.903
; EARLIER FILING DATE: 1998-01-07
; EARLIER APPLICATION NUMBER: PCT/US96/11206
; EARLIER FILING DATE: 1996-07-02
; EARLIER APPLICATION NUMBER: 60/000.971
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 1
; LENGTH: 26
; TYPE: DNA
```

```
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Oligonucleotide
US-09-003-903-1
Query Match      87.0%; Score 17.4; DB 4; Length 26;
Best Local Similarity 94.7%; Pred. No. 3.5;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY      1 GTATTCCAGAAAAGGA 19
      6 GTATTCCAGAAAAGGA 24
Db

RESULT 13
US-08-369-796-22
; Sequence 22, Application US/08369796
; Patent No. 5716622
; GENERAL INFORMATION:
; APPLICANT: James E. Darnell, Jr.
; APPLICANT: Zilong Wen
; APPLICANT: Curt M. Horvath
; APPLICANT: Zhong Zhong
; TITLE OF INVENTION: FUNCTIONALLY ACTIVE REGIONS OF SIGNAL
; NUMBER OF SEQUENCES: 39
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: Klauber & Jackson
; STREET: 411 Hackensack Avenue
; CITY: Hackensack
; STATE: New Jersey
; COUNTRY: USA
; ZIP: 07601
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/369,796
; FILING DATE: 06-JAN-1995
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Jackson Esq., David A.
; REGISTRATION NUMBER: 26,742
; REFERENCE/DOCKET NUMBER: 600-1-116
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 201 487-5800
; TELEFAX: 201 343-1684
; TELEX: 133521
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: DNA synthetic probe
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
US-08-369-796-22
Query Match      85.0%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 5.1;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY      1 GTATTCCAGAAAAGG 17
      1 GTATTCCAGAAAAGG 17
Db

RESULT 14
US-08-852-091-22
; Sequence 22, Application US/08852091
```

```

; Patent No. 5883228
; GENERAL INFORMATION:
; APPLICANT: James E. Darnell, Jr.
; APPLICANT: Zilong Wen
; APPLICANT: Curt M. Horvath
; APPLICANT: Zhong Zhong
; TITLE OF INVENTION: FUNCTIONALLY ACTIVE REGIONS OF SIGNAL
; TITLE OF INVENTION: TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION (STAT) PROTEINS
; NUMBER OF SEQUENCES: 39
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Klauber & Jackson
; STREET: 411 Hackensack Avenue
; CITY: Hackensack
; STATE: New Jersey
; COUNTRY: USA
; ZIP: 07601
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/852,091
; FILING DATE: 06-MAY-1997
; CLASSIFICATION: 424
; PRIORITY APPLICATION DATA:
; APPLICATION NUMBER: 08/369,796
; FILING DATE: 06-JAN-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Jackson Esq., David A.
; REGISTRATION NUMBER: 26,742
; REFERENCE/DOCKET NUMBER: 600-1-116
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 201 487-5800
; TELEFAX: 201 343-1684
; TELEX: 133521
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: DNA synthetic probe
; HYPOTHEICAL: NO
; ANTI-SENSE: NO
; US-08-852-091-22

Query Match      85.0%; Score 17; DB 2; Length 17;
Best Local Similarity 100.0%; Pred. No. 5.1;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 GATTTCGCCAGAAAAG 17
        |||||||
DB      1 GATTTCGCCAGAAAAG 17

RESULT 15
US-09-178-973B-14/C
; Sequence 14, Application US/09178973B
; Patent No. 6274710
; GENERAL INFORMATION:
; APPLICANT: Dumoutier, Laure
; APPLICANT: Louhed, Jamila
; APPLICANT: Renauld, Jean-Christophe
; TITLE OF INVENTION: Isolated Nucleic Acid Molecules which Encode T Cell Inducible Fac
; TITLE OF INVENTION: (Tifs)
; FILE REFERENCE: LUD 5543
; CURRENT APPLICATION NUMBER: US/09/178,973B
; CURRENT FILING DATE: 1998-10-26
; NUMBER OF SEQ ID NOS: 17
; SEQ ID NO 14
; LENGTH: 17

```

```

; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-178-973B-14

Query Match      85.0%; Score 17; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 5.1;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 GATTTCGCCAGAAAAG 17
        |||||||
DB      17 GATTTCGCCAGAAAAG 1

Search completed: June 26, 2003, 16:21:14
Job time : 31.2888 secs

```

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 26, 2003, 11:19:15 ; Search time 1529.13 Seconds

(without alignments)
211.826 Million cell updates/sec

Title: US-09-355-254F-8

Perfect score: 20

Sequence: 1 gattgcctgacgcagagag 20

Scoring table: IDENTITY_NUC

Searched: 16154066 segs, 8097743376 residues

Total number of hits satisfying chosen parameters: 32308132

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Database :

EST: *
1: em_estb: *
2: em_esth: *
3: em_estl: *
4: em_estm: *
5: em_estov: *
6: em_estpl: *
7: em_estro: *
8: em_hlc: *
9: gb_estl: *
10: gb_est2: *
11: gb_hlc: *
12: gb_est3: *
13: gb_est4: *
14: gb_est5: *
15: em_estfun: *
16: em_estom: *
17: gb_gss: *
18: em_gss_hum: *
19: em_gss_inv: *
20: em_gss_pln: *
21: em_gss_vrt: *
22: em_gss_fun: *
23: em_gss_man: *
24: em_gss_mus: *
25: em_gss_other: *
26: em_gss_pro: *
27: em_gss_rtd: *

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	17.4	87.0	509	17	AZ456210
2	17.4	87.0	525	17	AZ930991
3	16.8	84.0	580	12	BF571725
4	16.8	84.0	581	12	BG529082
5	16.8	84.0	812	12	BE855809
6	16.8	84.0	818	12	BG121636

7	16.8	84.0	984	17	AG085708	AG085708 Pan trogl
8	16.4	82.0	421	9	A1446142	A1446142 t107d08.x
9	16.4	82.0	455	9	A1377721	A1377721 tes6e04.x
10	16.4	82.0	462	9	AU147973	AU147973 AU147973
11	16.4	82.0	468	9	AA524774	AA524774 nh33f04.s
12	16.4	82.0	476	12	BF439459	BF439459 nab64g11.
13	16.4	82.0	570	17	AQ617221	AQ617221 HS_5152_B
14	16.4	82.0	630	17	AQ884463	AQ884463 CITBI-E1-
15	16.4	82.0	722	10	AV764299	AV764299 AV764299
16	16.4	82.0	737	12	BG707030	BG707030 602670345
17	16.4	82.0	1094	17	CNS05K18	AL340901 Tetradon
18	16.4	82.0	473	10	BB697276	BB697276 BB697276
19	16.4	82.0	668	17	BH306678	BH306678 CH230-98F
20	16.4	82.0	1032	17	CNS01V06	AL169179 Tetradon
21	15.8	79.0	123	9	AA750965	AA750965 ISRP0091
22	15.8	79.0	281	9	AA795454	AA795454 VV20D03.T
23	15.8	79.0	292	10	BB306386	BB306386 BB306386
24	15.8	79.0	304	10	BE191014	BE191014 sn83f10.Y
25	15.8	79.0	383	14	H64068	H64068 YF58f04.X1
26	15.8	79.0	410	12	BF709136	BF709136 MT-P-AYO-
27	15.8	79.0	424	10	AV407792	AV407792 AY407792
28	15.8	79.0	435	17	B41397	B41397 HS-1053-B1-
29	15.8	79.0	442	10	AW211525	AW211525 uc082b04.Y
30	15.8	79.0	444	13	BM174442	BM174442 TM.ad_29E
31	15.8	79.0	452	17	AQ179770	AQ179770 HS_3185_B
32	15.8	79.0	484	17	AQ460036	AQ460036 HS_5136_A
33	15.8	79.0	488	14	BQ312839	BQ312839 RC0-BM028
34	15.8	79.0	510	17	AO809522	AO809522 HS_4646_B
35	15.8	79.0	528	17	AQ471562	AQ471562 CITBI-E1-
36	15.8	79.0	529	17	BH200967	BH200967 Sm1-43K17
37	15.8	79.0	533	10	AW671751	AW671751 LG1_351.E
38	15.8	79.0	543	12	BE862853	BE862853 UT-M-BG0-
39	15.8	79.0	553	17	AO672151	AO672151 HS_2160_B
40	15.8	79.0	596	12	BF374971	BF374971 CM2-SF018
41	15.8	79.0	605	17	AO532396	AO532396 RPT-11-3
42	15.8	79.0	612	10	AW841675	AW841675 RC3-CN001
43	15.8	79.0	612	17	AZ083796	AZ083796 RPT-23-2
44	15.8	79.0	613	17	AQ305574	AQ305574 HS_2034_A
45	15.8	79.0	613	17	AQ305574	AQ305574 HS_2034_A

ALIGNMENTS

RESULT 1
LOCUS AZ456210 509 bp DNA linear GSS 04-OCT-2000
DEFINITION IM0258J21R Mouse 10kb plasmid UOCCIM library Mus musculus genomic
ACCESSION UOCCIM0258J21 R, DNA sequence.
VERSION AZ456210
KEYWORDS AZ456210.1 GI:10614335
SOURCE GSS.
ORGANISM house mouse.
MUS musculus

REFERENCE
1 (bases 1 to 509)
AUTHORS Dunn D., Aoyagi A., Barber M., Baecorn T., Duval B., Hamli C., Islam H., Longacre S., Mahmoud M., Meenen E., Pedersen T., Reilly M., Rose M., Rose R., Stokes R., Tinney A., von Niederhausern A. and Wright D., Weiss R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00

Plate: 0258 row: J column: 21
Seq primer: CACACAGAAACAGCTATACCC
Class: Plasmid ends
High quality sequence stop: 509.
Location/Qualifiers

FEATURES

source

1.509
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUCG1M0258721"
/clone_1lb="Mouse 10kb plasmid UUCG1M 1library"
/sex="Male"
/lab_host="E. coli strain XL10-Gold, T1-resistant, F-"
/note="Vector: PMD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of PMD42 (g11473211419b1AF129072.1), a copy-number inducible derivative of Plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

BASE COUNT

176 a 93 c 132 g 108 t

ORIGIN

Query Match 87.0%; Score 17.4; DB 17; Length 509;
Best Local Similarity 94.7%; Pred. No. 8.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 ATTCGCTGACGTGACAGAG 20
||||| ||||| ||||| |||||
DB 226 ATTCGCTGATGTCAGAGAG 244

RESULT 2
A2930991/c 535 bp DNA linear GSS 01-APR-2001
LOCUS 474.dhz60h07.s1 Saccharomyces unisporus NRRL Y-1556 Saccharomyces
DEFINITION unisporus genomic clone 474.dhz60h07.s1, DNA sequence.
ACCESSION A2930991
VERSION A2930991.1 GI:13501901
KEYWORDS GSS.
SOURCE Saccharomyces unisporus.
ORGANISM Saccharomyces unisporus.
Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes;
Saccharomycetaceae; Saccharomycetes.
1 (bases 1 to 535)
Clifton, P.F., Hillier, L.W., Fulton, L., Graves, T., Miner, T., Gish, W.R., Waterston, R.H. and Johnston, M.
Surveying Saccharomyces genomes to identify functional elements by comparative DNA sequence analysis
Unpublished (2001)

JOURNAL

Contact: Johnston M

Department of Genetics
Washington University Medical School
Box 8232, 4566 Scott Ave., St. Louis, MO 63110, USA
Tel: 314 362 2735
Fax: 314 362 7855

Email: mjgenetics.wustl.edu
Class: Random plasmid subclone.

FEATURES

source

1.525
/organism="Saccharomyces unisporus"

/strain="NRRL Y-1556 (CBS 398)"
/db_xref="taxon:27294"
/clone="474.dhz60h07.s1"
/clone_1lb="Saccharomyces unisporus NRRL Y-1556"
/note="Random genomic sequence"

BASE COUNT

133 a 119 c 77 g 196 t

ORIGIN

Query Match 87.0%; Score 17.4; DB 17; Length 525;
Best Local Similarity 94.7%; Pred. No. 8.8e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 GATTGCTGACGTGACAGAGA 19
||||| ||||| ||||| |||||
DB 384 GATTGCTGACGTGACAGAA 366

RESULT 3

BF571725/c 580 bp mRNA linear EST 12-DEC-2000
LOCUS 602076288F1 NIH_MGC_62 Homo sapiens cDNA clone IMAGE:4243820 5',
DEFINITION mRNA sequence.
ACCESSION BF571725
VERSION BF571725.1 GI:11645437
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens

REFERENCE NIH-MGC http://mgc.ncl.nih.gov/.
AUTHORS 1 (bases 1 to 580)
TITLE National Institutes of Health, Mammalian Gene Collection (MGC)
JOURNAL Unpublished (1999)
COMMENT Contact: Robert Strausberg, Ph.D.
Email: cgrabs-r@mail.nih.gov
Tissue Procurement: ATCC/DC/DTP
cDNA Library Preparation: CLOUTIERECH Laboratories, Inc.
cDNA Library Arrayed by: The I.M.A.G.E. Consortium (ILNLT)
DNA Sequencing by: Incyte Genomics, Inc.
Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/ILNLT at:
http://image.llnl.gov
Plate: LKCM1054 row: O column: 21
High quality sequence start: 6
High quality sequence stop: 488.
Location/Qualifiers

1.580
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone_1lb="NIH_MGC_62"
/clone_1lb="NIH_MGC_62"
/tissue_type="melanotic melanoma, high MDR"
/lab_host="DH10B (T1 phage-resistant)"
/note="organ: skin; Vector: pDRP-LTB (Clontech); Site: 1:
5'11 (ggcgcctgcgcgc); Site: 2: 5'11 (ggcgcctgcgcgc);
Double-stranded cDNA was prepared from cell line RNA. 5'
and 3' adaptors were used in cloning as follows: 5'
adaptor sequence: 5'-CACGCCATATATGCGC-3' and 3' adaptor
sequence: 5'-ATTCAGAGCGCCGCGCGCAGATG-dt(30)BN-3'
(where B = A, C, or G and N = A, C, G, or T). Average
insert size 1.75 kb (range 0.9-4.0 kb). 15/15 colonies
contained inserts by PCR. This library was enriched for
full-length clones and was constructed by Clontech
Laboratories (Palo Alto, CA)."

FEATURES

source

BASE COUNT 131 a 139 c 150 g 160 t
ORIGIN

Query Match 84.0%; Score 16.8; DB 12; Length 580;
Best Local Similarity 90.0%; Pred. No. 1.7e+03;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 GATTGCTGACGTGACAGAG 20
||||| ||||| ||||| |||||

DB	172	GATTGCGCTGAGCTCAGAGAG	153
RESULT 4			
LOCUS	BG529082	581 bp	MRNA
DEFINITION	60257918471 NIH_MGC_60 Homo sapiens CDNA clone IMAGE:4713261 5',		
ACCESSION	MRNA sequence.		
VERSION	BG529082		
KEYWORDS	BG529082.1 GI:13520619		
SOURCE	EST.		
ORGANISM	human.		
	Homo sapiens		
	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;		
	Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.		
REFERENCE	1 (bases 1 to 581)		
AUTHORS	NIH-MGC http://mgc.nci.nih.gov/ .		
TITLE	National Institutes of Health, Mammalian Gene Collection (MGC)		
JOURNAL	Unpublished (1999)		
COMMENT	Contact: Robert Strausberg, Ph.D. Email: cgapbs-remail.nih.gov Tissue Procurement: DCTD/DMP CDNA Library Preparation: CLONTECH Laboratories, Inc. CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LNLN) DNA Sequencing by: Incyte Genomics, Inc. Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LNLN at: http://Image.lnl.gov Plate: L16M1556 row: g column: 22 High quality sequence stop: 566. Location/Qualifiers 1..581 /organism="Homo sapiens" /db_xref="taxon:9606" /clone="IMAGE:4713261" /clone_lib="NIH_MGC_60" /tissue_type="adenocarcinoma" /lab_host="DH10B (T1 phage-resistant)" /note="Organ: prostate; Vector: pGNR-LIB (Clontech); Site 1: Sfil (ggcgccctggcc); Site 2: Sfil (ggcgatagcgc); Double-stranded cDNA was prepared from cell line RNA. 5' and 3' adaptors were used in cloning as follows: 5' adaptor sequence: 5'-CACTGCGCATTTAGGCC-3' and 3' adaptor sequence: 5'-ATTCTAGAGCCGAGGCGCCGACATG-dT(30)BN-3' (where B = A, C, or G and N = A, C, G, or T). Average insert size 1.5 kb (range 0.9-4.0 kb). 14/15 colonies contained inserts by PCR. This library was enriched for full-length clones and was constructed by Clontech Laboratories (Palo Alto, CA). Note: this is a NIH_MGC Library."		
BASE COUNT	175 a 110 c 100 g 196 t		
ORIGIN			
Query Match	84.0%; Score 16.8; DB 12; Length 581;		
Best Local Similarity	90.0%; Pred. No. 1.7e+03;		
Matches 18; Conservative	0; Mismatches 2; Indels 0; Gaps 0;		
OY	1 GATTGCGCTGAGCTCAGAGAG 20		
DB			
	56 GATTGCGCTGAGAGCAGAGAG 37		
RESULT 5			
LOCUS	BE865809	812 bp	MRNA
DEFINITION	60167820221 NIH_MGC_53 Homo sapiens CDNA clone IMAGE:3960888 5',		
ACCESSION	MRNA sequence.		
VERSION	BE865809		
KEYWORDS	BE865809.1 GI:10314585		
SOURCE	EST.		
ORGANISM	human.		
	Homo sapiens		
	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;		

REFERENCE	Mammalia; Eutheria; Primates; Carnivora; Homiidae; Homo.
AUTHORS	1 (bases 1 to 812)
TITLE	NIH-MGC http://mgc.nci.nih.gov/.
JOURNAL	National Institutes of Health, Mammalian Gene Collection (MGC)
COMMENT	Unpublished (1999) Contact: Robert Strausberg, Ph.D. Email: cgaabs-remail.nih.gov Tissue Procurement: ATCC CDNA Library Preparation: CLONTECH Laboratories, Inc. CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LNLN) DNA Sequencing by: Incyte Genomics, Inc. Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LNLN at: image.lnl.gov Plate: LNCM84 row: c column: 01 High quality sequence stop: 478. Location/Qualifiers 1..812
FEATURES	/organism="Homo sapiens" /db_xref="taxon:9606" /clone="IMAGE:396088" /clone_id="NIH-MGC_53" /tissue_type="carcinoma, cell line" /lab_host="DH10B (T1 phage-resistant)" /note="Organ: bladder; Vector: pMD19-LIB (Clontech); Site_1: SfiI (ggccgcctggcc); Site_2: SfiI (ggccatagcc); Double-stranded cDNA was prepared from cell line RNA. 5' and 3' adaptors were used in cloning as follows: 5' adaptor sequence: 5'-CACGCCCATATGAGCC-3' and 3' adaptor sequence: 5'-ATTCAGAGCGCCGCGCGCGCAGCAG-3' (30)BN-3' (where B = A, C, or G and N = A, C, G, or T). Average insert size 1.55 kb (range 0.9-4.0 kb). 15/15 colonies contained inserts by PCR. This library was enriched for full-length clones and was constructed by Clontech Laboratories (Palo Alto, CA)."
BASE COUNT	211 a 219 c 161 g 221 t
ORIGIN	
Query Match	84.0%; Score 16.8; DB 12; Length 812;
Best Local Similarity	90.0%; Pred. No. 2e+03;
Matches	18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Oy	1 GATGCCCTGAGCTCAGAGAG 20
Db	381 GATGCCCTGAGAGCAGAGAG 362
RESULT 6	
LOCUS	BG121636 818 bp mRNA linear EST 30-JAN-2001
DEFINITION	602351594F1 NIH-MGC_90 Homo sapiens CDNA clone IMAGE:4449935 5',
ACCESSION	BG121636
VERSION	BG121636.1 GI:12615145
KEYWORDS	EST.
SOURCE	human.
ORGANISM	Homo sapiens
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Carnivora; Homiidae; Homo.
AUTHORS	1 (bases 1 to 818)
TITLE	NIH-MGC http://mgc.nci.nih.gov/.
JOURNAL	National Institutes of Health, Mammalian Gene Collection (MGC)
COMMENT	Unpublished (1999) Contact: Robert Strausberg, Ph.D. Email: cgaabs-remail.nih.gov Tissue Procurement: ATCC CDNA Library Preparation: Life Technologies, Inc. CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LNLN) DNA Sequencing by: Incyte Genomics, Inc. Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LNLN at: http://image.lnl.gov Plate: LNCM10234 row: k column: 24 High quality sequence stop: 559.

```

FEATURES
  source      Location/Qualifiers
              1. 818
                /organism="Homo sapiens"
                /db_xref="taxon:9606"
                /clone="IMAGE:444935"
                /clone_1lb="NH_MGC-90"
                /tissue_type="adenoecarcinoma, cell line"
                /lab_host="DH10B (phage-resistant)"
                /note="Organ: liver; Vector: pCMV-SPORT6; Site_1: NotI;
                Site_2: SalI; Cloned unidirectionally; oligo-df primed.
                Average insert size 1.7 kb. Library enriched for
                full-length clones and constructed by Life Technologies.
                Note: this is a NH_MGC Library."
BASE COUNT
  211 a 192 c 192 g 223 t

Query Match
Best Local Similarity 90.0%; Pred. No. 26+03;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 GATTGCTGACGTACAGAG 20
    ||||||| |||||||
Db 528 GATTGCTGACGTACAGAG 509

RESULT 7
LOCUS AG085708 984 bp DNA linear GSS 03-NOV-2001
DEFINITION Pan troglodytes DNA, clone: PTB-083N10.R, genomic survey sequence.
ACCESSION AG085708
VERSION AG085708.1 GI:16637510
KEYWORDS GSS.
SOURCE Pan troglodytes male lymphoblast DNA, clone_1lb:PTB Chimpanzee Male
          BAC Library Clones:PTB-083N10.R.
          Pan troglodytes
          Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
          Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Pan.
ORGANISM
REFERENCE
  1 Fujiyama,A., Hattori,M., Toyoda,A., Taylor,T.D., Yada,T.,
    Tokokli,Y., Watanabe,H. and Sakaki,Y.
    BAC end sequences of library PTB
    Unpublished
    2 (bases 1 to 984)
    Fujiyama,A., Hattori,M., Toyoda,A., Taylor,T.D., Yada,T.,
    Tokokli,Y., Watanabe,H. and Sakaki,Y.
    Direct Submission
    Submitted (02-AUG-2001) Asao Fujiyama, The Institute of Physical
    and Chemical Research (RIKEN), Genomic Sciences Center (GSC);
    1-7-22 Suehiro-chou,Tsukumi-ku, Yokohama, Kanagawa 230-0045, Japan
    (E-mail:shimpo@gscc.riken.go.jp, URL:http://hgp.gscc.riken.go.jp/,
    Tel:81-45-503-9111, Fax:81-45-503-9170)
    Clones are derived from the chimpanzee BAC library PTB this BAC end
    was generated during the R&D process and may have higher chance of
    clone tracking errors.
    PRIMERS
    Sequencing: M13rev
    LIBRARY
    Vector : pKS145
    R.Site 1 : SacI
    R.Site 2 : SacI.
    Location/Qualifiers
      1. 984
        /organism="Pan troglodytes"
        /db_xref="taxon:9598"
        /clone="PTB-083N10.R"
        /sex="male"
        /cell_type="lymphoblast"
        /clone_1lb="PTB Chimpanzee Male BAC Library"
BASE COUNT
  292 a 249 c 192 g 250 t 1 others

Query Match
Best Local Similarity 90.0%; Pred. No. 2.2e+03;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 GATTGCTGACGTACAGAG 20
    ||||||| |||||||
Db 243 GACTGCTGACGTACAGAG 262

RESULT 8
LOCUS AI446142/c 421 bp mRNA linear EST 09-MAR-1999
DEFINITION t307d08.x1 NCI-CGAP_Gas4 Homo sapiens cDNA clone IMAGE:2140815.3'
          similar to contains Alu repetitive element;contains element MER22
          repetitive element ; mRNA sequence.
ACCESSION AI446142
VERSION AI446142.1 GI:4293138
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens
          Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
          Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.
REFERENCE
  1 (bases 1 to 421)
  NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
  National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
  Tumor Gene Index
  Unpublished (1997)
  Contact: Robert Strausberg, Ph.D.
  Email: cga@bbs-rt@mail.nih.gov
  Tissue Procurement: Christopher Koskalk, M.D., Ph.D., Michael R.
  Emmert-Buck, M.D., Ph.D.
  cDNA Library Preparation: Life Technologies, Inc.
  DNA Sequencing by: Greg Lennon, Ph.D.
  Cloned unidirectionally; oligo-df primed.
  Cloned through the I.M.A.G.E. Consortium/LLNL at:
  www-bio.llnl.gov/bhrp/image/image.html
  Seq primer: -40up from c1bco
  High quality sequence stop: 404.
  Location/Qualifiers
    1. 421
      /organism="Homo sapiens"
      /db_xref="taxon:9606"
      /clone="IMAGE:2140815"
      /clone_1lb="NCI-CGAP_Gas4"
      /tissue_type="poorly differentiated adenocarcinoma with
      signet ring cell features"
      /lab_host="DH10B"
      /note="Organ: stomach; Vector: pCMV-SPORT6; Site_1: SalI;
      Site_2: NotI; Cloned unidirectionally. Primer: Oligo df.
      Average insert size 1.69 kb. Life Technologies catalog #:
      11549-011"
BASE COUNT
  81 a 120 c 119 g 99 t 2 others

Query Match
Best Local Similarity 94.4%; Pred. No. 2.3e+03;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 GATTGCTGACGTACAGAG 18
    ||||||| |||||||
Db 227 GATTGCTGACGTACAGAG 210

RESULT 9
LOCUS AI377721/c 455 bp mRNA linear EST 28-MAR-1999
DEFINITION tes6e04.x1 Soares_NFL_T_GRC.S1 Homo sapiens cDNA clone
          IMAGE:2090718.3', mRNA sequence.
ACCESSION AI377721
VERSION AI377721.1 GI:4187574
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens
          Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

```

REFERENCE 1 (bases 1 to 455)
 AUTHORS NCI-CGAP <http://www.ncbi.nlm.nih.gov/ncicgap>.
 TITLE National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
 JOURNAL Tumor Gene Index
 COMMENT Unpublished (1997)
 Contact: Robert Strausberg, Ph.D.
 Email: cgaps-remail.nih.gov
 This clone is available royalty-free through LNL; contact the
 IMAGE Consortium (info@image.llnl.gov) for further information.
 Insert length: 700 Std Error: 0.00
 Seq primer: -400P from glbco
 High quality sequence stop: 444.
 Location/Qualifiers
 1..455
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone="IMAGE:2090718"
 /clone_1lb="Soares_NFL_T_GRC_S1"
 /lab_host="DH10B"
 /note="Organ: pooled; Vector: pTV73D-Pac (Pharmacia) with
 a modified polylinker; Site 1: Not I; Site 2: Eco RI;
 Equal amounts of plasmid DNA from three normalized
 libraries (fetal lung NBHL19W, testis NRT, and B cell
 NCI-CGAP-GB1) were mixed, and ss circles were made in
 vitro. Following HAP purification, this DNA was used as
 tracer in a subtractive hybridization reaction. The driver
 was PCR-amplified cDNAs from pools of 5,000 clones made
 from the same 3 libraries. The pools consisted of
 1 M.A.G.E. clones 297480-302087, 682632-687239,
 726408-728711, and 729096-731399. Subtraction by Bento
 Soares and M. Fatima Bonaldo."

BASE COUNT 130 a 92 c 97 g 136 t

ORIGIN

Query Match 82.0%; Score 16.4; DB 9; Length 455;
 Best Local Similarity 94.4%; Pred. No. 2.4e+03;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 GATTGCTGACGCTCAGAG 18
 |||||||
 Db 258 GATTGCTGACGCTCAGAG 241

RESULT 10
 AUI47973/c 462 bp mRNA linear EST 05-AUG-2002
 LOCUS AUI47973 MAMMAL1 Homo sapiens cDNA clone MAMMAL1002282 3', mRNA
 DEFINITION sequence.
 ACCESSION AUI47973
 VERSION AUI47973.1 GI:11009494
 KEYWORDS EST.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
 1 (bases 1 to 462)
 Ota,T., Nishikawa,T., Suzuki,Y., Ishii,S., Saito,K., Kawai,Y.,
 Yamamoto,J., Wakamatsu,A., Ozawa,M., Nakamura,Y., Nagai,T., Sugano
 S. and Isogai,T.).
 HRT human cDNA project (Ota,T., Nishikawa,T., Suzuki,Y., Ishii,S.,
 Saito,K., Kawai,Y., Yamamoto,J., Wakamatsu,A., Ozawa,M., Nakamura
 Y., Nagai,T., Sugano,S., Isogai,T.)
 Unpublished (2000)
 Contact: Takao Isogai
 Genomics Laboratory
 Helix Research Institute
 1532-3 Yana, Kisarazu, Chiba 292-0812, Japan
 Tel: 81-438-52-3975
 Fax: 81-438-52-3986
 Email: genomics@hri.co.jp
 HRT human cDNA project; 5'-6 3'-end one pass sequencing; Helix
 Research Institute; cDNA library construction; Department of

JOURNAL
 COMMENT

TITLE

REFERENCE

AUTHORS

KEYWORDS

ORGANISM

BASE COUNT

REFERENCE 11
 AA524774/c 468 bp mRNA linear EST 05-AUG-1997
 LOCUS AA524774 nh3f04.s1 NCI-CGAP_P3 Homo sapiens cDNA clone IMAGE:954175
 DEFINITION similar to contains Alu repetitive element; mRNA sequence.
 ACCESSION AA524774
 VERSION AA524774.1 GI:2265702
 KEYWORDS EST.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
 1 (bases 1 to 468)
 NCI-CGAP <http://www.ncbi.nlm.nih.gov/ncicgap>.
 National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
 Tumor Gene Index
 Unpublished (1997)
 Contact: Robert Strausberg, Ph.D.
 Email: cgaps-remail.nih.gov
 Tissue Procurement: W. Marston Linehan, M.D., Rodrigo Chuagui, M.D.,
 Michael Emmert-Buck, M.D., Ph.D.
 cDNA Library Preparation: David B. Krizman, Ph.D.
 DNA Sequencing by: Genome Systems Inc., Greg Lennon, Ph.D.
 Clone distribution: NCI-CGAP clone distribution information can be
 found through the I.M.A.G.E. Consortium/LNL at:
www-bio.llnl.gov/dbp/image/image.html
 Insert length: 421 Std Error: 0.00
 Seq primer: -40ml3 fwd. Ef from Amersham
 High quality sequence stop: 384.
 Location/Qualifiers
 1..468
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone="IMAGE:954175"
 /clone_1lb="NCI-CGAP_P3"
 /sex="Male"
 /dev_stage="45 years old"
 /lab_host="DH10B"
 /note="Vector: pAMP10; Site 1: NotI; Site 2: EcoRI; 1st
 strand cDNA was primed with oligo(dT)17 on 50 ng of
 DNase-treated, total cellular RNA obtained from 5,000-10,
 000 microdissected cells histologically-determined to be
 fully malignant prostate cancer cells. Double-stranded
 cDNA was ligated to EcoRI adaptors, 5 cycles of PCR
 applied to the cDNA with an adaptor-specific primer, and
 the resulting PCR product subcloned into pAMP10 by the
 UDG-cloning method (Life Technologies). Average insert
 size is 600 bp. NOTE: Not directionally cloned. This
 library was constructed by David Krizman."

BASE COUNT 103 a 119 c 101 g 145 t

ORIGIN

Query Match 82.0%; Score 16.4; DB 9; Length 462;
 Best Local Similarity 94.4%; Pred. No. 2.4e+03;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 GATTGCTGACGCTCAGAG 18
 |||||||
 Db 225 GATTGCTGACGCTCAGAG 208

RESULT 11
 AA524774/c 468 bp mRNA linear EST 05-AUG-1997
 LOCUS AA524774 nh3f04.s1 NCI-CGAP_P3 Homo sapiens cDNA clone IMAGE:954175
 DEFINITION similar to contains Alu repetitive element; mRNA sequence.
 ACCESSION AA524774
 VERSION AA524774.1 GI:2265702
 KEYWORDS EST.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
 1 (bases 1 to 468)
 NCI-CGAP <http://www.ncbi.nlm.nih.gov/ncicgap>.
 National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
 Tumor Gene Index
 Unpublished (1997)
 Contact: Robert Strausberg, Ph.D.
 Email: cgaps-remail.nih.gov
 Tissue Procurement: W. Marston Linehan, M.D., Rodrigo Chuagui, M.D.,
 Michael Emmert-Buck, M.D., Ph.D.
 cDNA Library Preparation: David B. Krizman, Ph.D.
 DNA Sequencing by: Genome Systems Inc., Greg Lennon, Ph.D.
 Clone distribution: NCI-CGAP clone distribution information can be
 found through the I.M.A.G.E. Consortium/LNL at:
www-bio.llnl.gov/dbp/image/image.html
 Insert length: 421 Std Error: 0.00
 Seq primer: -40ml3 fwd. Ef from Amersham
 High quality sequence stop: 384.
 Location/Qualifiers
 1..468
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone="IMAGE:954175"
 /clone_1lb="NCI-CGAP_P3"
 /sex="Male"
 /dev_stage="45 years old"
 /lab_host="DH10B"
 /note="Vector: pAMP10; Site 1: NotI; Site 2: EcoRI; 1st
 strand cDNA was primed with oligo(dT)17 on 50 ng of
 DNase-treated, total cellular RNA obtained from 5,000-10,
 000 microdissected cells histologically-determined to be
 fully malignant prostate cancer cells. Double-stranded
 cDNA was ligated to EcoRI adaptors, 5 cycles of PCR
 applied to the cDNA with an adaptor-specific primer, and
 the resulting PCR product subcloned into pAMP10 by the
 UDG-cloning method (Life Technologies). Average insert
 size is 600 bp. NOTE: Not directionally cloned. This
 library was constructed by David Krizman."

JOURNAL
 COMMENT

TITLE

REFERENCE

AUTHORS

KEYWORDS

ORGANISM

BASE COUNT

ORIGIN

Query Match 82.0%; Score 16.4; DB 9; Length 468;
 Best Local Similarity 94.4%; Pred. No. 2.4e+03;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1 GATTGCTGACCTGACAG 18
 |||||
 DB 240 GATTGCTGACCTGACAG 223

RESULT 12
 BF439459/c 476 bp mRNA linear EST 30-MAR-2001
 LOCUS nabe4g11.x1 Soares_NSF_F8_9W_OT_PA_P_S1 Homo sapiens cDNA clone
 DEFINITION IMAGE:3272660 3', mRNA sequence.
 ACCESSION BF439459
 VERSION BF439459.1 GI:11451976
 KEYWORDS EST.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
 REFERENCE 1 (bases 1 to 476)
 NCI-CCGAP <http://www.ncbi.nlm.nih.gov/ncicgap>.
 National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
 Tumor Gene Index
 Unpublished (1997)
 JOURNAL Contact: Robert Strausberg, Ph.D.
 COMMENT Email: cgaps-remail.nih.gov
 This clone is available royalty-free through LNL; contact the
 IMAGE Consortium (info@image.llnl.gov) for further information.
 Seq primer: -40UP from Gibco
 High quality sequence stop: 444.
 Location/Qualifiers

FEATURES
 source 1..476
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone="IMAGE:3272660"
 /clone_1lb="Soares_NSF_F8_9W_OT_PA_P_S1"
 /lab_host="DH10B"
 /note="Organ: pooled; Vector: pT7r3D-Pac (Pharmacia) with
 a modified polylinker; Site_1: Not I; Site_2: Eco RI;
 Equal amounts of plasmid DNA from five normalized
 libraries were mixed, and ss circles were made in vitro.
 Following HAP purification, this DNA was used as tracer in
 a subtractive hybridization reaction. The driver was
 PCR-amplified cDNAs from pools of 5,000 clones made from
 the same 5 libraries. The pools consisted of the following
 libraries and clones: Soares NBHF pool 1:
 309384-310919, 323208-325895 Soares NBHF pool 1:
 145032-147335, 147720-148103, 148872-149255, 15002 -
 150407, 151176-152327 Soares NBHF-9W pool 1:
 758280-760583, 772104-774407 Soares NBHF pool 1:
 304776-306311, 320136-322823, 326280-326663 Soares NBHF
 pool 1: 723720-726407, 739680-740999 Subtraction by Bento
 Soares and M. Fatima Bonaldi."

BASE COUNT 151 a 88 g 139 t
 ORIGIN

Query Match 82.0%; Score 16.4; DB 12; Length 476;
 Best Local Similarity 94.4%; Pred. No. 2.4e+03;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1 GATTGCTGACCTGACAG 18
 |||||
 DB 346 GATTGCTGACCTGACAG 329

RESULT 13
 AO617221/c 570 bp DNA linear GSS 15-JUN-1999
 LOCUS AO617221
 DEFINITION HS-5152_B1_B01_77A RPCR-11 Human Male BAC library Homo sapiens

ACCESSION AO617221
 VERSION AO617221.1 GI:5078497
 KEYWORDS GSS.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
 REFERENCE 1 (bases 1 to 570)
 Mahlras G.G., Wallace J.C., Smith K., Swartzell S., Holzman T.,
 Keller A., Shaker R., Furlong J., Young J., Zhao S., Adams M.D. and
 Hood L.
 Sequence-tagged connectors: A sequence approach to mapping and
 scanning the human genome
 Proc. Natl. Acad. Sci. U.S.A. 96 (17), 9739-9744 (1999)
 99380589
 COMMENT Contact: Mahlras G.G., Wallace J.C., Hood L.
 High Throughput Sequencing Center
 University of Washington
 401 Queen Anne Avenue North, Seattle, WA 98109, USA
 Tel: (206) 616-3618
 Fax: (206) 616-3887
 Email: jwallace@u.washington.edu
 Clones are derived from the human BAC library RPCR-11. For BAC
 library availability, please contact Pletier de Jong
 (pletier@edj.med.bufileo.edu). Clones may be purchased from
 BACPAC Resources (http://bacpac.med.bufileo.edu/ordering_bac.htm)
 or from Research Genetics (info@resgen.com). BAC end Web Server:
<http://www.htsc.washington.edu>
 Plate: 728 row: D column: 1
 Seq primer: 17
 Class: BAC ends
 High quality sequence stop: 570.
 Location/Qualifiers

FEATURES
 source 1..570
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone="Plate-728 Col-1 Row-D"
 /clone_1lb="RPCR-11 Human Male BAC library"
 /sex="male"
 /note="Vector: pBACe3.6; Site_1: EcoRI; Site_2: EcoRI;
 Male blood DNA was isolated from one randomly chosen donor
 and partially digested with a combination of EcoRI and
 EcoRI methylase. Size selected DNA was cloned into the
 pBACe3.6 vector at EcoRI sites"

BASE COUNT 170 a 111 c 113 g 167 t 9 others
 ORIGIN

Query Match 82.0%; Score 16.4; DB 17; Length 570;
 Best Local Similarity 94.4%; Pred. No. 2.6e+03;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 3 TTGCTGACCTGACAG 20
 |||||
 DB 147 TTGCTGACCTGACAG 130

RESULT 14
 AO392594 618 bp DNA linear GSS 06-MAR-1999
 LOCUS CITBI-EL-2546E7.TF CITBI-EL Homo sapiens genomic clone 2546E7, DNA
 DEFINITION sequence.
 ACCESSION AO392594
 VERSION AO392594.1 GI:4363617
 KEYWORDS GSS.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
 REFERENCE 1 (bases 1 to 618)
 Zhao S., Adams M.D., Nieman W., Malek J., Shituya H., Simon M. and
 Venter J.C.
 Use of BAC End Sequences from Caltech Libraries for Sequence-Ready

Map Building
Unpublished (1997)
Other-GSSs: CITBI-EI-2546E7.TR
Contact: Shaying Zhao, William Nierman, Mark Adams
Department of Eukaryotic Genomics
The Institute for Genomic Research
9712 Medical Center Dr., Rockville, MD 20850
Tel: 301 838 0200
Fax: 301 838 0208
Email: zhaoy@igmr.org
Clones are available from Research Genetics (info@resgen.com). BAC
end search page:
http://www.tigr.org/tdb/humgen/bac_end_search/bac_end_search.html.
Seq primer: M13-21
Class: BAC ends.

FEATURES
source
1. .618
/location/Qualifiers
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="2546E7"
/clone_id="CITBI-EI"
/sex="male"
/cell_type="sperm"
/note="Vector: pBelBAC11; Site_1: EcoRI; Site_2: EcoRI;
Caltech Human BAC Library D"

BASE COUNT
177 a 148 c 142 g 151 t

ORIGIN

Query Match 82.0%; Score 16.4; DB 17; Length 618;
Best Local Similarity 94.4%; Pred. No. 2.7e+03;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3 TTGCCTGACGTCAGAGAG 20
|||||

DB 435 TTGCCTGACGTCAGAGAG 452

RESULT 15
A0884463 630 bp DNA linear GSS 09-NOV-1999
LOCUS HS.5510.A2.H02.SP6E RPCI-11 Human Male BAC Library Homo sapiens
DEFINITION genomic clone Plate=9278 Col=4 Row=O, DNA sequence.
ACCESSION A0884463
VERSION A0884463.1 GI:6315930
KEYWORDS GSS.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
1 (bases 1 to 630)
Mahairas,G.G., Wallace,J.C., Smith,K., Swartzell,S., Holzman,T.,
Keller,A., Shaker,R., Furlong,J., Young,J., Zhao,S., Adams,M.D. and
Hood,L.
Sequence-tagged connectors: A sequence approach to mapping and
scanning the human genome
Proc. Natl. Acad. Sci. U.S.A. 96 (17), 9739-9744 (1999)
99380589
Contact: Mahairas GG, Wallace JC, Hood L
High Throughput Sequencing Center
University of Washington
401 Queen Anne Avenue North, Seattle, WA 98109, USA
Tel: (206) 616-3618
Fax: (206) 616-3887
Email: jwallace@u.washington.edu
Clones are derived from the human BAC library RPCI-11. For BAC
library availability, please contact Pieter de Jong
(pieter@dejong.med.buffalo.edu). Clones may be purchased from
BACPAC Resources (http://bacpac.med.buffalo.edu/ordering_bac.htm)
or from Research Genetics (<http://www.resgen.com>). BAC end Web Server:
<http://www.hbrc.washington.edu>
Plate: 9278 row: O column: 4
Seq primer: SP6
Class: BAC ends

JOURNAL
COMMENT

TITLE

JOURNAL
MEDLINE
COMMENT

REFERENCE

AUTHORS

High quality sequence stop: 630.
Location/Qualifiers
1. .630
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="Plate=9278 Col=4 Row=O"
/clone_id="RPCI-11 Human Male BAC Library"
/sex="male"
/note="Vector: pBACe3.6; Site_1: EcoRI; Site_2: EcoRI;
Male blood DNA was isolated from one randomly chosen donor
and partially digested with a combination of EcoRI and
EcoRI Methylase. Size selected DNA was cloned into the
pBACe3.6 vector at EcoRI sites"

BASE COUNT
189 a 117 c 125 g 181 t

ORIGIN

Query Match 82.0%; Score 16.4; DB 17; Length 630;
Best Local Similarity 94.4%; Pred. No. 2.8e+03;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3 TTGCCTGACGTCAGAGAG 20
|||||

DB 213 TTGCCTGACGTCAGAGAG 196

Search completed: June 26, 2003, 22:12:14
Job time: 1534.13 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 26, 2003, 10:58:25 ; Search time 30.2174 Seconds
(Without alignments)
202,980 Million cell updates/sec

Title: US-09-355-254f-8

Perfect score: 20

Sequence: 1 gattgcctgacgtcagagag 20

Scoring table: IDENTITY NUC
Gapop 10.0, Gapext 1.0

Searched: 441362 seqs, 15338381 residues

Total number of hits satisfying chosen parameters: 882724

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%

Listing first 45 summaries

Database :

Issued_Patents_NA.*
1: /cgn2_6/ptodata/1/1na/5A.COMB.seq.*
2: /cgn2_6/ptodata/1/1na/5B.COMB.seq.*
3: /cgn2_6/ptodata/1/1na/6A.COMB.seq.*
4: /cgn2_6/ptodata/1/1na/6B.COMB.seq.*
5: /cgn2_6/ptodata/1/1na/PCtus.COMB.seq.*
6: /cgn2_6/ptodata/1/1na/backfiles1.seq.*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	20	100.0	20	US-09-133-774-10	Sequence 10, Appl
2	20	100.0	20	US-09-303-862-10	Sequence 10, Appl
3	20	100.0	27	US-08-210-860B-2	Sequence 2, Appl1
4	20	100.0	27	US-08-771-411-2	Sequence 10, Appl1
5	16.8	84.0	12394	US-09-488-856A-10	Sequence 1, Appl1
6	16.4	82.0	32	US-09-215-098-1	Sequence 1, Appl1
7	16.4	82.0	50	US-08-171-389-451	Sequence 451, App
8	16.4	82.0	50	US-08-123-936-451	Sequence 451, App
9	16.4	82.0	50	US-08-473-228A-451	Sequence 451, App
10	16.4	82.0	50	US-08-482-080A-451	Sequence 451, App
11	16.4	82.0	50	US-09-354-947-451	Sequence 451, App
12	16.4	82.0	50	US-09-354-947-451	Sequence 451, App
13	15.8	79.0	5134	US-08-310-912A-157	Sequence 157, App
14	15.8	79.0	5134	US-09-301-085-157	Sequence 157, App
15	15.8	79.0	5134	PCT-US95-04589-157	Sequence 157, App
16	15.8	79.0	5475	US-08-680-327-1	Sequence 157, App
17	15.8	79.0	5475	US-09-228-246-3	Sequence 3, Appl1
18	15.8	79.0	10968	US-08-680-327-2	Sequence 3, Appl1
19	15.8	79.0	10968	US-08-680-327-2	Sequence 3, Appl1
20	15.2	76.0	2559	US-09-118-408-43	Sequence 1, Appl1
21	15.2	76.0	2559	US-09-506-855-43	Sequence 43, Appl1
22	15.2	76.0	1974	US-08-625-322-1	Sequence 43, Appl1
23	14.8	74.0	5687	US-09-221-017B-368	Sequence 368, App
24	14.8	74.0	48974	US-08-920-422-17	Sequence 368, App
25	14.4	72.0	1243	US-09-257-179-30	Sequence 30, Appl
26	14.4	72.0	4793	US-09-561-497-10	Sequence 10, Appl
27	14.4	72.0	5375	US-08-757-223-7	Sequence 7, Appl1

c 28	14.4	72.0	7676	1	US-08-451-777A-7	Sequence 7, Appl1
c 29	14.4	72.0	7676	2	US-08-451-778A-7	Sequence 7, Appl1
c 30	14.4	72.0	7676	2	US-08-998-208-7	Sequence 7, Appl1
c 31	14.4	72.0	7676	5	PCT-US95-06743-7	Sequence 7, Appl1
c 32	14.4	72.0	15297	4	US-09-817-180-3	Sequence 3, Appl1
c 33	14.4	72.0	16063	4	US-09-801-052-3	Sequence 3, Appl1
c 34	14.4	72.0	99500	4	US-09-798-056-10	Sequence 10, Appl1
c 35	14.4	72.0	162450	4	US-09-345-882-1	Sequence 1, Appl1
c 36	14.4	72.0	4403765	4	US-09-103-840A-2	Sequence 2, Appl1
c 37	14.4	72.0	4411529	4	US-09-103-840A-1	Sequence 1, Appl1
c 38	14.2	71.0	41	3	US-08-813-507-78	Sequence 78, Appl1
c 39	14.2	71.0	41	4	US-09-464-453-78	Sequence 78, Appl1
c 40	14.2	71.0	562	4	US-09-449-285A-16	Sequence 16, Appl1
c 41	14.2	71.0	1017	4	US-09-330-611-5	Sequence 5, Appl1
c 42	14.2	71.0	2100	1	US-08-332-576-1	Sequence 1, Appl1
c 43	14.2	71.0	2100	5	PCT-US95-13672-1	Sequence 1, Appl1
c 44	14.2	71.0	29598	4	US-09-341-587-6	Sequence 6, Appl1
c 45	13.8	69.0	71	4	US-08-870-930-25	Sequence 25, Appl1

ALIGNMENTS

```
RESULT 1
US-09-133-774-10
; Sequence 10, Application US/09133774B
; Patent No. 5962636
; GENERAL INFORMATION:
; APPLICANT: Bachmaler, Kurt
; APPLICANT: Hessel, Andrew J.
; APPLICANT: Neu M.D., Nikolaus
; APPLICANT: Penninger, Josef M.
; TITLE OF INVENTION: No. 5962636el Peptides Capable of Modulating Inflammatory Hear
; TITLE OF INVENTION: Disease
; FILE REFERENCE: A-536
; CURRENT APPLICATION NUMBER: US/09/133,774B
; CURRENT FILING DATE: 1998-08-12
; NUMBER OF SEQ ID NOS: 26
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 10
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Chlamydia trachomatis
; FEATURE:
; OTHER INFORMATION: An oligonucleotide derived from the DNA encoding a
; OTHER INFORMATION: 60 kDa cysteine rich outer membrane protein from
; OTHER INFORMATION: Chlamydia trachomatis.
US-09-133-774-10
Query Match 100.0%; Score 20; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.059;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 GATTGCTGACGTCAGAG 20
DB 1 GATTGCTGACGTCAGAG 20
RESULT 2
US-09-303-862-10
; Sequence 10, Application US/09303862
; Patent No. 6034230
; GENERAL INFORMATION:
; APPLICANT: Bachmaler, Kurt
; APPLICANT: Hessel, Andrew J.
; APPLICANT: Neu M.D., Nikolaus
; APPLICANT: Penninger, Josef M.
; TITLE OF INVENTION: No. 6034230el Peptides Capable of Modulating Inflammatory Hear
; TITLE OF INVENTION: Disease
; FILE REFERENCE: A-536
; CURRENT APPLICATION NUMBER: US/09/303,862
; CURRENT FILING DATE: 1999-05-03
; EARLIER APPLICATION NUMBER: 09/133,774
```

EARLIER FILING DATE: 1998-08-12
NUMBER OF SEQ ID NOS: 26
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 10
LENGTH: 20
TYPE: DNA
ORGANISM: Chlamydia trachomatis
FEATURE:
OTHER INFORMATION: An oligonucleotide derived from the DNA encoding a
OTHER INFORMATION: 60 kDa cysteine rich outer membrane protein from
OTHER INFORMATION: Chlamydia trachomatis.
US-09-303-862-10

Query Match 100.0%; Score 20; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.059;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GATTGCTGACGTCAGAGAG 20
DB 1 GATTGCTGACGTCAGAGAG 20

RESULT 3

US-08-210-880B-2
Sequence 2, Application US/08210880B
Patent No. 5641486
GENERAL INFORMATION:
APPLICANT: HINRICH, STEVEN H.
APPLICANT: ORTEN, DANA J.
TITLE OF INVENTION: METHOD AND COMPOSITION FOR INHIBITING
TITLE OF INVENTION: CREB/ATF1 FAMILY DETERMINED TRANSCRIPTION
NUMBER OF SEQUENCES: 11
CORRESPONDENCE ADDRESS:
ADDRESSEE: HENDERSON & STURM
STREET: 1125 S. 103RD ST., #330
CITY: OMAHA
STATE: NE
COUNTRY: US
ZIP: 68124
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/210,880B
FILING DATE: 18-MAR-1994
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: JONDL, ROBERT J.
REGISTRATION NUMBER: 33,915
REFERENCE/DOCKET NUMBER: 63066
TELECOMMUNICATION INFORMATION:
TELEPHONE: 402-398-9005
TELEFAX: 402-398-9005
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 27 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: unknown
MOLECULE TYPE: DNA (genomic)
US-08-210-880B-2

Query Match 100.0%; Score 20; DB 1; Length 27;
Best Local Similarity 100.0%; Pred. No. 0.062;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GATTGCTGACGTCAGAGAG 20
DB 4 GATTGCTGACGTCAGAGAG 23

RESULT 4

US-08-771-411-2
Sequence 2, Application US/08771411
Patent No. 5844096
GENERAL INFORMATION:
APPLICANT: HINRICH, STEVEN H.
APPLICANT: ORTEN, DANA J.
TITLE OF INVENTION: METHOD AND COMPOSITION FOR INHIBITING
TITLE OF INVENTION: CREB/ATF1 FAMILY DETERMINED TRANSCRIPTION
NUMBER OF SEQUENCES: 11
CORRESPONDENCE ADDRESS:
ADDRESSEE: HENDERSON & STURM
STREET: 1125 S. 103RD ST., #330
CITY: OMAHA
STATE: NE
COUNTRY: US
ZIP: 68124
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/771,411
FILING DATE: 20-DEC-1996
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/210,880
FILING DATE: 18-MAR-1994
ATTORNEY/AGENT INFORMATION:
NAME: JONDL, ROBERT J.
REGISTRATION NUMBER: 33,915
REFERENCE/DOCKET NUMBER: 63066
TELECOMMUNICATION INFORMATION:
TELEPHONE: 402-398-9005
TELEFAX: 402-398-9005
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 27 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: unknown
MOLECULE TYPE: DNA (genomic)
US-08-771-411-2

Query Match 100.0%; Score 20; DB 2; Length 27;
Best Local Similarity 100.0%; Pred. No. 0.062;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GATTGCTGACGTCAGAGAG 20
DB 4 GATTGCTGACGTCAGAGAG 23

RESULT 5

US-09-488-856A-10
Sequence 10, Application US/09488856A
Patent No. 6316259
GENERAL INFORMATION:
APPLICANT: Brett P. Monte
APPLICANT: Robert McKay
APPLICANT: Madeline M. Butler
APPLICANT: Jacqueline Wyatt
TITLE OF INVENTION: RNS-0115
TITLE OF INVENTION: ANTISENSE MODULATION OF GLYCOGEN SYNTHASE KINASE 3 ALPHA
FILE REFERENCE:
CURRENT APPLICATION NUMBER: US/09/488,856A
FILING DATE: 2000-01-21
NUMBER OF SEQ ID NOS: 88
SEQ ID NO 10
LENGTH: 12394
TYPE: DNA
ORGANISM: Homo sapiens
FEATURE:

NAME/KEY: CDS
LOCATION: (115)...(397)
NAME/KEY: CDS
LOCATION: (2438)...(2625)
NAME/KEY: CDS
LOCATION: (5639)...(5722)
NAME/KEY: CDS
LOCATION: (5864)...(5974)
NAME/KEY: CDS
LOCATION: (7902)...(8032)
NAME/KEY: CDS
LOCATION: (8121)...(8227)
NAME/KEY: CDS
LOCATION: (9197)...(9294)
NAME/KEY: CDS
LOCATION: (9375)...(9470)
NAME/KEY: CDS
LOCATION: (9898)...(10084)
NAME/KEY: CDS
LOCATION: (10431)...(10523)
NAME/KEY: CDS
LOCATION: (11713)...(11786)
US-09-488-856A-10

Query Match 84.0%; Score 16.8; DB 4; Length 12394;
Best Local Similarity 90.0%; Pred. No. 7;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1 GATGCTGACGTGACAGAG 20
DB 2949 GATGCTGACGTGACAGAG 2968

RESULT 6
US-09-215-098-1
Sequence 1, Application US/09215098
Patent No. 6194632
GENERAL INFORMATION:
APPLICANT: Leiden, Jeffery M
TITLE OF INVENTION: DILATED CARDIOMYOPATHY IN TRANSGENIC MICE EXPRESSING A
TITLE OF INVENTION: DOMINANT-NEGATIVE CREB TRANSCRIPTION FACTOR IN THE
TITLE OF INVENTION: HEART
FILE REFERENCE: 9189-4
CURRENT APPLICATION NUMBER: US/09/215, 098
CURRENT FILING DATE: 1998-12-18
PRIOR APPLICATION NUMBER: 60/068, 011
PRIOR FILING DATE: 1997-12-18
NUMBER OF SEQ ID NOS: 5
SOFTWARE: Patentin Ver. 2.1
SEQ ID NO 1
LENGTH: 32
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Oligonucleotide
OTHER INFORMATION: containing the CREB site from the somatostatin
OTHER INFORMATION: promoter
US-09-215-098-1

Query Match 82.0%; Score 16.4; DB 4; Length 32;
Best Local Similarity 94.4%; Pred. No. 5.1;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 3 TTGCTGACGTGACAGAG 20
DB 11 TTGCTGACGTGACAGAG 28

RESULT 7
US-08-171-389-451
Sequence 451, Application US/08171389
Patent No. 5578444
GENERAL INFORMATION:

APPLICANT: Edwards, Cynthia A.
APPLICANT: Cantor, Charles R.
APPLICANT: Andrews, Beth M.
APPLICANT: Turin, Lisa M.
APPLICANT: Fry, Kirk E.
TITLE OF INVENTION: Sequence-Directed DNA Binding
TITLE OF INVENTION: Molecules, Compositions and Methods
NUMBER OF SEQUENCES: 641
CORRESPONDENCE ADDRESS:
ADDRESS: Genelabs Technologies, Inc.
STREET: 505 Penobscot Drive
CITY: Redwood City
STATE: CA
COUNTRY: USA
ZIP: 94063
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/171,389
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/123,936
FILING DATE: 17-SEP-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/996,783
FILING DATE: 23-DEC-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/723,618
FILING DATE: 27-JUN-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/081,070
FILING DATE: 22-JUN-1993
ATTORNEY/AGENT INFORMATION:
NAME: Fabian, Gary R.
REGISTRATION NUMBER: 33,875
REFERENCE/DOCKET NUMBER: 4600-0175/G19P3
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 324-0880
TELEFAX: (415) 324-0960
INFORMATION FOR SEQ ID NO: 451:
SEQUENCE CHARACTERISTICS:
LENGTH: 50 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ORIGINAL SOURCE:
INDIVIDUAL ISOLATE: Human somatostatin I gene
US-08-171-389-451

Query Match 82.0%; Score 16.4; DB 1; Length 50;
Best Local Similarity 94.4%; Pred. No. 5.4;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 3 TTGCTGACGTGACAGAG 20
DB 1 TACGCTGACGTGACAGAG 18

RESULT 8
US-08-123-936-451
Sequence 451, Application US/08123936
Patent No. 5726014
GENERAL INFORMATION:
APPLICANT: Edwards, Cynthia A.
APPLICANT: Cantor, Charles R.
APPLICANT: Andrews, Beth M.
APPLICANT: Turin, Lisa M.

TITLE OF INVENTION: Screening Assay for the Detection of
TITLE OF INVENTION: DNA-Binding Molecules
NUMBER OF SEQUENCES: 640
CORRESPONDENCE ADDRESS:
ADDRESSEE: Genelabs Technologies, Inc.
STREET: 505 Penobscot Drive
CITY: Redwood City
STATE: CA
COUNTRY: USA
ZIP: 94063
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/123,936
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/996,783
FILING DATE: 23-DEC-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/723,618
FILING DATE: 27-JUN-1991
ATTORNEY/AGENT INFORMATION:
NAME: Fadian, Gary R.
REGISTRATION NUMBER: 33,875
REFERENCE/DOCKET NUMBER: 4600-0075.32/G19P2
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 324-0880
TELEFAX: (415) 324-0960
INFORMATION FOR SEQ ID NO: 451:
SEQUENCE CHARACTERISTICS:
LENGTH: 50 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ORIGINAL SOURCE:
INDIVIDUAL ISOLATE: Human somatostatin I gene
US-08-123-936-451
Query Match 82.0%; Score 16.4; DB 1; Length 50;
Best Local Similarity 94.4%; Pred. No. 5.4;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 3 TTGCTGAGCTCAGAG 20
DB 1 TTAGCTGAGCTCAGAG 18
RESULT 9
US-08-475-228A-451
Sequence 451, Application US/08475228A
Patent No. 5869241
GENERAL INFORMATION:
APPLICANT: Edwards, Cynthia A.
APPLICANT: Cantor, Charles R.
APPLICANT: Andrews, Beth M.
APPLICANT: Turin, Lisa M.
APPLICANT: Fry, Kirk E.
TITLE OF INVENTION: Sequence-Directed DNA Binding
TITLE OF INVENTION: Molecules, Compositions and Methods
NUMBER OF SEQUENCES: 664
CORRESPONDENCE ADDRESS:
ADDRESSEE: Genelabs Technologies, Inc.
STREET: 505 Penobscot Drive
CITY: Redwood City
STATE: CA
COUNTRY: USA
ZIP: 94063

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/475,228A
FILING DATE: 06-JUN-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/123,936
FILING DATE: 17-SEP-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/996,783
FILING DATE: 23-DEC-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/723,618
FILING DATE: 27-JUN-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/081,070
FILING DATE: 22-JUN-1993
ATTORNEY/AGENT INFORMATION:
NAME: Stratford, Carol A.
REGISTRATION NUMBER: 34,444
REFERENCE/DOCKET NUMBER: 4600-0175.21/G19P3D2
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 324-0880
TELEFAX: (415) 324-0960
INFORMATION FOR SEQ ID NO: 451:
SEQUENCE CHARACTERISTICS:
LENGTH: 50 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ORIGINAL SOURCE:
INDIVIDUAL ISOLATE: Human somatostatin I gene
US-08-475-228A-451
Query Match 82.0%; Score 16.4; DB 2; Length 50;
Best Local Similarity 94.4%; Pred. No. 5.4;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 3 TTGCTGAGCTCAGAG 20
DB 1 TTAGCTGAGCTCAGAG 18
RESULT 10
US-08-482-080A-451
Sequence 451, Application US/08482080A
Patent No. 6010849
GENERAL INFORMATION:
APPLICANT: Edwards, Cynthia A.
APPLICANT: Cantor, Charles R.
APPLICANT: Andrews, Beth M.
APPLICANT: Turin, Lisa M.
APPLICANT: Fry, Kirk E.
TITLE OF INVENTION: Sequence-Directed DNA Binding
TITLE OF INVENTION: Molecules, Compositions and Methods
NUMBER OF SEQUENCES: 664
CORRESPONDENCE ADDRESS:
ADDRESSEE: Genelabs Technologies, Inc.
STREET: 505 Penobscot Drive
CITY: Redwood City
STATE: CA
COUNTRY: USA
ZIP: 94063
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25

RESULT 11
 US-09-354-947-451
 Sequence 451: Application US/09354947
 Patent No. 6384208
 GENERAL INFORMATION:
 APPLICANT: Edwards, Cynthia A.
 APPLICANT: Cantor, Charles R.
 APPLICANT: Andrews, Beth M.
 APPLICANT: Turin, Lisa M.
 APPLICANT: Fry, Kirk E.
 TITLE OF INVENTION: Sequence-Directed DNA Binding
 TITLE OF INVENTION: Molecules, Compositions and Methods
 NUMBER OF SEQUENCES: 664
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Genelabs Technologies, Inc.
 STREET: 505 Penobscot Drive
 CITY: Redwood City
 STATE: CA
 COUNTRY: USA
 ZIP: 94063
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: Patentin Release #1.0, Version #1.25
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/09/354,947

RESULT 12
 PCT-US93-12388-451
 Sequence 451, Application PC/TUS9312388
 GENERAL INFORMATION:
 APPLICANT:
 TITLE OF INVENTION: Sequence-Directed DNA Binding
 TITLE OF INVENTION: Molecules, Compositions and Methods
 NUMBER OF SEQUENCES: 641
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Genelabs Technologies, Inc.
 STREET: 505 Penobscot Drive
 CITY: Redwood City
 STATE: CA
 COUNTRY: USA
 ZIP: 94063
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, Version #1.25
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: PCT/US93/12388
 FILING DATE:
 CLASSIFICATION:
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US 08/123,936
 FILING DATE: 17-SEP-1993

```

; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/996,783
; FILING DATE: 23-DEC-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Pabian, Gary R.
; REGISTRATION NUMBER: 33,875
; REFERENCE/DOCKET NUMBER: 4600-0175.41/G19PCT2
; TELEPHONE: (415) 324-0880
; TELEFAX: (415) 324-0960
; INFORMATION FOR SEQ ID NO: 451:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 50 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ORIGINAL SOURCE:
; INDIVIDUAL ISOLATE: Human somatostatin I gene
; PCT-US93-12388-451

```

```

Query Match      82.0%; Score 16.4; DB 5; Length 50;
Best Local Similarity 94.4%; Pred. No. 5.4;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

QY      3 TTGCTGACGTCAGAG 20
DB      1 TAGCTGACGTCAGAG 18

```

```

RESULT 13
US-08-310-912A-157/c
; Sequence 157, Application US/08310912A
; Patent No. 5981730
; GENERAL INFORMATION:
; APPLICANT: Ausubel, Frederick M.
; APPLICANT: Staskawicz, Brian J.
; APPLICANT: Brent, Andrew F.
; APPLICANT: Dahlbeck, Douglas
; APPLICANT: Katagiri, Fumiaki
; APPLICANT: Kunkel, Barbara N.
; APPLICANT: Mindinos, Michael N.
; APPLICANT: Yu, Guo-Liang
; TITLE OF INVENTION: RPS2 GENE FAMILY, PRIMERS, PROBES, AND DETECTION
; TITLE OF INVENTION: METHODS
; NUMBER OF SEQUENCES: 208
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: USA
; ZIP: 02110-2904
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent Release #1.0, Version #1.30B
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/310,912A
; FILING DATE: September 22, 1994
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/227,360
; FILING DATE: April 13, 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Lech, Karen F.
; REGISTRATION NUMBER: 35,238
; REFERENCE/DOCKET NUMBER: 00786/254001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 542-5070
; TELEFAX: (617) 542-8906

```

```

; TELIX: 100254
; INFORMATION FOR SEQ ID NO: 157:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 5134 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; US-08-310-912A-157

```

```

Query Match      79.0%; Score 15.8; DB 2; Length 5134;
Best Local Similarity 89.5%; Pred. No. 21;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

QY      2 ATTGCTGACGTCAGAG 20
DB      721 ATTGCTGACGTCAGAG 703

```

```

RESULT 14
US-09-301-085-157/c
; Sequence 157, Application US/09301085
; Patent No. 6262248
; GENERAL INFORMATION:
; APPLICANT: Ausubel, Frederick M.
; APPLICANT: Staskawicz, Brian J.
; APPLICANT: Brent, Andrew F.
; APPLICANT: Dahlbeck, Douglas
; APPLICANT: Katagiri, Fumiaki
; APPLICANT: Kunkel, Barbara N.
; APPLICANT: Mindinos, Michael N.
; APPLICANT: Yu, Guo-Liang
; TITLE OF INVENTION: RPS2 GENE FAMILY, PRIMERS, PROBES, AND
; TITLE OF INVENTION: DETECTION METHODS
; FILE REFERENCE: 00786/254002
; CURRENT APPLICATION NUMBER: US/09/301,085
; CURRENT FILING DATE: 1999-04-28
; EARLIER APPLICATION NUMBER: 08/310,912
; EARLIER FILING DATE: 1994-09-22
; EARLIER APPLICATION NUMBER: 08/227,360
; EARLIER FILING DATE: 1994-04-13
; NUMBER OF SEQ ID NOS: 208
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 157
; LENGTH: 5134
; TYPE: DNA
; ORGANISM: Arabidopsis thaliana
; US-09-301-085-157

```

```

Query Match      79.0%; Score 15.8; DB 4; Length 5134;
Best Local Similarity 89.5%; Pred. No. 21;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

QY      2 ATTGCTGACGTCAGAG 20
DB      721 ATTGCTGACGTCAGAG 703

```

```

RESULT 15
PCT-US95-04589-157/c
; Sequence 157, Application PC/TUS9504589
; GENERAL INFORMATION:
; APPLICANT: Ausubel, Frederick M.
; APPLICANT: Staskawicz, Brian J.
; APPLICANT: Brent, Andrew F.
; APPLICANT: Dahlbeck, Douglas
; APPLICANT: Katagiri, Fumiaki
; APPLICANT: Kunkel, Barbara N.
; APPLICANT: Mindinos, Michael N.
; APPLICANT: Yu, Guo-Liang
; TITLE OF INVENTION: RPS2 GENE AND USES THEREOF
; NUMBER OF SEQUENCES: 201
; CORRESPONDENCE ADDRESS:

```

Fri Jun 27 14:15:04 2003

us-09-355-254f-8.rni

Page 7

ADDRESSEE: Fish & Richardson
 STREET: 225 Franklin Street Suite 3100
 CITY: Boston
 STATE: MA
 COUNTRY: USA
 ZIP: 02110-2904
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, Version #1.30B
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: PCT/US95/04589
 FILING DATE:
 CLASSIFICATION:
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US 08/227,360
 FILING DATE: 13-APR-1994
 ATTORNEY/AGENT INFORMATION:
 NAME: Clark, Paul T.
 REGISTRATION NUMBER: 30,162
 REFERENCE/DOCKET NUMBER: 00786/230001
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (617) 542-5070
 TELEFAX: (617) 542-8906
 TELEX: 100254
 INFORMATION FOR SEQ ID NO: 157:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 5134 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 MOLECULE TYPE: DNA
 PCT-US95-04589-157

Query Match	79.0%	Score 15.8	DB 5	length 5134
Best Local Similarity	89.5%	Pred. No. 21		
Matches	17	Conservative	0	Mismatches 2
				Indels 0
				Gaps 0
QY	2	ATTGCCTGACCTCAGAGAG	20	
Db	721	ATTGCTTGCATCAGAGAG	703	

Search completed: June 26, 2003, 16:20:18
Job time : 37.2888 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using SW model

Run on: June 26, 2003, 09:43:36 ; Search time 226.087 Seconds
(without alignments)
199.215 Million cell updates/sec

Title: US-09-355-254f-8

Perfect score: 20

Sequence: 1 gattgcctgacgcagagag 20

Scoring table: IDENTITY_NUC

Gapop 10.0, Gapext 1.0

Searched: 2185239 seqs, 112599159 residues

Total number of hits satisfying chosen parameters: 4370478

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : N_Geneseq_101002.*

1: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1980.DAT.*

2: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1981.DAT.*

3: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1982.DAT.*

4: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1983.DAT.*

5: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1984.DAT.*

6: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1985.DAT.*

7: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1986.DAT.*

8: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1987.DAT.*

9: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1988.DAT.*

10: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1989.DAT.*

11: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1990.DAT.*

12: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1991.DAT.*

13: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1992.DAT.*

14: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1993.DAT.*

15: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1994.DAT.*

16: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1995.DAT.*

17: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1996.DAT.*

18: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1997.DAT.*

19: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1998.DAT.*

20: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1999.DAT.*

21: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA2000.DAT.*

22: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA2001A.DAT.*

23: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA2001B.DAT.*

24: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA2002.DAT.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length DB	ID	Description
1	20	100.0	20	AAV46000	Immune adjuvant AP
2	20	100.0	20	AAZ28189	Chlamydia trachoma
3	20	100.0	20	AAZ29172	Inflammatory cardi
4	20	100.0	20	AAZ39177	Murine Toll-like r
5	20	100.0	20	AAZ76047	CAMP response elem
6	20	100.0	27	AAZ85832	CRE oligonucleotide
7	20	100.0	27	AAZ82454	ATF comp oligonucle
8	20	100.0	27	AAV08336	CRE element coding
9	20	100.0	27	AAV70581	Transcription fact

10	20	100.0	27	AAH77396	Cyclic AMP respons
C 11	20	100.0	27	AAH77397	Cyclic AMP respons
12	20	100.0	27	AAH77396	Cyclic AMP respons
C 13	20	100.0	27	AAH77397	Cyclic AMP respons
14	20	100.0	27	AAH76267	CAMP response elem
15	20	100.0	27	AAH82274	CRE binding site o
16	20	100.0	27	ABA05538	Cyclic-AMP respons
17	20	100.0	20	AAV45997	Immune adjuvant CR
18	16.8	84.0	27	AAV45997	Human glycocon syn
19	16.4	82.0	28	AAH14052	Cyclic AMP respons
20	16.4	82.0	32	AAH77813	CREB probe derived
21	16.4	82.0	37	AAV04084	Somatostatin gene
22	16.4	82.0	50	AAO69701	Human somatostatin
23	16.4	82.0	50	AAH17451	Human somatostatin
24	16.4	82.0	50	AAH17451	Test sequence from
25	16.4	82.0	50	AAH82942	DNA binding molecu
C 26	16.4	82.0	462	AAH10445	Human cDNA clone (
27	16.4	82.0	723	AAH1392	Human normal pancr
28	16.4	82.0	2443	AAH17546	Human cDNA sequenc
29	16.4	82.0	2564	AAH19414	Mouse ischaemic co
30	16	80.0	462	AAV45999	Human prostate exp
31	15.8	79.0	20	AAV45999	Immune adjuvant CR
32	15.8	79.0	917	AAH84473	Human foetal cDNA,
C 33	15.8	79.0	2662	AAH86924	Human Immune/haema
C 34	15.8	79.0	2662	AAH86925	Human Immune/haema
C 35	15.8	79.0	2669	AAH86923	Human Immune/haema
C 36	15.8	79.0	3648	AAH37410	Human phospholipas
C 37	15.8	79.0	5475	AAV17777	Tomato Prf cDNA,
C 38	15.8	79.0	5592	AAH30935	Spodoptera frugipe
C 39	15.8	79.0	10968	AAV17789	Tomato Prf genomic
40	15.4	77.0	123	ABA6163	Human foetal liver
41	15.4	77.0	123	ABA6163	Probe #19180 for g
42	15.4	77.0	123	AAH24826	Human brain expres
43	15.4	77.0	123	AAH27849	Probe #17782 for g
44	15.4	77.0	123	AAH56827	Probe #25513 used
45	15.4	77.0	123	ABH24317	Human genome-deriv

ALIGNMENTS

RESULT 1	AAV46000	standard; DNA; 20 BP.
ID	AAV46000	
AC	AAV46000	
XX		
XX	16-OCT-1998	(first entry)
XX		
XX	Immune adjuvant AP-1 #1.	
DE		
XX		
XX	Immune system: adjuvant; vaccine; cancer; prophylactic; pathogenicity;	
KW	modulator; tolerance; regulator; helper cell; antigen; immunoglobulin;	
KW	Ig class; autoimmune response; T-cell; B-cell; tumour; ss.	
XX		
OS	Class Bacteria.	
XX		
XX	EP855184-A1.	
XX		
XX	29-JUL-1998.	
XX		
XX	23-JAN-1997;	97EP-0101019.
XX		
XX	23-JAN-1997;	97EP-0101019.
XX		
XX	23-JAN-1997;	97EP-0101019.
XX		
XX	(HEEG/) HEEG K.	
PA	(LIPF/) LIPFORD G B.	
PA	(WAGN/) WAGNER H.	
XX		
XX	Heeg K, Lipford GB, Wagner H;	
XX		
DR	WPI; 1998-389630/34.	

PT Antigenic composition comprises polynucleotide fragment and antigen
PT - used as vaccine to treat or prevent e.g. cancer or pathogen
PT infections and to modulate immune response e.g. tolerance break and
PT regulation of TH1/TH2 cells
PS Example 3; Page 7; 28pp; English.
XX
CC AAV5593-VA6019 are fragments of bacterial polynucleotides which are
CC used as immune adjuvants for inclusion into vaccines to treat cancer and
CC for prophylaxis and/or treatment of conditions caused by pathogenic
CC micro-organisms. The polynucleotide is used for modulation of an immune
CC response and the modulation is selected from the group break of
CC tolerance, regulation of TH1/TH2 helper cell responses, switch of Ig
CC classes, treatment of autoimmune responses and induction of tolerances.
CC DNA oligomers are used to enhance the reactivity of immune cells to
CC viral, bacterial and parasitic antigens, to break tolerance in anergic T
CC and B cells e.g. against tumour antigens, as adjuvants in vaccination
CC against tumour-defined antigens and immunostimulatory substances in an
CC immune response against tumours and to suppress immune reactions of the
CC innate and acquired immune system. The composition is inexpensive and
CC stable and does not cause lethal shock, which happens with prior art
CC bacterial sequences.
SQ Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 other;
QY Query Match 100.0%; Score 20; DB 19; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.48;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
DB 1 GATTGCGTGCCTGACGACAGAG 20
1 GATTGCGTGCCTGACGACAGAG 20
OY 1 GATTGCGTGCCTGACGACAGAG 20
1 GATTGCGTGCCTGACGACAGAG 20
DB 1 GATTGCGTGCCTGACGACAGAG 20
1 GATTGCGTGCCTGACGACAGAG 20
RESULT 2
AAZ28189
ID AAZ28189 standard; DNA; 20 BP.
XX
AC AAZ28189;
XX
DT 20-DEC-1999 (first entry)
XX
DE Chlamydia trachomatis outer membrane protein gene-derived Cpg oligo 2.
XX
KW Heart disease; inflammatory; autoimmune; cardiomyopathy; adjuvant;
XX Cpg motif; vaccine; ds.
XX
OS Synthetic.
OS Chlamydia trachomatis.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER = phosphorothioate linkage"
XX
PM US5962636-A.
XX
PD 05-OCT-1999.
XX
PF 12-AUG-1998; 98US-0133774.
XX
PR 12-AUG-1998; 98US-0133774.
XX
PA (AMGE-) AMGEN CANADA INC.
XX
PI Bachmaier K, Hessel AJ, Penninger JM, Neu N;
XX WPI: 1999-589735/50.
XX
PT Peptides that induce or suppress inflammatory cardiomyopathy -
XX Example 2; Column 25; 17pp; English.
PS

XX This sequence represents DNA encoding Chlamydia trachomatis 60 kD outer
CC membrane protein (OMP) gene-derived Cpg oligonucleotide 2. This
CC oligonucleotide contains a Cpg motif. It was tested for its ability to
CC act as an adjuvant for the M7A-alpha peptide (AAV4723), which can
CC induce inflammatory cardiomyopathy (ICM) in mice. It was found to act as
CC a potent immunostimulator, whereas a oligonucleotide from the same
CC source which did not contain a Cpg motif (AAZ28193) was hardly effective
CC as an adjuvant. Inflammatory cardiomyopathy peptides (AAV42723,
CC AAV42725-V42731) can be used with such an adjuvant and an excipient in a
CC vaccine for decreasing ICM.
SQ Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 other;
QY Query Match 100.0%; Score 20; DB 20; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.48;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
DB 1 GATTGCGTGCCTGACGACAGAG 20
1 GATTGCGTGCCTGACGACAGAG 20
OY 1 GATTGCGTGCCTGACGACAGAG 20
1 GATTGCGTGCCTGACGACAGAG 20
DB 1 GATTGCGTGCCTGACGACAGAG 20
1 GATTGCGTGCCTGACGACAGAG 20
RESULT 3
AAZ99172
ID AAZ99172 standard; DNA; 20 BP.
XX
AC AAZ99172;
XX
DT 21-JUN-2000 (first entry)
XX
DE Inflammatory cardiomyopathy immunostimulatory oligonucleotide #1.
XX
KW Cardiant; murine alpha myosin heavy chain; inflammatory myocarditis;
XX autoimmune inflammatory cardiomyopathy; Chlamydia; antibody; vaccine;
XX hybridization probe; immunostimulatory; ss.
XX
OS Synthetic.
XX
PN US60344230-A.
XX
PD 07-MAR-2000.
XX
PF 03-MAY-1999; 99US-0303862.
XX
PR 12-AUG-1998; 98US-0133774.
XX
PA (AMGE-) AMGEN CANADA INC.
XX
PI Neu N, Penninger JM, Bachmaier K, Hessel AJ;
XX WPI: 2000-255712/22.
XX
PT DNA molecules encoding novel myocardial peptides used for inhibiting
PT and inducing inflammatory cardiomyopathy in vivo -
XX
PM Disclosure; Column 17; 17pp; English.
XX
CC The invention relates to the isolation of sequences coding for peptide
CC sequences derived from bacteria and viruses which may cause inflammatory
CC cardiomyopathy. The peptide sequences are searched based on the sequence
CC of the M7A peptide derived from the murine alpha myosin heavy chain
CC polypeptide. The consensus sequence of the murine M7A-alpha/beta peptides
CC (Y83813) was used to search the PIR public database for similar bacterial
CC and viral sequences able to cause inflammatory cardiomyopathy. The screen
CC isolated the peptides Y83814-Y83819 and their corresponding coding
CC sequences Z99164-Z99169. The peptides encoded by the DNAs are used, alone
CC or in conjunction with other therapeutics, for inducing or inhibiting
CC inflammatory cardiomyopathy in vivo, where the cardiomyopathy is
CC autoimmune inflammatory cardiomyopathy, and inflammatory cardiomyopathy
CC caused by Chlamydia or other bacterial or viral infections that cause
CC inflammatory cardiomyopathy. The oligonucleotides Z99172-Z99176 were
CC shown to increase the immunogenicity of the immunostimulatory peptides

CC when injected simultaneously. The peptides may also be used for
CC increasing inflammatory myocarditis in a mammal. Antibodies against the
CC peptides and the peptides themselves are used for measuring the risk of
CC inflammatory cardiomyopathy in a mammal. The peptides may also be used
CC in vaccines. Nucleic acids encoding the peptides may be used as
CC hybridization probes, e.g. in diagnostic assays to test for the
CC presence of Chlamydia DNA.

XX
SQ Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 other;

Query Match 100.0%; Score 20; DB 21; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.48;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GATTGCTGACGTGACAGAG 20
|||||
DB 1 GATTGCTGACGTGACAGAG 20

RESULT 4
AAL39177
ID AAL39177 standard; DNA; 20 BP.

XX AAL39177;
XX
XX 05-SEP-2002 (first entry)

XX Murine Toll-like receptor related CpG DNA SEQ ID NO 52.

XX Murine Toll-like receptor; TLR9; TLR7; ISNA; ds.

XX Unidentified.

XX WO200222809-A2.

XX 21-MAR-2002.

XX 17-SEP-2001; 2001WO-US29229.

XX 15-SEP-2000; 2000US-233035P.

XX 23-JAN-2001; 2001US-263657P.

XX 17-MAY-2001; 2001US-291726P.

XX 22-JUN-2001; 2001US-300210P.

XX (COLE-) COLEY PHARM GMBH.

XX Bauer S, Lidfjord G, Wagner H;

XX WPI; 2002-393964/42.

XX New isolated murine Toll-like receptor (TLR)9, TLR7, TLR8 polypeptides,
XX useful for identifying species specificity of immunostimulatory nucleic
XX acid and identifying immunostimulatory nucleic acids

XX Disclosure: Page 76; 195pp; English.
XX
XX The invention relates to isolated murine Toll-like receptors (TLR)9,
XX TLR7 and TLR8 polypeptides. These polypeptides comprise fully defined
XX sequences of 1032, 1050 or 1032 amino acids as given in specification, or
XX their fragments, where TLR9, TLR7 and TLR8 polypeptides or their
XX fragments have an amino acid sequence which is identical to human TLR9,
XX TLR7 or TLR8 polypeptides or their fragment except for at least one amino
XX acid of a murine TLR polypeptide. The isolated nucleic acids of the
XX invention are useful for inhibiting TLR9 signalling activity in a cell.
XX TLR7, TLR8 and TLR9 polypeptides are useful for identifying nucleic acid
XX molecules which interact with a TLR polypeptide or its fragment. The
XX TLR7, TLR8 or TLR9 polypeptides are also useful for identifying ISNA. The
XX TLR7, TLR8 and TLR9 polypeptides are also useful for comparing TLR9
XX signalling activity of a test compound (that is not a nucleic acid, and
XX is a polypeptide or a part of a combinatorial library of compounds) with
XX an ISNA. The TLR7, TLR8 and TLR9 polypeptides are also useful for
XX identifying species specificity of an ISNA. The isolated nucleic acids of
XX the invention are useful as probes or primers. This polynucleotide

CC sequence represents DNA relating to the isolated Toll-like receptors of
CC the invention.

XX
SQ Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 other;

Query Match 100.0%; Score 20; DB 24; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.48;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GATTGCTGACGTGACAGAG 20
|||||
DB 1 GATTGCTGACGTGACAGAG 20

RESULT 5
AAK76047
ID AAK76047 standard; DNA; 26 BP.

XX AAK76047;
XX
XX 30-JUL-1999 (first entry)

XX CAMP response element oligonucleotide SEQ ID NO:15.

XX CRE; CAMP response element; transcription factor decoy; cis-element;
XX tumour growth inhibitor; palindromic; hairpin; cancer; metabolism;
XX gene transcription regulation; inhibiting proliferation; ds.

XX Synthetic.

XX WO9926634-A1.

XX 03-JUN-1999.

XX 23-NOV-1998; 98WO-US25307.

XX 24-NOV-1997; 97US-0977643.

XX (USSH) US DEPT HEALTH & HUMAN SERVICES.

XX Cho-Chung YS;

XX WPI; 1999-347612/29.

XX Nucleic acids that compete with response elements for transcription
XX factors

XX Example 10; Page 54; 83pp; English.

XX The present invention describes a composition (A) comprising one or more
XX nucleic acids (I) that compete with CAMP (cyclic adenosine monophosphate)
XX response element (CRE) enhancer DNA for binding to transcription factors
XX (TF). (I) are used to regulate gene transcription in cells, in vitro or
XX in vivo, specifically for inhibiting proliferation in cells, in vitro or
XX possibly also for regulation of metabolism in hepatitis B and other
XX viruses. HCT-15 human multidrug resistant colon carcinoma cells (2
XX million) were inoculated subcutaneously into the flank of nude mice,
XX then the CRE oligonucleotide 5'-TGAGTTCATGACGTGATGACGTCA-3' injected
XX intraperitoneally at doses of 0.1 mg, 5 times per week, once the tumour
XX had reached 30-50 mg. This treatment resulted in over 85% reduction in
XX tumour growth, relative to an untreated control. (I) have high affinity
XX for TF and can inhibit growth of cancer cells without adverse effects on
XX normal cells (contrast use of antisense RNA). The method does not
XX require knowledge of the target gene sequence, only of the response
XX element sequence. The present sequence is used in the exemplification
XX of the present invention.

XX Sequence 26 BP; 8 A; 4 C; 9 G; 5 T; 0 other;

Query Match 100.0%; Score 20; DB 20; Length 26;
Best Local Similarity 100.0%; Pred. No. 0.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GATTGCTGACGTACAGAG 20
 |||||||
 DB 4 GATTGCTGACGTACAGAG 23

RESULT 6
 AAT85832
 ID AAT85832 standard; DNA: 27 BP.

AC AAT85832;
 XX

DT 21-NOV-1997 (first entry)
 XX

DE CRE oligonucleotide used in gel shift assay.
 XX

KM Activating transcription factor 1; ATF1; CREB; recognition sequence;
 KM cyclic AMP responsive element binding protein; inhibition; binding;
 KM proliferation; virus; cancer; HTLV1; leukemia; antibody; ss.

OS Synthetic.
 XX

PN US5641486-A.
 XX

PD 24-JUN-1997.
 XX

PE 18-MAR-1994; 94US-0210880.
 XX

PR 18-MAR-1994; 94US-0210880.
 XX

PA (UYNE-) UNIV NEBRASKA.
 XX

PI Hinrichs SH, Orten DJ;
 XX

DR WPI; 1997-340900/31.
 XX

PT Inhibiting replication of cancer cells or viruses - with inhibitor
 PT that binds to peptide sequence of activating transcription factor 1

PS Example 2; Column 6; 17pp; English.
 XX

CC This oligonucleotide sequence corresponds to the cyclic AMP binding
 CC element (CRE) to which members of the activating transcription factor 1
 CC (ATF1)-cyclic AMP responsive element binding protein (CREB) family
 CC of protein bind. The sequence was used in a gel shift mobility assay to
 CC identify agents which inhibit the binding of ATF1 to its recognition
 CC sequence. The agents are preferably antibodies, small molecules or
 CC polypeptides, especially the complementarity determining region of
 CC monoclonal antibody Mab4. The agents cause inhibition of transcription
 CC by dissociating ATF1 from its target gene and thus will prevent
 CC proliferation of e.g. a virus or cancer cell, such as HTLV1-mediated
 CC leukemic cell proliferation.
 CC

SQ Sequence 27 BP; 8 A; 5 C; 9 G; 5 T; 0 other;

Query Match 100.0%; Score 20; DB 18; Length 27;
 Best Local Similarity 100.0%; Pred. No. 0.5;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GATTGCTGACGTACAGAG 20
 |||||||
 DB 4 GATTGCTGACGTACAGAG 23

RESULT 7
 AAV82454
 ID AAV82454 standard; DNA: 27 BP.

AC AAV82454;
 XX

DT 12-APR-1999 (first entry)
 XX

DE ATF comp oligonucleotide used in competition analysis.
 XX

KM Vascular endothelial growth factor; VEGF; human; hypoxia;
 KM vascular disease; tumour; cancer; angiogenesis; wound healing;
 KM therapy; diagnosis; ds.

OS Synthetic.
 OS Homo sapiens.
 PN WO9856936-A1.
 XX

PD 17-DEC-1998.
 XX

PE 10-JUN-1998; 98WO-EP03517.
 XX

PR 10-JUN-1997; 97EP-0109418.
 XX

PA (PLAC) MAX PLANCK GES FOERDERUNG WISSENSCHAFTEN.
 XX

PI Damerit A, Plate K, Risau W;
 XX

DR WPI; 1999-080911/07.
 XX

PT New recombinant DNA - contains sequence that regulates
 PT hypoxia-induced expression, used for, e.g. treatment and diagnosis
 PT of vascular disease
 XX

PS Example 6; Page 41; 80pp; English.
 XX

CC Oligonucleotides hVEGF, hVEGF 5' DEL, API1 and API2 (see
 CC AAV82449-52), and competitor oligonucleotides API comp, ATF comp
 CC and VL30 (see AAV82453-55) were used in electrophoretic mobility
 CC shift assays to determine which transcription factor(s) bind to
 CC the cis-acting element that is involved in the potentiation of
 CC hypoxia inducible factor 1 (HIF-1) mediated hypoxic induction
 CC of vascular endothelial growth factor (VEGF) gene regulatory
 CC sequences. Experiments were performed using normoxic or hypoxic
 CC C6 cell nuclear extracts. An API consensus binding site was shown
 CC to compete for DNA-protein-complex formation at potentiating
 CC sequences. The invention relates to recombinant DNA molecules
 CC comprising regulatory sequences of the VEGF gene, especially the
 CC 3' untranslated region (see AAV82439) and promoter (see AAV82440),
 CC being capable of modulating hypoxia inducible expression of a
 CC heterologous DNA in vivo. Such recombinant DNA molecules, vectors,
 CC host cells and transgenic animals can be used to identify and
 CC develop compounds and methods for diagnosing, treating, preventing
 CC and/or delaying a vascular or tumour disease.
 CC

SQ Sequence 27 BP; 8 A; 5 C; 9 G; 5 T; 0 other;

Query Match 100.0%; Score 20; DB 20; Length 27;
 Best Local Similarity 100.0%; Pred. No. 0.5;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GATTGCTGACGTACAGAG 20
 |||||||
 DB 4 GATTGCTGACGTACAGAG 23

RESULT 8
 AAV08336
 ID AAV08336 standard; DNA: 27 BP.

AC AAV08336;
 XX

DT 04-FEB-1999 (first entry)
 XX

DE CRE element coding sequence.
 XX

KM ATF1; activating transcription factor 1; inhibitor; gene transcription;
 KM cell proliferation; cancer cell; human; ds.

OS Synthetic.
 XX

PN US5844096-A.
 XX

XX 01-DEC-1998.
 PD
 XX
 XX 20-DEC-1996; 96US-0771411.
 PF
 XX
 PR 18-MAR-1994; 94US-0210880.
 PR 20-DEC-1996; 96US-0771411.
 XX
 PA (UYNE-) UNIV NEBRASKA.
 PI Hinrichs SH, Orten DJ;
 DR WPI; 1999-044667/04.
 XX
 XX Inhibitor of activating transcription factor 1 mediated gene
 PT transcription - useful as anticancer or antiviral agent
 XX
 PS Example 2; Column 6; 17pp; English.
 CC This sequence represents a CRE element coding sequence. This sequence
 CC was used to test the effect of the inhibitory compound of the
 CC invention. The inhibitory compound binds to ATF1 residues 167-181 with
 CC sufficient affinity to dissociate ATF1 from a gene to which it is bound
 CC and thereby prevent transcription of the gene. The inhibitory compound
 CC and its derivatives are useful for inhibiting the ATF1-mediated
 CC proliferation of cancer cells and viruses, e.g. HTLV I.
 XX
 SQ Sequence 27 BP; 8 A; 5 C; 9 G; 5 T; 0 other;
 Query Match 100.0%; Score 20; DB 20; Length 27;
 Best Local Similarity 100.0%; Pred. No. 0.5; Mismatches 0; Indels 0; Gaps 0;
 Matches 20; Conservative 0; Indels 0; Gaps 0;
 OY 1 GATTGCTGACGTGAGAG 20
 Db 4 GATTGCTGACGTGAGAG 23
 RESULT 9
 ID AAI70581 standard; DNA; 27 BP.
 XX
 AC AAI70581;
 XX
 XX 21-JAN-2002 (first entry)
 DE Transcription factor CREB consensus oligonucleotide.
 XX
 KW Transcription factor; CREB; screening; detection; quantification;
 KW probe; ds.
 XX
 OS Synthetic.
 XX
 PN EP1136567-A1.
 PD
 PD 26-SEP-2001.
 XX
 PF 24-MAR-2000; 2000EP-0870057.
 XX
 PR 24-MAR-2000; 2000EP-0870057.
 XX
 PA (ADAR-) ADVANCED ARRAY TECHNOLOGIES SA.
 PI Remacle J, Renard P, Art M;
 DR WPI; 2001-640391/74.
 XX
 XX Screening, detecting or quantifying transcriptional factors in a
 PT biological sample comprises contacting the transcriptional factor with
 PT a double-stranded DNA sequence bound to an insoluble solid support -
 XX
 PS Example 4; Page 8; 20pp; English.
 XX

CC The present sequence is that of a CREB transcription factor
 CC consensus oligonucleotide. Double-stranded probe nucleotide
 CC sequences were constructed from 100 bp of a CMV 5' sequence (see
 CC AAI70578) linked to this oligonucleotide and used in microwell
 CC colorimetric CREB and phospho-CREB assays. The double-stranded
 CC probe was biotinylated at its CMV 5' extremity and linked to
 CC streptavidin-coated 96-wells plates. The plates were contacted
 CC with a nuclear extract of L929 murine fibrosarcoma cells,
 CC incubated with anti-CREB or anti-phospho-CREB antibody and then
 CC with peroxidase-conjugated antibody. The presence of CREB or
 CC phospho-CREB was detected through the action of peroxidase on
 CC tetramethylbenzidine. This is an example of the method of the
 CC invention, involving the detection of a transcription factor using
 CC a double-stranded DNA probe bound to an insoluble solid support at
 CC a concentration of at least 0.01 pmole/sq cm of support surface and
 CC at a distance of at least 6.8 nm from the surface of the support.
 CC The method allows the screening, detection and/or quantification of
 CC one or more transcriptional factors, of molecules binding such
 CC factors, and of molecules that inhibit such binding, using
 CC non-radioactive detection methods.
 XX
 SQ Sequence 27 BP; 8 A; 5 C; 9 G; 5 T; 0 other;
 Query Match 100.0%; Score 20; DB 22; Length 27;
 Best Local Similarity 100.0%; Pred. No. 0.5; Mismatches 0; Indels 0; Gaps 0;
 Matches 20; Conservative 0; Indels 0; Gaps 0;
 OY 1 GATTGCTGACGTGAGAG 20
 Db 4 GATTGCTGACGTGAGAG 23
 RESULT 10
 ID AAH77396 standard; DNA; 27 BP.
 XX
 AC AAH77396;
 XX
 XX 05-NOV-2001 (first entry)
 DE Cyclic AMP response element CRE consensus oligonucleotide probe #1.
 XX
 KW Cancer; human; dithiocarbamate derivative; anticancer agent; probe; ss.
 XX
 OS Unidentified.
 XX
 PN US2001016600-A1.
 PD
 PD 23-AUG-2001.
 XX
 PF 12-DEC-2000; 2000US-0735205.
 XX
 PR 08-SEP-1998; 98US-0099390.
 PR 08-SEP-1999; 99US-0392122.
 PR 05-OCT-2000; 2000US-0679932.
 XX
 PA (KENN/) KENNEDY T P.
 PI Kennedy TP;
 DR WPI; 2001-557127/62.
 XX
 XX Treating cancer, asthma and cancer and reducing hypoxic or ischemic
 PT damage comprises administering dithiocarbamate thiolate anion or
 PT dithiocarbamate thiolate metal complex -
 XX
 XX Disclosure; Page 10; 36pp; English.
 PS
 XX The present invention describes a method of treating cancer, asthma and
 CC arthritis and reducing hypoxic or ischemic damage, involving
 CC administering a dithiocarbamate thiolate anion or metal ion complex to
 CC the patient. The present sequence is a probe for the cyclic AMP response
 CC element CRE, which was described in the exemplification of the invention.
 CC

XX Sequence 27 BP; 8 A; 5 C; 9 G; 5 T; 0 other;
 SQ
 Query Match 100.0%; Score 20; DB 22; Length 27;
 Best Local Similarity 100.0%; Pred. No. 0.5;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 1 GATTGCTGACGTGACAGAG 20
 ||||||||||||||||||
 DB 4 GATTGCTGACGTGACAGAG 23
 ||||||||||||||||||
 RESULT 11
 AAH77397/c
 ID AAH77397 standard; DNA; 27 BP.
 XX
 AC AAH77397;
 XX
 DT 05-NOV-2001 (first entry)
 XX
 DE Cyclic AMP response element CRE consensus oligonucleotide probe #2.
 XX
 KW Cancer; human; dithiocarbamate derivative; anticancer agent; probe; ss.
 XX
 OS Unidentified.
 XX
 PN US2001016600-A1.
 XX
 PD 23-AUG-2001.
 XX
 PF 12-DEC-2000; 2000US-0735205.
 XX
 PR 08-SEP-1998; 98US-0099390.
 PR 08-SEP-1999; 99US-0392122.
 PR 05-OCT-2000; 2000US-0679932.
 XX
 PA (KENNEDY) KENNEDY T P.
 XX
 PI Kennedy TP;
 XX
 DR WPI; 2001-557127/62.
 XX
 PT Treating cancer, asthma and cancer and reducing hypoxic or ischemic
 PT damage comprises administering dithiocarbamate thiolate anion or
 PT dithiocarbamate thiolate metal complex -
 XX
 PS Disclosure; Page 10; 36pp; English.
 XX
 CC The present invention describes a method of treating cancer, asthma and
 CC arthritis and reducing hypoxic or ischemic damage, involving
 CC administering a dithiocarbamate thiolate anion or metal ion complex to
 CC the patient. The present sequence is a probe for the cyclic AMP response
 CC element CRE, which was described in the exemplification of the invention.
 XX
 SQ Sequence 27 BP; 5 A; 9 C; 5 G; 8 T; 0 other;
 Query Match 100.0%; Score 20; DB 22; Length 27;
 Best Local Similarity 100.0%; Pred. No. 0.5;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 1 GATTGCTGACGTGACAGAG 20
 ||||||||||||||||||
 DB 24 GATTGCTGACGTGACAGAG 5
 ||||||||||||||||||
 RESULT 12
 AAF87956
 ID AAF87956 standard; DNA; 27 BP.
 XX
 AC AAF87956;
 XX
 DT 20-JUL-2001 (first entry)
 XX

DE Cyclic AMP responsive element CRE consensus oligo for EMSA #1.
 XX
 KW Cyclic AMP responsive element; electrophoretic mobility shift assay;
 KW EMSA; CRE; NF-kappaB; cancer; tetraethyl thium disulphide;
 KW dithiocarbamate; tumour; metal ion; copper ion; cytokine;
 KW ceruloplasmin; anticancer; cytostatic; ss.
 XX
 OS Synthetic.
 XX
 PN WO200117522-A1.
 XX
 PD 15-MAR-2001.
 XX
 PF 15-NOV-1999; 99WO-US27193.
 XX
 PR 08-SEP-1999; 99US-0392122.
 XX
 PA (CHAR-) CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY.
 XX
 PI Kennedy TP;
 XX
 DR WPI; 2001-281426/29.
 XX
 PT Treating cancer, e.g. melanoma, lung cancer, breast cancer or prostatic
 PT carcinoma, comprises administration of a thium disulfide optionally
 PT in combination with a heavy metal ion, ceruloplasmin or a cytokine e.g.
 PT interferon-alpha
 XX
 PS Disclosure; Page 24; 60pp; English.
 XX
 CC The present invention describes a method for treating established cancer
 CC in a mammal. The method comprises administering a thium disulfide (I).
 CC (I) has anticancer and cytostatic activities. (I) induces apoptosis and
 CC G2 cell-cycle arrest, by reducing expression of cyclin A (by preventing
 CC binding of transcription factors to DNA regulatory elements involved in
 CC control of cyclin A expression). The method can be used to treat cancers,
 CC e.g. melanoma, non-small cell lung cancer, small cell lung cancer, renal
 CC cancer, colorectal cancer, breast cancer, pancreatic cancer, gastric
 CC cancer, bladder cancer, ovarian cancer, uterine cancer, lymphoma and
 CC prostate cancer, especially melanoma, lung cancer, breast cancer and
 CC prostate carcinoma. The tumour-inhibiting effect of (I) is dependent on
 CC heavy metal ions, so administering (I) together with such ions (or with
 CC their intracellular carriers, e.g. ceruloplasmin or with serum
 CC ceruloplasmin stimulants, e.g. interferon-alpha) will increase the
 CC antiproliferative/anticarcinogenic effect. (I) also potentiates the
 CC effect of standard anticancer agents. (I) is already known for treating
 CC alcohol abuse (inhibitor of aldehyde dehydrogenase) and is relatively
 CC nontoxic and safe. The present sequence represents a cyclic-AMP
 CC responsive element CRE consensus oligonucleotide for use in an
 CC electrophoretic mobility shift assay (EMSA), which is used in the
 CC exemplification of the present invention.
 XX
 SQ Sequence 27 BP; 8 A; 5 C; 9 G; 5 T; 0 other;
 Query Match 100.0%; Score 20; DB 22; Length 27;
 Best Local Similarity 100.0%; Pred. No. 0.5;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 1 GATTGCTGACGTGACAGAG 20
 ||||||||||||||||||
 DB 4 GATTGCTGACGTGACAGAG 23
 ||||||||||||||||||
 RESULT 13
 AAF87957/c
 ID AAF87957 standard; DNA; 27 BP.
 XX
 AC AAF87957;
 XX
 DT 20-JUL-2001 (first entry)
 XX
 DE Cyclic AMP responsive element CRE consensus oligo for EMSA #2.

KW Cyclic-AMP responsive element; electrophoretic mobility shift assay;
KW EMSA; CRE; NF-kappaB; cancer; tetraethylthiuram disulfide;
KW dithiocarbamate; tumour; metal ion; copper ion; cytokine;
KW ceruloplasmin; anticancer; cytostatic; ss.
OS Synthetic.
XX WO200117522-A1.
XX PD 15-MAR-2001.
XX PE 15-NOV-1999; 99WO-US27193.
XX PR 08-SEP-1999; 99US-0392122.
XX PA (CHAR-) CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY.
XX PI Kennedy TP;
XX DR WPI; 2001-281426/29.
XX PT Treating cancer, e.g. melanoma, lung cancer, breast cancer or prostatic
PT carcinoma, comprises administration of a thiuram disulfide optionally
PT in combination with a heavy metal ion, ceruloplasmin or a cytokine e.g.
PT interferon-alpha
XX PS Disclosure; Page 24; 60pp; English.
XX XX The present invention describes a method for treating established cancer
CC in a mammal. The method comprises administering a thiuram disulfide (1).
CC (1) has anticancer and cytostatic activities. (1) induces apoptosis and
CC G2 cell-cycle arrest, by reducing expression of cyclin A (by preventing
CC binding of transcription factors to DNA regulatory elements involved in
CC control of cyclin A expression). The method can be used to treat cancers,
CC e.g. melanoma, non-small cell lung cancer, small cell lung cancer, renal
CC cancer, colorectal cancer, breast cancer, pancreatic cancer, gastric
CC cancer, bladder cancer, ovarian cancer, uterine cancer, lymphoma and
CC prostate carcinoma. The tumour-inhibiting effect of (1) is dependent on
CC heavy metal ions, so administering (1) together with such ions (or with
CC their intracellular carriers, e.g. ceruloplasmin or with serum
CC ceruloplasmin stimulants, e.g. interferon-alpha) will increase the
CC antiproliferative/antineoplastic effect. (1) also potentiates the
CC effect of standard anticancer agents. (1) is already known for treating
CC alcohol abuse (inhibitor of aldehyde dehydrogenase) and is relatively
CC nontoxic and safe. The present sequence represents a cyclic-AMP
CC responsive element CRE consensus oligonucleotide for use in an
CC electrophoretic mobility shift assay (EMSA), which is used in the
CC exemplification of the present invention.
XX SQ Sequence 27 BP; 5 A; 9 C; 5 G; 8 T; 0 other;
QY Query Match 100.0%; Score 20; DB 22; Length 27;
DB Best Local Similarity 100.0%; Pred. NO. 0.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GATGCTGACGTGAGAG 20
DB 24 GATGCTGACGTGAGAG 5
RESULT 14
AAAF76267
ID AAF76267 standard; DNA; 27 BP.
XX AAF76267;
XX 05-JUN-2001 (first entry)
XX CAMP response element (CRE) competitor EMSA probe.
XX NF-kappa-B; nuclear factor-kappa-B; CAMP response element; CRE;
KW nuclear translocation inhibition; heparin; internalisation;

KW NF-kappa-B dependent gene expression inhibition; cytokine;
KW tumour necrosis factor; TNF; interleukin; IL-1; IL-2; IL-6; IL-8;
KW interferon-beta; interferon-gamma; tissue factor-1; complement;
KW inducible nitric oxide synthase; diabetic vascular disease;
KW heart failure; asthma; sepsis; ischaemic-reperfusion injury;
KW electrophoretic mobility shift assay; competitor EMSA probe; ds.
XX Unidentified.
XX OS
XX WO200119376-A2.
XX PN 22-MAR-2001.
XX PD 12-SEP-2000; 2000WO-US24910.
XX PE 13-SEP-1999; 99US-0395081.
XX PR (CHAR-) CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY.
XX PA Kennedy TP;
XX PI WPI; 2001-244698/25.
XX DR Inhibiting NF-kappa-B activity, useful for treating e.g. diabetic
XX PT vascular disease, heart failure, asthma and sepsis, comprises
XX PT administering heparin to cells in patient to inhibit translocation of
XX PT NF-kappa-B from cytoplasm to nucleus -
XX PS Examples; Page 22; 68pp; English.
XX XX The invention relates to a method of inhibiting nuclear factor-kappa-B
CC (NF-kappa-B) activity in a patient, comprising the administration of
CC heparin to the cells in the patient, such that the heparin is
CC internalised into the cytoplasm of cells in the patient. The invention
CC is based on the discovery that heparin is able to block the
CC translocation of NF-kappa-B from the cytoplasm to the nucleus. This in
CC turn inhibits NF-kappa-B dependent gene expression. Such NF-kappa-B
CC dependent genes include genes encoding cytokines such as tumour necrosis
CC factor (TNF), IL-1 (interleukin-1), IL-2, IL-6, IL-8, interferon-beta,
CC interferon-gamma, tissue factor-1, complement and inducible nitric
CC oxide synthase. The method of the invention is used for treating or
CC preventing diabetic vascular disease, heart failure, asthma, sepsis and
CC ischaemic-reperfusion injury. Heparin may be administered in combination
CC with other active agents that treat or prevent another disease or
CC symptom in the patient, e.g., antiviral agents, antibiotics, antifungal
CC agents and antiinflammatory agents. The method of the invention offers
CC significant advantages over prior art treatments for the above
CC conditions. Heparin is relatively non-toxic and safe, and should not
CC produce the side effects such as hypertension, glucose intolerance
CC and bone demineralisation that are encountered with the use of
CC glucocorticoids for blocking the NF-kappa-B nuclear translocation.
CC Additionally, heparin is readily available and easily used. Sequences
CC AAF76266-AAF76267 represents EMSA (electrophoretic mobility shift assay)
CC probes used to measure the effect of heparin on NF-kappa-B nuclear
CC translocation. EMSA probe AAF76266 comprises a consensus NF-kappa-B
CC response element, and EMSA competitor probe AAF76267 comprises a
CC CAMP response element (CRE).
XX SQ Sequence 27 BP; 8 A; 5 C; 9 G; 5 T; 0 other;
QY Query Match 100.0%; Score 20; DB 22; Length 27;
DB Best Local Similarity 100.0%; Pred. NO. 0.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GATGCTGACGTGAGAG 20
DB 4 GATGCTGACGTGAGAG 23
RESULT 15
ABA92274
ID ABA92274 standard; DNA; 27 BP.
XX

AC ABA92274;
 XX
 DT 10-JUN-2002 (first entry)
 XX
 DE CRE binding site oligonucleotide, used in EMSA.
 XX
 KM CRE; electrophoretic mobility shift assay; EMSA; ds.
 XX
 OS Homo sapiens.
 XX
 PN WO200215912-A1.
 XX
 PD 28-FEB-2002.
 XX
 PF 24-AUG-2001; 2001WO-0S26527.
 XX
 PR 25-AUG-2000; 2000US-228201P.
 PR 26-OCT-2000; 2000US-243295P.
 XX
 PA (BETH-) BETH ISRAEL DEACONESS MEDICAL CENT.
 XX
 PI Ratan RR, Chatterjee S;
 XX
 DR WPI: 2002-242023/29.
 XX
 PT Diagnosing and treating diseases associated with oxidative stress, DNA
 PT damage or growth factor depletion, e.g. Alzheimer's and Parkinson's, by
 PT administering e.g. mithramycin, chromomycin, daunomycin, olivomycin and
 PT WP631 -
 XX
 PS Example 1; Page 23; 69pp: English.
 XX
 CC The present sequence is that of a CRE binding site oligonucleotide,
 CC which was radiolabelled and used in an electrophoretic mobility shift
 CC assay (EMSA) to parallel an EMSA performed with Sp-1 oligonucleotides
 CC (see ABA92271-72). The EMSAs were used to determine the effect of
 CC oxidative stress on Sp-1 DNA binding, and the effects of candidate
 CC compounds on Sp-1 protein levels. Sp-1 DNA binding activity in
 CC cortical neurons was shown to be low, but was dramatically enhanced
 CC by oxidative stress. The invention provides methods for detecting
 CC and treating diseases associated with oxidative stress, DNA damage
 CC or growth factor depletion, and identifying agents for their
 CC treatment. A compound is deemed to be an inhibitor of oxidative
 CC stress, DNA damage, growth factor depletion or cell death if it
 CC reduces the protein level of an Sp family member or if it decreases
 CC the binding of an Sp family member to DNA. A method for preventing
 CC or treating a disease or disorder of the nervous system, the ageing
 CC process or associated with apoptosis involves administering a
 CC compound that inhibits the induction of an Sp family member or the
 CC binding of an Sp family member to DNA, e.g. mithramycin,
 CC chromomycin, daunomycin, olivomycin or WP631. Diseases and
 CC disorders that can be treated include Alzheimer's disease,
 CC Creutzfeldt-Jacob disease, kuru, Huntington's disease, aneurysm,
 CC stroke associated with an increase in blood pressure, spinal cord
 CC disease, spinal cord injury, brain injury, multiple system atrophy,
 CC amyotrophic lateral sclerosis, progressive supranuclear palsy,
 CC neurodegeneration associated with the ageing process, mitochondrial
 CC disease, HIV infection, herpes infection and multiple sclerosis
 CC (all claimed).
 XX
 SQ Sequence 27 BP; 8 A; 5 C; 9 G; 5 T; 0 other:
 Query Match 100.0%; Score 20; DB 24; Length 27;
 Best Local Similarity 100.0%; Pred. No. 0.5;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 GATTCCTGACCTCAGAG 20
 ||||||||||||||||
 DB 4 GATTCCTGACCTCAGAG 23

Search completed: June 26, 2003, 12:16:10
 Job time : 228.158 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 26, 2003, 09:43:36 ; Search time 226.087 Seconds
(without alignments)
199.215 Million cell updates/sec

Title: US-09-355-254f-21

Perfect score: 20

Sequence: 1 gatttccagaaaggaac 20

Scoring table: IDENTITY_NUC
Gapop 10.0, Gapext 1.0

Searched: 2185239 segs, 1125999159 residues 4370478

Total number of hits satisfying chosen parameters:

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : N_Geneseq_101002.*

1:	/SID52/gcgdata/geneseq/geneseq-emb1/NA1980.DAT.*
2:	/SID52/gcgdata/geneseq/geneseq-emb1/NA1981.DAT.*
3:	/SID52/gcgdata/geneseq/geneseq-emb1/NA1982.DAT.*
4:	/SID52/gcgdata/geneseq/geneseq-emb1/NA1983.DAT.*
5:	/SID52/gcgdata/geneseq/geneseq-emb1/NA1984.DAT.*
6:	/SID52/gcgdata/geneseq/geneseq-emb1/NA1985.DAT.*
7:	/SID52/gcgdata/geneseq/geneseq-emb1/NA1986.DAT.*
8:	/SID52/gcgdata/geneseq/geneseq-emb1/NA1987.DAT.*
9:	/SID52/gcgdata/geneseq/geneseq-emb1/NA1988.DAT.*
10:	/SID52/gcgdata/geneseq/geneseq-emb1/NA1989.DAT.*
11:	/SID52/gcgdata/geneseq/geneseq-emb1/NA1990.DAT.*
12:	/SID52/gcgdata/geneseq/geneseq-emb1/NA1991.DAT.*
13:	/SID52/gcgdata/geneseq/geneseq-emb1/NA1992.DAT.*
14:	/SID52/gcgdata/geneseq/geneseq-emb1/NA1993.DAT.*
15:	/SID52/gcgdata/geneseq/geneseq-emb1/NA1994.DAT.*
16:	/SID52/gcgdata/geneseq/geneseq-emb1/NA1995.DAT.*
17:	/SID52/gcgdata/geneseq/geneseq-emb1/NA1996.DAT.*
18:	/SID52/gcgdata/geneseq/geneseq-emb1/NA1997.DAT.*
19:	/SID52/gcgdata/geneseq/geneseq-emb1/NA1998.DAT.*
20:	/SID52/gcgdata/geneseq/geneseq-emb1/NA1999.DAT.*
21:	/SID52/gcgdata/geneseq/geneseq-emb1/NA2000.DAT.*
22:	/SID52/gcgdata/geneseq/geneseq-emb1/NA2001A.DAT.*
23:	/SID52/gcgdata/geneseq/geneseq-emb1/NA2001B.DAT.*
24:	/SID52/gcgdata/geneseq/geneseq-emb1/NA2002.DAT.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match Length	DB ID	Description
1	20	100.0	20 17 AAT33591	Fcgr1 gene interie
2	20	100.0	20 17 AAT03680	Fc-gamma RI IIL St
3	20	100.0	20 19 AA46013	Immune adjuvant ST
4	20	100.0	20 20 AA428360	Probe for Human St
5	20	100.0	20 20 AA428365	PCR primer for Hum
6	20	100.0	20 21 AA292039	STAF binding sequ
7	20	100.0	20 24 AAI39188	Murine Toll-like r
8	20	100.0	42 15 AA063859	Protein binding mo
9	20	100.0	100 22 AA454479	DNA fragment compr

C	10	20	100.0	100	22	AA454480	DNA fragment compr
C	11	20	100.0	100	24	ABA93801	K2134 plasmid cons
C	12	20	100.0	100	24	ABA93802	K2134 plasmid cons
C	13	20	100.0	100	24	AA520691	Plasmid K2 134 O11
C	14	20	100.0	100	24	AA520692	Plasmid K2 134 O11
C	15	20	100.0	100	24	AA520693	BaF3/K2134/2alpha1
C	16	20	100.0	100	24	AA520694	Human FC gamma R1
C	17	20	100.0	100	24	AA520695	K2159/mlt4 reporte
C	18	20	100.0	100	24	AA520696	Genomic sequence #
C	19	19	95.0	21710	22	AA542185	GAS motif biotinyl
C	20	18.4	92.0	62	18	AAT76784	Human CDNA differe
C	21	18.4	92.0	655	24	ABK84058	Fc(gamma)RI promot
C	22	17.4	87.0	26	18	AAT59532	Human CDNA differe
C	23	17.4	87.0	149671	24	ABK84797	STAR probe GRR S
C	24	17	85.0	17	17	AAT31284	Oligo GRR, contain
C	25	17	85.0	17	21	AA28829	Human GRR oligo #2
C	26	17	85.0	17	24	AAD20634	GRR probe lower st
C	27	17	85.0	17	24	AAD27140	Arachidonic acid m
C	28	16.8	84.0	1001	21	AAK57470	Human immune/haema
C	29	16.4	82.0	474	22	AAK52617	Human CDNA clone (
C	30	16.4	82.0	806	22	AAK52617	Drosophila melanog
C	31	16.4	82.0	5749	23	AB128262	Human immune/haema
C	32	16.4	82.0	17070	22	AAK80632	Human immune/haema
C	33	16.4	82.0	27324	22	ABK89226	Escherichia coli p
C	34	16.4	82.0	36651	24	AAD28072	Human kinase genom
C	35	16.4	82.0	76798	24	ABN97454	Gene #3952 used to
C	36	16.4	82.0	130263	24	ABK83573	Human CDNA differe
C	37	16.4	82.0	1503900	22	AAK95240	Human neutrophil-1
C	38	16.4	82.0	1503900	22	AAK96733	Human neutrophil-1
C	39	16	80.0	25	16	AAK99341	Fc-gamma-RI recept
C	40	16	80.0	30	17	AAT37047	Probe containing I
C	41	16	80.0	409	22	AA191382	Human polynucleoti
C	42	16	80.0	428	22	AAK55159	Human immune/haema
C	43	15.8	79.0	239	21	AAK04878	Human secreted pro
C	44	15.8	79.0	375	22	AA186131	Human polynucleoti
C	45	15.8	79.0	386	22	AA180344	Human polynucleoti

ALIGNMENTS

RESULT 1
ID AAT33591 standard; DNA: 20 BP.

AC AAT33591;

DT 06-DEC-1996 (first entry)

DE Fcgr1 gene Interleukin-4 response element.

KW Interleukin-4 response element; Fcgr1; probe: Stat 5

KW signal transducer and activator of transcription 5; Stat 5;

KW Interleukin-2; signal transduction; cell proliferation;

KW Immune disorder; ss.

OS Synthetic.

FT key

FT misc.feature

FT W09626292-A1

PD 29-AUG-1996.

XX 22-FEB-1996;

XX 23-FEB-1995;

XX (TULAR-) TULARIK INC.

location/Qualifiers
/*tag- a
/note- *5' biotin label*

PI Hou J, McKnight SL, Schindler U;
 DR WPI; 1996-402382/40.
 XX
 XX Human signal transducer and activator of transcription 5 protein -
 PT used for treating cellular proliferation disorders, pref. of immune
 PT cells
 PS Example; Page 22; 42pp; English.
 XX
 XX The interleukin-4 (IL-4) response element (AAT33591) of the gene
 CC encoding PcgRIA was biotinylated and attached to streptavidin
 CC agarose to form a DNA-affinity resin. Proteins obtd. from nuclear
 CC extracts of IL-2-induced human lymphocyte YT cells were mixed with
 CC the resin. After incubation, the affinity matrix was washed with
 CC buffer or with buffer contg. a mutated variant (AAT33592) of the IL-4
 CC response element to isolate IL-2-induced transcription factors.
 CC Complexes between DNA and an isolated protein were visualised by a
 CC gel mobility shift assay utilising the same IL-4 response elements
 CC as probes.
 XX
 XX Sequence 20 BP; 8 A; 4 C; 4 G; 4 T; 0 other;
 SO

Query Match 100.0%; Score 20; DB 17; Length 20;
 Best Local Similarity 100.0%; Pred. No. 4.1;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GATATTCGAGAAAGAAC 20
 DB 1 GATATTCGAGAAAGAAC 20

RESULT 2
 AAT03680
 ID AAT03680 standard; cDNA; 20 BP.
 XX
 AC AAT03680;
 XX
 DT 29-MAR-1996 (first entry)
 XX
 DE Fc-gamma RI IL4 Stat cytokine binding domain cDNA.
 XX
 KW Interleukin-4 signal transducer and activator of transcription;
 KW IL-4 Stat; transcription factor; immunosuppressive; Fc-gamma RI; ds.
 XX
 OS Homo sapiens.
 XX
 PN EP692488-A2
 XX
 PD 17-JAN-1996.
 XX
 PF 05-JUL-1995; 95EP-0304715.
 XX
 PR 15-JUL-1994; 94US-0276099.
 PR 05-JUL-1994; 94US-0269604.
 XX
 PA (TULA-) TULARIK INC.
 XX
 PI Hou J, McKnight SL;
 DR WPI; 1996-070143/08.
 XX
 XX IL-4 signal transducer and activator of transcription (IL-4 Stat)
 PT peptide(s) - bind to natural intracellular IL-4 Stat binding target
 PT and are useful to identify cpds. for treatment and diagnosis of
 PT immune diseases
 PS Disclosure; Page 5; 22pp; English.
 XX
 XX Interleukin-4 signal transducer and activator of transcription
 CC (IL-4 Stat) (AAR88320) is characterized by selective binding to
 CC intracellular domains of cytokine receptors; nucleic acids
 CC encoding IL-4 Stat binding sites are given in AAT03680-86.

CC Preferred binding sites include 2 trinucleotides (TTC and GAA)
 CC separated by 1-5 nucleotides.
 XX
 XX Sequence 20 BP; 8 A; 4 C; 4 G; 4 T; 0 other;
 SO

Query Match 100.0%; Score 20; DB 17; Length 20;
 Best Local Similarity 100.0%; Pred. No. 4.1;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GATATTCGAGAAAGAAC 20
 DB 1 GATATTCGAGAAAGAAC 20

RESULT 3
 AAV46013
 ID AAV46013 standard; DNA; 20 BP.
 XX
 AC AAV46013;
 XX
 DT 16-OCT-1998 (first entry)
 XX
 DE Immune adjuvant SNTS/6.
 XX
 KW Immune system; adjuvant; vaccine; cancer; prophylactic; pathogenicity;
 KW modulator; tolerance; regulator; helper cell; antigen; immunoglobulin;
 KW Ig class; autoimmune response; T-cell; B-cell; tumour; ss.
 XX
 OS Class Bacteria.
 XX
 PN EP85184-A1.
 XX
 PD 29-JUL-1998.
 XX
 PR 23-JAN-1997; 97EP-0101019.
 XX
 PF 23-JAN-1997; 97EP-0101019.
 XX
 PA (HEG/) HEG K.
 PA (LIFE/) LIPFORD G B.
 PA (WAGN/) WAGNER H.
 XX
 PI Heeg K, Lipford GB, Wagner H;
 DR WPI; 1998-389630/34.
 XX
 XX Antigenic composition comprises polynucleotide fragment and antigen
 PT - used as vaccine to treat or prevent e.g. cancer or pathogen
 PT infections and to modulate immune response e.g. tolerance break and
 PT regulation of TH1/TH2 cells
 PS Example 5; Page 9; 28pp; English.
 XX
 XX AAV45993-VA6019 are fragments of bacterial polynucleotides which are
 CC used as immune adjuvants for inclusion into vaccines to treat cancer and
 CC for prophylaxis and/or treatment of conditions caused by pathogenic
 CC micro-organisms. The polynucleotide is used for modulation of an immune
 CC response and the modulation is selected from the group break of
 CC tolerance, regulation of TH1/TH2 helper cell responses, switch of Ig
 CC classes, treatment of autoimmune responses and induction of tolerances.
 CC DNA oligomers are used to enhance the reactivity of immune cells to
 CC viral, bacterial and parasitic antigens, to break tolerance in anergic T
 CC and B cells e.g. against tumour antigens, as adjuvants in vaccination
 CC against tumour-defined antigens and immunostimulatory substances in an
 CC immune response against tumours and to suppress immune reactions of the
 CC innate and acquired immune system. The composition is inexpensive and
 CC stable and does not cause lethal shock, which happens with prior art
 CC bacterial sequences.
 XX

Query Match 100.0%; Score 20; DB 19; Length 20;
 Best Local Similarity 100.0%; Pred. No. 4.1;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTATTTCAGAAAAGCAGAC 20
|||||
1 GTATTTCAGAAAAGCAGAC 20

Db

RESULT 4
AAK28360
ID AAK28360 standard; DNA; 20 BP.

AC AAK28360;

DT 18-JUN-1999 (first entry)

DE Probe for Human Stat6 coding sequence.

Stat6; Stat6b; human; signal transducers and activators of transcription;
isoform; myeloid cancer; asthma; sarcoma; scleroderma; fibrotic disease;
bone marrow fibrosis; AIDS; Stat6c; probe; ss.

Synthetic.
OS Homo sapiens.

PN W09910493-A1.

PD 04-MAR-1999.

PF 27-AUG-1998; 98WO-US17821.

PR 05-JAN-1998; 98US-0070397.

PR 27-AUG-1997; 97US-0056075.

(USSH) US DEPT HEALTH & HUMAN SERVICES.

Larochelle WJ, Patel B, Pierce JH;

WPI; 1999-214517/18.

New isoforms of Stat6 - having differential effects on the
modulation of Stat6 activity in cells

Example 1; Page 20; 88pp; English.

This sequence is a probe for DNA encoding human Stat6 (signal transducers
and activators of transcription). The invention relates to
isoforms of human Stat6. The detection and quantitation of DNA
or mRNA encoding Stat6 and/or Stat6b and/or Stat6c can be used to detect
differential expression of Stat6 isoforms in numerous diseases, including
myeloid cancer, asthma, sarcoma, scleroderma, bone marrow fibrosis,
fibrotic diseases and AIDS. The nucleic acids can be used to screen
genomic or cDNA libraries or to identify complementary sequences. The
identification of the genetic locus of the Stat6 gene can be used for
detection of chromosomal aberrations and translocations involving the
Stat6 gene. Antibodies against the isoforms can be used to detect the
presence of Stat6 and/or Stat6b and/or Stat6c in a sample. Because of the
variation of the roles of Stat6b and Stat6c in regulating gene
transcription of the isolated and purified forms can be used to study gene
regulation and in screening assays for identifying drug candidates which
may be used as agonists or antagonists. The two polypeptides may also be
used in gene therapy protocols. In particular, Stat6b and/or Stat6c can
therapeutically modulate the development and differentiation of B and
T cells and can enhance IL-4 immunological function in immunocompromised
individuals. Stat6 activation correlates with functional responses
induced by interleukin-4 (IL-4), IL-13 and platelet-derived growth factor
(PDGF). Stat6b when compared Stat6 is an attenuated regulator of gene
transcription. Stat6c is a dominant negative regulator of gene
transcription.

Sequence 20 BP; 8 A; 4 C; 4 G; 4 T; 0 other;

Query Match 100.0%; Score 20; DB 20; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.1;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTATTTCAGAAAAGCAGAC 20
|||||
1 GTATTTCAGAAAAGCAGAC 20

Db

RESULT 5
AAK28365
ID AAK28365 standard; DNA; 20 BP.

AC AAK28365;

DT 18-JUN-1999 (first entry)

DE PCR primer for Human Stat6 coding sequence.

Stat6; Stat6b; human; signal transducers and activators of transcription;
isoform; myeloid cancer; asthma; sarcoma; scleroderma; fibrotic disease;
bone marrow fibrosis; AIDS; Stat6c; primer; ss.

Synthetic.
OS Homo sapiens.

PN W09910493-A1.

PD 04-MAR-1999.

PF 27-AUG-1998; 98WO-US17821.

PR 05-JAN-1998; 98US-0070397.

PR 27-AUG-1997; 97US-0056075.

(USSH) US DEPT HEALTH & HUMAN SERVICES.

Larochelle WJ, Patel B, Pierce JH;

WPI; 1999-214517/18.

New isoforms of Stat6 - having differential effects on the
modulation of Stat6 activity in cells

Example 2; Page 30; 88pp; English.

This sequence is a primer for DNA encoding human Stat6 (signal
transducers and activators of transcription). The invention relates to
isoforms of human Stat6. The detection and quantitation of DNA
or mRNA encoding Stat6 and/or Stat6b and/or Stat6c can be used to detect
differential expression of Stat6 isoforms in numerous diseases, including
myeloid cancer, asthma, sarcoma, scleroderma, bone marrow fibrosis,
fibrotic diseases and AIDS. The nucleic acids can be used to screen
genomic or cDNA libraries or to identify complementary sequences. The
identification of the genetic locus of the Stat6 gene can be used for
detection of chromosomal aberrations and translocations involving the
Stat6 gene. Antibodies against the isoforms can be used to detect the
presence of Stat6 and/or Stat6b and/or Stat6c in a sample. Because of the
variation of the roles of Stat6b and Stat6c in regulating gene
transcription of the isolated and purified forms can be used to study gene
regulation and in screening assays for identifying drug candidates which
may be used as agonists or antagonists. The two polypeptides may also be
used in gene therapy protocols. In particular, Stat6b and/or Stat6c can
therapeutically modulate the development and differentiation of B and
T cells and can enhance IL-4 immunological function in immunocompromised
individuals. Stat6 activation correlates with functional responses
induced by interleukin-4 (IL-4), IL-13 and platelet-derived growth factor
(PDGF). Stat6b when compared Stat6 is an attenuated regulator of gene
transcription. Stat6c is a dominant negative regulator of gene
transcription.

Sequence 20 BP; 8 A; 4 C; 4 G; 4 T; 0 other;

Query Match 100.0%; Score 20; DB 20; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.1;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GATTTCACGAGAAAGAAC 20
 |||||
 DB 1 GATTTCACGAGAAAGAAC 20

RESULT 6

AA292039
 ID AA292039 standard; DNA; 20 BP.

AC AA292039;

DT 08-JUN-2000 (first entry)

DE STAT5 binding sequence oligonucleotide STAT5/STAT6.

KM STAT5 protein: signal transducer and activator of transcription 5;
 KW protein binding sequence; transcription factor modulator; inhibitor;
 KM malignant cell removal; proliferative malignancy; neoplastic disease;
 KM immunological disorder; inflammatory disorder; therapy; ds.

OS Synthetic.

XX WO200006696-A2.

PD 10-FEB-2000.

PF 30-JUL-1999; 99WO-US17366.

PR 30-JUL-1998; 98US-0094695.

PA (USF-) UNIV SOUTH FLORIDA.

PI Zuckerman KS, Liu RY;

DR WPI, 2000-195281/17.

PT Therapeutic agent for treating transcription factor-related illnesses
 PT such as proliferative malignancies, comprises an oligonucleotide for
 regulating transcription factor function -

PS Claim 15; Page 34; 43pp; English.

CC This sequence represents a STAT5 (signal transducer and activator of
 CC transcription 5) protein binding sequence. The invention relates to a
 CC therapeutic agent comprising an effective amount of an oligonucleotide
 CC (1) for modulating the function of transcription factors and a
 CC pharmaceutical acceptable carrier. The oligonucleotides can be used in a
 CC method of removing malignant cells in vitro. The oligonucleotides can be
 CC used in compositions to inhibit transcription factors in illnesses where
 CC transcription factors play a role, especially proliferative malignancies,
 CC neoplastic diseases, and immunological and inflammatory disorders.

XX Sequence 20 BP; 8 A; 4 C; 4 G; 4 T; 0 other;

Query Match 100.0%; Score 20; DB 21; Length 20;
 Best Local Similarity 100.0%; Pred. No. 4.1;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GATTTCACGAGAAAGAAC 20
 |||||
 DB 1 GATTTCACGAGAAAGAAC 20

RESULT 7

AA139188
 ID AA139188 standard; DNA; 20 BP.

AC AA139188;

DT 05-SEP-2002 (first entry)

DE Murine Toll-like receptor related CpG DNA SEQ ID No 63.

XX Murine Toll-like receptor; TLR9; TLR7; TLR8; ISNA; ds.

XX Unidentified.

OS WO200222809-A2.

XX 21-MAR-2002.

PD 17-SEP-2001; 2001WO-US29229.

PF 15-SEP-2000; 2000US-233035P.

PR 23-JAN-2001; 2001US-263657P.

PR 17-MAY-2001; 2001US-291726P.

PR 22-JUN-2001; 2001US-300210P.

XX (COLE-) COLEY PHARM GMBH.

PA Bauer S, Lipford G, Wagner H;

PI WPI, 2002-393964/42.

DR New isolated murine Toll-like receptor (TLR)9, TLR7, TLR8 polypeptides,
 XX useful for identifying species specificity of immunostimulatory nucleic
 XX acid and identifying immunostimulatory nucleic acids -

PT Disclosure; Page 76; 195pp; English.

CC The invention relates to isolated murine Toll-like receptors (TLR)9,
 CC TLR7 and TLR8 polypeptides. These polypeptides comprise fully defined,
 CC sequences of 1032, 1050 or 1032 amino acids as given in specification, or
 CC their fragments, where TLR9, TLR7 and TLR8 polypeptides or their
 CC fragments have an amino acid sequence which is identical to human TLR9,
 CC TLR7 or TLR8 polypeptides or their fragment except for at least one amino
 CC acid of a murine TLR polypeptide. The isolated nucleic acids of the
 CC invention are useful for inhibiting TLR9 signalling activity in a cell.
 CC TLR7, TLR8 and TLR9 polypeptides are useful for identifying nucleic acid
 CC molecules which interact with a TLR polypeptide or its fragment. The
 CC TLR7, TLR8 or TLR9 polypeptides are also useful for identifying ISNA. The
 CC TLR7, TLR8 and TLR9 polypeptides are also useful for comparing TLR9
 CC signalling activity of a test compound (that is not a nucleic acid, and
 CC is a polypeptide or a part of a combinatorial library of compounds) with
 CC an ISNA. The TLR7, TLR8 and TLR9 polypeptides are also useful for
 CC identifying species specificity of an ISNA. The isolated nucleic acids of
 CC the invention are useful as probes or primers. This polynucleotide
 CC sequence represents DNA relating to the isolated Toll-like receptors of
 CC the invention.

XX Sequence 20 BP; 8 A; 4 C; 4 G; 4 T; 0 other;

Query Match 100.0%; Score 20; DB 24; Length 20;
 Best Local Similarity 100.0%; Pred. No. 4.1;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GATTTCACGAGAAAGAAC 20
 |||||
 DB 1 GATTTCACGAGAAAGAAC 20

RESULT 8

AA063869
 ID AA063869 standard; DNA; 42 BP.

AC AA063869;

DT 10-NOV-1994 (first entry)

DE Protein binding motif GIRE from human R gene 5'-UTR.

KM Immunoglobulin; Igg receptor; gamma-Interferon activation; g-IFN;

KM haematopoietic cell; protein factor; binding site; GRR motif;
 KM human high affinity Fc receptor for Igg; human Fc gamma RI; R gene;

KM DNA response element; MATE motif; GIRE motif; gene therapy; ds.
 XX
 OS Homo sapiens.
 XX
 PN FR2696181-A.
 XX
 PD 01-APR-1994.
 XX
 PF 25-SEP-1992; 92FR-0011498.
 XX
 PR 25-SEP-1992; 92FR-0011498.
 XX
 PA (INRM) INSERM INST NAT SANTE & RECH MEDICALE.
 XX
 PI Benech P, Perez C, Wietzerbin J;
 XX
 DR WPI; 1994-128281/16.
 XX
 PT New nucleotide sequences are specific target for proteins
 PT exclusive to hematopoietic cells - used to impart, to partic.
 PT cells, a response to gamma-interferon, e.g. for gene therapy
 XX
 PS Claim 10; Page 25; 37pp; French.
 XX
 CC The region immediately upstream of the sequence which codes for the
 CC human high affinity Fc receptor for IgG (the R gene) comprises
 CC binding sites specific for haematopoietic cells (see AA063866-8).
 CC The sequence AA063869, designated the "GIRE" motif, is recognised by
 CC proteins present in both haematopoietic and non-haematopoietic cells
 CC and controls induction by interferon-gamma. The GIRE motif is used
 CC (opt. in multimeric form) with AA063866-8 for conferring on a gene
 CC a transcriptional activity limited to haematopoietic cells. The DNA
 CC motif thus has potential in gene therapy.
 XX
 SQ Sequence 42 BP; 14 A; 6 C; 10 G; 12 T; 0 other;
 XX
 Query Match 100.0%; Score 20; DB 15; Length 42;
 Best Local Similarity 100.0%; Pred. No. 4.4;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 1 GTATTTCACGAAAGGAC 20
 DB 23 GTATTTCACGAAAGGAC 42
 XX
 RESULT 9
 AA54479
 ID AA54479 standard; DNA: 100 BP.
 XX
 AC AA54479;
 XX
 DT 11-APR-2001 (first entry)
 XX
 DE DNA fragment comprising STAT transcription factors.
 XX
 KW zcytor 10 cytokine receptor; cytokine; receptor; antibody; ligand;
 KW binding; detection; modulation; recombinant cell;
 KW hematopoietic cell; lymphoid cell; myeloid cell; lymph;
 KW immune system; blood; bone; inflammatory response; inflammation;
 KW spleen; human; primer; ss.
 XX
 OS Synthetic.
 XX
 PN WO200068381-A1.
 XX
 PD 16-NOV-2000.
 XX
 PF 11-MAY-2000; 2000WO-US12924.
 XX
 PR 11-MAY-1999; 99US-0309861.
 XX
 PA (ZYMO) ZYMOGENETICS INC.
 XX

PI Presnell SR, Foster DC, Hammond AR, Lok S;
 XX
 DR WPI; 2001-016096/02.
 XX
 PT New cytokine receptor mouse zcytor 10, useful for detecting ligands
 PT that stimulate proliferation or development of hematopoietic,
 PT lymphoid and myeloid cells
 XX
 PS Example 19; Page 128; 134pp; English.
 XX
 CC Isolating a nucleotide which encodes the zcytor 10 cytokine
 CC receptor enables the production of recombinant cells expressing the
 CC receptor. Those cells can then be used to detect the presence of a
 CC modulator of zcytor10 protein by culturing the cells in the presence
 CC of a test ligand and comparing levels of activity of mouse zcytor10
 CC in the presence and absence of the test sample. Similarly, detection
 CC of zcytor10 receptor ligand within a test sample can be achieved.
 CC The method comprising contacting a test sample containing an amino
 CC acid sequence from Cys15 or Gly25 to Pro230 of the zcytor 10
 CC cytokine receptor and detecting the binding of the polypeptide to a
 CC ligand in the sample. Specified peptide fragments of the zcytor 10
 CC cytokine receptor and the methods described are used to identify
 CC ligands that stimulate the proliferation and/or development of
 CC hematopoietic, lymphoid and myeloid cells. Peptide fragments of
 CC the cytokine receptor are useful for treating lymphoid, immune,
 CC inflammatory, splenic, blood or bone disorders and for generating
 CC antibodies directed against the receptor. An exemplary luciferase
 CC mammalian expression vector is the R213 plasmid which was
 CC constructed with two complementary oligonucleotides (AA54479,
 CC AA54480) which comprise STAT transcription factors from 4 genes
 CC (a modified c-fos 5' element, the p21 SIE1 from the p21 WAF1
 CC gene, the mammary gland response element of the beta-casein gene
 CC and a STAT inducible element of the Fcg R1 gene.
 XX
 SQ Sequence 100 BP; 24 A; 33 C; 17 G; 26 T; 0 other;
 XX
 Query Match 100.0%; Score 20; DB 22; Length 100;
 Best Local Similarity 100.0%; Pred. No. 4.8;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 1 GTATTTCACGAAAGGAC 20
 DB 44 GTATTTCACGAAAGGAC 63
 XX
 RESULT 10
 AA54480/C
 ID AA54480 standard; DNA: 100 BP.
 XX
 AC AA54480;
 XX
 DT 11-APR-2001 (first entry)
 XX
 DE DNA fragment comprising STAT transcription factors.
 XX
 KW zcytor 10 cytokine receptor; cytokine; receptor; antibody; ligand;
 KW binding; detection; modulation; recombinant cell;
 KW hematopoietic cell; lymphoid cell; myeloid cell; lymph;
 KW immune system; blood; bone; inflammatory response; inflammation;
 KW spleen; human; primer; ss.
 XX
 OS Synthetic.
 XX
 PN WO200068381-A1.
 XX
 PD 16-NOV-2000.
 XX
 PF 11-MAY-2000; 2000WO-US12924.
 XX
 PR 11-MAY-1999; 99US-0309861.
 XX
 PA (ZYMO) ZYMOGENETICS INC.
 XX

```

PI Presnell SR, Foster DC, Hammond AK, Lok S;
DR WPI: 2001-016096/02.
XX
XX New cytokine receptor mouse zcytor 10, useful for detecting ligands
PT that stimulate proliferation or development of haematopoietic,
PR lymphoid and myeloid cells
XX
XX Example 19; Page 128; 134pp; English.
XX
XX Isolating a nucleotide which encodes the zcytor 10 cytokine
CC receptor enables the production of recombinant cells expressing the
CC receptor. Those cells can then be used to detect the presence of a
CC modulator of zcytor10 protein by culturing the cells in the presence
CC of a test ligand and comparing levels of activity of mouse zcytor10
CC in the presence and absence of the test sample. Similarly, detection
CC of zcytor10 receptor ligand within a test sample can be achieved.
CC The method comprising contacting a test sample containing an amino
CC acid sequence from Cys15 or Gly25 to Pro230 of the zcytor 10
CC cytokine receptor and detecting the binding of the polypeptide to a
CC ligand in the sample. Specified peptide fragments of the zcytor 10
CC cytokine receptor and the methods described are used to identify
CC ligands that stimulate the proliferation and/or development of
CC haematopoietic, lymphoid and myeloid cells. Peptide fragments of
CC the cytokine receptor are useful for treating lymphoid, immune,
CC inflammatory, splenic, blood or bone disorders and for generating
CC antibodies directed against the receptor. An exemplary luciferase
CC mammalian expression vector is the K134 plasmid which was
CC constructed with two complementary oligonucleotides (AA54479,
CC AA54480) which comprise SPAT transcription factors from 4 genes
CC (a modified c-fos sis element, the p21 stei from the p21 WAF1
CC gene, the mammary gland response element of the beta-casein gene
CC and a STAT inducible element of the fcg RI gene.
XX
XX Sequence 100 BP; 26 A; 17 C; 33 G; 24 T; 0 other;
XX
XX Query Match 100.0%; Score 20; DB 22; Length 100;
XX Best Local Similarity 100.0%; Pred. NO. 4.8;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1 GTATTCCCGAGAAAAGAAC 20
XX ||||||||||||||||
XX 61 GTATTCCCGAGAAAAGAAC 42
XX
XX RESULT 11
XX ABA93801
XX ID ABA93801 standard; DNA; 100 BP.
XX AC
XX ABA93801;
XX
XX 01-MAY-2002 (first entry)
XX
XX K2134 plasmid construction oligonucleotide SEQ ID NO:43.
XX
XX zcytor17; chromosome 5; 5q11; cytokine receptor; immunomodulatory;
XX antiinflammatory; antiviral; antirheumatic; antiaerthritic; cytostatic;
XX muscular; lymphoid; immune; inflammatory; splenic; blood; bone;
XX infection; immunosuppression; cytotoxicity; leukopenia; Crohn's disease;
XX autoimmune disease; rheumatoid arthritis; multiple sclerosis; cancer;
XX inflammatory disease; pancreatitis; inflammatory bowel disease;
XX PCR primer; probe; ss.
XX
XX Synthetic.
XX
XX WO200200721-A2.
XX
XX 03-JAN-2002.
XX
XX 26-JUN-2001; 2001WO-US20484.
XX
XX 26-JUN-2000; 2000US-214282P.
XX 29-JUN-2000; 2000US-214953P.
XX
XX

```

XX	08-FEB-2001; 2001US-267963P.
PA	(ZYMO) ZYMOGENETICS INC.
PI	Sprecher CA, Presnell SR, Gao Z, Whitmore TE, Kujper JL,
PI	Maurer ME;
XX	
DR	WPI: 2002-090519/12.
XX	
PT	Isolated polynucleotide encoding a cytokine receptor zcytor17 which is
PT	useful for treating and diagnosing lymphoid, immune, inflammatory,
PT	splenic, blood or bone disorders -
XX	
PS	Example 19; Page 190; 235pp; English.
XX	
CC	The present invention describes a cytokine receptor designated zcytor17.
CC	Zcytor17 has immunomodulatory, antiinflammatory, antiviral, cytostatic,
CC	antitumetic, antiallergic and muscular activities. The zcytor17
CC	proteins are useful for treating and diagnosing lymphoid, immune,
CC	inflammatory, splenic, blood or bone disorders. Agonists or
CC	anti-zcytor17 antibodies are useful in stimulating cell-mediated
CC	immunity and for stimulating lymphocyte proliferation, such as in the
CC	treatment of infections involving immunosuppression, including certain
CC	vital infections. They are also useful for inducing cytotoxicity and
CC	for treating leukopenias. Antagonist of zcytor17 polypeptides are useful
CC	for treating autoimmune diseases (e.g. rheumatoid arthritis and multiple
CC	sclerosis), inflammatory diseases (e.g. Crohn's disease), cancer,
CC	pneocystitis, and inflammatory bowel disease. Zcytor17 was mapped to
CC	chromosome 5, specifically to the 5q11 chromosomal region. ABA93843 to
CC	ABA93843 and ABB05730 to ABB05745 represent sequences used in the
CC	exemplification of the present invention.
XX	
XQ	Sequence 100 BP; 24 A; 33 C; 17 G; 26 T; 0 other;
	Query Match 100.0%; Score 20; DB 24; Length 100;
	Best Local Similarity 100.0%; Pred. No. 4.8;
	Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY	1 GTATTTCCTCCAGAAAAGGAC 20
DB	44 GTATTTCCTCCAGAAAAGGAC 63
RESULT 12	
ABA93802/c	
ID	ABA93802 standard; DNA; 100 BP.
XX	
AC	ABA93802;
XX	
DT	01-MAY-2002 (first entry)
XX	
DE	K2134 plasmid construction oligonucleotide SEQ ID NO:44.
XX	
RW	Zcyto17; chromosome 5; 5q11; cytokine receptor; immunomodulatory;
RW	antiinflammatory; antiviral; antirheumatic; antiallergic; cytotstatic;
RW	mucular; lymphoid; immune; inflammatory; splenic; blood; bone;
RW	infection; immunosuppression; cytotoxicity; leukopenia; Crohn's disease;
RW	autoimmune disease; rheumatoid arthritis; multiple sclerosis; cancer;
RW	inflammatory disease; pancreatitis; inflammatory bowel disease;
RW	PCR primer; probe; ss.
XX	
OS	Synthetic.
XX	
FN	WO200200721-A2.
XX	
PD	03-JAN-2002.
XX	
PF	26-JUN-2001; 2001WO-US20484.
XX	
PR	26-JUN-2000; 2000US-214282P.
PR	29-JUN-2000; 2000US-214955P.
PR	08-FEB-2001; 2001US-267963P.
XX	

PA (ZYMO) ZYMOGENETICS INC.
XX Sprecher CA, Presnell SR, Gao Z, Whitmore TE, Kuijper JR;
PI Maurer MF;
XX WPI: 2002-090519/12.
DR Isolated polynucleotide encoding a cytokine receptor zcytor17 which is
XX useful for treating and diagnosing lymphoid, immune, inflammatory,
PT splenic, blood or bone disorders -
XX
XX Example 19; Page 190; 235pp; English.
XX The present invention describes a cytokine receptor designated zcytor17.
CC Zcytor17 has immunomodulatory, antiinflammatory, antiviral, cytostatic,
CC antineoplastic, antitumor and muscular activities. The zcytor17
CC proteins are useful for treating and diagnosing lymphoid, immune,
CC inflammatory, splenic, blood or bone disorders. Agonists or
CC anti-zcytor17 antibodies are useful in stimulating cell-mediated
CC immunity and for stimulating lymphocyte proliferation, such as in the
CC treatment of infections involving immunosuppression, including certain
CC viral infections. They are also useful for inducing cytotoxicity and
CC for treating leukopenias. Antagonist of zcytor17 polypeptides are useful
CC for treating autoimmune diseases (e.g. rheumatoid arthritis and multiple
CC sclerosis), inflammatory diseases (e.g. Crohn's disease), cancer,
CC pancreatitis, and inflammatory bowel disease. Zcytor17 was mapped to
CC chromosome 5, specifically to the 5q11 chromosomal region. ABA93767 to
CC ABA93843 and ABB05730 to ABB05745 represent sequences used in the
CC exemplification of the present invention.
XX
XX Sequence 100 BP; 26 A; 17 C; 33 G; 24 T; 0 other;
SQ
Query Match 100.0%; Score 20; DB 24; Length 100;
Best Local Similarity 100.0%; Pred. No. 4.8;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 GTATTTCACAGAAAGGAC 20
DB 61 GTATTTCACAGAAAGGAC 42
RESULT 13
AAS20691
ID AAS20691 standard; DNA; 100 BP.
XX
XX AAS20691;
AC
XX
XX 09-APR-2002 (first entry)
DT
XX
XX Plasmid K2 134 oligonucleotide ZC12749.
DE
XX
XX Cytokine; zalphal1 ligand; zalphal1 receptor; NK cell progenitor;
KW natural killer cell proliferation; T-cell proliferation;
KW B-cell proliferation; anti-tumour response; immune system;
KW Immunostimulant; cytostatic; primer; ss.
XX
XX Synthetic.
OS
XX
XX US6307024-B1.
PN
XX
XX 23-OCT-2001.
PD
XX
XX 09-MAR-2000; 2000US-0522217.
PF
XX
XX 09-MAR-1999; 99US-123547P.
PR 11-MAR-1999; 99US-123904P.
PR 01-JUL-1999; 99US-142013P.
XX
XX (ZYMO) ZYMOGENETICS INC.
PA
XX
XX Novak JE, Presnell SR, Sprecher CA, Foster DC, Holly RD, Gross JA;
PI Johnston JV, Nelson AJ, Dillon SR, Hammond AK;
XX

DR WPI: 2002-040208/05.
XX
XX New zalphal1 ligand polypeptides and polynucleotides, useful for
PT stimulating proliferation, activation, differentiation and/or induction
PT of inhibition of specialized cell function, or for stimulating an
PT antigenic response -
XX
XX Example 20; Column 149-150; 105pp; English.
XX The present invention relates to the isolation of a novel cytokine,
CC zalphal1 ligand and the polynucleotide encoding it. The invention
CC also gives the sequence for the zalphal1 receptor and the polynucleotide
CC encoding it. The zalphal1 ligand polypeptide stimulates proliferation of
CC natural killer (NK) cells or NK cell progenitors, the activation of NK
CC cells, proliferation of T-cells, proliferation of B-cells stimulated
CC with anti-CD40 antibodies, stimulates an antigenic response in a mammal,
CC and reduces proliferation of B-cells stimulated with anti-IGM antibodies.
CC The zalphal1 ligand polypeptide is also useful in preparing antibodies
CC that bind to zalphal1 ligand epitopes. The zalphal1 ligand
CC polynucleotides can be used as probes or primers to clone regions
CC of a zalphal1 ligand gene, and in gene therapy. Zalphal1 ligand may
CC also be used to identify inhibitors of its activity, to enhance the
CC generation of anti-tumour responses with or without the infusion of
CC donor lymphocytes, and to activate or stimulate the immune system.
CC The present sequence represents an oligonucleotide used to construct
CC plasmid K2 134 in the methods of the present invention.
XX
XX Sequence 100 BP; 25 A; 32 C; 17 G; 26 T; 0 other;
SQ
Query Match 100.0%; Score 20; DB 24; Length 100;
Best Local Similarity 100.0%; Pred. No. 4.8;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 GTATTTCACAGAAAGGAC 20
DB 44 GTATTTCACAGAAAGGAC 63
RESULT 14
AAS20692/C
ID AAS20692 standard; DNA; 100 BP.
XX
XX AAS20692;
AC
XX
XX 09-APR-2002 (first entry)
DT
XX
XX Plasmid K2 134 oligonucleotide ZC12748.
DE
XX
XX Cytokine; zalphal1 ligand; zalphal1 receptor; NK cell progenitor;
KW natural killer cell proliferation; T-cell proliferation;
KW B-cell proliferation; anti-tumour response; immune system;
KW Immunostimulant; cytostatic; primer; ss.
XX
XX Synthetic.
OS
XX
XX US6307024-B1.
PN
XX
XX 23-OCT-2001.
PD
XX
XX 09-MAR-2000; 2000US-0522217.
PF
XX
XX 09-MAR-1999; 99US-123547P.
PR 11-MAR-1999; 99US-123904P.
PR 01-JUL-1999; 99US-142013P.
XX
XX (ZYMO) ZYMOGENETICS INC.
PA
XX
XX Novak JE, Presnell SR, Sprecher CA, Foster DC, Holly RD, Gross JA;
PI Johnston JV, Nelson AJ, Dillon SR, Hammond AK;
XX
XX WPI: 2002-040208/05.
PT New zalphal1 ligand polypeptides and polynucleotides, useful for

PT stimulating proliferation, activation, differentiation and/or induction
 PT of inhibition of specialized cell function, or for stimulating an
 PT antigenic response -
 XX
 PS Example 20; Column 149-151; 105pp; English.
 XX
 CC The present invention relates to the isolation of a novel cytokine,
 CC zaiapha1 ligand and the polynucleotide encoding it. The invention
 CC also gives the sequence for the zaiapha1 receptor and the polynucleotide
 CC encoding it. The zaiapha1 ligand polypeptide stimulates proliferation of
 CC natural killer (NK) cells or NK cell progenitors, the activation of NK
 CC cells, proliferation of T-cells, proliferation of B-cells stimulated
 CC with anti-CD40 antibodies, stimulates an antigenic response in a mammal,
 CC and reduces proliferation of B-cells stimulated with anti-19m antibodies.
 CC The zaiapha1 ligand polypeptide is also useful in preparing antibodies
 CC that bind to zaiapha1 ligand epitopes. The zaiapha1 ligand
 CC polynucleotides can be used as probes or primers to clone regions
 CC of a zaiapha1 ligand gene, and in gene therapy. Zaiapha1 ligand may
 CC also be used to identify inhibitors of its activity, to enhance the
 CC generation of anti-tumour responses with or without the infusion of
 CC donor lymphocytes, and to activate or stimulate the immune system.
 CC The present sequence represents an oligonucleotide used to construct
 CC plasmid K2 134 in the methods of the present invention.
 CC
 XX
 SQ Sequence 100 BP; 26 A; 17 C; 32 G; 25 T; 0 other;

Query Match 100.0%; Score 20; DB 24; Length 100;
 Best Local Similarity 100.0%; Pred. No. 4.8;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTAATTCGAGAAAGAAC 20
 Db 61 GTAATTCGAGAAAGAAC 42

RESULT 15
 AAD22953

ID AAD22953 standard; DNA; 100 BP.

AC AAD22953;

DT 26-FEB-2002 (first entry)

DE Baf3/K2134/zaiapha1 cell line constructing ZC12.749 oligonucleotide.

XX zaiapha1; cytokine receptor; immunosuppressive; cytostatic; haemostatic;
 KW inflammatory disorder; cell proliferation; immune disorder; cancer; SLE;
 KW systemic lupus erythematosus; myasthenia gravis; rheumatoid arthritis;
 KW diabetes; autoimmune disease; multiple sclerosis; ulcerative colitis;
 KW inflammatory bowel disease; sepsis; Crohn's disease; viral infection;
 KW asthma; ss.

XX Unidentified.

PN WO200177171-A2.

PD 18-OCT-2001.

PF 03-APR-2001; 2001WO-US10872.

PR 05-APR-2000; 2000US-194731P.

PR 28-JUL-2000; 2000US-222121P.

XX (ZYMO) ZYMOGENETICS INC.

PI Sprecher CA, Novak JE, West JW, Presnell SR, Holly RD, Nelson AJ;

DR WPI; 2002-025898/03.

XX Novel soluble receptor polypeptides and polynucleotides used as
 PT cytokine antagonist for stimulating ligand activity-induced
 PT proliferation of hematopoietic cells and for suppressing immune
 PT response in a mammal -

XX
 PS Example 19; Page 213; 243pp; English.
 XX

CC The invention relates to an isolated soluble zaiapha1 cytokine receptor
 CC polypeptide and their cDNA molecules. Zaiapha proteins are useful for
 CC inhibiting or antagonizing the ligand activity-induced proliferation of
 CC hematopoietic cells and hematopoietic cell progenitors preferably
 CC lymphoid cells which are natural killer cells or cytotoxic T cells.
 CC Zaiapha is useful for treating immune and inflammatory disorders, for
 CC reducing proliferation of neoplastic B or T cells, for suppressing an
 CC immune response in a mammal exposed to an antigen or pathogen. Zaiapha is
 CC useful for treating diseases that require immune regulation including
 CC autoimmune diseases such as rheumatoid arthritis, multiple sclerosis,
 CC myasthenia gravis, systemic lupus erythematosus (SLE) and diabetes;
 CC asthma, ulcerative colitis, inflammatory bowel disease, Crohn's disease,
 CC sepsis, viral infection (dengue virus infection) and cancer. The present
 CC sequence is an oligonucleotide used for Baf3/K2134/zaiapha1 cell line
 CC construction.

XX
 SQ Sequence 100 BP; 24 A; 33 C; 17 G; 26 T; 0 other;

Query Match 100.0%; Score 20; DB 24; Length 100;
 Best Local Similarity 100.0%; Pred. No. 4.8;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTAATTCGAGAAAGAAC 20
 Db 44 GTAATTCGAGAAAGAAC 63

Search completed: June 26, 2003, 12:16:35
 Job time : 229.158 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 26, 2003, 09:56:18 ; Search time 1028.48 Seconds

(without alignments)
565.939 Million cell updates/sec

Title: US-09-355-254F-16

Perfect score: 20

Sequence: 1 gtcacatcccgtaactct 20

Scoring table: IDENTITY_NTC

Searched: 2054640 segs, 14551402878 residues

Total number of hits satisfying chosen parameters: 4109280

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Database :

Listing first 45 summaries

GenBank:*

1: gb_ba:*

2: gb_hcg:*

3: gb_in:*

4: gb_om:*

5: gb_ov:*

6: gb_pat:*

7: gb_ph:*

8: gb_pl:*

9: gb_pr:*

10: gb_ro:*

11: gb_sts:*

12: gb_sy:*

13: gb_un:*

14: gb_vi:*

15: em_ba:*

16: em_fun:*

17: em_hum:*

18: em_in:*

19: em_mu:*

20: em_om:*

21: em_or:*

22: em_ov:*

23: em_pat:*

24: em_ph:*

25: em_pl:*

26: em_ro:*

27: em_sts:*

28: em_un:*

29: em_vi:*

30: em_hcg_hum:*

31: em_hcg_iny:*

32: em_hcg_other:*

33: em_hcg_mus:*

34: em_hcg_pln:*

35: em_hcg_rtd:*

36: em_hcg_mam:*

37: em_hcg_vrt:*

38: em_sy:*

39: em_hcg_hum:*

40: em_hcg_mus:*

41: em_hcg_other:*

Pred. No. is the number of results predicted by chance to have a

score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	20	100.0	20	6	A89795
2	20	100.0	20	6	A89882
3	20	100.0	20	6	AA55587
4	19	95.0	123291	6	AC104070
5	17.4	87.0	22	6	AX040434
6	17.4	87.0	105428	2	AC094579
7	17.4	87.0	164383	2	AC127444
8	17	85.0	19	6	181948
9	16.8	84.0	2274	1	AF498313
10	16.8	84.0	35409	3	CEC44C10
11	16.8	84.0	36727	9	AL512289
12	16.8	84.0	37154	3	AF025467
13	16.8	84.0	71198	2	AC127624
14	16.8	84.0	76922	5	AC087104
15	16.8	84.0	95594	2	AC122615
16	16.8	84.0	96075	2	AC018294
17	16.8	84.0	97242	8	AC051630
18	16.8	84.0	97310	2	AC103083
19	16.8	84.0	107658	2	AC119592
20	16.8	84.0	108713	2	AC108963
21	16.8	84.0	110000	2	CEX11182.2
22	16.8	84.0	115530	2	AC120980
23	16.8	84.0	115984	9	HS292F10
24	16.8	84.0	127695	2	AC111722
25	16.8	84.0	139838	2	AL357652
26	16.8	84.0	141908	2	AC123282
27	16.8	84.0	142157	2	AC102412
28	16.8	84.0	146056	2	AC128899
29	16.8	84.0	152854	2	AC110514
30	16.8	84.0	159933	2	AC109935
31	16.8	84.0	164583	2	AC098073
32	16.8	84.0	165454	2	AC113097
33	16.8	84.0	169620	2	AC012674
34	16.8	84.0	169656	2	AC097292
35	16.8	84.0	173548	2	AC094369
36	16.8	84.0	173906	2	AC121059
37	16.8	84.0	177786	2	AC093609
38	16.8	84.0	179260	3	AC007770
39	16.8	84.0	182730	2	AC016735
40	16.8	84.0	184258	2	AC117231
41	16.8	84.0	184380	10	AC124521
42	16.8	84.0	192761	2	AC125874
43	16.8	84.0	196785	2	AC120065
44	16.8	84.0	199289	9	AC012378
45	16.8	84.0	236774	2	AL772275

ALIGNMENTS

RESULT 1

A89795 LOCUS 20 bp DNA linear PAT 22-JAN-2000

DEFINITION Sequence 17 from Patent WO9832462.

ACCESSION A89795

VERSION A89795.1 GI:6738309

KEYWORDS

SOURCE unidentified.

ORGANISM unclassified.

REFERENCE 1 (bases 1 to 20)

AUTHORS Lipford, G.B. and Heeg, K.

TITLE PHARMACEUTICAL COMPOSITIONS COMPRISING A POLYNUCLEOTIDE AND

JOURNAL OPTIONALLY AN ANTIGEN ESPECIALLY FOR VACCINATION

Patent: WO 9832462-A 17 30-JUL-1998;

FEATURES LIPFORD GRAYSON B (DE); HEBG KLAUS (DE)
 Source Location/Qualifiers
 1..20
 /organism="unidentified"
 /db_xref="taxon:32644"

BASE COUNT 4 a 6 c 2 g 8 t

ORIGIN

Query Match 100.0%; Score 20; DB 6; Length 20;
 Best Local Similarity 100.0%; Pred. No. 6;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTCATTTCGGTAATCTT 20
 |||||
 1 GTCATTTCGGTAATCTT 20

DB 1 GTCATTTCGGTAATCTT 20

RESULT 2

LOCUS A90882 20 bp DNA linear PAT 22-JAN-2000
 DEFINITION Sequence 17 from Patent EP0855184.
 ACCESSION A90882
 VERSION A90882.1 GI:6739307
 KEYWORDS
 SOURCE unidentified.
 ORGANISM unidentified.
 REFERENCE 1 (bases 1 to 20)
 Heeg, K.P. and Lipford, G.B.
 Pharmaceutical composition comprising a polynucleotide and an
 antigen especially for vaccination
 Patent: EP 0855184-A 17 29-JUL-1998;
 JOURNAL HEBG KLAUS PROF DR (DE); LIPFORD GRAYSON B DR (DE)
 TITLE Location/Qualifiers
 1..20
 /organism="unidentified"
 /db_xref="taxon:32644"

BASE COUNT 4 a 6 c 2 g 8 t

ORIGIN

Query Match 100.0%; Score 20; DB 6; Length 20;
 Best Local Similarity 100.0%; Pred. No. 6;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTCATTTCGGTAATCTT 20
 |||||
 1 GTCATTTCGGTAATCTT 20

DB 1 GTCATTTCGGTAATCTT 20

RESULT 3

LOCUS AX455587 20 bp DNA linear PAT 06-JUL-2002
 DEFINITION Sequence 64 from Patent WO0222809.
 ACCESSION AX455587
 VERSION AX455587.1 GI:21714655
 KEYWORDS
 SOURCE synthetic construct.
 ORGANISM synthetic construct.
 REFERENCE 1
 Bauer, S., Lipford, G. and Wagner, H.
 Process for high throughput screening of cpg-based
 immuno-agonist/antagonist
 Patent: WO 0222809-A 64 21-MAR-2002;
 JOURNAL Coley Pharmaceutical GmbH (DE)
 TITLE Location/Qualifiers
 1..20
 /organism="synthetic construct"
 /db_xref="taxon:32630"
 /note="Synthetic oligonucleotide"

BASE COUNT 4 a 6 c 2 g 8 t

ORIGIN

Query Match 100.0%; Score 20; DB 6; Length 20;
 Best Local Similarity 100.0%; Pred. No. 6;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTCATTTCGGTAATCTT 20
 |||||
 1 GTCATTTCGGTAATCTT 20

DB 1 GTCATTTCGGTAATCTT 20

RESULT 4

LOCUS AC104070 123291 bp DNA linear PRI 29-MAY-2002
 DEFINITION Homo sapiens BAC clone RP11-279K24 from 4, complete sequence.
 ACCESSION AC104070 AC068461
 VERSION AC104070.3 GI:20279508
 KEYWORDS HTG.
 SOURCE Homo sapiens.
 ORGANISM Homo sapiens.
 REFERENCE 1
 Mammalia; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
 1 (bases 1 to 123291)
 Sulston, J.E. and Waterston, R.
 TITLE Howard, a complete human genome sequence
 JOURNAL Genome Res. 8 (11), 1097-1108 (1998)
 MEDLINE 99063792
 PUBMED 9847074

REFERENCE 2 (bases 1 to 123291)
 Desai, A., Kozlowicz, A. and Boyer, E.
 The sequence of Homo sapiens BAC clone RP11-279K24
 Unpublished (2001)
 3 (bases 1 to 123291)
 Waterston, R.H.
 REFERENCE 3
 Direct Submission
 Submitted (03-DEC-2001) Genome Sequencing Center, Washington
 University School of Medicine, 4444 Forest Park Parkway, St. Louis,
 MO 63108, USA
 4 (bases 1 to 123291)
 Waterston, R.H.
 REFERENCE 4
 Direct Submission
 Submitted (24-APR-2002) Genome Sequencing Center, Washington
 University School of Medicine, 4444 Forest Park Parkway, St. Louis,
 MO 63108, USA
 5 (bases 1 to 123291)
 Waterston, R.
 REFERENCE 5
 Direct Submission
 Submitted (29-MAY-2002) Department of Genetics, Washington
 University, 4444 Forest Park Avenue, St. Louis, Missouri 63108, USA
 On Apr 24, 2002 this sequence version replaced gi:18030153.

COMMENT

Genome Center
 Center: Washington University Genome Sequencing Center
 Center code: WUGSC
 Web site: http://genome.wustl.edu/gsc
 Contact: sapliens@wustl.edu
 Summary Statistics
 Center project name: H_NH0279K24
 Drafting Center: WIBR

NOTICE: This sequence may not represent the entire insert of this clone. It may be shorter because we only sequence overlapping clone sections once, or longer because we provide a small overlap between neighboring data submissions.

This sequence was finished as follows unless otherwise noted:
 all regions were double stranded, sequenced with an alternate chemistry or covered by high quality data (i.e., phred quality >= 30); an attempt was made to resolve all sequencing problems, such as compressions and repeats; all regions were covered by sequence from more than one subclone; and the assembly was confirmed by restriction digest.

MAPPING INFORMATION:
 Mapping information for this clone was provided by Dr. John D.

Nov, 98.

McPherson, Department of Genetics, Washington University, St. Louis MO. For additional information about the map position of this sequence, see <http://genome.wustl.edu/gsc>

SOURCE INFORMATION: The RPEC-11 human PAC library was made from the blood of one male donor, as described by Oosagawa, K., Moon, P.Y., Zhao, B., Frengen, E., Rateno, M., Camnache, J.-J. and de Jong, P.J. (1998). An improved approach for construction of bacterial artificial chromosome libraries. *Genetics* 51:1-8. The clone may be obtained either from Resgen Genetics, Inc. (<http://www.resgen.com>) or Pieter de Jong and coworkers at <http://www.chori.org>
VECTOR: pBAC3.6

NEIGHBORING SEQUENCE INFORMATION:
The clone sequenced to the left is Rp11-45120, 2000 bp overlap; the
clone sequenced to the right is Rp11-173M11. Actual start of this
clone sequenced to the right is 108871 of Rp11-45120; actual end is at
clone 15 at base position 123291 of Rp11-279624.

base position. Unresolved tandem repeats exist between 44681 and 46316. AC0110771 was used to finish AC104070. Data polymorphisms exist between AC096659, AC0110771 and AC104070.

from AC1107/1 was used in the study. It has been incorporated into AC104070.

The sequence of AC008102
location/qualifiers

```

FEATURES
source
1. .123291
/organism="Homo sapiens"
0606"

```

```
repeat_region    174..350      /rpt_family="MERI_type  
repeat_region    1085..1129     /rpt_family="(CA)n"  
repeat_region    2938..3252     /rpt_family="Alu"  
repeat_region    3691..3908     /rpt_family="L2"  
repeat_region    4040..4334     /rpt_family="Alu"  
repeat_region    4345..4322     /rpt_family="Alu"  
repeat_region    4525..5166     /rpt_family="ERV1"  
repeat_region    5269..5343     /rpt_family="MIR"  
repeat_region    5469..5535     /rpt_family="MIR"  
repeat_region    5866..6417     /rpt_family="ERV_L"  
repeat_region    7027..7321     /rpt_family="L2"  
repeat_region    7331..7424     /rpt_family="L2"  
repeat_region    7535..7724     /rpt_family="ERV1"  
repeat_region    7739..8079     /rpt_family="ERV1"  
repeat_region    11056..11367   /rpt_family="ERV1"  
repeat_region    12482..12789   /rpt_family="Alu"  
repeat_region    12790..12814   /rpt_family="Alu"  
repeat_region    13276..13375   /rpt_family="AT-rich"  
repeat_region    13504..13774   /rpt_family="L2"  
repeat_region    13776..14086   /rpt_family="L1"  
repeat_region    13776..14086   /rpt_family="Alu"
```

```

repeat_region      14090..14277      /rpt_family="L1"
repeat_region      14307..14427      /rpt_family="L1"
repeat_region      14642..14709      /rpt_family="U4"
repeat_region      14802..14883      /rpt_family="CT-rich"
repeat_region      15149..15220      /rpt_family="ERV1"
repeat_region      15221..15419      /rpt_family="MALR"
repeat_region      15420..16124      /rpt_family="ERV1"
repeat_region      16124..16356      /rpt_family="MALR"
repeat_region      16357..16729      /rpt_family="ERV1"
repeat_region      16730..17029      /rpt_family="Alu"
repeat_region      17030..17494      /rpt_family="ERV1"
repeat_region      17517..17607      /rpt_family="L2"
repeat_region      18972..19151      /rpt_family="ERV1"
repeat_region      19204..19453      /rpt_family="ERV1"
repeat_region      19564..19640      /rpt_family="GA-rich"
repeat_region      20193..21044      /rpt_family="ERV1"
repeat_region      21501..21793      /rpt_family="Alu"
repeat_region      23724..23747      /rpt_family="AT-rich"
repeat_region      24122..24419      /rpt_family="Alu"
repeat_region      24525..24920      /rpt_family="MALR"
repeat_region      25364..25788      /rpt_family="ERV1"
repeat_region      26725..27020      /rpt_family="Alu"
repeat_region      27333..27551      /rpt_family="MIR"
repeat_region      28646..28951      /rpt_family="Alu"
repeat_region      28952..29088      /rpt_family="Alu"
repeat_region      29204..29740      /rpt_family="L1"
repeat_region      29741..30050      /rpt_family="Alu"
repeat_region      30051..30244      /rpt_family="L1"
repeat_region      30245..30462      /rpt_family="Alu"
repeat_region      30463..30556      /rpt_family="L1"
repeat_region      30733..30767      /rpt_family="U2"
repeat_region      30768..30845      /rpt_family="L1"
repeat_region      32081..32145

Query Match      95.0%: Score 19; DB 9; Length 123291;
Best Local Similarity 100.0%: Pred. No. 60; 0; Indels 0; Gaps 0
Matches 19; Conservative

```


9846	11154:	contlg of 1309 bp in length
11135	11154:	gap of unknown length
11235	12679:	contlg of 1425 bp in length
12680	12771:	gap of unknown length
12780	12771:	contlg of 1002 bp in length
13782	13881:	gap of unknown length
13882	13881:	contlg of 1606 bp in length
15488	15587:	gap of unknown length
15588	15587:	contlg of 1667 bp in length
17255	17354:	gap of unknown length
17255	17354:	contlg of 1567 bp in length
17922	18921:	contlg of 1567 bp in length
18922	19021:	gap of unknown length
19022	20501:	gap of unknown length
20402	21923:	contlg of 1422 bp in length
20502	22023:	gap of unknown length
21924	23458:	contlg of 1435 bp in length
22024	23558:	gap of unknown length
23459	24766:	contlg of 1208 bp in length
23559	24766:	gap of unknown length
24767	24867:	contlg of 1340 bp in length
24867	24866:	gap of unknown length
26207	26306:	gap of unknown length
26307	27501:	contlg of 1195 bp in length
27502	27601:	gap of unknown length
27602	29140:	contlg of 1439 bp in length
29041	29140:	gap of unknown length
29141	30123:	contlg of 1073 bp in length
30214	30313:	gap of unknown length
30314	32113:	contlg of 1800 bp in length
32114	32213:	gap of unknown length
32214	33713:	contlg of 1400 bp in length
33714	33713:	gap of unknown length
33714	33543:	contlg of 1830 bp in length
35544	35643:	gap of unknown length
35544	35643:	contlg of 1822 bp in length
35644	37465:	gap of unknown length
37466	37565:	gap of unknown length
37566	39308:	contlg of 1743 bp in length
39309	39408:	gap of unknown length
39409	41144:	contlg of 1736 bp in length
41145	41144:	contlg of unknown length
41245	43290:	gap of unknown length
43290	43290:	contlg of 1946 bp in length
43291	44853:	gap of unknown length
44853	44853:	contlg of 1563 bp in length
44854	46524:	contlg of 1571 bp in length
44954	46524:	contlg of unknown length
46525	48160:	contlg of 1536 bp in length
46525	48160:	contlg of unknown length
48161	48260:	gap of unknown length
48261	49738:	contlg of 1478 bp in length
49739	49838:	gap of unknown length
49839	51496:	contlg of 1658 bp in length
51497	51596:	gap of unknown length
51597	53511:	contlg of 1915 bp in length
53512	53611:	gap of unknown length
53612	54616:	contlg of 1005 bp in length
54617	54716:	gap of unknown length
54717	55994:	contlg of 1278 bp in length
55995	56094:	gap of unknown length
56095	57817:	contlg of 1723 bp in length
57818	57817:	contlg of 1320 bp in length
57918	59337:	contlg of unknown length
59238	59337:	gap of unknown length
59338	61841:	contlg of 2504 bp in length
59342	61841:	gap of unknown length
61842	61941:	gap of unknown length
61942	63171:	contlg of 1230 bp in length
63172	63271:	gap of unknown length
63272	64768:	contlg of 1497 bp in length
64769	64868:	gap of unknown length
64869	66113:	contlg of 1245 bp in length
66114	66213:	gap of unknown length
66214	67915:	contlg of 1702 bp in length
67916	68015:	gap of unknown length
68016	69570:	contlg of 1555 bp in length

	*	69571	69670:	gap of unknown length	
	*	69671	72019:	contig of 2349 bp in length	
	*	72020	72119:	gap of unknown length	
	*	72120	74669:	contig of 2550 bp in length	
	*	74670	74769:	gap of unknown length	
	*	74770	76723:	contig of 1954 bp in length	
	*	76724	76823:	gap of unknown length	
	*	76824	80072:	contig of 3249 bp in length	
	*	80073	80172:	gap of unknown length	
	*	80173	82228:	gap of 2056 bp in length	
	*	82229	82328:	gap of unknown length.	
	*	82329	85455:	contig of 3127 bp in length	
	*	85456	85555:	gap of unknown length	
	*	85556	88149:	contig of 2594 bp in length	
	*	88150	88249:	gap of unknown length	
	*	88250	91553:	contig of 3304 bp in length	
	*	91554	91653:	gap of unknown length	
	*	91654	94432:	contig of 2779 bp in length	

	87.0%:	Score 17.4:	DB 2:	length 105428;	
	Best Local Similarity	94.7%:	Pred. No. 4.2e+02;		
	Matches 18:	Conservative	0:	Mismatches 1:	Indels 0:
	Gaps				

OY	2	TCCATTCCCGTAACCTT	20			96443
DB		TCCATTCGCCGTAACTTT				

RESULT	7
ACI127444/c	
LOCUS	
DEFINITION	ACI127444 Rattus norvegicus clone CH20-25dF10.
ACCESION	ACI127444
VERSION	ACI127444.2 GI:21953857
KEYWORDS	HMG; HTGS; PHASEL.
SOURCE	Norway rat.
ORGANISM	Rattus norvegicus
REFERENCE	Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
AUTHORS	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae;
	Ratus. 1 (bases 1 to 164383) Adio-Onoduola,B., Ali-osman,F.R., Allen,C., Munzy,D.M., Adams,C.C., Are,J.R., Ayele,K., Banks,T., Alshrooks,S.L., Amaratunga,H.C., Arc,J.R., Ayalew,K., Bonnin,D.P., Blankenburg,K., Blankenburg,K., Bonnin,D.P.,
	DNA linear HVG 31-JULY-2000 *** SEQUENCING IN PROGRESS

Barbaria, J., Benton, J., Bamey, Brown, E., Brown, M., Bryan, ...
Bouch, J., Bowle, S., Birleva, M., Burkett, C., Burrell, K. L., Byrd, N. C.,
Bunyah, C., Burch, P., Burkett, C., Burrell, K. L., Chavez, D.,
Carroll, T. F., Carter, M., Cavazos, S. R., Chacko, J., Chavez, D.,
Chen, G., Chen, R., Chen, Z., Chowdhury, I., Christopoulos, C.,
Cleveland, C. D., Cox, C., Coyle, M. D., Dathorne, S. R., David, R.,
Devilla, M. L., Davis, C., Davy-Carroll, L., Decker, D. A.,
Delaney, K. R., Delgado, O., Denn, A. L., Ding, Y., Dinh, H. H.,
Douthwaite, K. J., Draper, H., Dugan-Rocha, S., Durbin, R. J.,
Eberhart, C., Edgar, D., Edwards, C. C., Elhaj, C., Escotto, M.,
Falls, T., Ferraguto, D., Flagg, N., Ford, J., Foster, P., Franz, P.,
Gao, J., Garcia, A., Garner, T., Garza, N., Gill, R.,
Gibbs, A., Guevara, W., Gunaratne, P., Hale, S., Hamilton, R.,
Gorell, J. H., Guevara, W., Gunaratne, P., Hawes, A., Hernandez, J.,
Harris, C., Harris, K., Hart, M., Havak, P., Hawes, A., Hernandez, J.,
Harris, C., Hodgson, A., Hognes, M., Holloway, C., Hollins, L. E.,
Hernandez, O., Hodgson, A., Huber, J., Huliy, S., Hume, J.,
Homs, F., Howard, S., Johnson, R., Jolivet, S., Joudah, S.,
Jacobson, B., Jia, T., Khan, U., King, L., Korvan, J., Kovar, C.,
Karlsson, E., Kelly, S., Khan, U., Leal, B., Lewis, J. C., Lewis, L.,
Kratovic, J., Kureshi, A., Landry, N., Leal, B., Liu, J., Liu, W.,
Li, J., Li, Z., Lichtarge, O., Lien, C., Liu, J., Liu, W.,
Lozano, R. J., Lu, X., Lucier, A., Lucier, R., Luna, R., Ma, J.,
Maheshwari, M., Mapua, P., Mattin, R., Mendro, M., Mel, G., Metzger, M.,
Massey, E., Miner, Z., Mitchell, T., Monabbat, K., Morgan, M., Morris, S.,
Moser, M., Neal, D., Newton, J., Newton, N., Nguyen, A., Nguyen, N.,
Nguyen, N., Nickerson, E., Nwokenkwo, S., Ogun, W., Okunnu, G.,
Oragunye, N., Oviedo, R., Pace, A., Payton, B., Peery, J., Perez, L.,
Peters, L., Pickens, R., Plimue, E., Pu, L. L., Quiles, M., Ren, Y.,
Rives, M., Rojas, A., Rojudoan, I., Rolfe, M., Ruiz, S., Saverly, G.,

Scherer, S., Scott, G., Shen, H., Shooshari, N., Sisson, I.,
 Sodergren, E., Sonke, T., Sparks, A., Stanley, H., Stone, H.,
 Sutton, A., Swalek, A., Tabor, P., Tamerisa, A., Tamerisa, K., Tang, H.,
 Tansey, J., Taylor, C., Taylor, T., Telford, B., Thomas, N., Thomas, S.,
 Uemami, K., Vasquez, L., Vera, V., Villalob, D., Vlasov, R., Wang, O.,
 Wang, S., Ward-Moore, S., Warren, R., Washington, C., Wellington, S.,
 Williams, C., Williamson, A., Wleczek, R., Wooden, S., Worley, K.,
 Wu, C., Wu, Y., Wu, Y., Zhou, J., Zorilla, S., Nelson, D.,
 Weinstein, G., and Gibbs, R.,
 Direct Submission
 Unpublished
 2 (bases 1 to 164383)
 Morley, K.C.
 Direct Submission
 Submitted (17-JUL-2002) Human Genome Sequencing Center, Department
 of Molecular and Human Genetics, Baylor College of Medicine, One
 Baylor Plaza, Houston, TX 77030, USA
 3 (bases 1 to 164383)
 Morley, K.C.
 Direct Submission
 Submitted (31-JUL-2002) Human Genome Sequencing Center, Department
 of Molecular and Human Genetics, Baylor College of Medicine, One
 Baylor Plaza, Houston, TX 77030, USA
 On Jul 24, 2002 this sequence version replaced gi:21866827.
 ----- Genome Center
 Center: Baylor College of Medicine
 Center code: BCM
 Web site: <http://www.hgsc.bcm.tmc.edu/>
 Contact: hgsc-help@bcm.tmc.edu/
 ----- Project Information
 Center project name: GNRV
 Center clone name: CH230-254F10
 ----- Summary Statistics
 Sequencing vector: Plasmid:
 Chemistry: Dye-terminator Big Dye: 100% of reads
 Assembly program: Phrap: version 0.990329
 Consensus quality: 110846 bases at least Q40
 Consensus quality: 116562 bases at least Q30
 Consensus quality: 120375 bases at least Q20

* NOTE: Estimated insert size may differ from sequence length
 * (see http://www.hgsc.bcm.tmc.edu/docs/genbank_draft_data.html).
 * NOTE: This is a 'working draft' sequence. It currently
 * consists of 58 contigs. The true order of the pieces
 * is not known and their order in this sequence record is
 * arbitrary. Gaps between the contigs are represented as
 * runs of N, but the exact sizes of the gaps are unknown.
 * This record will be updated with the finished sequence
 * as soon as it is available and the accession number will
 * be preserved.

1
 1068: contig of 1068 bp in length
 1169 1168: gap of unknown length
 2251 2250: contig of 1082 bp in length
 2351 3542: gap of unknown length
 3543 3542: contig of 1192 bp in length
 3643 3642: gap of unknown length
 4662 4661: contig of 1019 bp in length
 4762 4761: gap of unknown length
 5959 5958: contig of 1197 bp in length
 6059 6058: gap of unknown length
 7098 7097: contig of 1039 bp in length
 7198 7197: gap of unknown length
 8624 8623: contig of 1426 bp in length
 8724 8723: gap of unknown length
 10323 10322: contig of 1599 bp in length
 10423 10422: gap of unknown length
 11683 11682: contig of 1260 bp in length
 11783 11782: gap of unknown length
 13597 13597: contig of 1815 bp in length
 13698 13697: gap of unknown length
 14895 14894: contig of 1197 bp in length
 14995 14994: gap of unknown length
 16266: contig of 1272 bp in length

16267 16266: gap of unknown length
 16367 16366: contig of 1217 bp in length
 17584 17583: gap of unknown length
 17684 17683: contig of 1159 bp in length
 18853 18852: gap of unknown length
 18953 18952: contig of 1947 bp in length
 20900 20999: gap of unknown length
 21000 22340: contig of 1341 bp in length
 22341 22440: gap of unknown length
 22441 23863: contig of 1423 bp in length
 23864 23963: gap of unknown length
 23964 25333: contig of 1370 bp in length
 25334 25434: gap of unknown length
 25434 27590: contig of 2157 bp in length
 27591 30206: gap of unknown length
 30207 30306: gap of unknown length
 30307 32494: contig of 2187 bp in length
 32494 32594: gap of unknown length
 32594 34681: contig of 2088 bp in length
 34682 34781: gap of unknown length
 34782 36994: contig of 2213 bp in length
 36995 37094: gap of unknown length
 37095 38293: contig of 1199 bp in length
 38294 38393: gap of unknown length
 38394 40151: contig of 1758 bp in length
 40152 40252: gap of unknown length
 40252 43157: contig of 2906 bp in length
 43158 43257: gap of unknown length
 43258 44696: contig of 1438 bp in length
 44696 44795: gap of unknown length
 44795 47433: contig of 2637 bp in length
 47433 47533: gap of unknown length
 47533 49807: contig of 2275 bp in length
 49808 49907: gap of unknown length
 49908 52733: contig of 2825 bp in length
 52733 52833: gap of unknown length
 52833 54683: contig of 1850 bp in length
 54683 54782: gap of unknown length
 54782 57133: contig of 2350 bp in length
 57133 57233: gap of unknown length
 57233 59754: contig of 2521 bp in length
 59754 59854: gap of unknown length
 59854 63234: gap of unknown length
 63235 63334: contig of 3381 bp in length
 63335 66353: contig of 2919 bp in length
 66354 66534: gap of unknown length
 66534 69879: contig of 3526 bp in length
 69880 72675: gap of unknown length
 72676 72775: gap of unknown length
 72775 75756: gap of unknown length
 75756 79291: contig of 2981 bp in length
 79291 79391: contig of 3434 bp in length
 79391 83502: gap of unknown length
 83503 83602: contig of 4112 bp in length
 83603 85786: gap of unknown length
 85786 85885: gap of unknown length
 85885 89741: contig of 3856 bp in length
 89741 93885: gap of unknown length
 93885 97426: gap of unknown length
 97426 97526: contig of 3541 bp in length
 97527 101477: gap of unknown length
 101478 101577: contig of 3951 bp in length
 101578 104361: gap of unknown length
 104362 104461: gap of unknown length
 104462 108173: contig of 2784 bp in length
 108174 108273: contig of 3712 bp in length
 108274 112365: gap of unknown length
 112366 112465: contig of 4092 bp in length
 112466 gap of unknown length

[illegible]

gene
DS
gene
DS

gene="comb"
13.. 1452
/gene="comb"
/odon_start=1
/transl_table=1
/product="histidine kinase Comb"
/protein_id="AA18090.1"
/db_xref="GI:20269893"
translation="MDLKLITVLIHLILNNSYELICKATKREYLFISWTIIOI
FVLLFVLIHOLGEMKISFCILFVYLVGKPKNKRAFLFISLISLVOSTHRA
VILFISLGSFSEIKEDYLFVYVMDYATVIRKIFIEHFIYEDKDLSPFPRAT
FAFALHILFISDMVNIHFIISFSSITATVFCILLFEMNDAKQVILKINAT
OKRECHQLOFTYDELVALYELISGSPHRYACMLMSDKRQEDIRITLSDIL
KANOKESDXYETFLDINNIEDTALSLIOSIVYVRNDEFTLEVDKLTISLIDIL
DLVIRNGLVILNNVVECAASYSKQENFVATIKDLEIVDIONSKTMMPSDLELQ
PSTRGNNGIGLNNVEILDOENILLETMEDSKFROIIRKREF"

1453.. 2205
/gene="comb"
1453.. 2205
/gene="comb"

Oy 1 GTCCATTTCGCCGTAATCTT 20
 ||| ||||| ||||| |||
 Db 936 GTCATTTTCCTGTAAATCTT 91

REFERENCE AUTHORS TITLE JOURNAL MEDLINE REMARK REFERENCE AUTHORS TITLE JOURNAL	
1 none. Genome sequence of the nematode <i>C. elegans</i> : a platform for investigating biology. The <i>C. elegans</i> Sequencing Consortium Science 282 (5396), 2012-2018 (1998) 99069613 The <i>C. elegans</i> Sequencing Consortium. 2 (bases 1 to 35409) Cottage/A. Submitted (28-FEB-1996) Nematode Sequencing Project, Sanger Institute, Hinxton, Cambridge CB10 1SA, England and Department of	

gene
KSPESPAQFLMCRPPLVPSVAIIINDPNNRNDVCYHAENASLFPNSFVIGHCY
NCLTLRFV
join(177408..7548,7641..7883)
/gene="C44C10.10"
join(7408..7548,7641..7883)
/gene="C44C10.10"
note="Similarity to Bacillus subtilis DNA repair protein
REC4 (SW:REC4_BACSU)"
/codon_start=1
/protein_id="CAA93640.1"
/db_xref="GI:3874982"
/translation="MDPRITRRKCKCTFTFALSTTHETLYLPPLSMASGGFTIKL
ISMOLLSIVKNNKCLDEYKESFGKTTTTPGNCGSALVRAIGLITDEVTES
SNOQAVRGKTYKNNPMLVWSFPPK"
join(8203..8384,8502..8580,8700..8949,9003..9061,
9106..9306,9404..9550)
/gene="C44C10.5"
join(8203..8384,8502..8580,8700..8949,9003..9061,
9106..9306,9404..9550)
/gene="C44C10.5"
note="Similarity to Yeast chromosome segregation protein
SMC-1 (SW:SMC1_YEAST)"
/codon_start=1
/protein_id="CAA93639.1"
/db_xref="GI:3874981"
/db_xref="SPTREMBL:O18617"
/translation="MVNLRKTYEELRELDITLRYHGRTLSYSSSKVTQDVAED
ALAKAPALFJDSIEHKPKLPTLNDLERSKLEKLTQYKLTINAKSOKRVTQDVAED
ODLDPAKEAGTGFYDKRDISSLDEKESNDALFVKNHLLTQQAQGRKTIKAVTL
VGRVATRESDPDSTYSLASSNEDPEYC"
join(10560..10757,10802..11290,11372..11609,11658..11716,
11765..11968,12057..12377,12582..12686)
/gene="C44C10.4"
join(10560..10757,10802..11290,11372..11609,11658..11716,
11765..11968,12057..12377,12582..12686)
/gene="C44C10.4"
note="Similarity to Yeast chromosome segregation protein
CNA HSI EMBL:BJ138908 comes from this gene"
/codon_start=1
/protein_id="CAA93638.2"
/db_xref="GI:2265835"
/db_xref="SPTREMBL:O18616"
/translation="MTYPOORLLITVDILNFKCYOHKSGPDDHTTIGNGGKSI
MTEINAVFEGEDLPDRKNPNHNLHYDYNIFNCYVSLKPFMPGSRKTRIGLTYSTI
EPEKYEDELKAKINPESVLYNMAKMDISIVYKTKLTATRSALSAEAFDVAISNI
FVAQLTVNAKNAKMDLAKISYSEAIKPKQSPFNNAIYVRIKLCODEIETEK
LANSINKEVTERRELLQFVNHVPMNIRFEESEPNNIYAREIDYLEEPEYKESDDII
ATSKRSKLEKTIKRIQCMDENNIRKIDANDINIMTKATTKHTLALINIESBRI
NMKLLVMVSAFNNFMAPIQTSLSRIYAEIADODSDSLATFRLDDEEPIADIAFK
SRKQNPQVITKGSNIVDALIPAIHEKMPSPFLVYDIDIRNLHYEASKIRPYL
join(115478..15499,15592..15765,15953..16014,16061..16192)
/gene="C44C10.6"
join(115478..15499,15592..15765,15953..16014,16061..16192)
/gene="C44C10.6"
/codon_start=1
/protein_id="CAA93641.1"
/db_xref="GI:3874983"
/db_xref="SPTREMBL:O18619"
/translation="MRHVPFLTSRNPNOSTMKLEKTOSDYIKKTRTQOLEHAEP
LRNKLNKPPDMGTFPSTSNVLEFPSSVSMFLTFPRVAALTSKKCIYGEPSKCF
FKSTDHATQGRKTRNTNPYFGILBP"
join(19631..19848,20165..20420,20559..20954,20999..21256,
21300..21386)
/gene="C44C10.3"
join(19631..19848,20165..20420,20559..20954,20999..21256,
21300..21386)
/gene="C44C10.3"

27 14:14:47 2003

us-09-355-254f-16.rge

/note="predicted using GeneFINDER
contains similarity to Pfam domain: PF00083 (Sugar (and
other) transporter), Score=-98.8, E-value=0.00078, N=1"
/codon_start=1
/protein_id="CA93635.1"
/db_xref="GI:3874977"
/db_xref="SPRMBL:Q18613"
/translation="MEYDNRPHLCVETVWOLNFRNGOYIFNPSIHVPMKGDGP
VTRDKVYOSCKNDITFPDIFTSVAMEFSCGLSAGTACVIMESILSHORAV
IRAFNMGKTRVETITVYCYVIOEHLASVCACTVPAIMIKIPLVIMAFVAVC
TAMIESERFMAKINGVSYVPIEHLISHTLLETNTGLERKIFVIMAFVAVC
GFANDNSNLSAGNLTQALFGILVLSKIVLEVTFRKFRKPTTHOGSGMIT
SFILAFILMIDYHGTGFLIVTIFGTMEIETMDAVYLCAIESMRSASVGSCL
MARIGSLAFPLVATWMPVAVTTIVLGVLLISFELDETANVMDVGVND
EAOERKIAMLQF
complement(Join(21983..22039,22085..22371,22741..22945,
22983..23172,23659..23847,23892..24010,25399..26203,
26251..26301,26703..26846,27118..27279))
/gene="C44C10.2"
complement(Join(21983..22039,22085..22371,22741..22945,
22983..23172,23659..23847,23892..24010,25399..26203,
26251..26301,26703..26846,27118..27279))
/note="Similarity to Drosophila cytochrome P450 (P450 Acc.
No. S34291), contains similarity to Pfam domain: PF00067
(Cytochrome P450), Score=155.8, E-value=9.4e-44, N=2
CDNA EST EMBL:AV211318 comes from this gene"
CDNA EST EMBL:AV199850 comes from this gene"
/codon_start=1
/protein_id="CA93636.1"
/db_xref="GI:3874978"
/db_xref="SPRMBL:Q27480"

Query Match 84.0%; Score 16.8; DB 3; Length 35409;
Best Local Similarity 90.0%; Pred. No. 7.6e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 GTCCATTCCCGTAATCTT 20
DB 10892 GTCCATTCCCGTAATCTT 10873

RESULT 11
AL512289/c 36727 bp DNA linear PRI 10-APR-2002
LOCUS Human DNA sequence from clone RP11-256L9 on chromosome 6, complete
DEFINITION
ACCESSION AL512289
VERSION AL512289
KEYWORDS
SOURCE human
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.

REFERENCE
AUTHORS Lloyd,D.
TITLE Direct Submission
JOURNAL Submitted (10-APR-2002) Wellcome Trust Sanger Institute, Hinxton,
Cambridgeshire, CB10 1SA, UK. E-mail enquiries:
humany@sanger.ac.uk
On Apr 12, 2002 this sequence version replaced 91.16944069.
During sequence assembly data is compared from overlapping clones.
Where differences are found these are annotated as variations
together with a note of the overlapping clone name. Note that the
variation annotation may not be found in the sequence submission
corresponding to the overlapping above.
only a small overlap as described above.
this sequence was finished as follows unless otherwise noted: all
regions were either double-stranded or sequenced with an alternate
chemistry or covered by high quality data (i.e., phased quality >
30); an attempt was made to resolve all sequencing problems, such
as compressions and repeats: all regions were covered by at least
one plasmid subclone or more than one M13 subclone; and the

assembly was confirmed by restriction digest. The following
abbreviations are used to associate primary accession numbers given
in the feature table with their source databases: Em.: EMBL; Sw.:
SWISSPROT; Tr.: TrEMBL; Wp.: WormPEP; Information on the WormPEP
database can be found at
http://www.sanger.ac.uk/projects/C.-elegans/wormpep this sequence
was generated from part of bacterial clone contigs of human
chromosome 6, constructed by the Sanger Centre Chromosome 6 Mapping
Group. Further information can be found at
http://www.sanger.ac.uk/Ref/Chr6
RP11-256L9 is from the library RPc1-11.1 constructed by the group
of Plier de Jong. For further details see
http://www.chori.org/dacpac/home.htm
VECTOR: pNac3.6
Location/Qualifiers
1..36727
/organism="Homo sapiens"
/db_xref="taxon:9606"
/chromosome="6"
/clone="RP11-256L9"
/clone_lib="RPc1-11.1"
/clone_1lb="6909 c 7196 g 11456 t
6909 c 6909 c 7196 g 11456 t

BASE COUNT 11166 a 6909 c 7196 g 11456 t
ORIGIN
Query Match 84.0%; Score 16.8; DB 9; Length 36727;
Best Local Similarity 90.0%; Pred. No. 7.6e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 GTCCATTCCCGTAATCTT 20
DB 18407 GACCAATTCCTGTAATCTT 18388

RESULT 12
AF025467/c 37154 bp DNA linear INV 31-MAY-2002
LOCUS Caenorhabditis elegans cosmid R148, complete sequence.
DEFINITION
ACCESSION AF025467
VERSION AF025467.1
KEYWORDS
SOURCE HTG.
ORGANISM Caenorhabditis elegans.
Eukaryota; Metazoa; Nematoda; Chromadorea; Rhabdillida;
Rhabdillida; Rhabdillida; Peloderinae; Caenorhabditis.
1 (bases 1 to 37154)
Waterson,R.
Genome sequence of the nematode C. elegans: a platform for
investigating biology. The C. elegans Sequencing Consortium
Science 282 (5396), 2012-2018 (1998)

REFERENCE
AUTHORS Waterson,R.
TITLE The sequence (2001)
JOURNAL Unpublished (2001)
AUTHORS 3 (bases 1 to 37154)
Waterson,R.
Direct Submission
Submitted (16-SEP-1997) Department of Genetics, Washington
University, 4444 Forest Park Avenue, St. Louis, Missouri 63108, USA
4 (bases 1 to 37154)
Waterson,R.
Direct Submission
Submitted (25-JUL-2001) Department of Genetics, Washington
University, Genome Sequencing Center, 4444 Forest Park Avenue, St.
Louis, MO 63110, USA
5 (bases 1 to 37154)
Waterson,R.
Direct Submission
Submitted (23-MAY-2002) Department of Genetics, Washington
University, Genome Sequencing Center, 4444 Forest Park Avenue, St
Louis, MO 63110, USA
6 (bases 1 to 37154)

Department of Genetics, Washington University
St. Louis, MO 63110, USA, and
Sanger Centre, Hinxton Hall
Cambridge CB10 1RQ, England
email: twenematoda@wustl.edu

This sequence was finished as follows unless otherwise noted: all regions were double stranded, sequenced with an alternate chemistry or covered by high quality data (i.e., phred quality >= 30); an attempt was made to resolve all sequencing problems, such as compressions and repeats; all regions were covered by sequence from more than one m13 subclone.

For a graphical representation of this cosmid sequence and its analysis see: <http://www.wormbase.org/ab>

NEIGHBORING COSMID INFORMATION

The 5' cosmid is C44B11, 900 bp overlap; the 3' cosmid is H09GC3 2400 bp overlap. Actual start of this cosmid is 895 of R148; actual end is at 37154 of R148.

NOTES:

Coding sequences below are the result of integration and manual review of the following data: Computer analysts using the program GeneFinder (P. Green and L. Hillier, personal communication), the large scale EST projects of Yui Kohara (http://www.ddbj.nig.ac.jp/c-elegans/html/CE_INDEX.html) and the elegans ORFome cloning project (<http://wormfdb.dcel.harvard.edu/>) similarly to other proteins from Blast analyses (<http://blast.wustl.edu/>), sequence conservation with C. briggsae using Jim Kent's MABA alignment program (Genome Research 10:1115-1125, 2000), individual C. elegans GenBank submissions, and personal communications with C. elegans researchers. tRNAs are predicted using the program tRNAscan-SE (Lowe, T.M. and Eddy, S.R., 1997, Nucleic Acids. Res., 25, 955-964). Location/Qualifiers 1..37154

CDS
 source
 1997, Nucl. Acids. Res., 25, 955-964).
 Location/Qualifiers
 1..37154
 /organism="Caenorhabditis elegans"
 /strain="Bristol N2"
 /db_xref="taxon:6239"
 /chromosome="III"
 /clone="R148"
 95..4939
 /gene="R148.5"
 /note="for a graphical representation of this gene see:
 Sequence" [http://www.wormbase.org/db/seq/sequence?name=R148.5;class=join\(95..435,939..1303,2277..2489,3336..4014,4475..4559,4844..4939\)](http://www.wormbase.org/db/seq/sequence?name=R148.5;class=join(95..435,939..1303,2277..2489,3336..4014,4475..4559,4844..4939))
 /gene="R148.5"
 /note="contains similarity to drosophila DNA-binding protein R10 (MID:98148); coded for by the following C.
 elegans cDNAs: yk11a11.3, yk466a5.3 yk17d12.3,
 yk113f3.3 yk113f3.5, yk64h11.3, yk19b6.3, yk79b6.5,
 yk185e1.5, yk185f1.5, yk186h12.5, yk186f1.5, yk172e2.5,
 yk466a5.5, yk186h12.5, CBB860F, yk11a11.5, yk46h13.5,
 /codon_start=1

/product="Hypothetical protein R148.5"
/protein_id="AB071039.1"
/db_xref="GI:2429509"
/translation="MVRDKKIQETKMWISKYSIDMSNCKNKLKFLKPKKPEEP
AREPDTFTLLPEKNSNTPOMPILCRQRYLITGSSVPTILKDGLOIOOLKPEEP
GSDPTRGIDSLIWSNSGYLLETYSKEKTLVGFSPITIKDGLIOOLKPEEP
GSDPTRGIDSLIWSNSGYLLETYSKEKTLVGFSPITIKDGLIOOLKPEEP
VVAITEEDSPFANINSPNPHPIATIRRTQGVKVECHGICITVYANVAGVFP
QARVEITMLMDERIRGLKATKEGSTGIDRNSNSSEIEGNSPEEDYVPEEKNAI/VNC
VAITEEDSYDVISISSLLKAKKKEGASOGIGALVPPDEPIRAGSGDNL/STRG
PNHAYGPHPHMHNPYAMPMPMPKFKKSGAPGHPHPPHMRGMPPEPMPPHGF
MOPRGGMPNPPHMPRGCPITPPPPPPPPPHFMMSPDPDGGIITGSEYVGMFR
GAYEELVYATGSGPEASVYOPANGGSGGYETIYDPPKCKGSLIKGESA/VNSTAD
AMDYDEAGTIRKHIIEKASGTLINSMKAKETSMATLNSSEIHAESA/VQSEETLRD
SPDVEAYKELKENSRRRAQPTN"
5716..6332

Sequence" www.ncbi.nlm.nih.gov/db/seq/sequence?name=R148.4.c1
 totin/571c

```

/protein_id="P06012"
/db_xref="GI:2429505"
/translation="MSKEANSEFGALPSRFPTRHCCIGVENSVLKLLTALTTLOIT  

VFYIIEHPDELRAMLNINPKONQDILLITLAMSIVLWLSFSGFKKTKTYSH  

LPLIAIERQNSACIRQICRLIEDATVPRGQIISCKPANNV  

9383..14111  

/gene="R148_3"

```

```

CDS
    http://www.graphicalrepresentation.org/this gene see:
    Sequence
    join(93983..9415,9572..9662,9706..9842,9887..10744,
    10855..11330,11689..11841,11895..13234,13852..14111)
    /gene="R148.3"
    /note="contains weak similarity to human Bcr1 protein
    and transcription activator Bcr1 protein (GB:566910)
    coded for by the following C. elegans CDNAs: YK51D12.5,
    YK168F9.5, YK598C4.5"
    /codon_start=1
    /product="Hypothetical protein R148.3"
    /protein_id="AB71038.2"
    /db_xref="GI:15011786"
    /translation=""

```

gene
 HEMPLSLAPPGGCAKPKLCKRRFOTGEF
 17695..17694
 /gene="R148.2"
 /note="for a graphical representation of this gene see:
 http://www.wormbase.org/db/seq/sequence?name=R148.2;class=
 Sequence"
 join(17695..17729,18063..18141,18456..18581,18849..19004
 /gene="R148.2"
 /note="Coded for by the following C elegans contigs:
 CE5594F"


```

*      22598      24237: contig of 1640 bp in length
*      24338      24337: gap of unknown length
*      25473      25473: contig of 1136 bp in length
*      25474      25473: gap of unknown length
*      25574      25573: gap of unknown length
*      26801      26800: contig of 1227 bp in length
*      26901      26900: gap of unknown length
*      28145      28144: contig of 1244 bp in length
*      28245      28244: gap of unknown length
*      29917      29916: contig of 1672 bp in length
*      30017      30016: gap of unknown length
*      32126      32125: contig of 2109 bp in length
*      32226      32225: gap of unknown length
*      34043      34042: contig of 1817 bp in length
*      35903      35903: contig of 1761 bp in length
*      35904      35903: gap of unknown length
*      36004      36003: gap of unknown length
*      37019      37018: contig of 1016 bp in length
*      37119      37118: gap of unknown length
*      38950      38950: contig of 1831 bp in length
*      38951      38950: gap of unknown length
*      39051      39050: gap of unknown length
*      40222      40221: contig of 1171 bp in length
*      40322      40321: gap of unknown length
*      41558      41557: contig of 1236 bp in length
*      41558      41557: gap of unknown length
*      42752      42752: contig of 1095 bp in length
*      42852      42852: gap of unknown length
*      44089      44088: contig of 1556 bp in length
*      44509      44508: gap of unknown length
*      46147      46146: contig of 1638 bp in length
*      46247      46246: gap of unknown length
*      47569      47568: contig of 1322 bp in length
*      47669      47668: gap of unknown length
*      49273      49272: contig of 1604 bp in length
*      49373      49372: gap of unknown length
*      51789      51788: contig of 2416 bp in length
*      51889      51888: gap of unknown length
*      54561      54560: contig of 2672 bp in length
*      54660      54660: gap of unknown length
*      56173      56172: contig of 1512 bp in length
*      56773      56772: gap of unknown length
*      57893      57893: contig of 1621 bp in length
*      57994      57993: gap of unknown length
*      60509      60508: contig of 2515 bp in length
*      60609      60608: gap of unknown length
*      63454      63453: contig of 2845 bp in length
*      63554      63553: gap of unknown length
*      66714      66714: contig of 3161 bp in length
*      66815      66814: gap of unknown length
*      71198      71198: contig of 4384 bp in length.
FEATURES
  source
    1..71198
    /organism="Rattus norvegicus"
    /db_xref="taxon:10116"
    /clone="CH230-26313"
BASE COUNT   19367 a 14382 c 13896 g 18404 t 5149 others
ORIGIN
Query Match      84.08; Score 16.8; DB 2; Length 71198;
Best Local Similarity 90.08; Pred. No. 8.3e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY      1 GTCAATTCCTGTAATCTT 20
Db      11923 GTCAATTCCTGTAATCTT 11904

```

```

RESULT 14
AC087104/c AC087104 76922 bp DNA linear VRT 04-JUL-2001
Dantio rerio clone 20A7, complete sequence.
AC087104 GI:14595788
AC087104.2

```

```

SOURCE
ORGANISM
  Dantio rerio.
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Actinopterygii; Neopterygii; Teleostei; Ostariophysi;
  Cypriniformes; Cyprinidae; Dantio.
REFERENCE
  1 (bases 1 to 76922)
  Ayele, K., Beckstrom-Sternberg, S.M., Benjamin, B., Blakesley, R.W.,
  Bouffard, G.E., Breen, K., Brinkley, C., Brooks, S., Dietrich, N.L.,
  Griffin, S., Guan, X., Gupta, J., Ho, S.-L., Idol, J.R., Karlins, E.,
  Lee, L.S.-O., Legaspi, R., Lin, M., Maduro, O.L., Maduro, V.B.,
  Mastelloni, C., Mastrian, S.D., McCluskey, J.C., McDowell, J.,
  Pearson, R., Prasad, A., Shevchenko, Y., Snyder, B., Stancir, P.,
  Thomas, J.W., Thomas, P.J., Touchman, J.W., Tsaur, C., Vogt, J.L.,
  Walker, M.A., Welham, R.D., Zhang, L.-H. and Green, E.D.,
  NISC Comparative Sequencing Initiative
  2 (bases 1 to 76922)
  Unpublished
  3 (bases 1 to 76922)
  Direct Submission
  Submitted (04-JUL-2001) NIH Intramural Sequencing Center, 8717
  Grovemont Circle, Gaithersburg, MD 20877, USA
  On Jul 4, 2001 this sequence version replaced gi:11596995.
COMMENT
  ----- Genome Center
  Center: NIH Intramural Sequencing Center
  Web site: http://www.nisc.nih.gov
  Contact: nisc.mouse@nih.gov
  ----- Project Information
  Center project name: acb
  Center clone name: 020A07

  This sequence was finished as follows unless otherwise noted:
  all regions were double-stranded, sequenced with an
  alternate chemistry, or covered by high quality data
  (i.e., paired quality >= 30); an attempt was made to resolve
  all sequencing problems, such as compressions and repeats;
  or more than one M13 subclone; and the assembly was confirmed
  by restriction digest.

  CLONE LENGTH: This sequence represents the entire insert of
  this clone unless otherwise noted. If there are overlapping
  clones, the overlaps are noted in the beginning and end of
  the features section.
FEATURES
  source
    1..76922
    /organism="Dantio rerio"
    /db_xref="taxon:7935"
    /clone="20A7"
    /clone.lib="Incyte Genomics"
    3861..3902
    /note="single clone coverage"
    9095..9096
    /note="bacterial transposon excised; IS2 element sequence
    can be found in GenBank Accession Number AF000237.1"
    24082..24103
    /note="single clone coverage"
    24907..25101
    /note="single clone coverage"
    29277..29335
    /note="single clone coverage"
    35086..35142
    /note="single clone coverage"
    47307..47345
    /note="single clone coverage"
    61397..61584
    /note="single clone coverage"

```

JUN 27 14:14:47 2003

us-09-355-254f-16.19e

```

misc_feature      62723..62756
                   /note="single clone coverage"
BASE COUNT      24246 a 13965 c 13603 g 25108 t
ORIGIN
Query Match      84.0%; Score 16.8; DB 5; Length 76922;
Best Local Similarity 90.0%; Fred. No. 8.3e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
1 GTCATTTCCTTATCTT 20
|||||
GTCATTTCCTTATCTT 40792
Db      40811 GTCATTTCCTTATCTT 40792

RESULT 15
AC122615/c      95594 bp      DNA      linear      HTG 14-JUL-2002
LOCUS      Rattus norvegicus clone CH230-62B1, *** SEQUENCING IN PROGRESS ***
DEFINITION      52 unordered pieces.
ACCESSION      AC122615
VERSION      AC122615.2 GI:21735366
KEYWORDS
SOURCE
ORGANISM
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae;
Eutaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Rattus.
1 (bases 1 to 95594)
Muzny,D.M., Adams,C., Adio-Oduola,B., Al-Osman,F.R., Allen,C.,
Alshrocks,S.L., Amaratunga,H.C., Aye,J.R., Ayele,M., Banks,T.,
Barbarta,J., Benson,B., Blevins,M., Brown,E., Brown,N.P.,
Buck,J., Burck,P., Burkett,C., Burrell,K.L., Byrd,N.C.,
Carrion,T.F., Carter,M., Cavazos,S.R., Chacko,J., Chavez,D.,
Chen,G., Chen,R., Chen,Z., Chowdhury,I., Christopoulos,C.,
Cleveland,C.D., Cox,C., Coyle,M.D., Dathorne,S.R., David,R.,
Dellavalle,M.L., Davis,C., Davy-Carroll,L., Dedrich,D.A.,
Delaney,K.R., Delgado,O., Denna,A.L., Ding,Y., Dinh,H.H.,
Douthett,K.J., Drepper,H., Dugan-Rocha,S., Durbin,K.J.,
Edwards,C.C., Elhaj,C., Escotto,M.,
Farrar,C., Ferraguto,D., Edwards,C.C., Elhaj,C., Escotto,M.,
Farrar,C., Ferraguto,D., Edwards,C.C., Elhaj,C., Escotto,M.,
Falls,T., Ferraguto,D., Edwards,C.C., Elhaj,C., Escotto,M.,
Gabsi,A., Gao,J., Garcia,A., Garner,T., Garza,N., Gill,R.,
Gorrell,J.H., Guevara,W., Gunaratne,P., Hale,S., Hamilton,K.,
Harris,C., Harris,K., Hart,M., Havlak,P., Hawes,A., Hernandez,J.,
Hernandez,O., Hodgson,A., Hognes,M., Hume,J., Jackson,L.E.,
Homsli,F., Howard,S., Huber,J., Huliyil,S., Joudah,S.,
Jacobson,B., Jia,L., Khan,U., King,L., Koryak,J., Kovar,C.,
Karlovic,J., Kureshi,A., Landry,N., Leal,B., Lewis,L.C., Lewis,L.,
Li,J., Li,Z., Lichtenberg,O., Lieu,C., Liu,J., Liu,W., Lousseng,E.,
Lorado,R.J., Lu,X., Lucier,A., Lucier,R., Luna,R., Martinez,E.,
Maheshwari,M., Mapua,P., Martin,R., Martindale,A., Mel,G., Metzger,M.,
Massey,E., Mawhney,E., McLeod,M.P., Meador,M., Morgan,M., Morris,N.,
Miner,G., Miner,Z., Mitchell,T., Mohabbat,K., Nguyen,A., Nguyen,N.,
Moser,M., Neal,D., Newton,S., Nwokwenkwo,S., Ogum,H., Okunuga,G.,
Nguyen,N., Nickerson,E., Nwokwenkwo,S., Ogum,H., Okunuga,G.,
Ogunyeye,N., Oviedo,R., Pace,A., Payton,B., Peery,J., Perez,L.,
Peters,L., Pickens,R., Primus,E., Pu,L.L., Quiles,M., Rauls,S.,
Rivers,M., Rojas,A., Rojibokan,I., Rolfe,M., Ruiz,S., Savary,G.,
Scherer,S., Scott,G., Shen,H., Shooshari,N., Slason,I.,
Sodergren,E., Sonalke,T., Sparks,A., Stanley,H., Stone,H.,
Tateno,A., Swalek,A., Taylor,C., Taylor,T., Tellrod,B., Thomas,N., Thomas,S.,
Tunney,J., Taylor,C., Taylor,T., Tellrod,B., Thomas,N., Thomas,S.,
Usmani,K., Vasquez,L., Vera,V., Villalobos,D., Vinson,R., Wang,Q.,
Wang,S., Ward-Moore,S., Warren,R., Washington,C., Wellington,S.,
Williams,G., Williamson,A., Wlarczyk,R., Woodson,S., Worley,K.,
Wu,C., Wu,Y., Wu,Y.F., Zhou,J., Zorilla,S., Nelson,D.,
Weinstock,G. and Gibbs,R.
TITLE
JOURNAL
Unpublished
2 (bases 1 to 95594)
REFERENCE
Worley,K.C.
AUTHORS
Direct Submission
TITLE

```

JOURNAL
Submitted (25-MAY-2002) Human Genome Sequencing Center, Department
of Molecular and Human Genetics, Baylor College of Medicine, One
Baylor Plaza, Houston, TX 77030, USA
3 (bases 1 to 95594)
REFERENCE
Worley,K.C.
TITLE
Submitted (14-JUL-2002) Human Genome Sequencing Center, Department
of Molecular and Human Genetics, Baylor College of Medicine, One
Baylor Plaza, Houston, TX 77030, USA
On Jul 12, 2002 this sequence version replaced g1:21205932.
COMMENT
Genome Center of Medicine
Center: Baylor College of Medicine
Center code: BCM
Center site: http://www.hgsc.bcm.tmc.edu/
Web site: hgsc-help@bcm.tmc.edu
Contact: hgsc-help@bcm.tmc.edu
Project information
Project name: GKBL
Center project name: CH230-62B1
Summary Statistics
Sequencing vector: Plasmid
Chemistry: Dye-terminator Big Dye 100% of reads
Assembly program: Phrap: version 0.990329
Consensus quality: 44317 bases at least Q40
Consensus quality: 47172 bases at least Q30
Consensus quality: 48975 bases at least Q20

***** NOTE: Estimated insert size may differ from sequence length
(see http://www.hgsc.bcm.tmc.edu/docs/genbank/draft_data.html).
***** NOTE: This is a 'working draft' sequence. It currently
consists of 52 contigs. The true order of the pieces
is not known and their order in this sequence record as
arbitrary. Gaps between the contigs are represented as
runs of N, but the exact sizes of the finished sequence
as soon as it is available and the accession number will
be preserved.

1	1758	contig of 1758 bp in length
1	1759	1856: gap of unknown length
1	1859	contig of 1084 bp in length
1	2942	contig of unknown length
1	3042	gap of 1546 bp in length
1	3043	contig of unknown length
1	4588	gap of unknown length
1	4589	gap of 1228 bp in length
1	4689	contig of unknown length
1	5917	gap of unknown length
1	6016	contig of 1296 bp in length
1	7312	contig of unknown length
1	7412	gap of 1017 bp in length
1	7413	contig of unknown length
1	8429	contig of 1325 bp in length
1	8430	gap of unknown length
1	8530	contig of unknown length
1	9534	gap of unknown length
1	9535	contig of 1033 bp in length
1	10987	gap of unknown length
1	10988	contig of 1328 bp in length
1	12415	contig of unknown length
1	12416	gap of unknown length
1	12417	contig of 1275 bp in length
1	13791	contig of unknown length
1	13792	gap of 1586 bp in length
1	13793	contig of unknown length
1	15476	contig of unknown length
1	15477	gap of unknown length
1	15478	contig of 1078 bp in length
1	16754	gap of unknown length
1	16755	contig of 1325 bp in length
1	16756	gap of unknown length
1	18079	contig of 1382 bp in length
1	18179	gap of unknown length
1	18180	contig of unknown length
1	18181	gap of 1339 bp in length
1	19562	contig of unknown length
1	19563	gap of unknown length
1	21000	contig of 1716 bp in length
1	21001	gap of unknown length
1	22816	contig of 1441 bp in length
1	22817	contig of unknown length
1	24357	contig of 1114 bp in length
1	24358	gap of unknown length
1	25571	contig of 1306 bp in length
1	25572	gap of unknown length
1	25677	contig of 1306 bp in length

FEATURES	source
26978	26978: gap of unknown length
27078	27077: gap of unknown length
28818	28817: contig of 1740 bp in length
28918	28917: gap of unknown length
29818	30270: contig of 1353 bp in length
30271	30370: gap of unknown length
30371	31639: contig of 1269 bp in length
31640	31739: gap of unknown length
31740	33141: contig of 1402 bp in length
33142	33241: gap of unknown length
33242	34943: contig of 1702 bp in length
34944	35043: gap of unknown length
35044	36744: contig of 1701 bp in length
36745	36844: gap of unknown length
36845	38572: contig of 1728 bp in length
38573	38677: gap of unknown length
38673	40892: contig of 2223 bp in length
40896	40992: gap of unknown length
40996	43538: contig of 2553 bp in length
43559	43658: gap of unknown length
43659	44698: contig of 1040 bp in length
44699	44798: gap of unknown length
44798	47265: contig of 2467 bp in length
47266	47365: gap of unknown length
47366	48435: contig of 1070 bp in length
48336	48535: gap of unknown length
48536	50462: contig of 1927 bp in length
50463	50562: gap of unknown length
50563	51111: contig of 1149 bp in length
51112	51811: gap of unknown length
51812	52825: contig of 1014 bp in length
52826	52925: gap of unknown length
52926	54065: contig of 1140 bp in length
54066	54165: gap of unknown length
54166	55170: contig of 1005 bp in length
55171	55271: gap of unknown length
55271	56773: contig of 1503 bp in length
56774	56873: gap of unknown length
56874	59367: contig of 2494 bp in length
59368	59467: gap of unknown length
59468	61502: contig of 2033 bp in length
61503	61602: gap of unknown length
61602	62859: contig of 1257 bp in length
62860	62959: gap of unknown length
62960	65235: contig of 2276 bp in length
65236	65335: gap of unknown length
65336	67974: contig of 2639 bp in length
67975	68074: gap of unknown length
68075	70326: contig of 2252 bp in length
70327	72204: contig of 1778 bp in length
72205	72304: gap of unknown length
72305	73946: contig of 1642 bp in length
73947	77136: gap of unknown length
77137	77236: contig of 3090 bp in length
77237	77433: gap of unknown length
77434	79433: contig of 2197 bp in length
79434	81547: gap of unknown length
81548	83499: contig of 1752 bp in length
83500	83599: gap of unknown length
83600	86636: gap of unknown length
86637	90821: contig of 4085 bp in length
90821	90921: gap of unknown length
90922	95941: contig of 4673 bp in length
95941	95958: Location/Qualifiers

```

      /db_xref="taxon:10116"
      84.08; Score 16.8; DB 2; Length 95594;
      arily 90.08; Pred. No. 8.6e+02;

```

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 26, 2003, 09:56:18 ; Search time 925.63 Seconds

(without alignments)
565.939 Million cell updates/sec

Title: US-09-355-254F-10

Perfect score: 18

Sequence: 1 agctagacgtcccaagg 18

Scoring table: IDENTITY_NUC

Gapop 10.0 , Gapext 1.0

Searched: 2054640 segs, 14551402878 residues

Total number of hits satisfying chosen parameters: 4109280

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : GenBank:*

1: gb.Da:*

2: gb.Htg:*

3: gb.In:*

4: gb.Om:*

5: gb.Ov:*

6: gb.Pat:*

7: gb.Ph:*

8: gb.Pl:*

9: gb.Pr:*

10: gb.Ro:*

11: gb.Sts:*

12: gb.Sy:*

13: gb.Un:*

14: gb.Vl:*

15: em.Da:*

16: em.Fun:*

17: em.Hum:*

18: em.In:*

19: em.Mu:*

20: em.Om:*

21: em.Or:*

22: em.Ov:*

23: em.Pat:*

24: em.Ph:*

25: em.Pl:*

26: em.Ro:*

27: em.Sts:*

28: em.Un:*

29: em.Vl:*

30: em.Htg.Hum:*

31: em.Htg.Inv:*

32: em.Htg.Other:*

33: em.Htg.Mus:*

34: em.Htg.Plh:*

35: em.Htg.Rod:*

36: em.Htg.Man:*

37: em.Htg.Vrl:*

38: em.Sy:*

39: em.Htgo.Hum:*

40: em.Htgo.Mus:*

41: em.Htgo.Other:*

Pred. No. is the number of results predicted by chance to have a

score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	18	100.0	18	6	A89789
2	18	100.0	18	6	A80876
3	18	100.0	18	6	AX105148
4	18	100.0	18	6	AX455555
5	18	100.0	1000	10	S8242063
6	18	100.0	76047	10	AL665944
7	18	100.0	110000	2	AC073744.2
8	18	100.0	110000	2	AC073744.3
9	18	100.0	189236	10	AL607020
10	18	100.0	268294	2	AC020885
11	18	100.0	287927	2	AC079530
12	17	94.4	18	6	AX104114
13	17	94.4	18	6	AX355358
14	17	94.4	24	6	AX463126
15	17	94.4	24	6	AX463127
16	16.4	91.1	3184	3	DHPDMP
17	16.4	91.1	4663	3	AY122244
18	16.4	91.1	70886	2	AC099321
19	16.4	91.1	80254	2	AC019531
20	16.4	91.1	101607	8	AP004334
21	16.4	91.1	102237	8	AC099322
22	16.4	91.1	152448	8	AP004339
23	16.4	91.1	162726	9	AL157881
24	16.4	91.1	169905	9	AL442064
25	16.4	91.1	186465	2	AC122541
26	16.4	91.1	192681	3	AC011905
27	16.4	91.1	252828	2	AL590646
28	16.4	91.1	300829	2	AE003475
29	16.4	88.9	157225	2	AC114086
30	15.4	85.6	1832	3	AB055144
31	15.4	85.6	2401	3	AB055144
32	15.4	85.6	9640	9	AC092955
33	15.4	85.6	54623	2	AC098392
34	15.4	85.6	63507	2	AC079266
35	15.4	85.6	80195	2	AC103059
36	15.4	85.6	94212	2	AC091848
37	15.4	85.6	94296	2	AL160261
38	15.4	85.6	98366	2	AC108548
39	15.4	85.6	98775	2	AC121723
40	15.4	85.6	107454	2	AC106689
41	15.4	85.6	114144	8	U78721
42	15.4	85.6	122556	9	AL391863
43	15.4	85.6	135203	9	AC025278
44	15.4	85.6	140596	2	RN75P15
45	15.4	85.6	142504	2	AC129671

ALIGNMENTS

RESULT 1

LOCUS A89789 18 bp DNA linear PAT 22-JAN-2000

DEFINITION Sequence 11 from Patent WO9832462.

ACCESSION A89789

VERSION A89789.1 GI:6738303

KEYWORDS

SOURCE

ORGANISM

REFERENCE 1 (bases 1 to 18)

AUTHORS Lipford, G. B. and Heeg, K.

TITLE PHARMACEUTICAL COMPOSITIONS COMPRISING A POLYNUCLEOTIDE AND OPTIONALLY AN ANTIGEN ESPECIALLY FOR VACCINATION

JOURNAL Patent: WO 9832462-A 11 30-JUL-1998;

LIPFORD GRAYSON B (DE); HERG KLAUS (DE)

FEATURES
Source
1. .18
/db_xref="taxon:32644"

BASE COUNT 5 a 4 c 5 g 4 t

Query Match 100.0%; Score 18; DB 6; Length 18;
Best Local Similarity 100.0%; Pred. No. 7.4;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGCTATGACGTTCCAAG 18
DB 1 AGCTATGACGTTCCAAG 18

RESULT 2

LOCUS A90876 18 bp DNA linear PAT 22-JAN-2000
DEFINITION Sequence 11 from Patent EP0855184.
ACCESSION A90876
VERSION A90876.1 GI:6739275

KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE

1 (bases 1 to 18)
Heeg, K.P. and Lipford, G.B.

Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
Patent: EP 0855184-A 11 29-JUL-1998;
HERG KLAUS PROF DR (DE); LIPFORD GRAYSON B DR (DE)

FEATURES
Source
1. .18
/db_xref="taxon:32644"

BASE COUNT 5 a 4 c 5 g 4 t

Query Match 100.0%; Score 18; DB 6; Length 18;
Best Local Similarity 100.0%; Pred. No. 7.4;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGCTATGACGTTCCAAG 18
DB 1 AGCTATGACGTTCCAAG 18

RESULT 3
AX105148 18 bp DNA linear PAT 30-APR-2001
DEFINITION Sequence 46 from Patent WO0122990.
ACCESSION AX105148
VERSION AX105148.1 GI:13921298

KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE

1 (bases 1 to 18)
Hartmann, G.D., Bratzler, R.L. and Krieg, A.U.
Methods related to immunostimulatory nucleic acid-induced interferon
Patent: WO 0122990-A 46 05-APR-2001;
Coley Pharmaceutical Group, Inc. (US); UNIVERSITY OF IOWA RESEARCH FOUNDATION (US)

JOURNAL

Location/Qualifiers
1. .18
/db_xref="taxon:32630"

FEATURES
Source
1. .18
/db_xref="taxon:32630"

BASE COUNT 5 a 4 c 5 g 4 t

Query Match 100.0%; Score 18; DB 6; Length 18;
Best Local Similarity 100.0%; Pred. No. 7.4;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGCTATGACGTTCCAAG 18
DB 1 AGCTATGACGTTCCAAG 18

RESULT 4
AX455555 18 bp DNA linear PAT 06-JUL-2002
LOCUS AX455555
DEFINITION Sequence 32 from Patent WO0222809.
ACCESSION AX455555
VERSION AX455555.1 GI:21714623

KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE

1
Bauer, S., Lipford, G. and Wagner, H.

Process for high throughput screening of cpg-based immuno-agonist/antagonist
Patent: WO 0222809-A 32 21-MAR-2002;
Coley Pharmaceutical GmbH (DE)

FEATURES
Source
1. .18
/db_xref="taxon:32630"

BASE COUNT 5 a 4 c 5 g 4 t

Query Match 100.0%; Score 18; DB 6; Length 18;
Best Local Similarity 100.0%; Pred. No. 7.4;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGCTATGACGTTCCAAG 18
DB 1 AGCTATGACGTTCCAAG 18

RESULT 5
S8242053 1000 bp DNA linear ROD 03-DEC-1996
LOCUS S8242053
DEFINITION Interleukin-12 p40 subunit [mice, Genomic, 1000 nt, segment 3 of 7].
ACCESSION S82422
VERSION S82422.1 GI:1699185

KEYWORDS
SEGMENT
SOURCE
ORGANISM

3 of 7
Mus sp.
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus. 1 (bases 1 to 1000)
Tone, Y., Thompson, S.A., Babik, J.M., Nolan, K.F., Tone, M., Raven, C. and Waldmann, H.

Structure and chromosomal location of the mouse Interleukin-12 p35 and-p40 subunit genes
Eur. J. Immunol. 26 (6), 1222-1227 (1996)

JOURNAL

Genbank staff at the National Library of Medicine created this entry [NCBI gisbseq 178372] from the original journal article.
This sequence comes from Fig. 4.
Map location: 11.

FEATURES
Source
1. .1000
/db_xref="taxon:10095"

BASE COUNT 314 a 221 c 207 g 258 t

ILC

```
Oy      1 ACGATGACGTCCAGG 45
         |||||
Db      28 ACGTATGACGTCCAGG
```

LOCUS	Mouse DNA sequence
DEFINITION	complete sequence.
ACCESSION	AL669944
VERSION	AL669944.8 GI:20068715

REFERENCE
AUTHORS
TITLE
1
Dunn, M.
Submission
Direct Wellcome Trust Sanger Institute, Hinxton,
Submitted (04-APR-2002) E-mail enquiries:
E-mail enquiries: submit@sanger.ac.uk

Where variation is observed, the sequence of the overlapping clones may not be found in the sequence annotation. Variation may not be found in the sequence annotation, as we submit sequences together with a note of the overlapping clones, as we submit sequences with a note of the overlapping clones, as we submit sequences with a note of the overlapping clones.

[illegible]

constructed by line yacof
For further details see <http://www.cnoil.org/>
VECTOR: pBACE3.6.
Location/Qualifiers

	BASE COUNT	ORIGIN
22455 a	/clone_1lb-nrc1_25	DB 10;
16245 c	16275 g	Length 76047;
21072 t		

QY	1	AGCTATGACGTTCC	930
Db	913	AGCTATGACGTTCC	

Query	Local Similarity	Best Local	Mismatches
1 AGCTATGACGCTCCAGG	100.0%	0	0
Matches	18	Conservative	

	LOCUS AC073744	Accession AC073744
AC073744_3		
RESULT 8		
IMPORTED		
5 fragments		

Continuation (4	of 5)	Score 18; DB 2;	Length 110000;
AC073744_3	3000001	466859	AC073744 Mus musculus
AC073744_4	4000001	from base	3000001 (AC073744 Mus musculus

QY	1		5607
DB	5590	AGCTATGACGTTCCAGG	

Comp 07030 GI:19847865
AL607030
AL607030.15
ACCESSION
VERSION
KEYWORDS
HTC: mouse
Entelegostomi;

[illegible]

variation annotation above, as noted: all variation annotation above, as noted: all corresponding to the overlapping clone, as noted: all corresponding to the overlapping clone, as noted: all only a small overlap as follows unless otherwise noted: all only a small overlap as follows unless otherwise noted: all this sequence was finished as follows unless otherwise noted: all this sequence was finished as follows unless otherwise noted: all

one P was confirmed by independent assembly was confirmed by independent abbreviations are used to associate primary accessions

In the feature table with their source databases: Em: EMBL; SW: SWISSPROT; Tr: TrEMBL; Wp: WormPep; Information on the WormPep database can be found at http://www.sanger.ac.uk/Projects/C_elegans/wormpep constructed by the RPI-23 Mouse PAC library For further details see <http://www.chori.org/jacpac/home.htm> VECTOR: PACES.6.

FEATURES
Source
1..189236
Location/Qualifiers
/organism="Mus musculus"
/db.xref="taxon:10090"
/chromosome="11"
/clone="RP23-304012"
/clone.lib="RPI-23"

BASE COUNT
55297 a 41962 c 40531 g 51446 t

Query Match
Best Local Similarity 100.0%; Score 18; DB 10; Length 189236.
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 189148 AGCTATGACCTTCCACAG 188165
|||||

RESULT 10
LOCUS AC020885 268294 bp DNA linear HTG 16-FEB-2000
DEFINITION Mus musculus clone RP23-46411, LOW-PASS SEQUENCE SAMPLING.
ACCESSION AC020885
VERSION AC020885.2 GI:6980212
KEYWORDS HTG, HTGS, PHASEO.
SOURCE Mus musculus.
ORGANISM Mus musculus.
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE
AUTHORS Doe Joint Genome Institute.
TITLE Sequencing of Mouse
JOURNAL Unpublished
AUTHORS Doe Joint Genome Institute.
JOURNAL Direct Submission
COMMENT
Submitted (10-JAN-2000) Production Sequencing Facility, DOE Joint Genome Institute, 2800 Mitchell Drive, Walnut Creek, CA 94598, USA
On Feb 16, 2000 this sequence version replaced g1:6686423.
* NOTE: This record contains 183 individual
* sequencing reads that have not been assembled into
* contigs. Runs of N are used to separate the reads
* and the order in which they appear is completely
* arbitrary. Low-pass sequence sampling is useful for
* identifying clones that may be gene-rich and allows
* overlap relationships among clones to be deduced.
* However, it should not be assumed that this clone
* will be sequenced to completion. In the event that
* the record is updated, the accession number will
* be preserved.

1013: contig of 1013 bp in length
1014 1615: gap of unknown length
1616 2405: gap of unknown length
2406 3234: gap of 829 bp in length
3234: gap of unknown length
3533: contig of 299 bp in length
4467: gap of unknown length
5401: contig of 934 bp in length
gap of unknown length
gap of unknown length

5402 6154: contig of 753 bp in length
6155 gap of unknown length
6155 6629: contig of 475 bp in length
6630 7176: gap of unknown length
7177 7824: gap of 547 bp in length
7825 8656: gap of unknown length
8657 8865: gap of 832 bp in length
8866 9544: gap of unknown length
9545 10280: gap of 679 bp in length
10281 10975: gap of unknown length
10976 11742: gap of 736 bp in length
11743 12178: gap of 695 bp in length
12179 12887: gap of 767 bp in length
12888 13607: gap of unknown length
13608 13911: gap of 709 bp in length
13912 14819: gap of unknown length
14820 15571: gap of 720 bp in length
15572 15872: gap of 304 bp in length
15873 16608: gap of unknown length
16609 17277: gap of 908 bp in length
17278 18057: gap of 752 bp in length
18058 18704: gap of unknown length
18705 19414: gap of 301 bp in length
19415 20372: gap of 736 bp in length
20373 21010: gap of unknown length
21011 21258: gap of 243 bp in length
21259 22363: gap of unknown length
22364 23639: gap of 426 bp in length
23640 24853: gap of unknown length
24854 25795: gap of 780 bp in length
25796 27027: gap of 667 bp in length
27028 27729: gap of unknown length
27730 28722: gap of 710 bp in length
28723 29714: gap of 938 bp in length
29715 30858: gap of 638 bp in length
30859 31397: gap of unknown length
31398 31671: gap of 958 bp in length
gap of unknown length
gap of unknown length
gap of 992 bp in length
gap of 993 bp in length
gap of 992 bp in length
gap of 1144 bp in length
gap of unknown length
gap of 539 bp in length
gap of unknown length
contig of 274 bp in length

31672 32959: contig of 1288 bp in length
 32960 33791: contig of 832 bp in length
 33792 34848: contig of 1057 bp in length
 34849 35060: contig of 212 bp in length
 35061 35776: contig of 716 bp in length
 35777 35903: contig of 127 bp in length
 35904 36602: contig of 699 bp in length
 36603 37110: contig of 508 bp in length
 37111 38059: contig of 949 bp in length
 38060 38730: contig of 671 bp in length
 38731 39790: contig of 1060 bp in length
 39791 40327: contig of 537 bp in length
 40328 40442: contig of 115 bp in length
 40443 41688: contig of 1246 bp in length
 41689 42688: contig of 1000 bp in length
 42689 43847: contig of 1159 bp in length
 43848 44511: contig of 664 bp in length
 44512 45780: contig of 1269 bp in length
 45781 47202: contig of 1422 bp in length
 47203 48647: contig of 1445 bp in length
 48648 49652: contig of 1005 bp in length
 49653 50485: contig of 833 bp in length
 50486 51527: contig of 1042 bp in length
 51528 53119: contig of 1592 bp in length
 53120 53623: contig of 504 bp in length
 53624 54669: contig of 1046 bp in length
 54670 55309: contig of 640 bp in length
 55310 56382: contig of 1073 bp in length
 56383 56625: contig of 243 bp in length
 56626 57345: contig of 720 bp in length
 57346 57505: contig of 160 bp in length
 57506 58908: contig of 1403 bp in length
 58909 59968: contig of 1060 bp in length
 59969 61377: contig of 1409 bp in length
 61378 62291: contig of 914 bp in length
 62292 63319: contig of 1028 bp in length
 gap of unknown length

63320 63818: contig of 499 bp in length
 63819 64823: contig of 1005 bp in length
 64824 65269: contig of 446 bp in length
 65270 65904: contig of 635 bp in length
 65905 66815: contig of 911 bp in length
 gap of unknown length

100.0% Score 18; DB 2: Length 268294;
 Best Local Similarity 100.0%; Pred. No. 9.9; 0; Indels 0; Gaps 0;
 Matches 18; Conservative 0; Mismatches

1 AGCTATGACCTTCACAG 18
 217636 AGCTATGACCTTCACAG 217619

RESULT 11
 AC079530
 LOCUS
 DEFINITION
 ACCESSION
 VERSION
 KEYWORDS
 SOURCE
 ORGANISM

REFERENCE
 AUTHORS
 TITLE
 JOURNAL
 REFERENCE
 AUTHORS
 TITLE
 JOURNAL
 COMMENT

AC079530 287927 bp DNA linear HTG 02-SEP-2000
 Mus musculus clone RP23-342G15, WORKING DRAFT SEQUENCE, 53
 unordered pieces.
 AC079530.1 GI:9964895
 HTG; HTGS; PHAS1; HTGS_DRAFT.
 Mus musculus.
 Mus musculus; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Eukaryota; Eutheria; Rodentia; Sclurognathi; Muridae; Murinae; Mus.
 1 (bases 1 to 287927)
 DOE Joint Genome Institute.
 Sequencing of Mouse
 Unpublished
 2 (bases 1 to 287927)
 DOE Joint Genome Institute.
 Direct Submission
 Submitted (02-SEP-2000) Production Sequencing Facility, DOE Joint
 Genome Institute, 2800 Mitchell Drive, Walnut Creek, CA 94598, USA
 -----Genome Center
 Center: Joint Genome Institute
 Center Code: JGI
 Web site: http://www.jgi.doe.gov

 Project Information
 Center Project Name: 1868359
 Center Clone name: RPCT-23_342G15

 Summary Statistics
 Consensus quality: 236925 bases at least Q40
 Consensus quality: 254207 bases at least Q20
 Consensus quality: 258663 bases at least Q20
 Consensus quality: 210000; pulse field gel estimation
 Estimated insert size: 28727; sum-of-contigs estimation
 Estimated coverage: 14.02 in Q20 bases; pulse field gel estimation
 Quality coverage: 10.41 in Q20 bases; sum-of-contigs estimation
 Quality coverage: 10.41 in Q20 bases; sum-of-contigs estimation
 NOTE: This is a 'working draft' sequence. It currently
 consists of 53 contigs. The true order of the pieces
 is not known and their order in this sequence record is
 arbitrary. Gaps between the contigs are represented as
 runs of N, but the exact sizes of the gaps are unknown.
 This record will be updated with the finished sequence
 as soon as it is available and the accession number will
 be preserved.
 1
 1637 1636: contig of 1636 bp in length
 1737 1736: gap of unknown length
 3080 3079: contig of 1343 bp in length
 3180 3179: gap of unknown length
 4716 4715: contig of 1536 bp in length
 4816 4815: gap of unknown length
 5816 5815: contig of 1001 bp in length

```

5817 5916: gap of unknown length
5917 7443: contig of 1527 bp in length
7444 7543: gap of unknown length
7544 9268: contig of 1725 bp in length
9269 9368: gap of unknown length
9369 10740 10738: contig of 1371 bp in length
10740 10839: gap of unknown length
10840 12239: contig of 1400 bp in length
12240 12339: gap of unknown length
12340 14093: contig of 1754 bp in length
14094 14193: gap of unknown length
14194 15523: contig of 1330 bp in length
15524 15624: gap of unknown length
15624 17085: contig of 1462 bp in length
17086 17185: gap of unknown length
17186 18330: contig of 1045 bp in length
18331 18523: gap of unknown length
18524 18623: contig of 1193 bp in length
18624 20712: gap of unknown length
20713 20812: contig of 1089 bp in length
20813 21950: gap of unknown length
21951 22050: contig of 1138 bp in length
22051 23825: gap of unknown length
23825 25235: contig of 1774 bp in length
25235 25325: gap of unknown length
25326 26350: contig of 1301 bp in length
26351 26531: gap of unknown length
26531 28598: contig of 1205 bp in length
28598 28698: gap of unknown length
28699 29722: contig of 1968 bp in length
29723 29822: gap of unknown length
29823 30922: contig of 1024 bp in length
30923 31022: gap of unknown length
31023 32970: contig of 1100 bp in length
32971 33070: gap of unknown length
33071 35474: contig of 1948 bp in length
35475 35574: gap of unknown length
35575 36870: contig of 2404 bp in length
36871 36970: gap of unknown length
36971 38093: contig of 1236 bp in length
38094 38193: gap of unknown length
38194 40123: contig of 1123 bp in length
40124 40223: gap of unknown length
40224 41625: contig of 1930 bp in length
41626 41725: gap of unknown length
41726 46312: contig of 1402 bp in length
46313 46412: gap of unknown length
46413 50230: contig of 4587 bp in length
50231 50330: gap of unknown length
50331 51665: contig of 3818 bp in length
51666 51765: gap of unknown length
51766 53285: contig of 1335 bp in length
53286 53385: gap of unknown length
53386 56499: contig of 1520 bp in length
56499 56599: gap of unknown length
56600 57787: contig of 3114 bp in length
57787 57887: gap of unknown length
57888 63353: contig of 1187 bp in length
63354 63454: gap of unknown length
63454 69163: contig of 5467 bp in length
69164 69263: gap of unknown length
69264 74152: contig of 5710 bp in length
74153 74252: gap of unknown length
74253 79702: contig of 4889 bp in length
79703 79802: gap of unknown length
79803 86526: contig of 5450 bp in length
86527 86626: gap of unknown length
86627 92661: contig of 6724 bp in length
92661 92761: gap of unknown length
92761 97809: contig of 6035 bp in length
97809 97909: gap of unknown length
97909 97909: contig of 5048 bp in length

```

```

97910 102776 102775: contig of 4866 bp in length
102776 102876 102875: gap of unknown length
102876 108736 108735: contig of 5861 bp in length
108736 108837 108836: gap of unknown length
108837 117123 117122: contig of 8286 bp in length
117123 117223 117222: gap of unknown length
117223 124267 124266: contig of 7044 bp in length
124267 124367 124366: gap of unknown length
124367 137828 137827: contig of 1462 bp in length
137828 137929 137928: gap of unknown length
137929 144300 144300: contig of 6372 bp in length
144301 144401 144400: gap of unknown length
144401 159887 159887: contig of 15487 bp in length
159887 159988 159987: gap of unknown length
159988 170527 170526: contig of 10539 bp in length
170527 170627 170626: gap of unknown length
170627 185958 185957: contig of 15332 bp in length
185958 186058 186057: gap of unknown length
186058 203429 203428: contig of 17371 bp in length
203429 203530 203529: gap of unknown length
203530 222636 222635: contig of 19106 bp in length
222636 222736 222735: gap of unknown length
222736 242871 242870: contig of 20136 bp in length
242871 242972 242971: gap of unknown length
242972 287927 287926: contig of 44956 bp in length.

```

FEATURES

```

1. 287927
   location/Qualifiers

```

```

BASE COUNT      81254 a 63612 c 61615 g 76140 t 5306 others
ORIGIN

```

```

Query Match
Best Local Similarity 100.0%; Score 18; DB 2; Length 287927;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Db 174744 AGCTATGACGTTCCAAAG 174761
1 AGCTATGACGTTCCAAAG 18
|||||
RESULT 12
LOCUS AX104114 18 bp DNA linear PAT 30-APR-2001
DEFINITION Sequence 306 from Patent WO0122972.
ACCESSION AX104114
VERSION AX104114.1 GI:13920311
KEYWORDS
SOURCE
ORGANISM synthetic construct.
REFERENCE 1 (bases 1 to 18)
AUTHORS Kriegl, A.M., Schetter, C. and Vollmer, J.C.
TITLE Immunostimulatory nucleic acids
JOURNAL Patent: WO 0122972-A 306 05-APR-2001.
UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) ; Coley Pharmaceutical
GmbH (DE)

```

```

FEATURES
SOURCE location/Qualifiers
1. 18
   /organism="synthetic construct"
   /db_xref="taxon:32630"
4 a 4 c 6 g 4 t

```

```

BASE COUNT      4 a 4 c 6 g 4 t
ORIGIN

```

```

Query Match
Best Local Similarity 94.4%; Score 17; DB 6; Length 18;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Db 2 GCTATGACGTTCCAAAG 18
|||||
1 GCTATGACGTTCCAAAG 17

```

Fri Jun 27

RESULT 13
AX355358 18 bp DNA linear PAT 06-FEB-2002
LOCUS AX355358
DEFINITION Sequence 386 from Patent WO0197843.
ACCESSION AX355358
VERSION AX355358.1 GI:18620026
KEYWORDS
SOURCE synthetic construct.
ORGANISM synthetic construct
artificial sequences.

REFERENCE
1 Weimer, G., and Hartmann, G.
METHODS for enhancing antibody-induced cell lysis and treating
TITLE
AUTHORS
JOURNAL
FEATURES
source
cancer
Patent: WO 0197843-A 386 27-DEC-2001;
UNIVERSITY OF IOWA RESEARCH FOUNDATION (US)
Location/Qualifiers
1. .18
/organism="synthetic construct"
/db_xref="taxon:32630"
/note="Synthetic oligonucleotide-phosphorothioate
backbone"

BASE COUNT 4 a 4 c 6 g 4 t
ORIGIN

Query Match 94.4%; Score 17; DB 6; Length 18;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 2 GCTATGACGTTCCAAG 18
|||||
1 GCTATGACGTTCCAAG 17
Db

RESULT 14
AX463126 24 bp DNA linear PAT 15-JUL-2002
LOCUS AX463126
DEFINITION Sequence 9 from Patent WO0250108.
ACCESSION AX463126
VERSION AX463126.1 GI:21886107
KEYWORDS
SOURCE synthetic construct.
ORGANISM synthetic construct
artificial sequences.

REFERENCE
1 Marchal, G., Pescher, P. and Romaln, F.
TITLE Immunogenic glycopeptides, screening, preparation and uses
JOURNAL Patent: WO 0250108-A 9 27-JUN-2002;
PASTEUR INSTITUTE (FR)
Location/Qualifiers
1. .24
/organism="synthetic construct"
/db_xref="taxon:32630"
/note="linker"

BASE COUNT 5 a 8 c 7 g 4 t
ORIGIN

Query Match 94.4%; Score 17; DB 6; Length 24;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 2 GCTATGACGTTCCAAG 18
|||||
4 GCTATGACGTTCCAAG 20
Db

RESULT 15
AX463127 24 bp DNA linear PAT 15-JUL-2002
LOCUS AX463127
DEFINITION Sequence 10 from Patent WO0250108.
ACCESSION AX463127

VERSION AX463127.1 GI:21886108
KEYWORDS
SOURCE synthetic construct.
ORGANISM synthetic construct
artificial sequences.

REFERENCE
1 Marchal, G., Pescher, P. and Romaln, F.
TITLE Immunogenic glycopeptides, screening, preparation and uses
JOURNAL Patent: WO 0250108-A 10 27-JUN-2002;
PASTEUR INSTITUTE (FR)
Location/Qualifiers
1. .24
/organism="synthetic construct"
/db_xref="taxon:32630"
/note="linker"

BASE COUNT 4 a 7 c 8 g 5 t
ORIGIN

Query Match 94.4%; Score 17; DB 6; Length 24;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 2 GCTATGACGTTCCAAG 18
|||||
21 GCTATGACGTTCCAAG 5
Db

Search completed: June 26, 2003, 16:13:10
Job time : 929.63 secs

THIS PAGE BLANK (USPTO)

